Search by Journal
- HOME
- > Search by Journal
- > Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Volume , Issue suppl.1 / 2023
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
YPL. Of the clinical pharmacy is the message to 12 years after this 三浦昌朋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1-1, 2023. |
|---|
|
|
PL. The activity of the Japanese cure association and future problem 山本康次郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2-2, 2023. |
|---|
|
|
SL1. The pharmacist who plays an active part in the society which greatly undergoes a complete change 大久保正人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 3-3, 2023. |
|---|
|
|
SL2. Challenge of the molecular target therapy for - CML to cure leukemia with oral medication 高橋直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 4-4, 2023. |
|---|
|
|
SL3. Quantitative prediction and clinical studies of transporter-mediated drug interactions 楠原洋之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 5-5, 2023. |
|---|
|
|
SL4. Personalized medicine of the psychiatry domain 古郡規雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 6-6, 2023. |
|---|
|
|
EL. A role and evidence of medical herbal medicinal products in the cancer supportive care 元雄良治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 7-7, 2023. |
|---|
|
|
Receiving a prize -1. Clinical pharmacy study on individual differences of drug interactions 大谷壽一1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 8-8, 2023. |
|---|
|
|
Receiving a prize -2. Reverse translational study aiming at drug body change control and individual optimization of the medical therapy 崔吉道 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 9-9, 2023. |
|---|
|
|
Receiving a prize -3. Study on outcome evaluation of clinical drug duties by the multi-type of job collaboration in the cancer medical therapy 池末裕明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 10-10, 2023. |
|---|
|
|
Receiving a prize -4. Practice of the clinical pharmacy study that pointed to improvement in patients outcome by the antimicrobial proper use promotion 岡田直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 11-11, 2023. |
|---|
|
|
Receiving a prize -5. Clinical studies to offer optimal medical therapy to the patients with HIV infection 日笠真一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 12-12, 2023. |
|---|
|
|
Receiving a prize -6. Clinical reactions of drugs study on Drug-drug/Drug-condition interaction based on PK-PD theory and the data science 八木達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 13-13, 2023. |
|---|
|
|
PA-1. Pharmacometrics study aiming at the proper use of the immunosuppressive drug in the organ transplantation 糸原光太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 14-14, 2023. |
|---|
|
|
PA-2. Study on functional role of the glial type glutamic acid transporter in the feeling movement of the mental disorder, the cognitive function 内田美月1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 15-15, 2023. |
|---|
|
|
PA-3. Study on nucleic acid pharmaceutical products development that assumed the change control in cells a base 梅村圭祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 16-16, 2023. |
|---|
|
|
PA-4. Examination of the economic load in Japanese medical facilities by the drug resistance 莊司智和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 17-17, 2023. |
|---|
|
|
PA-5. Clinical reactions of drugs study based on blood kinetic analysis of tramadol in patients with head and neck cancer and the optical isomer of the demethylation metabolite 鈴木光路 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 18-18, 2023. |
|---|
|
|
PA-6. Examination about the factor associated with the pancreatic cancer cachexia 鈴木秀隆1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 19-19, 2023. |
|---|
|
|
PA-7. Contribution to medical security by analysis of the Medication errors and the inspection 鈴木亮平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 20-20, 2023. |
|---|
|
|
PA-8. Construction of the effective rating system of the therapeutic drug based on the change out of the feces using the Clostridioides difficile infection mouse model 田代渉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 21-21, 2023. |
|---|
|
|
PA-9. Study on effectiveness of the medical therapy in the digestive organ surgery domain and safety 中澤孝文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 22-22, 2023. |
|---|
|
|
PA-10. Construction of the type of cancer cross-sectional registry of the use of immune checkpoint inhibitor patients and study about the prediction of the onset of effect of treatment, immunity-related adverse event 松金良祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 23-23, 2023. |
|---|
|
|
A special plan symposium. It is the term of the organizer for the development expansion of the medical technology for Precision dosing 福土将秀, 新岡丈典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 25-25, 2023. |
|---|
|
|
SP-1. The development of the high-throughput assay of blood drug concentration using the LC-MS/MS and clinical implementation 菊地正史1,2, 眞野成康1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 26-26, 2023. |
|---|
|
|
SP-2. Development of the individualization administration plan based on the PGx analysis and clinical implementation 平大樹, 杉本充弘, 寺田智祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 27-27, 2023. |
|---|
|
|
SP-3. Pay the attention to search - CYP3A of the new PK-related biomarker and OATP1B; and ... 炭本隆宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 28-28, 2023. |
|---|
|
|
SP-4. Establishment of the individualization administration that assumed a PK regulations factor an index of anticancer medicine 今村知世 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 29-29, 2023. |
|---|
|
|
SP-5. Development of the individualization administration plan of antibody pharmaceutical products 福土将秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 30-30, 2023. |
|---|
|
International Symposium 1. Messages for Pharmaceutical Health Care and Sciences in the Next Decade 1 Ikuko Yano, Yasuo Takeda Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 31-31, 2023. |
|---|
|
|
IS01-1. The development and practice of pharmacist-managed clinic in Chinese hospitals Bo Zhang Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 32-32, 2023. |
|---|
|
|
IS01-2. Introduction of Certified Pharmacy Specialists in South Korea Myung Sook Min Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 33-33, 2023. |
|---|
|
|
IS01-3. Comparing the Effectiveness and Safety Profiles of Anticoagulants in Thai Patients with Cancer-Associated Thrombosis : Insights from a Real-World Study Suphat Subongkot1, Kirati Kengkla1,2, Warunsuda Sripakdee3, Surakit Nathisuwan4, Pirun Saelue5, Aumkhae Sookprasert6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 34-34, 2023. |
|---|
|
|
IS01-4. The trajectory of hospital pharmacists and their expected future Yasuo Takeda Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 35-35, 2023. |
|---|
|
|
International Symposium 2. Messages for Pharmaceutical Health Care and Sciences in the Next Decade 2 Ikuko Yano, Yasuo Takeda Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 36-36, 2023. |
|---|
|
|
IS02-1. Population pharmacokinetics of vancomycin for special populations Yuko Shimamoto Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 37-37, 2023. |
|---|
|
|
IS02-2. Clinical application of steroid-sparing strategies in cancer patients receiving carboplatin-based chemotherapy Toshinobu Hayashi Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 38-38, 2023. |
|---|
|
|
IS02-3. Leadership of Pharmacists in Cancer Chemotherapy Hirotoshi Iihara Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 39-39, 2023. |
|---|
|
|
IS02-4. Effects of proton pump inhibitor use on the risk of acute kidney injury Shunsaku Nakagawa, Keiko Ikuta, Tomohiro Terada Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 40-40, 2023. |
|---|
|
|
IS02-5. Critical Care Pharmacists in Japan Mikihiro Maeda Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 41-41, 2023. |
|---|
|
|
Pharmacist Certifying Council plan symposium specialized in a cancer. Term of suggestion - organizer whom one step stepped into from effectively utilizing it and the suit of patients of point - clinical image examination of the pharmaceutical intervention of the pharmacist specialized in a cancer 池田龍二, 河原昌美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 42-42, 2023. |
|---|
|
|
CP1-1. Purpose explanation and the authorized situation of 2022 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 43-43, 2023. |
|---|
|
|
CP1-2. A form to be handed down and the point where you should be careful about 佐野元彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 44-44, 2023. |
|---|
|
|
CP1-3. Case ... avoiding the suggestion of breast cancer - cardiac activity evaluation and accidental drug interactions 近森綾子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 45-45, 2023. |
|---|
|
|
CP1-4. Approach ... in consideration of the characteristic of the stomach cancer - cancer species 堀川美帆 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 46-46, 2023. |
|---|
|
|
CP1-5. Correspondence ... to colon cancer - special population 松谷直樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 47-47, 2023. |
|---|
|
|
CP1-6. Correspondence ... to lung cancer - drug-related QT prolonged 平塚公己 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 48-48, 2023. |
|---|
|
|
CP1-7. Approach as the master of specialized pharmacy to cancer medical therapy to diversify 河原昌美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 49-49, 2023. |
|---|
|
|
Clinical studies promotion Committee plan symposium. Utilize excellent ability for study and high specialty, and improve patients outcome; is the term of the organizer 山口浩明, 鈴木小夜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 50-50, 2023. |
|---|
|
|
CP2-1. Upbringing of the pharmacist with ability for study and the specialty to improve patients outcome 山口浩明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 51-51, 2023. |
|---|
|
|
CP2-2. Efforts for the evidence construction in the nourishment domain 稲毛あずさ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 52-52, 2023. |
|---|
|
|
CP2-3. Pharmacist-led efforts and outcome evaluation in the antimicrobial proper use 宇田篤史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 53-53, 2023. |
|---|
|
|
CP2-4. For patients outcome improvement in the cancer medical therapy 那須いずみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 54-54, 2023. |
|---|
|
|
CP2-5. By power of the medical big data and machine learning, we aim at the patients outcome improvement! 今井俊吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 55-55, 2023. |
|---|
|
|
A medical therapy intensive lecture plan, administration subcommittee plan symposium. Let's become a specialist in ... medical therapy to diversify for a high quality specialty pharmacist; is the term of ... organizer 樋口則英, 鈴木貴明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 56-56, 2023. |
|---|
|
|
CP3-1. Drug administration design of the hemocatharsis therapy to understand by clearance 山本武人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 57-57, 2023. |
|---|
|
|
CP3-2. Medical therapy - RCT and RWE - of the attention lack, hyperkinesis symptom (ADHD) 佐々木剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 58-58, 2023. |
|---|
|
|
CP3-3. Pharmaceutical care of the pharmacist specialized in the medical therapy for the delicate health patients 小川敦1,2, 石澤啓介1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 59-59, 2023. |
|---|
|
|
CP3-4. How do you write it? It is ... with the point of "the case report with the pharmaceutical intervention" from the situation as ... applicant, the leader 八木達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 60-60, 2023. |
|---|
|
|
Pharmacist Certifying Council plan symposium specialized in local pharmacy care. Term of the present and the future organizer of the pharmacist specialized in local pharmacy care 豊見敦, 宮崎長一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 61-61, 2023. |
|---|
|
|
CP4-1. The improvement of the pharmacist in nature and problem of that purpose 太田美紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 62-62, 2023. |
|---|
|
|
CP4-2. Acquirement of the high specialty to aim at from study throughout the life 高松登 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 63-63, 2023. |
|---|
|
|
CP4-3. - to practice pharmacist training method - oneself specialized in local pharmacy care in the Kanazawa University Hospital, and to learn, and to be brought up together 原祐輔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 64-64, 2023. |
|---|
|
|
CP4-4. About the present after the pharmacist (cancer) specialized in local pharmacy care provisional authorized acquisition and future directionality 岩崎章吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 65-65, 2023. |
|---|
|
|
CP4-5. Efforts for the present and the future after the provisional authorized acquisition 松浦綾子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 66-66, 2023. |
|---|
|
|
CP4-6. About the approach in consciousness and the drugstore necessary for improvement of the local pharmacy care from the position of - drugstore pharmacist 松本由加里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 67-67, 2023. |
|---|
|
|
Symposium 1. Term of the directional organizer of the pharmacist after this concerned with the infection domain for 12 years 北原隆志, 村木優一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 68-68, 2023. |
|---|
|
|
3-1-S01-1. It is directional ... of the clinical duties for 12 years task shift/share ... in the infection domain after this 足立参希1, 田中鉄也1, 中野祐樹2, 小武和正3, 梅永真弓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 69-69, 2023. |
|---|
|
|
3-1-S01-2. It is the directionality of the clinical pharmacy study in the infection domain for 12 years after this 岡田直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 70-70, 2023. |
|---|
|
|
3-1-S01-3. It is directionality of the specialized pharmacist education in the infection domain for 12 years after this 田中昌代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 71-71, 2023. |
|---|
|
|
3-1-S01-4. It is directionality of the before graduation education in the infection domain for 12 years after this 村木優一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 72-72, 2023. |
|---|
|
|
Symposium 2. Hospital pharmacist, term of the sustainable way of working, research activities and carrier vision organizer of the female pharmacist 祝千佳子, 河添仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 73-73, 2023. |
|---|
|
|
3-2-S02-1. Contribution to society wants to extremely do a study from a university hospital pharmacist to the world of the academia 祝千佳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 74-74, 2023. |
|---|
|
|
3-2-S02-2. My career path which is formed in the connection with people: From hospital pharmacist to a teacher 鈴木景子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 75-75, 2023. |
|---|
|
|
3-2-S02-3. To walk the carrier which can realize a quality of oneself 流石学1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 76-76, 2023. |
|---|
|
|
3-2-S02-4. How to make workplace which both an individual and the organization make a sustainable way of working 大西友美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 77-77, 2023. |
|---|
|
|
3-2-S02-5. The problem of the healthcare worker judging from hospital management and the future prospects (as MBA holder) 大里洋一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 78-78, 2023. |
|---|
|
|
Symposium 3. Term of the new evidence organizer to "the exposure measures instruction to patient for foreign tumor chemotherapy practice charges" 野村久祥, 中山季昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 79-79, 2023. |
|---|
|
|
3-2-S03-1. Purpose explanation of this symposium 野村久祥1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 80-80, 2023. |
|---|
|
|
3-2-S03-2. Pharmacist duties and exposure instruction of the foreign chemotherapy room 橋口宏司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 81-81, 2023. |
|---|
|
|
3-2-S03-3. Practice of the occupational exposure measures and medication counseling for the oral anticancer medicine 小室雅人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 82-82, 2023. |
|---|
|
|
3-2-S03-4. About an excretion period of cyclophosphamide included in the sweat of the patients who received high-dose cyclophosphamide therapy in the hematopoietic stem cell transplantation pre-treatment 谷川大夢1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 83-83, 2023. |
|---|
|
|
3-2-S03-5. Risk communication about explanation of anticancer medicine second exposure measures 宮澤真帆1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 84-84, 2023. |
|---|
|
|
3-2-S03-6. Exposure to exposure measures measures ... to roll up the Next stage - whole society 中山季昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 85-85, 2023. |
|---|
|
|
Symposium 4. Term of the practice organizer of the medical therapy that assumed a clinical pharmacy study to support community medical care a base 吉山友二, 高橋寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 86-86, 2023. |
|---|
|
|
3-2-S04-1. Practice and clinical pharmacy of the community medical care 吉山友二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 87-87, 2023. |
|---|
|
|
3-2-S04-2. The training of the medical care person that fixes the eyes on future society and area, and ties a variety of places and people, and can play an active part 大久保正人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 88-88, 2023. |
|---|
|
|
3-2-S04-3. Local pharmacy care and clinical pharmacy study 山本康次郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 89-89, 2023. |
|---|
|
|
3-2-S04-4. Practice of the pharmacy management in the community medical care 山本雄一郎1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 90-90, 2023. |
|---|
|
|
3-2-S04-5. With - pharmacy education model core curriculum revision to think about the way of the clinical pharmacy education in the community medical care near at hand - 根岸健一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 91-91, 2023. |
|---|
|
|
3-2-S04-6. Practice of the health support drugstore bought for community medical care 高橋寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 92-92, 2023. |
|---|
|
|
Symposium 5. Term of significance - organizer whom ... "cooperation that a DI room develops" to think about new development now of drug information room duties results in 若林進, 大幸淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 93-93, 2023. |
|---|
|
|
3-3-S05-1. The significance that "the cooperation that a DI room presents" brings 若林進 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 94-94, 2023. |
|---|
|
|
3-3-S05-2. The current situation and DI cooperation of DI duties in our hospital 大竹三保 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 95-95, 2023. |
|---|
|
|
3-3-S05-3. DI cooperation to think about from the hospital of the small and medium size scale 大庭理寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 96-96, 2023. |
|---|
|
|
3-3-S05-4. A person in charge of drug information room be made in a person in charge of ward 飯村諒 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 97-97, 2023. |
|---|
|
|
3-3-S05-5. Is the DI person in charge lonely? We think about the possibility of the DI duties change by the cooperation 大幸淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 98-98, 2023. |
|---|
|
|
Symposium 6. Term of the practice lecture organizer that intellect profits and manages drug information 後藤伸之, 高橋一栄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 99-99, 2023. |
|---|
|
|
3-3-S06-1. We will estimate the basic information of pharmaceutical products as a package insert using interview form 金井紀仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 100-100, 2023. |
|---|
|
|
3-3-S06-2. Let's gather and evaluate information on medicines for special populations - Taking pregnant and breastfeeding women as an example - 小原拓1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 101-101, 2023. |
|---|
|
|
3-3-S06-3. We collect the information about the pharmaceutical products of nonrecognition, the off-label use and will evaluate it scientifically 鴫田江理嘉, 冨田隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 102-102, 2023. |
|---|
|
|
3-3-S06-4. We evaluate safe information using pharmaceutical products risk management plan and will take safety measures 林昌洋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 103-103, 2023. |
|---|
|
|
3-3-S06-5. We collect the information of the real world data about pharmaceutical products and will evaluate it 永田健一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 104-104, 2023. |
|---|
|
|
Symposium 7. It is the term of - organizer with - that purpose to think about the second use of data 折井孝男, 高田敦史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 105-105, 2023. |
|---|
|
|
3-3-S07-1. About the second use of medical data 飯村康夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 106-106, 2023. |
|---|
|
|
3-3-S07-2. Efforts of the standardization necessary for use of data second through MID-NET(R) 岸塲真理1, 大田有佳里1, 村山一茂2, 宇山佳明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 107-107, 2023. |
|---|
|
|
3-3-S07-3. Including invention of unevenly distributed - collection of names (poking each other) of the hospital pharmacist thinking from the second use of public data - 外山聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 108-108, 2023. |
|---|
|
|
3-3-S07-4. Problem - to feel where the electronic prescription information can use the back to from - setting and operation 宮森伸一, 北本真一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 109-109, 2023. |
|---|
|
|
3-3-S07-5. It is ... from the viewpoint of the staff of ... secretariat through the current situation investigation of the hospital pharmacy gate 稲富海帆 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 110-110, 2023. |
|---|
|
|
Symposium 8. A beginning is the term of ... organizer whom we advance, and the master of ... way intervenes in in this way from the first time of the interview a game in the first time 守内匡, 寺沢匡史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 111-111, 2023. |
|---|
|
|
3-4-S08-1. A beginning is a merit of the interview enforcement a game in the first time 守内匡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 112-112, 2023. |
|---|
|
|
3-4-S08-2. Information cooperation with hospitalization support and the ward pharmacist of the pharmacist in the perioperative center 阿部猛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 113-113, 2023. |
|---|
|
|
3-4-S08-3. The specialist in kidney disease medical therapy checks here in the first time! 浦田元樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 114-114, 2023. |
|---|
|
|
3-4-S08-4. The specialist in polypharmacy measures checks here in the first time! 武藤浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 115-115, 2023. |
|---|
|
|
3-4-S08-5. Art of how to write initial interview record "handed down" 寺沢匡史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 116-116, 2023. |
|---|
|
|
Symposium 9. Term of the organizer that effectively utilizing it optimizes medical treatment of the clinical pharmacy X laboratory study medicine laboratory study 前川正充, 城野博史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 117-117, 2023. |
|---|
|
|
3-4-S09-1. Inspection of the usefulness of the CYP active predictive biomarker measurement in the drug doses design 公文代將希, 前川正充, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 118-118, 2023. |
|---|
|
|
3-4-S09-2. Drug administration design based on the inflammatory marker 中川潤一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 119-119, 2023. |
|---|
|
|
3-4-S09-3. Individualization and laboratory study of the medical therapy 荒木拓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 120-120, 2023. |
|---|
|
|
3-4-S09-4. Examination for pharmacogenomics (PGx) to connect with achievement of Precision medicine 磯野哲一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 121-121, 2023. |
|---|
|
|
3-4-S09-5. Practice and pit fall of the antibiotic exposure that took clinical test value into account 尾田一貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 122-122, 2023. |
|---|
|
|
Symposium 10. Complex case conference - Let's think about drug therapy for complex cases together with professional pharmacists : Message from the organizer 木村丈司, 鈴木大介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 123-123, 2023. |
|---|
|
|
3-4-S10-1. We will think about medical treatment of the cancer X cardiovascular disease 伊勢崎竜也1, 木下照常2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 124-124, 2023. |
|---|
|
|
3-4-S10-2. We will think about acute renal failure and the treatment of patients with rheumatoid arthritis who had the pancytopenia 角田隆紀1, 林八恵子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 125-125, 2023. |
|---|
|
|
Symposium 11. Term of the organizer thinking about the role of the pharmacist in every scene of the psychiatry domain 保田和哉, 加藤剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 126-126, 2023. |
|---|
|
|
3-5-S11-1. Proper use of the psychiatry therapeutic drug based on blood drug levels, drug interactions 福山雄卯介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 127-127, 2023. |
|---|
|
|
3-5-S11-2. Efforts ... of cancellation risk factor elucidation - - hospital pharmacist of the early period of Clozapine start 築地茉莉子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 128-128, 2023. |
|---|
|
|
3-5-S11-3. Significance ... which sleeping drug formula re... pharmacist to make with the multi-type of job participates in 水村亮介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 129-129, 2023. |
|---|
|
|
3-5-S11-4. Result of the medication adequacy business by four person (medical association, pharmacist society, university, administration) cooperation 加藤剛1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 130-130, 2023. |
|---|
|
|
3-5-S11-5. Expectation to the further achievement of the pharmacist in every scene of the psychiatry domain and the future prospects 土井信幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 131-131, 2023. |
|---|
|
|
Symposium 12. Term of the rehabilitation drug organizer whom a pharmacist challenges 小瀬英司, 中村直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 132-132, 2023. |
|---|
|
|
3-5-S12-1. Concept of the rehabilitation drug 中道真理子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 133-133, 2023. |
|---|
|
|
3-5-S12-2. Evidence of the rehabilitation drug which we can practice from tomorrow 小瀬英司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 134-134, 2023. |
|---|
|
|
3-5-S12-3. Efforts of the rehabilitation drug in the convalescent ward 藤原久登1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 135-135, 2023. |
|---|
|
|
3-5-S12-4. Efforts (from the position of the pharmacist) of the rehabilitation drug in the convalescent ward 樋島学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 136-136, 2023. |
|---|
|
|
3-5-S12-5. Role of the nurse in the rehabilitation drug 永野彩乃 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 137-137, 2023. |
|---|
|
|
Symposium 13. That diabetes and the term of stigma - you reach the patients definitely or practice true medical therapy support; the term of ... organizer 大東敏和, 本田一春 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 138-138, 2023. |
|---|
|
|
3-5-S13-1. With Diabetes stigma and the advocacy 田中永昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 139-139, 2023. |
|---|
|
|
3-5-S13-2. I who am ... patients am conscious as a healthcare worker because we do not give patients a stigma 住吉加奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 140-140, 2023. |
|---|
|
|
3-5-S13-3. Importance to be engaged as a diabetes team pharmacist in the front line, and to support "a quality of oneself" not instruction to patient for 15 years 大東敏和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 141-141, 2023. |
|---|
|
|
3-5-S13-4. Introduction of the advocacy activity in the Japanese medicine and diabetes association 朝倉俊成 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 142-142, 2023. |
|---|
|
|
Symposium 14. How to teach formularies in university education? - Examples and ideas for formulary education - : Words from the organizer 岩澤真紀子, 大津史子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 143-143, 2023. |
|---|
|
|
3-6-S14-1. Pharmaceutical information training aimed at formulary formulation in clinical preparation education 上田昌宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 144-144, 2023. |
|---|
|
|
3-6-S14-2. Formulary training during practical training at Kitasato University Hospital 岩澤真紀子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 145-145, 2023. |
|---|
|
|
3-6-S14-3. Formulary preparation training in hospitals 上田智弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 146-146, 2023. |
|---|
|
|
3-6-S14-4. Formulary education in university education : To what extent should it be taught at universities? 大津史子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 147-147, 2023. |
|---|
|
|
Symposium 15. The medication explanation to patients with nursing that we want to convey even if it is not the nursing and medicine - specialty, an authorized pharmacist and term of improvement in skill - organizer 笠原英城, 實川東洋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 148-148, 2023. |
|---|
|
|
3-6-S15-1. In the nursing and a variety of scenes about the medicine, which information can you convey it using to where? 笠原英城 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 149-149, 2023. |
|---|
|
|
3-6-S15-2. Let's move away from the idea of ​​"just to be safe, stop breastfeeding." - Aiming to become a DI representative who can make proposals with confidence - 安島秀友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 150-150, 2023. |
|---|
|
|
3-6-S15-3. Because do not make stop self to come from agent and nursing - anxiety complex for the mental nerve; ... 鈴木秀明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 151-151, 2023. |
|---|
|
|
3-6-S15-4. One or ... which must put up with single headache pill and nursing - headache 上森恵里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 152-152, 2023. |
|---|
|
|
3-6-S15-5. Medication explanation ... to control antiepileptic drug and nursing - attack 松岡順子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 153-153, 2023. |
|---|
|
|
Symposium 16. Term of ... organizer who does fusion (merge) in "we give it it" in pharmacist education theory - new age to expect 12 years later saying "we make it" 柴田啓智, 近藤悠希 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 154-154, 2023. |
|---|
|
|
3-6-S16-1. It is ... from the position to know education theory - clinical practice and the education of the department of a pharmacy student and the medicine university graduate in the new age 今井俊吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 155-155, 2023. |
|---|
|
|
3-6-S16-2. The reason that I was young, and was able to create evidence 國津侑貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 156-156, 2023. |
|---|
|
|
3-6-S16-3. Coexistence ... of bridge ... "(make) growing up" of a player and the manager and "(give) to bring up" 小林一男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 157-157, 2023. |
|---|
|
|
3-6-S16-4. Role of duties system ... that the management gives a young person - learning for new age 北原加奈之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 158-158, 2023. |
|---|
|
|
Symposium 17. Let's start research with the JADER database - Beware of pitfalls! - Organizer's message 土屋雅美, 小原拓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 159-159, 2023. |
|---|
|
|
3-13-S17-1. Point to keep in mind in a check list and the study accomplishment in the study using JADER 酒井隆全 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 160-160, 2023. |
|---|
|
|
3-13-S17-2. A study using JADER carried out in the healthcare setting and pit fall 岡田直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 161-161, 2023. |
|---|
|
|
3-13-S17-3. The enforcement of the clinical studies using side effect report data and pit fall (than a study on vaccine) 宮崎真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 162-162, 2023. |
|---|
|
|
3-13-S17-4. Efforts to a quality evaluation and the improvement of the report included in JADER in quality 土屋雅美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 163-163, 2023. |
|---|
|
|
Symposium 18. It is the term of ... organizer based on role ... latest trend and laws and regulations of the pharmacist to aim at the clinical experimental medicine administration that secured the safety of subjects 鶴丸雅子, 近藤直樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 164-164, 2023. |
|---|
|
|
3-13-S18-1. Of the management of the use of trial medicine that secured quality, actually 老本名津子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 165-165, 2023. |
|---|
|
|
3-13-S18-2. With the role of the open-label pharmacist, actually 森山菜緒 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 166-166, 2023. |
|---|
|
|
3-13-S18-3. Efforts of the Japan Pharmaceutical Manufacturers Association for the appropriate handling of the use of trial medicine 實雅昭1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 167-167, 2023. |
|---|
|
|
3-13-S18-4. About movement of the regulation to affect the current situation of DCT and a problem, an approach and a clinical experimental medicine for the development of the guidance 福田祐介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 168-168, 2023. |
|---|
|
|
3-13-S18-5. New role of the clinical experimental medicine manager on the basis of the trend of the decentralization clinical study and clinical experimental medicine-related laws and regulations 近藤直樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 169-169, 2023. |
|---|
|
|
Symposium 19. Let's use our knowledge of clinical pharmacology to contribute to the proper use of medicines - Evidence and the Three Sacred Treasures - : Words from the organizers 岩本卓也, 本間真人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 170-170, 2023. |
|---|
|
|
3-13-S19-1. Inflection for a close inspection and the individual optimization of the evidence to support standard treatment 上田昌宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 171-171, 2023. |
|---|
|
|
3-13-S19-2. TDM by the interpretation of the free form blood level 花田和彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 172-172, 2023. |
|---|
|
|
3-13-S19-3. Pit fall and interpretation of the genetic polymorphism evaluation 鈴木嘉治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 173-173, 2023. |
|---|
|
|
3-13-S19-4. Quantitative evaluation, pit fall of drug interactions 平井利典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 174-174, 2023. |
|---|
|
|
Symposium 20. Let's discuss drug interaction management again now - Guide, case studies, and perspectives - : Words from the organizer 米澤淳, 大野能之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 175-175, 2023. |
|---|
|
|
3-14-S20-1. General statement of purpose explanation and the guide 米澤淳1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 176-176, 2023. |
|---|
|
|
3-14-S20-2. Drug interactions of the case conference (an evaluation and the management of DDI) 1-COVID-19 therapeutic drug 木村丈司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 177-177, 2023. |
|---|
|
|
3-14-S20-3. Drug interactions ... with the case conference (an evaluation and the management of DDI) 2 ... antiHIV therapy 増田純一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 178-178, 2023. |
|---|
|
|
3-14-S20-4. Drug interactions ... with the case conference (an evaluation and the management of DDI) 3 - chemotherapy 大野能之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 179-179, 2023. |
|---|
|
|
3-14-S20-5. A limit and the prospects of the drug interactions management 樋坂章博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 180-180, 2023. |
|---|
|
|
Symposium 21. Term of the organizer reconsidering a tablet crush 倉田なおみ, 鈴木慶介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 181-181, 2023. |
|---|
|
|
3-14-S21-1. We reconsider a tablet crush 倉田なおみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 182-182, 2023. |
|---|
|
|
3-14-S21-2. The dosage form design of the tablet and effect of the crush 原田努1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 183-183, 2023. |
|---|
|
|
3-14-S21-3. Point of problems and the oral cavity function observation of the medicine noticing by mouth care 石井良昌 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 184-184, 2023. |
|---|
|
|
3-14-S21-4. The current situation of the tablet crush for children 石川洋一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 185-185, 2023. |
|---|
|
|
3-14-S21-5. It is a challenge to the issue of tablet crush in the hospital juxtaposition type care health center for the elderly from "a thing to humans" 鈴木慶介1, 山嵜真里1, 小林紘子1, 鶴崎亮太1, 齋藤千夏1, 中野博美2, 齋藤真美2, 高橋泰知3, 高梨友花3, 片見厚夫4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 186-186, 2023. |
|---|
|
|
Symposium 22. Term of the kidney disease medical therapy organizer learning from CKD practice guidelines 2023 竹内裕紀, 古久保拓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 187-187, 2023. |
|---|
|
|
3-14-S22-1. Way of thinking of the renal function estimation type to use for drug doses setting according to the renal function 竹内裕紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 188-188, 2023. |
|---|
|
|
3-14-S22-2. Up to date of the antiherpesvirus therapeutic drug 水野智博1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 189-189, 2023. |
|---|
|
|
3-14-S22-3. Pain-killer choice to patients in elderly people, CKD with the pain 平田純生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 190-190, 2023. |
|---|
|
|
3-14-S22-4. Instruction and medicine medicine cooperation using the concept of the chic day of patients in CKD 田中章郎1, 太田達也1, 伊藤さおり1, 鰐田芽未1, 金子智慈1, 野澤文香1, 高村京香1, 濱田眞里亜1, 平澤菜々子2, 等浩太郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 191-191, 2023. |
|---|
|
|
3-14-S22-5. Extension inhibition of the chronic kidney disease with the SGLT2 inhibitor 浦田元樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 192-192, 2023. |
|---|
|
|
Symposium 23. Because a pharmacist will play an active part in the clinical studies from now on; is the term of ... organizer for ... professional ability expansion, evidence creation 萩原宏美, 石澤啓介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 193-193, 2023. |
|---|
|
|
3-15-S23-1. It is ... from a viewpoint of way - CRC of the contribution of the pharmacist in the pharmaceutical products development 山本明子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 194-194, 2023. |
|---|
|
|
3-15-S23-2. Need that ethic knowledge - ethic examination that becomes required when a pharmacist pushes forward clinical studies is why or ... 内倉健 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 195-195, 2023. |
|---|
|
|
3-15-S23-3. An effect and the prospects by hospital pharmacist being engaged in a clinical study 野中祐二朗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 196-196, 2023. |
|---|
|
|
3-15-S23-4. We make use of the experience of the clinical study in the specialty reinforcement of the disease domain: You read, and how do you solve protocol? 萩原宏美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 197-197, 2023. |
|---|
|
|
3-15-S23-5. With the clinical studies aiming at social implementation 八木健太1,2, 新村貴博1,2, 坂口暁1, 石澤啓介1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 198-198, 2023. |
|---|
|
|
Symposium 24. Term of utilization - current situation of pharmacokinetic "modeling & simulation" and future - organizer 工藤敏之, 佐藤正延 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 199-199, 2023. |
|---|
|
|
3-15-S24-1. Proper use of the oral special preparation which drug absorption change simulation brings: Effect of CYP3A/P-gp changing with administration preparation 白坂善之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 200-200, 2023. |
|---|
|
|
3-15-S24-2. Utilization and the prospects of M&S in pediatric clinical settings 齊藤順平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 201-201, 2023. |
|---|
|
|
3-15-S24-3. Reporting - use dose to a package insert based on M&S, - that we set it in this way 吉次広如 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 202-202, 2023. |
|---|
|
|
3-15-S24-4. New challenge to apply an artificial intelligence (AI) technique to modeling & simulation 辻泰弘1, 関弘翔2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 203-203, 2023. |
|---|
|
|
Symposium 25. Do you not think about the problem of sex differences in the medical therapy? Term of approach - organizer from ... basics and clinical practice 櫻下弘志, 高井靖 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 204-204, 2023. |
|---|
|
|
3-15-S25-1. Point of view of the sex differences in the basic pharmacy study 黒川洵子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 205-205, 2023. |
|---|
|
|
3-15-S25-2. Sex differences in the renal function evaluation 加藤隆児 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 206-206, 2023. |
|---|
|
|
3-15-S25-3. Medical therapy and sex differences of the cancer domain 櫻下弘志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 207-207, 2023. |
|---|
|
|
3-15-S25-4. Medical therapy and sex differences of the circulatory organ domain 高井靖 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 208-208, 2023. |
|---|
|
|
Symposium 26. Term of impact - organizer to give for a tide and the pharmacist duties of - robot that the anticancer agent preparation robot came to here 近藤勝弘, 日比陽子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 209-209, 2023. |
|---|
|
|
4-2-S26-1. From the perspective of manufacturing and supply - Kemoro - The past, present and future of robot preparation 家田啓史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 210-210, 2023. |
|---|
|
|
4-2-S26-2. From the perspective of manufacturing and supply - Roccioni/Apotheca The history of automated preparation of anticancer drugs and the future 樋口耕平, ベレーニ フェデリーコ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 211-211, 2023. |
|---|
|
|
4-2-S26-3. The effects from the viewpoint of the healthcare setting to the pharmacist duties that - Darwin chemo - anticancer medicine preparation robot (DARWIN-Chemo) results in and further expectation 榊原隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 212-212, 2023. |
|---|
|
|
4-2-S26-4. From the perspective of the medical field - Apotheca - …Current status and issues of anticancer drug preparation support equipment operation at Yokohama City University Medical Center… 栗島直希 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 213-213, 2023. |
|---|
|
|
4-2-S26-5. From the perspective of the medical field - Kemoro - The use of two types of robots in our hospital and future prospects 外海友規 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 214-214, 2023. |
|---|
|
|
Symposium 27. Is not only cancer pharmacist outpatient department ... medication counseling indicating the result for patients; the term of practice - organizer of the fur Matthew tical care 川上和宜, 原田知彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 215-215, 2023. |
|---|
|
|
4-2-S27-1. Is not only cancer pharmacist outpatient department ... medication counseling indicating the result for patients; practice ... of the fur Matthew tical care 川上和宜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 216-216, 2023. |
|---|
|
|
4-2-S27-2. The pharmacist outpatient targeted for oral anticancer medicine has the usefulness; or is ... from the analysis of the treatment cancellation case by significance and the side effect of ... Residual medicine confirmation 郷真貴子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 217-217, 2023. |
|---|
|
|
4-2-S27-3. Relation of the pharmacist outpatient offering the adjuvant postoperative treatment that secured intensity of treatment 奥田泰考 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 218-218, 2023. |
|---|
|
|
4-2-S27-4. The prescription suggestion by the pharmacist is side effect management ... from effect - intensity of treatment to bring for treatment continuation 中村匡志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 219-219, 2023. |
|---|
|
|
4-2-S27-5. Cyclopedic fixed-quantity evaluation ... of new value - quality of life that a pharmacist gives for supportive care 藤井宏典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 220-220, 2023. |
|---|
|
|
Symposium 28. Term of utilization - organizer of IoT for the purpose of the early correspondence of side effect management - side effect of the cancer medical therapy that went step further that fixed its eyes on a point for 12 years 高山慎司, 横川貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 221-221, 2023. |
|---|
|
|
4-2-S28-1. Prevent Oncology Emergency; is construction ... of the safety management support system utilizing ... cyclopedic test value extraction application 橋本幸輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 222-222, 2023. |
|---|
|
|
4-2-S28-2. Experience application introduction and improvement; and ... ideal and reality and wall ... which stands in the way 藤堂真紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 223-223, 2023. |
|---|
|
|
4-2-S28-3. That the IT tool from development - this of the electronic patients diary connecting an electronic medical chart and the health insurance pharmacy is "to protect it safely of the medicine"; ... 香取哲哉1, 小茂田昌代1, 河本怜史1, 木村敦1, 石嵜知里2, 遠藤直樹3, 浅野俊彦4, 佐藤大輔4, 山田琴美4, 野村浩子5, 石川大介6, 真辺篤6, 藤村義明6, 出雲貴文1, 柿本應貴7, 岡元るみ子8, 高橋智5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 224-224, 2023. |
|---|
|
|
4-2-S28-4. That online medication counseling results for the side effect management? It is ... based on the follow-up example in ... health insurance pharmacy 木村大地, 山崎綾香, 鎌谷崇弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 225-225, 2023. |
|---|
|
|
4-2-S28-5. Fusion and utilization ... of development - medical care cooperation notebook and the prescription notebook of the patients participation type medical care cooperation support system in the treatment with breast cancer hormone 高山慎司1, 田中裕子2, 笠原里紗3, 土田寧恵5, 尹尹玲花4, 山内英子3, 中村清吾3,5, 後藤一美1, 林直輝3,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 226-226, 2023. |
|---|
|
|
Symposium 29. Term of the evidence creation organizer of the infection with young pharmacist domain for drug resistant bacterium measures of the near future 枦秀樹, 山田智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 227-227, 2023. |
|---|
|
|
4-3-S29-1. About administration plan of vancomycin in first aid, the ICU domain 石郷友之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 228-228, 2023. |
|---|
|
|
4-3-S29-2. Creation of the evidence for the antimicrobial proper use by the cooperation with middle scale hospital and university 並木孝哉1,2, 枦秀樹1, 織田錬太郎3, 横山雄太2,4, 中村智徳2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 229-229, 2023. |
|---|
|
|
4-3-S29-3. Evidence creation in preventive measures against hospital infection 中出順也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 230-230, 2023. |
|---|
|
|
4-3-S29-4. Evidence creation of infection measures in the lung transplantation 片田佳希 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 231-231, 2023. |
|---|
|
|
4-3-S29-5. Study on Teicoplanin 24 hours loading dose method utilizing the machine learning 近藤昭志1,2, 尾田一貴1, 金子哲也1, 城野博史1,2, 齋藤秀之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 232-232, 2023. |
|---|
|
|
Symposium 30. The pharmacist of task shift/share times can make the wonderful future with "career path" "career up"; or the term of the organizer 岸本真, 小枝伸行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 233-233, 2023. |
|---|
|
|
4-3-S30-1. With the career path career up in the pharmacist 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 234-234, 2023. |
|---|
|
|
4-3-S30-2. Hint ... from the area to the career path formation of the initial women that it lives in one step in what "is spun" - lissomeness "to spin" who learned 小原道子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 235-235, 2023. |
|---|
|
|
4-3-S30-3. For hospital pharmacist making the wonderful future 渡邉学1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 236-236, 2023. |
|---|
|
|
4-3-S30-4. Possibility ... to career path - management hospital pharmacist's post 荒木隆一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 237-237, 2023. |
|---|
|
|
4-3-S30-5. The management and career path career up of task shift/shares from a pharmacist to other types of job 岸本真1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 238-238, 2023. |
|---|
|
|
Symposium 31. It is the term of ... organizer from this of balance - hospital pharmacist duties of a task shift and the ward drug duties of the pharmacist 守内匡, 河井良智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 239-239, 2023. |
|---|
|
|
4-3-S31-1. From environment and this of ward duties surrounding ward duties 守内匡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 240-240, 2023. |
|---|
|
|
4-3-S31-2. Practice of "the task shift of pharmacist duties" 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 241-241, 2023. |
|---|
|
|
4-3-S31-3. Want to balance it; is ward drug duties and drug control instruction 寺沢匡史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 242-242, 2023. |
|---|
|
|
4-3-S31-4. The management and task shift to calculate ward drug duties enforcement addition 2 木村真策 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 243-243, 2023. |
|---|
|
|
4-3-S31-5. Ward pharmacist who seeks it from a viewpoint of the hospital management in the future 石井富美1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 244-244, 2023. |
|---|
|
|
Symposium 32. It is possible for what to save the children whom there is in relation ... future of the pharmacist to "children, neonates" X "intensive care"; or the term of ... organizer 内田淳, 冨家俊弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 245-245, 2023. |
|---|
|
|
4-4-S32-1. How do evaluate the medical therapy of relation ... neonates of the pharmacist in the NICU; ... 清水啓道 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 246-246, 2023. |
|---|
|
|
4-4-S32-2. There is it to save a certain child in role - future of the pharmacist in the pediatric intensive care unit 小川隆弘1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 247-247, 2023. |
|---|
|
|
4-4-S32-3. It is participation in planning ... to correspondence at an offer of relation ... safe children intensive care of the pharmacist for the childhood intensive care in the ICU where adults are mixed with children and a childhood sudden change 内田淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 248-248, 2023. |
|---|
|
|
4-4-S32-4. TDM in children, the neonatal intensive care domain 齊藤順平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 249-249, 2023. |
|---|
|
|
4-4-S32-5. The thing which is bought in the relation of a physician and the pharmacist in the institution specialized in a childhood circulatory organ 藤井隆成 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 250-250, 2023. |
|---|
|
|
Symposium 33. Term of the efforts to the polypharmacy solution that we worked on by the multi-type of job team and the future problem organizer 尾上雅英, 古俵孝明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 251-251, 2023. |
|---|
|
|
4-4-S33-1. From the situation of the corresponding physician to the polypharmacy that became one area 冨田尚希1,2, 村中美千帆1,2, 高野由美1,2, 舘脇康子1,2, 中瀬泰然1,2, 瀧靖之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 252-252, 2023. |
|---|
|
|
4-4-S33-2. It is ... from position of current situation and problem - hospital pharmacist for the polypharmacy measures area unification 三宅麻文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 253-253, 2023. |
|---|
|
|
4-4-S33-3. Problem for efforts and the regional alliances to a polypharmacy solution 古俵孝明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 254-254, 2023. |
|---|
|
|
4-4-S33-4. Process of pharmaceutical products proper use at the health insurance pharmacy by the cooperation with a hospital and the multi-type of job 畑世剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 255-255, 2023. |
|---|
|
|
4-4-S33-5. Process of pharmaceutical products proper use by regional alliances 吉岡睦展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 256-256, 2023. |
|---|
|
|
Symposium 34. Term of the management method organizer for a pharmacist to manage IMiDs in community medical care cooperation appropriately 上ノ段友里, 小枝伸行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 257-257, 2023. |
|---|
|
|
4-4-S34-1. Fetal prevention of exposure of IMiDs and the role that a pharmacist should fulfil for treatment with specific drug management charges 2 遠藤一司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 258-258, 2023. |
|---|
|
|
4-4-S34-2. Importance of the medical security and information to a pharmacist and a medical person to ask for from a harmful effect victim 間宮清 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 259-259, 2023. |
|---|
|
|
4-4-S34-3. The occupational exposure measures from a pharmacist to medical personnel to report and the way of the information sharing 間宮伸幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 260-260, 2023. |
|---|
|
|
4-4-S34-4. It is information sharing for the safety management for the healthcare worker of inside the hospital, the outside Parliament from hospital pharmacist preparing IMiDs 上ノ段友里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 261-261, 2023. |
|---|
|
|
4-4-S34-5. The example that an insurance pharmacist was concerned with appropriate management of IMiDs in regional alliances 川口敏弘1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 262-262, 2023. |
|---|
|
|
Symposium 35. Let's share how to manage electrolyte abnormalities with pharmaceuticals : Words from the organizers 三宅健文, 門脇大介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 263-263, 2023. |
|---|
|
|
4-5-S35-1. How to for the condition of a patient grasp of the electrolyte abnormality to be helpful when we know it 志水英明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 264-264, 2023. |
|---|
|
|
4-5-S35-2. How to for the condition of a patient grasp of the electrolyte (Ca, P) abnormality 吉田拓弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 265-265, 2023. |
|---|
|
|
4-5-S35-3. How to for the condition of a patient grasp of the electrolyte (K, Mg) abnormality 平井利典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 266-266, 2023. |
|---|
|
|
4-5-S35-4. How to for the condition of a patient grasp of the electrolyte (Na, Cl) abnormality 柴田啓智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 267-267, 2023. |
|---|
|
|
Symposium 36. Term of extension - organizers from - "clinical pharmacy" to think about pharmacy education, pharmacist upbringing in response to social needs to "clinical pharmacy" 松尾宏一, 吉村知哲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 268-268, 2023. |
|---|
|
|
4-5-S36-1. With "the clinical pharmacy" in the pharmacy education model core curriculum 石井伊都子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 269-269, 2023. |
|---|
|
|
4-5-S36-2. How do you make, "it is difficult" education? 川口崇1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 270-270, 2023. |
|---|
|
|
4-5-S36-3. Individual optimization of ability - medical therapy necessary for pharmacist in the future 高橋克之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 271-271, 2023. |
|---|
|
|
4-5-S36-4. Practice ... of education - clinical pharmacy, the clinical pharmacy in the front line about the cancer medical therapy 池末裕明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 272-272, 2023. |
|---|
|
|
Symposium 37. Term of the new development organizer of the postgraduate education for upbringing of the pharmacist carrying the next generation 山田成樹, 高橋一栄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 273-273, 2023. |
|---|
|
|
4-5-S37-1. Postgraduate training and the carrier formation of the pharmacist 山田清文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 274-274, 2023. |
|---|
|
|
4-5-S37-2. About after graduation clinical practice model business and a report, future directionality 石井伊都子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 275-275, 2023. |
|---|
|
|
4-5-S37-3. Core Cali revision: From the pharmacist education at university for an after graduation clinic 鈴木匡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 276-276, 2023. |
|---|
|
|
4-5-S37-4. About the need of a fact and the multi-type of job cooperation education of the postgraduate education of the medical type of job 木内祐二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 277-277, 2023. |
|---|
|
|
Symposium 38. Term of industrialization - organizer of DX strategy - innovation-like technical seeds to realize sustainable pharmacist duties 座間味義人, 村木優一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 278-278, 2023. |
|---|
|
|
4-6-S38-1. Development of medical specialization type EdTech aiming at the visualization of the thought 牛尾聡一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 279-279, 2023. |
|---|
|
|
4-6-S38-2. Medication follow DX with the IoT medicine calendar 佐古卓人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 280-280, 2023. |
|---|
|
|
4-6-S38-3. Until the social implementation of development - results of research of the pharmaceutical products proper use promotion system in consideration of renal function - 近藤悠希 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 281-281, 2023. |
|---|
|
|
4-6-S38-4. Construction of advanced drug duties utilizing DX in the university hospital pharmacy 座間味義人1, 牛尾聡一郎2, 武田達明3, 濱野裕章1, 鍛治園誠1, 西原茂樹1, 村川公央1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 282-282, 2023. |
|---|
|
|
4-6-S38-5. Practice of the advanced clinical pharmacy education utilizing DX in the pharmacy school 村木優一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 283-283, 2023. |
|---|
|
|
Symposium 39. It is the term of ... organizer from the practice of pharmacist duties - ward duties of the small and medium size hospital to think about together to securing of human resources, a local action, cooperation 宮川哲也, 濱浦睦雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 284-284, 2023. |
|---|
|
|
4-6-S39-1. It is ... for the efficiency of PBPM, task shift/share - duties that we can practice at a small and medium size hospital and improvement of the quality 瀧祐介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 285-285, 2023. |
|---|
|
|
4-6-S39-2. Treatment at home and the Advance Care Planning (ACP) activity that we can practice simply because it is a small and medium size hospital 横山敏紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 286-286, 2023. |
|---|
|
|
4-6-S39-3. It is ... about efforts for the improvement in fixation rate of the human resources in the small and medium size hospital towards the workplace with ... worth doing 渡部学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 287-287, 2023. |
|---|
|
|
4-6-S39-4. Turn connections into power! - Activities of the Nagano Prefecture Hospital Pharmacists Association Small and Medium Hospital Committee - 伴野一樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 288-288, 2023. |
|---|
|
|
4-6-S39-5. With trust and expectation from a large hospital to small and medium size hospital - cooperation which looked at - 筒井由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 289-289, 2023. |
|---|
|
|
Symposium 40. How do you make use of the intervention point ... feeling rehabilitation of the pharmacist for the heart failure case and a viewpoint of the medical treatment instruction in there of the prescription suggestion? Term of ... organizer 吉国健司, 芦川直也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 290-290, 2023. |
|---|
|
|
4-6-S40-1. Here is important; is medical treatment instruction and the heart rehabilitation for the heart failure case 西崎公貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 291-291, 2023. |
|---|
|
|
4-6-S40-3. How is the monitoring - heart rehabilitation instruction person of patients with heart failure practice? ... 向井一樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 292-292, 2023. |
|---|
|
|
4-6-S40-5. It is ... to the one step of challenge - usual medication counseling of the pharmacist challenging a heart failure pandemic 石井聡一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 293-293, 2023. |
|---|
|
|
Symposium 41. Term of ... organizer that we will think about case report, and the ... pharmacist's experience saves patients from the viewpoint of CARE guidelines 藤宮龍祥, 小澤有輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 294-294, 2023. |
|---|
|
|
4-12-S41-1. Why case reports now? - Improve the quality of case reports with CARE - 藤宮龍祥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 295-295, 2023. |
|---|
|
|
4-12-S41-2. About the originality that is important in SIADH - case report by the ST medical mixture, message characteristics - 米澤龍1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 296-296, 2023. |
|---|
|
|
4-12-S41-3. Description of liver damage - CARE guidelines on Abemaciclib experience - 小澤有輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 297-297, 2023. |
|---|
|
|
4-12-S41-4. About a way of thinking of the clinical reasoning sought by case report 鈴木信也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 298-298, 2023. |
|---|
|
|
4-12-S41-5. How to use case report to think about in a viewpoint of CARE 上塚朋子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 299-299, 2023. |
|---|
|
|
Symposium 42. Term of - organizer learning from a successful example for the clinical question which should be settled in - truth aiming at the high quality evidence creation by the pharmacist 石澤啓介, 田崎嘉一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 300-300, 2023. |
|---|
|
|
4-12-S42-1. Method - to test improvement, the change of evaluation - duties of the antimicrobial proper use support task by the pharmacist scientifically 山口諒 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 301-301, 2023. |
|---|
|
|
4-12-S42-2. Secret - of multi-organization collaborative investigation - study planning and the administration to create the evidence of the high level 飯原大稔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 302-302, 2023. |
|---|
|
|
4-12-S42-3. Examination of the pharmacokinetic allied genetic information application in the Parkinson's disease medical treatment 山本譲, 田崎嘉一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 303-303, 2023. |
|---|
|
|
4-12-S42-4. The new truth to be found by the power of fundamental researches: For solution to clinical question 川田敬1,2, 石田智滉3, 阿部真治1, 合田光寛2,4, 石澤啓介2,4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 304-304, 2023. |
|---|
|
|
4-12-S42-5. Creation of the clinical evidence by the data science that assumed medical big data utilization a base 濱野裕章1, 牛尾聡一郎2, 松本准3, 新村貴博4, 相澤風花5, 八木健太4, 合田光寛5,6, 石澤啓介4,5,6, 座間味義人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 305-305, 2023. |
|---|
|
|
Symposium 43. Term of - organizer who reviews that we can do it in pharmacy management - now of the orthopedics domain, and thinks about possibility after this 長谷川裕矢, 三浦誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 306-306, 2023. |
|---|
|
|
4-12-S43-1. The intervention to an injury, an infection: To prevent Preventable Trauma Disability 檜山洋子1, 大饗和憲2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 307-307, 2023. |
|---|
|
|
4-12-S43-2. Cancer chemotherapy and the multi-type of job cooperation of the orthopedics domain 中川祐紀子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 308-308, 2023. |
|---|
|
|
4-12-S43-3. Efforts of pharmacist duties and the conference according to the Kyoto hospital pharmacist society domain to join together from hospitalization to a discharge 天満智也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 309-309, 2023. |
|---|
|
|
4-12-S43-4. Of the pharmaceutical intervention of the orthopedics domain mainly on a pain-killer, a sleeping drug, the osteoporosis therapeutic drug, actually 長谷川裕矢 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 310-310, 2023. |
|---|
|
|
4-12-S43-5. The osteoporotic liaison service that a pharmacist conducts 長谷奈那子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 311-311, 2023. |
|---|
|
|
Symposium 44. Term of the The progress of international exchange program in oncology pharmacy practice organizer Masami Tsuchiya, Yukiyoshi Fujita Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 312-312, 2023. |
|---|
|
|
4-13-S44-1. International exchange programs in pre-graduate pharmacy education at Keio University Faculty of Pharmacy Sayo Suzuki Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 313-313, 2023. |
|---|
|
|
4-13-S44-2. International Exchange Initiatives at Kameda General Hospital Yukari Kataoka Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 314-314, 2023. |
|---|
|
|
4-13-S44-3. Participate in cancer pharmacist training overseas... Yumi Morioka Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 315-315, 2023. |
|---|
|
|
4-13-S44-4. International exchange program experience in Thailand Manit Saeteaw Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 316-316, 2023. |
|---|
|
|
Symposium 45. Have of "perioperative drug control" and invention - such a thing in "postoperative pain management team" settings; is the term of ... organizer 舟越亮寛, 柴田ゆうか Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 317-317, 2023. |
|---|
|
|
4-14-S45-1. Fine-view ... future for the task shift from an anesthesiologist for ... perioperative period from a team setup 藤田翔1, 金城勝大1, 宮良遥奈1, 吾津千秋1, 小杉卓大1, 國分千代1, 梶原理恵2, 新里泰一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 318-318, 2023. |
|---|
|
|
4-14-S45-2. We challenge the pharmaceutical management in the operating room 亀田皓介, 内田会美, 山本卓矢, 増田大輔, 上野正夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 319-319, 2023. |
|---|
|
|
4-14-S45-3. We obtained the map called the Japanese Society of Hospital Pharmacists check list and will begin to row it to the sea called the operating room! 金森麻土香1, 中丸朗1, 柿沼宏幸2, 小島正夫3, 佐藤学1, 金子和生1, 戸村さよ子4, 伊藤裕子4, 遠藤千晴4, 益子ひろみ4, 浅利圭介4, 田村華恵1, 小川結花1, 清水美子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 320-320, 2023. |
|---|
|
|
4-14-S45-4. For the future of the drug control perioperative from a postoperative pain management team start 小林大祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 321-321, 2023. |
|---|
|
|
4-14-S45-5. Relation of the pharmacist in the postoperative pain management team 村川公央, 勝部理早, 小沼利光, 西原茂樹, 座間味義人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 322-322, 2023. |
|---|
|
|
4-14-S45-6. Towards the best postoperative pain management team 竹之内正記 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 323-323, 2023. |
|---|
|
|
Symposium 46. It will be to the pharmacist who prepare for a medical all-out war of 2035, and is connected with thought movement in Warning signs of the sudden change; is the term of the organizer 中薗健一, 今井徹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 324-324, 2023. |
|---|
|
|
4-14-S46-1. Warning signs: Approach to a breathing change 鈴木善樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 325-325, 2023. |
|---|
|
|
4-14-S46-2. The serious illness that did not miss it, and was covered in alteration of consciousness (delirium) 岩内大佑 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 326-326, 2023. |
|---|
|
|
4-14-S46-3. Fever as Warning Sign which we do not overlook fever, and a pharmacist should evaluate 西田祥啓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 327-327, 2023. |
|---|
|
|
4-14-S46-4. Do not suppress the tachycardia by force, and let's think about every possibility. 若杉和美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 328-328, 2023. |
|---|
|
|
Symposium 47. Term of ... first aid, perioperative period, intensive care, acute phase, community medical care - organizer regarding a macroviewpoint care shift as a micro through 1 case 齋藤靖弘, 吉川博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 329-329, 2023. |
|---|
|
|
4-14-S47-1. Role of the seamless medical therapy and pharmacist beginning with the emergency visit 川島裕明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 330-330, 2023. |
|---|
|
|
4-14-S47-2. It is Zoom out until the issue of care of the Zoom in surgery patients for the issue of postoperative complications 猪狩賢蔵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 331-331, 2023. |
|---|
|
|
4-14-S47-3. medication reconciliation - evaluation and plan ... which are carried out by an intensive care team 安藝敬生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 332-332, 2023. |
|---|
|
|
4-14-S47-4. To connect to role - community medical care of the pharmacist in the ward for acute phase; ... 菅原隆文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 333-333, 2023. |
|---|
|
|
4-14-S47-5. Pharmaceutical support and cooperation of medical care, the care to spend time in an area 宮坂善之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 334-334, 2023. |
|---|
|
|
Symposium 48. Clinical pharmacists start research into the field of blood cancer - Know-how from on-site realizations to practice - : Words from the organizers 安武夫, 伊藤佳織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 335-335, 2023. |
|---|
|
|
4-15-S48-1. It is ... from prescription suggestion - clinical duties of the pharmacist in patients with blood-forming organ tumor to a study 南貴之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 336-336, 2023. |
|---|
|
|
4-15-S48-2. We think about the palliative care intervention of the blood cancer domain as a clinical pharmacist 伊藤佳織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 337-337, 2023. |
|---|
|
|
4-15-S48-3. Let's incorporate a clinical pharmacological perspective into patient observation - To protect patients who are administered a large number of high-alert drugs - 土手賢史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 338-338, 2023. |
|---|
|
|
4-15-S48-4. Drug interactions in the hematopoietic stem cell transplantation judging from the viewpoint of the pharmacist 中島寿久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 339-339, 2023. |
|---|
|
|
4-15-S48-5. Usefulness of the supportive care of the blood cancer domain by the multi-type of job collaboration and safe examination 内田まやこ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 340-340, 2023. |
|---|
|
|
Symposium 49. Term of the current situation and the problem organizer for the clinical implementation of the examination for pharmacogenomics 寺田智祐, 新岡丈典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 341-341, 2023. |
|---|
|
|
4-15-S49-1. About a proposal about the operation of the examination for pharmacogenetics in the practice 寺田智祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 342-342, 2023. |
|---|
|
|
4-15-S49-2. PK-PGx analysis of oral factor Xa inhibitors 中川潤一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 343-343, 2023. |
|---|
|
|
4-15-S49-3. Search of the genetic polymorphism associated with the onset of the drug-related interstitial lung disease 田中庸一1, 福永航也2, 牛木淳人3, 花岡正幸3, 齋藤嘉朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 344-344, 2023. |
|---|
|
|
4-15-S49-4. The examination for PGx implementation to an electronic medical chart and clinical usefulness 杉本充弘, 平大樹, 寺田智祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 345-345, 2023. |
|---|
|
|
4-15-S49-5. Problem for the spread situation of the examination for pharmacogenomics by the true clinical practice and the clinical implementation 辻大樹1, 齋藤嘉朗2, 莚田泰誠3, 三浦昌朋4, 平大樹5, 寺田智祐5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 346-346, 2023. |
|---|
|
|
Symposium 50. Of the past, the present of the TDM look back, is also the term of the development organizer to the next generation 尾田一貴, 榎屋友幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 347-347, 2023. |
|---|
|
|
4-15-S50-1. From this of the TDM in intensive care, the infection domain 尾田一貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 348-348, 2023. |
|---|
|
|
4-15-S50-2. Therapeutic drug monitoring in consideration of the maturation value of children 辻泰弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 349-349, 2023. |
|---|
|
|
4-15-S50-3. Therapeutic drug monitoring of the molecular target anticancer medicine 野田哲史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 350-350, 2023. |
|---|
|
|
4-15-S50-4. About therapeutic drug monitoring in the psychiatry domain 猿渡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 351-351, 2023. |
|---|
|
|
4-15-S50-5. The blood level measurement in the acute drug intoxication domain: The current situation and problem 榎屋友幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 352-352, 2023. |
|---|
|
|
Symposium 51. Should do the action that how about us to push on to current situation of the medicine medicine cooperation in the cancer chemotherapy and future ... new step; or the term of ... organizer 杉山弘樹, 木村緑 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 353-353, 2023. |
|---|
|
|
5-1-S51-1. Thought ... which we loaded mission - book symposium holding of the hospital pharmacist concerned with medicine medicine cooperation with 杉山弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 354-354, 2023. |
|---|
|
|
5-1-S51-2. With "the information that a drugstore pharmacist wants" to get simply because it is a person who experienced hospital pharmacist? 木村緑 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 355-355, 2023. |
|---|
|
|
5-1-S51-3. "WHY" The true intention of cooperation and the drugstore pharmacist for patients beginning with this 笹原侑祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 356-356, 2023. |
|---|
|
|
5-1-S51-4. Usefulness of the reporting from a pharmacist in cancer treatment: From the situation of the on koro distrike 森川直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 357-357, 2023. |
|---|
|
|
5-1-S51-5. Patients expect it for a pharmacist and medicine medicine cooperation, illness medicine cooperation 西村和佳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 358-358, 2023. |
|---|
|
|
Symposium 52. How should the pharmacist be engaged in medical care, the care cooperation in the problem in 2040? Term of the organizer 尾上雅英, 辻井聡容 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 359-359, 2023. |
|---|
|
|
5-2-S52-1. From the viewpoint of the teacher of the medical B-school 多湖雅博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 360-360, 2023. |
|---|
|
|
5-2-S52-2. From position of the hospital pharmacist who learned in a medical B-school 尾上雅英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 361-361, 2023. |
|---|
|
|
5-2-S52-3. Fine-view ... of the health insurance pharmacy future through medical care, current situation and problem - drugstore 3.0 from the situation of the health insurance pharmacy cooperating with care 安里芳人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 362-362, 2023. |
|---|
|
|
5-2-S52-4. From the position of the pharmacist of the area core hospital with the qualification of the care manager 辻井聡容 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 363-363, 2023. |
|---|
|
|
5-2-S52-5. From a viewpoint of the hospital pharmacist conducting the hospitalization and release support addition futuristically 堀内賢一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 364-364, 2023. |
|---|
|
|
Symposium 53. Collaboration between hospital formularies and local formularies - Aiming for better local medical care - Words from the organizers 渡辺善照, 高橋將喜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 365-365, 2023. |
|---|
|
|
5-2-S53-1. Appropriate use of medicines and expectations of pharmacists - Appropriate use with an eye on medical Dx (including the use of local formularies) - 中井清人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 366-366, 2023. |
|---|
|
|
5-2-S53-2. Formularies in the era of community-based comprehensive care: differentiation, strengthening, and collaboration of medical functions and sustainable treatment management 川上純一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 367-367, 2023. |
|---|
|
|
5-2-S53-3. Outlook for pharmaceutical formularies in Japan 小池博文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 368-368, 2023. |
|---|
|
|
5-2-S53-4. The key to British formula re... pawn and coexistence of the economy 佐々江龍一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 369-369, 2023. |
|---|
|
|
5-2-S53-5. Construction and operation of pharmaceutical formularies in Sendai City 渡辺善照1,2, 男澤貴子2, 菅原茂樹2, 花井拓斗2, 一戸集平3,4, 栃窪克行2,3,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 370-370, 2023. |
|---|
|
|
Symposium 54. It is the term of the fact organizer of the efforts of each institution accompanied with the "proposal (No. 15) for the prevention of recurrence of the mishaps in medical practice" public announcement the safety measures that you do for what 西原雅美, 河瀬留美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 371-371, 2023. |
|---|
|
|
5-3-S54-1. What is the behavior sought to a medical institution associated with a proposal for recurrent prevention of the mishaps in medical practice? 土屋文人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 372-372, 2023. |
|---|
|
|
5-3-S54-2. Receive a proposal (No. 15) for recurrent prevention of the mishaps in medical practice; and is ... from the position of the medical security working full time pharmacist in ... special functioning hospital 菊田裕規1,2, 西原雅美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 373-373, 2023. |
|---|
|
|
5-3-S54-3. Receive a proposal (No. 15) for recurrent prevention of the mishaps in medical practice; and is ... from position of the ex-Emperor ... serious illness 菅野浩1, 齋藤謙治1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 374-374, 2023. |
|---|
|
|
5-3-S54-4. Receive a proposal (No. 15) for recurrent prevention of the mishaps in medical practice; and is ... from the situation of the cottage-hospital out of ... 町谷安紀1,2,3, 東川明子2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 375-375, 2023. |
|---|
|
|
5-3-S54-5. Receive a proposal (No. 15) for recurrent prevention of the mishaps in medical practice; and ... and current situation and efforts ... of the local government Hospital which there is 岸本真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 376-376, 2023. |
|---|
|
|
Symposium 55. Term of approach - organizer of Tokyo where the breeding of the medicine medicine cooperation aims at relief, the security of ... cancer medical therapy from the standardization of the tracing report 清水久範, 山口正和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 377-377, 2023. |
|---|
|
|
5-3-S55-1. About the process of the "Tokyo cancer medical therapy council" start 山口正和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 378-378, 2023. |
|---|
|
|
5-3-S55-2. From the situation of the Tokyo health service bureau 鎌田智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 379-379, 2023. |
|---|
|
|
5-3-S55-3. From the situation of Tokyo pharmacist society medicine medicine cooperation Committee 島田淳史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 380-380, 2023. |
|---|
|
|
5-3-S55-4. To embody "ideal" of the medicine medicine cooperation; ... ... which thinks about breeding of the medicine medicine cooperation from position of ... hospital pharmacist seriously 小川千晶 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 381-381, 2023. |
|---|
|
|
5-3-S55-5. It is ... from the position of way and problem - drugstore pharmacist of the tracing report which we examined after the hospital training 辻将成 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 382-382, 2023. |
|---|
|
|
Symposium 56. The securing of pharmacist supporting the poor area of medical resources and upbringing, term of the collaboration organizer with the local government 崔吉道, 堀里子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 383-383, 2023. |
|---|
|
|
5-5-S56-1. To push forward the securing of pharmacist supporting the poor area of medical resources and upbringing, the collaboration with the local government 崔吉道 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 384-384, 2023. |
|---|
|
|
5-5-S56-2. The poor local problem of medical resources and role of a drugstore, the pharmacist 堀里子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 385-385, 2023. |
|---|
|
|
5-5-S56-3. About the securing of pharmacist for the unevenly distributed cancellation 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 386-386, 2023. |
|---|
|
|
5-5-S56-4. Local one body type business training "Maizuru program" 楠本正明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 387-387, 2023. |
|---|
|
|
5-5-S56-5. Initiatives to secure pharmacists in Ishikawa Prefecture - Ishikawa Prefecture Regional Collaboration Pharmacist Co-education Program - 松下悠希1, 福井優子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 388-388, 2023. |
|---|
|
|
Symposium 57. Will support a back of role - you of the pharmacist in prevention of bedsore, the treatment; is the term of ... organizer 飯塚雄次, 武藤理恵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 389-389, 2023. |
|---|
|
|
5-5-S57-1. A pressure sore association in Japan expect it from a pharmacist 館正弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 390-390, 2023. |
|---|
|
|
5-5-S57-2. Role of the pharmacist in the medical service fees revision about pressure sore measures 関根祐介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 391-391, 2023. |
|---|
|
|
5-5-S57-3. A pharmacist's perspective directly linked to the pharmaceutical management plan for inpatient bedsores - Topical medication treatment for bedsores utilizing base characteristics and drug retention: Furuta Method - 古田勝経 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 392-392, 2023. |
|---|
|
|
5-5-S57-4. Grasp of the overall status about pressure sore treatment, the prevention 溝神文博1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 393-393, 2023. |
|---|
|
|
5-5-S57-5. Role ... in the at-home pressure sore of thing - drugstore pharmacist that it seemed that a pharmacist intervened in a pressure sore 小黒佳代子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 394-394, 2023. |
|---|
|
|
Symposium 58. Term of efforts - organizer that we go for medical care and current situation report from the DX - healthcare setting of the hospital pharmacist and coming 12 years 高橋正明, 山中理 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 395-395, 2023. |
|---|
|
|
5-6-S58-1. About medical DX including the electronic prescription or future movement, and the like 高橋悠一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 396-396, 2023. |
|---|
|
|
5-6-S58-2. Efforts of the bringing medicine formulations utilizing the YJ cord 田中正臣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 397-397, 2023. |
|---|
|
|
5-6-S58-3. Problem of duties improvement by the inflection of the GS-1 bar code and the hospital pharmacist duties in the super aging society 中尾元紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 398-398, 2023. |
|---|
|
|
5-6-S58-4. Reinforcement of the cooperation between health insurance pharmacy ... hospital using the on admission medication reporting book with the QR cord 五十嵐敏明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 399-399, 2023. |
|---|
|
|
5-6-S58-5. About pharmacist education contents to have simulated experience of true clinical practice utilizing the advanced IT 牛尾聡一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 400-400, 2023. |
|---|
|
|
Symposium 59. It which learn from a side effect case, and protects patients is our mission; the term of the organizer 前田頼伸, 冨岡謙二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 401-401, 2023. |
|---|
|
|
5-6-S59-1. Prescription adequacy by the kinetic analysis of the side effect case 前田頼伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 402-402, 2023. |
|---|
|
|
5-6-S59-2. Information on adverse drug reactions management using an electronic medical chart 冨岡謙二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 403-403, 2023. |
|---|
|
|
5-6-S59-3. Usefulness of the uniform management system of a side effect, the allergic information 荒木良介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 404-404, 2023. |
|---|
|
|
5-6-S59-4. Importance of the proper use judging from a non-supply example in the Relief System for Sufferers from Adverse Drug Reactions 薄井健介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 405-405, 2023. |
|---|
|
|
5-6-S59-5. How do you protect patients from the health hazard of the pharmaceutical products through the side effect monitor activity in the health insurance pharmacy? 廣田憲威 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 406-406, 2023. |
|---|
|
|
Symposium 60. Term of the organizer regarding upbringing of the pharmacist carrying the next generation as the clinic of cancer 上ノ段友里, 佐藤雄己 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 407-407, 2023. |
|---|
|
|
5-12-S60-1. It is ... from the position of the ... University teacher regarding upbringing of the pharmacist carrying the next generation as the clinic of cancer 佐藤雄己 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 408-408, 2023. |
|---|
|
|
5-12-S60-2. In a cancer special hospital about education system 松井礼子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 409-409, 2023. |
|---|
|
|
5-12-S60-3. What pharmacy of the Osaka cancer practice base Hospital works on 萱野勇一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 410-410, 2023. |
|---|
|
|
5-12-S60-4. The specialty of the pharmacist is ... from the situation of clinic - health insurance pharmacy of cancer to support 久田健登 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 411-411, 2023. |
|---|
|
|
5-12-S60-5. Clinic of cancer to pursue in the healthcare setting to think about from the situation that experienced business training 道原あやな Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 412-412, 2023. |
|---|
|
|
Symposium 61. Term of the efforts organizer of the medical security in the domain mild for an at-home shift 高瀬久光, 井手口直子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 413-413, 2023. |
|---|
|
|
5-12-S61-1. A thought necessary for hospitalization and release cooperation and medical mind 小林篤史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 414-414, 2023. |
|---|
|
|
5-12-S61-2. Point of the medical security at home care patient acceptance 佐久間詠理1, 川内潤也1, 渡邉淳子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 415-415, 2023. |
|---|
|
|
5-12-S61-3. Our being thinking as a health insurance pharmacy accepting patients of the sustained subcutaneous injection enforcement 宇都宮励子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 416-416, 2023. |
|---|
|
|
5-12-S61-4. It is ... for advice - safe injection drug intravenous feeding route choice of the medical drug injection drug combination management based on the incompatibility test in the mild medical care 近藤匡慶 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 417-417, 2023. |
|---|
|
|
5-12-S61-5. Is the intervention that hospital pharmacist can snuggle up to patients on the site now for time left patients with cancer anything? 藤堂真紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 418-418, 2023. |
|---|
|
|
Symposium 62. Term of the adequacy relaxation medical therapy strategy organizer according to the patients unit for pharmacist image specialized palliative care for 2035 to kill the pain of patients 伊東俊雅, 金子健 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 419-419, 2023. |
|---|
|
|
5-13-S62-1. Specialty - of the pharmacist sought in - relaxation medical care domain where a pharmaceutical discussion turns mild medical care into 的場元弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 420-420, 2023. |
|---|
|
|
5-13-S62-2. A skill and problem in the mild medical domain necessary for a clinical pharmacist 山田正実 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 421-421, 2023. |
|---|
|
|
5-13-S62-3. Mild medical care education and problem to see in Tokyo hospital pharmacist society mild medical regional pharmacist training workshop 金子健1,2, 竹内麻理2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 422-422, 2023. |
|---|
|
|
5-13-S62-4. Relaxation cafe - Tokyo Supportive Oncology Pharmacist Pain Board - hospital pharmacy simultaneous educational program administration and the problem 伊東俊雅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 423-423, 2023. |
|---|
|
|
5-13-S62-5. The thing which is seen from a medical therapy skill and the problem mild medical drugstore certification system design in the mild medical domain necessary for a drugstore pharmacist 小林篤史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 424-424, 2023. |
|---|
|
|
Symposium 63. Term of the problem organizer of an injection drug in the at-home cancer palliative care, the supply of the medical drug and the family function of a pharmacist, the drugstore 串田一樹, 伊東俊雅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 425-425, 2023. |
|---|
|
|
5-13-S63-1. Drugstore investigation [medicine bacteria] Ergonomy and cooperation of the drugstore in the at-home cancer palliative care to be able to see from this 串田一樹, 廣原正宜, 宮崎生子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 426-426, 2023. |
|---|
|
|
5-13-S63-2. At-home cancer palliative care to be able to see through a visit activity 佐々木健 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 427-427, 2023. |
|---|
|
|
5-13-S63-3. The cooperation between the drugstores in the local inclusion care system and the problem 白石丈也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 428-428, 2023. |
|---|
|
|
5-13-S63-4. Work - of the pharmacist supporting at-home cancer palliative care living-in-; supporting; examine; from the viewpoint of the pharmacist 大須賀悠子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 429-429, 2023. |
|---|
|
|
Symposium 64. Term of the organizer thinking about who should do a discussion to solve the supply anxiety problem of pharmaceutical products where 室井延之, 四方敬介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 430-430, 2023. |
|---|
|
|
5-14-S64-1. To raise ... pharmaceutical products supply information sharing and transparency to think about who should do a discussion to solve the supply anxiety problem of pharmaceutical products where; ... 室井延之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 431-431, 2023. |
|---|
|
|
5-14-S64-2. Usefulness of the effect on inquiry of the outside Parliament prescription of the understock of pharmaceutical products and the simplification protocol for inquiry 高瀬友貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 432-432, 2023. |
|---|
|
|
5-14-S64-3. Anti-stress of the current situation and the drugstore team in confrontation with the understock of pharmaceutical products 廣田有紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 433-433, 2023. |
|---|
|
|
5-14-S64-4. Administrative approach to affect the steady supply of pharmaceutical products 浅野智央 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 434-434, 2023. |
|---|
|
|
5-14-S64-5. About efforts of association of generic medicine manufacture for the securing of trust of the generic drug in Japan 川俣知己 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 435-435, 2023. |
|---|
|
|
Symposium 65. The support necessary to conduct clinical studies at a drugstore? - We learn a company and an art of the study support of university! - Term of the organizer 岡田浩, 天野学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 436-436, 2023. |
|---|
|
|
5-15-S65-1. Clinical studies to develop: Way to foolproof clinical studies 片岡裕貴1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 437-437, 2023. |
|---|
|
|
5-15-S65-2. Problem in the clinical studies enforcement of the drugstore pharmacist 天野学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 438-438, 2023. |
|---|
|
|
5-15-S65-3. Feel it about study enforcement from the situation of the drugstore 角佳亮 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 439-439, 2023. |
|---|
|
|
5-15-S65-4. Clinical studies to conduct at university and a drugstore 岡田浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 440-440, 2023. |
|---|
|
|
5-15-S65-5. It is = about the study support system in academic activity = companies at the health insurance pharmacy 長谷川佳孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 441-441, 2023. |
|---|
|
|
Symposium 66. It is the term of ... organizer for 12 years to aim with people taking new team Building ... antiHIV medicine in the local inclusion care 阿部憲介, 國本雄介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 442-442, 2023. |
|---|
|
|
5-15-S66-1. It is ... from the local inclusion care system and pharmacist's experience of relation ... cancer practice 岡田浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 443-443, 2023. |
|---|
|
|
5-15-S66-2. It is ... from the role of the pharmacist in the HIV practice team and position of medication support - hospital pharmacist in the future 阿部憲介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 444-444, 2023. |
|---|
|
|
5-15-S66-3. The prospects to the role of the health insurance pharmacy in the HIV practice and local inclusion care 田橋美佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 445-445, 2023. |
|---|
|
|
5-15-S66-4. To live like the person regardless of an activity and expectation - AIDS end and status in the community to a pharmacist of outbreak; ... 岩橋恒太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 446-446, 2023. |
|---|
|
|
5-15-S66-5. Practice - team building of the team approach in medical care in the HIV practice and joint decision making - 田沼順子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 447-447, 2023. |
|---|
|
|
We will write case report necessary for a pharmacist specialized in medical therapy! 日本医療薬学会 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 448-448, 2023. |
|---|
|
|
MS01-1. ... that the thought circuit is forged in skill - conference of the pharmacist to see cardiovascular disease 高井靖 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 450-450, 2023. |
|---|
|
|
MS01-2. We do not make pharmaceutical cooperation and task share - heart failure stage of the heart failure practice utilized Fantastic four advance! We will find "passing away feeling imperfection" 佐藤宏行1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 451-451, 2023. |
|---|
|
|
MS02. Pharmacist and the new generation irAE management that ePRO opens up 桂英之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 453-453, 2023. |
|---|
|
|
MS03. Expect generic development with medical economic issue - added value in cancer treatment; ... 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 455-455, 2023. |
|---|
|
|
MS04. Inflection of the Sino-Japanese traditional medicine for the acute phase disease 中永士師明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 457-457, 2023. |
|---|
|
|
MS05. The pain management and constipation measures 安藤秀明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 459-459, 2023. |
|---|
|
|
MS06. Importance of the postgraduate education mediating between community medical care, health care 井関健 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 461-461, 2023. |
|---|
|
|
MS07. Mainly on initial treatment by treatment strategy - bortezomib of the multiple myeloma on the basis of effect mechanism and a side effect and subsequent treatment preferences 今井陽一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 463-463, 2023. |
|---|
|
|
MS08. Generic drug recommendation medicine choice ... of a role and the steady supply of commentary - hospital pharmacist of the local formula reenforcement guidelines on released academic conference 今井博久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 465-465, 2023. |
|---|
|
|
MS09-1. The basic knowledge "cancer cachexia" that is sought now by a pharmacist 二村昭彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 467-467, 2023. |
|---|
|
|
MS09-2. What pharmacists can do to treat cancer cachexia - It is the Courage to Continue that Counts - 藤井宏典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 468-468, 2023. |
|---|
|
|
MS10-1. "We can do it at home too!!" - Therapeutic drug monitoring practice and innovations at a single-specialty psychiatric hospital - 阿部裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 470-470, 2023. |
|---|
|
|
MS10-2. "Let's extend Here we go, TDM duties"; is introduction and practice case ... of ... LM1010 森川剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 471-471, 2023. |
|---|
|
|
MS11. The change of the HER2-positive breast cancer medical therapy 石田孝宣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 473-473, 2023. |
|---|
|
|
MS12. The exposure measures at mixed preparation of the antineoplastic and effect to give to medical expenses 佐々木忠徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 475-475, 2023. |
|---|
|
|
MS13. Significance - of fine-view - multidirectional painkilling and post-operative pain management team analgesic after the operation 飯田宏樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 477-477, 2023. |
|---|
|
|
MS14. Aiming to break away from clinical inertia in migraine treatment - A paradigm shift in migraine treatment with the arrival of Emgality and REYVOW - 小田正哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 479-479, 2023. |
|---|
|
|
MS15. Expectation to a pharmacist supporting septicemic DIC treatment strategy community medical care in the future 辻喜久1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 481-481, 2023. |
|---|
|
|
MS16-2. Efforts of the hepatitis B reactivation surveillance that a physician and a pharmacist work on 萱野勇一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 483-483, 2023. |
|---|
|
|
MS17. Characteristic of the TDM in the cyclosporine micro emulsion preparation 竹内裕紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 485-485, 2023. |
|---|
|
|
MS18. ... which thinks about cancer medical care and nourishment management from patients power necessary for a work-style reform model and coimpressive power of an art" - ECAM model, medicine medicine cooperation, PBPM, promotion of PHR 木本真司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 487-487, 2023. |
|---|
|
|
MS19. It is ... led by four vaccine - herpes zoster vaccine thing RIX now necessary for adults and elderly people 渡辺彰1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 489-489, 2023. |
|---|
|
|
MS20. It is ... from the viewpoint of correspondence ... drug interactions to a new coronavirus infection 増田純一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 491-491, 2023. |
|---|
|
|
MS21. ... to think about based on the activity guideline of the pharmacist for way - sepsis-related DIC practice of the pharmacist in the intensive care team 安藝敬生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 493-493, 2023. |
|---|
|
|
MS22. Blanding ... of importance - specialty/authorization pharmacist of HIV infection/specialty pharmacist 小谷宙 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 495-495, 2023. |
|---|
|
|
MS23. Now of the antiemesis therapy in the highly emetic risk medicine 橋本浩伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 497-497, 2023. |
|---|
|
|
MS24. New positioning of new oral medication and psoriasis treatment 渡部大輔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 499-499, 2023. |
|---|
|
|
MS25. About possibility of breast cancer endocrine therapy - equol which focused on quality of life - 大竹徹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 501-501, 2023. |
|---|
|
|
MS26. It is ... mainly on relation ... side effect measures of the pharmacist to cancer chemotherapy 安室修 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 503-503, 2023. |
|---|
|
|
3-7-O01-1. Efforts of the pharmaceutical products stock amount of money inhibition in the southern part of Saiseikai Yokohama-shi Hospital and the result 深沢貴志, 田辺真里, 飯村諒, 生田和之, 藤巻智則, 平間盛吾, 上原美佐, 加藤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 505-505, 2023. |
|---|
|
|
3-7-O01-2. Correspondence ... to efforts ... patients with disposal pharmaceutical products reduction in the South Wakayama medical center-limited medicine 喜田孝史, 辻田司, 木原理絵, 古川順章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 506-506, 2023. |
|---|
|
|
3-7-O01-3. Inspection of the used pharmaceutical products PTP sheet recycling effect with a drugstore, the hospital 田口りか1, 堀英生2, 供田将志3, 神保美紗子4, 浅井治行5, 間瀬定政6, 白川茉由9, 大澤伸夫7, 長谷川照恭8, 鈴木匡2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 507-507, 2023. |
|---|
|
|
3-7-O01-4. Efforts and the result to minimize the pharmaceutical products disposal in the hospital 植木哲也, 實松絵美子, 緒方彰子, 岸本たかね, 川道直子, 篠原義剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 508-508, 2023. |
|---|
|
|
3-7-O01-5. Factorial experiments to influence pharmaceutical products loss 谷口潤1, 國生道代2, 松田吉憲3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 509-509, 2023. |
|---|
|
|
3-7-O02-1. Problems of the medicine charge revision that we were able to see from standard conversion system operation 齊藤安昌, 喜多村裕子, 島田雅彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 511-511, 2023. |
|---|
|
|
3-7-O02-2. Pulmonary toxic evaluation by bevacizumab using adverse drug reaction database (JADER) 神林祐子1, 内田まやこ2, 柏木美粋2, 秋葉仁美2, 清水忠3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 512-512, 2023. |
|---|
|
|
3-7-O02-3. Investigation of the effect that combination of the steroid in patients with rheumatoid arthritis gives for a change of the molecular target medicine 中川千拓1, 太田涼介2, 平田敦士2, 宇野貴哉1, 横山聡1, 細見光一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 513-513, 2023. |
|---|
|
|
3-7-O02-4. Comparison of patient backgrounds in clinical trials and real-world clinical practice of Sacubitril/Valsartan 伊東愛理, 門口直仁, 公文登代, 段松雅弘, 田中聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 514-514, 2023. |
|---|
|
|
3-7-O02-5. Do the discharge prescription days and the consultation out of the reservation affect the prognosis in the patients with heart failure? 林太祐1, 久保田芳明2, 岩出佳樹1, 西野拓也3, 橘貴大2, 渡邉将央2, 松田淳也2, 加藤活人4, 太良修平2, 時田祐吉2, 宮地秀樹2, 伊勢雄也1, 岩崎雄樹2, 浅井邦也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 515-515, 2023. |
|---|
|
|
3-7-O03-1. Precaution - of examination - dose setting about the proper use intervention of direct action type oral anticoagulant drug (DOAC) in the heart failure inpatient 菅原拓也, 荒井潤, 関口徳志, 田中沙織, 岡田美桜, 松田圭一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 517-517, 2023. |
|---|
|
|
3-7-O03-2. Look at the rear about the patients with pharmacist disadvantage who had it after the prescription intervention; a mark investigation 西牟田昇吾, 村上翔梧, 的場麻知子, 佐古守人, 黒沢秀夫, 野村剛久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 518-518, 2023. |
|---|
|
|
3-7-O03-3. Prospective study about medicine, the discontinuation support decreasing by it of the benzodiazepine receptor agonist which we performed as part of a ward activity 齊藤伸, 吹谷真紀子, 木元健寛, 瀬戸亘, 鈴木ひとみ, 仙葉悠紀, 齋藤香織, 篠田和人, 山崎恵葉, 金美紀, 一関美江子, 八代佳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 519-519, 2023. |
|---|
|
|
3-7-O03-4. The evaluation of pharmacist-led polypharmacy measures and future problem 白戸信行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 520-520, 2023. |
|---|
|
|
3-7-O03-5. Efforts of the heart failure medical treatment instruction person in the revision of the use of morphine manual 藤堂朱香1, 磯谷彰宏2, 大峠敬洋3, 武下千朝3, 町田聖治1, 入江利行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 521-521, 2023. |
|---|
|
|
3-7-O04-1. About contribution to improvement in prescription rate of the osteoporosis therapeutic drug by the secondary bone fracture prevention team 岩城慎平, 山崎彬史, 松岡勇作, 奥野昌宏, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 523-523, 2023. |
|---|
|
|
3-7-O04-2. Examination about the current situation and osteoporosis treatment of patients admitted to the elderly people bone fracture center of our hospital 野口直子, 植田緑, 竹本契史, 延藤勇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 524-524, 2023. |
|---|
|
|
3-7-O04-3. Examination about an evaluation rate of the prescription suggestion in ward drug duties and the improvement of the quality 志田幸平, 菅原拓也, 有川真理, 五十嵐綾乃, 松田圭一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 525-525, 2023. |
|---|
|
|
3-7-O04-4. The need of the pharmacy care for patients with neuromuscular disease intractable disease 山形真一1, 鈴木寛人2,6, 敦賀叶女3, 阿部香澄3, 渡嘉敷崇4, 津曲恭一5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 526-526, 2023. |
|---|
|
|
3-7-O04-5. Medication adherence and a character trait and association with the decision-making tangle 宮崎元康1,2, 高木聡子1, 三崎桃子1, 森由夏子1, 戸倉歌緒子1, 平田ひとみ1, 佐藤夏季3, 岡島義4, 柳田温子4, 中島章雄1,2, 今給黎修1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 527-527, 2023. |
|---|
|
|
3-7-O05-1. Effect of the efforts for the acquisition of the drug global assessment adjustment addition by the intensive care unit permanent residence pharmacist 大塚晋也, 林隼輔, 関根綾子, 長塚さおり, 長谷川英雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 529-529, 2023. |
|---|
|
|
3-7-O05-2. Questionary survey for the emergency visit attending nurse about the pharmacist duties in the emergency visit 立石裕樹1, 齋藤靖弘2, 宮田祐一3, 坂口結斗4, 山本浩二郎5, 武田瑛司6, 岩崎睦3, 宮崎雄二7, 前川大輔8, 吉川眞維樹9, 竹内陽亮10, 矢野洋平1, 後藤貴央1, 宮津大輔1, 渡邊裕之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 530-530, 2023. |
|---|
|
|
3-7-O05-3. Comparison of patients with acute drug intoxication with the nonprescription drug before and after the COVID-19 outbreak 廣瀬正幸1, 平川昭彦2, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 531-531, 2023. |
|---|
|
|
3-7-O05-4. The introduction of the Andexanet alpha administration protocol aiming at operation by the multi-type of job cooperation and the evaluation 加藤公人1, 西川嘉広1, 河村理沙1, 小出哲朗1, 渡辺俊文2, 早川武司3, 濱田和秀4, 伊藤久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 532-532, 2023. |
|---|
|
|
3-7-O05-5. It is efforts of our hospital for the standardization of the dilution magnification in drugs to use in an intensive care domain 西川嘉広1, 今西義紀1, 河村理沙1, 加藤公人1, 早川武司2, 山田典一2, 大村崇3, 宮原ひろみ4, 濱田和秀5, 湯浅右人6, 伊藤久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 533-533, 2023. |
|---|
|
|
3-7-O06-1. Efforts and evaluation for the perioperative drug control addition calculation 森脇典弘, 神崎愛, 清水星香, 佐々木史香, 池内忠宏, 兼重晋, 神村英利 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 535-535, 2023. |
|---|
|
|
3-7-O06-2. The operational construction of perioperative drug control duties and the evaluation 田中里奈, 鈴木寿樹, 松浦正樹, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 536-536, 2023. |
|---|
|
|
3-7-O06-3. Effect of the non-pharmacist placement to the surgery region to give it at the duties time of the exclusive duty pharmacist concerned with the perioperative drug control addition 本木絵梨奈, 岩間創, 岩下わかな, 坂上進, 堀口香織, 中内佳奈, 松澤菜津子, 太田早紀, 竹澤崇, 土屋広行, 内藤隆文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 537-537, 2023. |
|---|
|
|
3-7-O06-4. Investigation of the factor associated with response rate and nausea post-operative, vomiting of ondansetron in the gynecologic surgery, operation under laparoscopy, cholecystectomy patients 仲宗根千佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 538-538, 2023. |
|---|
|
|
3-7-O06-5. The effectiveness of ondansetron for postoperative retching, vomiting poor at general anesthesia 村井陽一1, 天野杏南1, 渕上翔太1, 水谷早希2, 棚橋順治2, 木全司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 539-539, 2023. |
|---|
|
|
3-7-O06-6. Examination of the effectiveness of granisetron and droperidol for postoperative retching, vomiting of the gynecologic surgery 中川義浩1, 桑村恒夫1, 原田智子1, 武田なつか1, 杉山和英2, 園田豪之介3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 540-540, 2023. |
|---|
|
|
3-8-O07-1. Cost-effectiveness of nirmatrelvir/ritonavir in outpatient treatment of COVID-19 patients 水野貴仁, 近藤有, 酒井幹康, 小嶋亮太, 實安健市, 三宅芳男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 542-542, 2023. |
|---|
|
|
3-8-O07-2. Relationship between side effects of nirmatrelvir/ritonavir and patient background 杉田裕貴1,2, 長谷香織1, 小林奈央1, 楠本真子1, 近藤佳奈子1,2, 小田怜1,2, 瀬戸崇光1,2, 吉井直子2,3, 西島正剛2,3, 松村友和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 543-543, 2023. |
|---|
|
|
3-8-O07-3. Evaluation of drug interaction management of nirmatrelvir/ritonavir tablets by pharmacists 渡部紘三, 林豊, 加藤純 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 544-544, 2023. |
|---|
|
|
3-8-O07-4. Study on the effectiveness of pregnancy risk minimization program for outpatients prescribed molnupiravir 池澤直樹, 新井達也, 小川直紀, 大野悠, 谷古宇修平, 佐藤渚, 出雲貴文, 小茂田昌代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 545-545, 2023. |
|---|
|
|
3-8-O07-5. Drug interactions management - utilizing cooperation - PBPM of a physician, hospital pharmacist, the drugstore pharmacist in the COVID-19 ambulatory practice 小林真也1, 米田和夫1, 田村克也1, 福家麻美1, 原伸行2, 高根沢暢己2, 佐藤智恵美2, 阿部真治2, 松浦大輔3, 近藤彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 546-546, 2023. |
|---|
|
|
3-8-O08-1. Safety assessment of the rem decibuilding in patients with COVID-19 infection with the impaired renal function 村瀬大翔1,2, 段林正明3, 山田正実1, 村木優一4, 高橋一栄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 548-548, 2023. |
|---|
|
|
3-8-O08-2. Observational study of a rem decibuilding and the antimicrobial combination use actual situation in the COVID-19 inpatient 風間彩1, 村山彩1, 大穂祐介1, 福田哲也1, 益田博司2, 船木孝則3, 中村知夫2, 大宜見力3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 549-549, 2023. |
|---|
|
|
3-8-O08-3. Pharmacist duties in the ward for exclusive use of the new coronavirus infection in the middle scale hospital 井上大奨, 橋本崇広, 野口亜希子, 小薮真紀子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 550-550, 2023. |
|---|
|
|
3-8-O08-4. One patient who conducted insulin instruction for patients with COVID-19 gestational diabetes using Web meeting service Zoom 高橋怜史1, 増尾昌則1, 内藤裕次2, 三澤晴雄2, 河崎さつき2, 仲鉢英夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 551-551, 2023. |
|---|
|
|
3-8-O08-5. Thought for the influenza vaccine, comparison between COVID-19 vaccine and impression by the social media analysis using the text mining 森喜郎1,2, 宮武伸行2, 鈴木裕美2, 森裕香3, 岡田節雄1, 谷本清隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 552-552, 2023. |
|---|
|
|
3-8-O09-1. Examination about the usefulness of PBPM for the hypomagnesemia by the panitumumab 小中健1,2, 斉藤辰彦1,2, 森本美由樹2,3, 渡邉貴紀4, 都築大輔1,2, 伏谷秀治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 554-554, 2023. |
|---|
|
|
3-8-O09-3. Evaluation of frequency and the risk factor of the extravasation by the docetaxel using the large-scale insurance claim information 柳澤里奈, 豕瀬諒, 後藤良太, 村木優一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 556-556, 2023. |
|---|
|
|
3-8-O09-4. Study on tendency to anticancer medicine-induced arrhythmic expression using the large-scale side effect database 渡部真由1, 奥中真白1,2, 植沢芳広2, 加納大輔1, 川澄賢司1, 渋谷悠真1, 川崎敏克1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 557-557, 2023. |
|---|
|
|
3-8-O09-5. It is a single institution observational study about the association of a surgical site and the onset in patients who received adjuvant chemotherapy of diarrhea after the colon cancer technique using the capecitabine 掛谷雅之1, 諸角一成2, 原賢康3, 三井章3, 佐藤由美子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 558-558, 2023. |
|---|
|
|
3-8-O10-1. 1 case that caused a lower digestive tract during the chemoradiotherapy enforcement in head and neck cancer 佐藤朗, 佐藤紀宏, 前川正充, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 560-560, 2023. |
|---|
|
|
3-8-O10-2. We look at the estrangement of the dose at Carboplatin enforcement in the Osaka City comprehensive medical care center and the rear for the relationship of the adverse event and search for a mark 石坂崚1,2, 藤本亜弓2, 山崎直樹2, 中尾將彦2, 森宏幸2, 土井克彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 561-561, 2023. |
|---|
|
|
3-8-O10-3. A case which developed steroid-resistant erythema multiforme severe by the Pembrolizumab 清水克次1, 角川幸男1, 竹田健志1, 糀谷嘉起2, 大塚倫之2, 菊澤千秋3, 爲政大幾3, 工藤敏啓2, 高木麻里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 562-562, 2023. |
|---|
|
|
3-8-O10-4. Intervention effect on patients with head and neck cancer - multicenter prospective cohort study - by the hospital pharmacist for oral mucositis measures receiving chemoradiotherapy 吉田謙介1, 渡邉真一2, 星野直人1, 朴慶純3, 飛鷹範明4, 金野昇5, 中井昌紀4, 安藤智七美5, 矢吹剛6, 鈴木直人1, 勝良剛詞7, 冨原圭8, 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 563-563, 2023. |
|---|
|
|
3-8-O10-5. One case that was able to contribute to a diagnosis of the irAE hypoadrenalism by the Pembrolizumab by pharmacist intervention, but suffered from treatment 高木明子, 高本裕子, 津田優里香, 牛丸星, 古川莉彩, 正木拓也, 長島裕樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 564-564, 2023. |
|---|
|
|
3-8-O11-1. Real-world clinical survey of adverse events in PRRT (peptide receptor radionuclide therapy) using lutetium oxodotreotide (177Lu) 黒岩勇人1, 上田綾佳1, 眞継賢一1, 河本泉2, 多代尚広2, 柳原一広3, 板垣康4, 岡田務5, 服部悦子6, 高井剛7, 濱口良彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 566-566, 2023. |
|---|
|
|
3-8-O11-2. Search of patient factors affecting the onset of the antiEGFR antibody medicine-induced dermatopathy 内山数貴1, 齋藤佳敬1,2, 武隈洋1, 小松嘉人3, 菅原満1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 567-567, 2023. |
|---|
|
|
3-8-O11-3. The anamorelin improves the nutritional status of patients with metastatic urothelium cancer during chemotherapy 小田切州広1, 内木拓2, 杉山洋介1,3, 田崎慶彦1,3, 三村佳久1,3, 飯田萌子1,3, 木村優花3, 伊藤菜浪3, 堀田祐志1,3, 安井孝周2, 日比陽子1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 568-568, 2023. |
|---|
|
|
3-8-O11-4. Fact-finding of the high blood pressure, heart disorder in the Isa-Kd therapy 粂哲雄1, 村田志帆1, 原田翔平1, 徳武和馬1, 深谷真史2, 吉嗣加奈子2, 式郁恵2, 榎並輝和2, 篠道弘1, 池田宇次2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 569-569, 2023. |
|---|
|
|
3-8-O11-5. Protective efficacy of the infusion reaction of the trastuzumab with the dexamethasone pre-medication 後藤愛実1,2,3, 畑武生1, 細見誠1,3, 畑智恵子1, 西原雅美1, 根尾昌志1, 岩本充彦4, 木村光誠4, 後藤昌弘3, 力武良行2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 570-570, 2023. |
|---|
|
|
3-8-O12-1. Analysis ... of the drug interaction using effect - adverse drug reaction database (JADER) of the concomitant drug giving it to the QT prolonged with the tyrosine kinase inhibitor 槙原克也, 基村佳世, 福井梨乃, 木本大樹, 沖礼子, 松村友和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 572-572, 2023. |
|---|
|
|
3-8-O12-2. The thrombosis onset situation investigation in patients receiving VEGF inhibitor 森川記道, 福長豊己, 西倉教子, 高橋恭平, 大山展弘, 横山匠太, 安原昌宏, 滝雪歩, 原田靖子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 573-573, 2023. |
|---|
|
|
3-8-O12-3. Examination of the risk factor to be involved in side effect of Osimertinib aggravation 元日田阿子1, 中澤佑介1, 内海裕文2, 荒屋潤2, 川久保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 574-574, 2023. |
|---|
|
|
3-8-O12-4. 1 case that the coinfusion administration of butylscopolamine note was effective for stomachache at the irinotecan administration 板倉祥嗣1,2, 苅田明子1, 藤原恵2, 高橋佳孝1, 島田明日香1, 松岡彩友美2, 山本沙織2, 小森桂子1, 土谷有美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 575-575, 2023. |
|---|
|
|
3-8-O12-5. Evaluation of frequency of the thromboembolism in patients receiving immune checkpoint inhibitor and the risk factor 井出貴之1, 荒木太亮2, 内藤隆文1, 小泉知展3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 576-576, 2023. |
|---|
|
|
3-9-O13-1. Construction of the supply situation contact system of the in-hospital adoption medicine which cooperated, and utilized DSJP (ethical drug supply situation database) and SAFE-DI (drug information offer site) 櫻田穣, 中嶋紘文, 坂田幸雄, 長浜谷耕司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 578-578, 2023. |
|---|
|
|
3-9-O13-2. AI chat bot integration type drug information platform architectural efforts aiming at new reporting - medical care person, pharmaceutical company cooperation 前川正充1, 佐藤紀宏1, 丹羽覚浩2, 蓮見修2, 神崎浩孝2, 小川竜一3, メイジャー真知子3, 上林彩3, 鈴木利享3, 山本誠3, 前川麻央1, 五十嵐敏明1, 松浦正樹1, 大津真理3, 木村隆夫2, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 579-579, 2023. |
|---|
|
|
3-9-O13-3. An investigation and proof experiments such as the drug information database application, and the like of the non-pharmacist common use 鈴木高弘1, 氣賀澤郁1, 寺内恭平2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 580-580, 2023. |
|---|
|
|
3-9-O13-4. A passage-related evaluation to affect the drug transluminal administration to neonates and examination of the remedy 岡野真澄美1, 小森智也1, 小池博文1, 佐橋幸子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 581-581, 2023. |
|---|
|
|
3-9-O13-5. The deletion situation investigation of the package insert of the before course measures time limit PMDA publication to be able to put 山中理1, 山村篤史2, 早川太朗2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 582-582, 2023. |
|---|
|
|
3-9-O14-1. Examination about the administration of theophylline adequacy in elderly people: Approach based on a large-scale database and the Pharmacometrics 岡田章1,2, 世良庄司1,2, 田口真穂3, 山田博章3, 永井尚美1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 584-584, 2023. |
|---|
|
|
3-9-O14-2. Association between urine sugar and uric acid level before and after the SGLT2 inhibitor remedy in patients with type 2 diabetes 田中侑希1,2, 太田涼介2, 平田士2, 横山聡1, 宇野貴哉1, 細見光一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 585-585, 2023. |
|---|
|
|
3-9-O14-3. A tendency to onset of diabetes-related adverse event with the non-fixed form antipsychotics in patients with dementia: Analysis using JADER 羽渕風雅1, 石田奈津子2, 柏宗伸2, 石崎純子2, 松下良2, 菅幸生2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 586-586, 2023. |
|---|
|
|
3-9-O14-4. Prediction of the transluminal administration advisability by the simple suspension method using the machine learning 友田吉則, 小林昌宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 587-587, 2023. |
|---|
|
|
3-9-O14-5. Application of spontaneous report database aiming at an effective evaluation to the long-term survival of the pulmonary artery-related pulmonary hypertension therapeutic drug 鈴木光路, 八木達也, 川上純一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 588-588, 2023. |
|---|
|
|
3-9-O15-1. Effect by the addition of the thickness adjustment food on vancomycin hydrochloride sprinkling solution 小見暁子1, 秋山滋男2, 石岡大成3, 野澤彰4, 土井信幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 590-590, 2023. |
|---|
|
|
3-9-O15-2. The effect that educational intervention gives to patients prognosis on loading dose of vancomycin based on Antimicrobial Stewardship Program 朝居祐貴1, 小西知美1, 武田紗和1, 近澤香織2, 井端英憲3, 高橋昌明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 591-591, 2023. |
|---|
|
|
3-9-O15-3. The effectiveness of the arbekacin for the childhood febrile neutropenia and safe examination 寺川央一1, 中馬真幸1, 都築仁美1, 寒藤雅俊1, 吉田祐花1, 上杉紘一1, 眞鍋貴行1,2, 神山直也1,2, 岩山訓典1,3, 山本譲1, 田崎嘉一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 592-592, 2023. |
|---|
|
|
3-9-O15-4. About the relations of aim Time Above MIC achievement quotient and the clinical response of the meropenem in patients with Pseudomonas aeruginosa bacteremia 中島一1, 桑村恒夫2, 芳賀由美3, 宮崎美穂1, 高木祐真1, 小倉秀美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 593-593, 2023. |
|---|
|
|
3-9-O15-5. Efforts and antimicrobial consumption change for proper use promotion of the third generation oral cephalosporin medicine 村山彩1, 風間彩1, 福田哲也1, 大穂祐介1, 庄司健介2, 大宜見力2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 594-594, 2023. |
|---|
|
|
3-9-O16-1. Multifaceted intervention to empiric treatment of the working full time pharmacist-led intravenous antimicrobial in the small municipal hospital 佐々木康弘1, 山口明子2, 梅原亜佑美3, 田頭保彰4, 矢野雅隆5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 596-596, 2023. |
|---|
|
|
3-9-O16-2. The effect that feedback using J-SIPHE gives for proper use of the carbapenem-based medicine 大池恵生1, 渡邊崇平2, 杉村聡2, 高岡龍蔵2, 田中孝正1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 597-597, 2023. |
|---|
|
|
3-9-O16-3. Efforts and result for the drug-resistant (AMR) measures action plan accomplishment of the fluoroquinolone antibacterial 吉村昌紘1, 加藤一雲1, 坂野昌志1, 杉浦茂樹1, 竹内章2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 598-598, 2023. |
|---|
|
|
3-9-O16-4. The effectiveness of the cefmetazole for the large intestine diverticulitis without complications 星野祐太1, 伊藤亮太1, 菊地未由1, 高橋賢一2, 内山弘子1, 外岡久和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 599-599, 2023. |
|---|
|
|
3-9-O16-5. Effective and safe examination - cefepime of the intravenous antimicrobial for the febrile neutropenia vs. tazobactam piperacillin vs. meropenem ... 木原星衣, 湯川真里, 加藤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 600-600, 2023. |
|---|
|
|
3-9-O17-1. Pulmonary suppuration by Achromobacter xylosoxidans where chronic administration of Sulfamethoxazole/trimethoprim was successful 柏原道志1, 本田勝亮1, 光定健太2, 長岡翔1, 堤克成1, 塩田亮介1, 石野清亮1, 土手尚2, 渥美生弘2, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 602-602, 2023. |
|---|
|
|
3-9-O17-2. The effect that the introduction of the examination of nucleic acid amplification in patients with Clostridioides difficile infection gives for clinical prognosis 山田楊太1,3, 宮崎元康1,3, 串間尚子2,3, 中島章雄1, 小川新1,3, 石井寛1,3, 今給黎修1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 603-603, 2023. |
|---|
|
|
3-9-O17-3. The effect that a meropenem supply stop gave for treatment of the Enterobacter genus 長谷川浩司, 山田真人, 宮崎祐介, 岩本里味 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 604-604, 2023. |
|---|
|
|
3-9-O17-4. Choice of the therapeutic drug for Daptomycin non-sensitivity Staphylococcus capitis subspecies urealyticus isolated from chronic osteomyelitis 西出(山田)景子1,2, 畑中公基3, 武田明4, 木戸裕勝5, 佐川美恵5, 吉川誠一5, 小野伸高5,6, 荒川宜親7,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 605-605, 2023. |
|---|
|
|
3-9-O17-5. Examination of the use of aztreonam case in our hospital 吉田博昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 606-606, 2023. |
|---|
|
|
3-9-O18-1. Examination of the domestic long-term storage condition of the histidine copper hospital preparation which is a Menkes disease therapeutic drug 上野裕大1, 眞鍋貴行1,2, 新田悠一朗1, 岩山訓典1,3, 神山直也1,2, 小野尚志1, 山本譲1, 中馬真幸1, 田崎嘉一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 608-608, 2023. |
|---|
|
|
3-9-O18-2. Development of the clinical preparation which pointed to light stability improvement of Sugammadex 阿部雅也1, 内田淳2, 山田幸平1, 佐藤秀行1, 尾上誠良1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 609-609, 2023. |
|---|
|
|
3-9-O18-3. Development and evaluation - of efforts - hospital preparation, the selenium private business FAST-DISINTEGRATING TABLET for the improvement in quality of life of patients with selenium deficiency 赤垣恵太1, 田村尚久1,2, 石田智滉1, 白石久1, 加賀屋陽子1, 門田亜紀1, 山本雅樹3, 森田靖代1, 常風興平1, 藤枝幹也3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 610-610, 2023. |
|---|
|
|
3-9-O18-4. Control ... of the drug absorption speed by basic examination - dosage form to assume a nasal agent the substitute preparation of the oral formulation 古林呂之1, 田中晶子1, 藏屋幸輝1, 岩永一範2, 坂根稔康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 611-611, 2023. |
|---|
|
|
3-9-O18-5. The effect that a combination of eyedropper and medicinal solution of suspensibility eye drops gives in redispersibility 小畑友紀雄1, 出口粧央里2, 吉富丈治2, 浦嶋庸子1, 小堀宅郎1, 細見光一2, 長井紀章2, 中田雄一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 612-612, 2023. |
|---|
|
|
3-10-O19-1. Examination of the skin absorption factor of the forerunner, the generic medicine of the indometacin liniment 寺山和利1, 奥平倫世1, 渡部多真紀1,2, 久保田篤司1, 土屋雅勇2, 安野伸浩1,2, 渡辺茂和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 614-614, 2023. |
|---|
|
|
3-10-O19-2. Examination about the economic effect by the Biosimilar introduction in our hospital 後藤隆, 久松大祐, 石橋由佳, 高野豪, 衛藤智章, 藤田強記, 清水裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 615-615, 2023. |
|---|
|
|
3-10-O19-3. Examination of the evaluation using the use amount ratio of the Biosimilar introduction effect 橋本美紀恵, 九良賀野司, 高木昭佳, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 616-616, 2023. |
|---|
|
|
3-10-O19-4. One case with suspected allergy of the biofollowing article of the trastuzumab 松由幸司1, 近藤章吾1, 曽根章貴1, 高澤圭輔1, 安田翔1, 生駒辰夫1, 宮部芳之1, 大野元嗣2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 617-617, 2023. |
|---|
|
|
3-10-O19-5. Therapeutic safe comparison between precedent biomedicine and biofollowing article of the bevacizumab 小原直紘1, 関本裕美2,3, 本田芳久2,4, 土井敏行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 618-618, 2023. |
|---|
|
|
3-10-O20-1. Does the presence or absence of discontinuation before SGLT2 inhibitor technique influence perioperative care of the pancreatectomy case? Single institution past starting point cohort study 吉川和美, 土手賢史, 漣航平, 仲原隆史, 松尾基樹, 小林由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 620-620, 2023. |
|---|
|
|
3-10-O20-2. The diabetes medical therapy that is optimal for an individual 富岡節子1, 山崎直毅2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 621-621, 2023. |
|---|
|
|
3-10-O20-3. The effect that the complexity of prescription contents gives for achievement of hemoglobin A1c target value of patients with type 2 diabetes 丸山慧, 茂木孝弘, 木村直也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 622-622, 2023. |
|---|
|
|
3-10-O20-4. One case with suspected drug-related hypoglycemia by the paliperidone 中島璃沙, 奥美和, 谷口一成 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 623-623, 2023. |
|---|
|
|
3-10-O20-5. One patient whom normoglycemia diabetic ketoacidosis developed in in start two days of the ipragliflozin 佐古守人, 美甘早紀, 西口真代, 黒沢秀夫, 野村剛久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 624-624, 2023. |
|---|
|
|
3-10-O21-1. Examination of the risk factor of nausea post-operative vomiting in patients who underwent thoracoscopic esophagectomy 村岡健太1,2,4, 里美貴3, 米澤龍4, 栗原竜也5, 樋口慧6,7, 向後麻里3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 626-626, 2023. |
|---|
|
|
3-10-O21-2. Identification of the factor predicting the onset of the antipsychotics-induced weight gain 石川修平1, 橋本直樹2, 大久保亮3, 久住一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 627-627, 2023. |
|---|
|
|
3-10-O21-3. The renin-angiotensin system inhibition medicine inhibits the onset of diabetic peripheral neuropathy: Inspection in a retrospective cohort study and the fundamental researches at 3 hospitals 岩根詩織1,2, 根本亙3, 宮本朋佳2,4, 林友典5, 田中雅幸1, 打谷和記1, 小泉祐一6, 平田敦士5, 坪田真帆2, 関口富美子2, 丹野孝一3, 川畑篤史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 628-628, 2023. |
|---|
|
|
3-10-O21-4. Effect on vital prognosis of the factor which is not associated with the cardiac function in patients with acute decompensated heart failure 丸岡由奈1, 石田智滉1, 川田敬2,3, 濱田知幸4, 門田亜紀1, 森田靖代1, 福田仁5, 久保亨4, 常風興平1, 北岡裕章4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 629-629, 2023. |
|---|
|
|
3-10-O21-5. The effect that a pharmacist outpatient gives for the long-term clinical outcome of the antithrombotic drug remedy patients 栗村朋子1, 山本和宏1, 田中秀和2, 鳥羽敬義2, 木村丈司1, 土生康司3, 糸原光太郎1, 北廣優実1, 大村友博1, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 630-630, 2023. |
|---|
|
|
3-10-O22-1. Identification of the onset time of the excessive renal clearance in the seriously ill patients and duration and the associated factor 三上龍生1,2, 早川峰司3, 今井俊吾4, 菅原満1,2, 武隈洋2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 632-632, 2023. |
|---|
|
|
3-10-O22-2. An evaluation of eGFR slope in the proton pump inhibitor long-term use patients: Vertical section study using DPC Hospital data 室伏琢磨1,2, 八木達也2, 田中達也2, 辻大樹1, 伊藤邦彦1, 川上純一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 633-633, 2023. |
|---|
|
|
3-10-O22-3. Examination of the effect that AUC of mycophenolic acid in renal-transplant recipients gives for side effect expression 佐伯友里1, 福澤翔太1, 鷲野友亮1, 南島拓矢1, 石田昇平2, 加藤真史2, 佐野優太2, 溝口博之1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 634-634, 2023. |
|---|
|
|
3-10-O22-4. Effect of the vonoprazan giving it to renal function after the radiation combination high dose cisplatin therapy enforcement 辻田彩1, 近藤優義2, 池村健治1, 山本智也1, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 635-635, 2023. |
|---|
|
|
3-10-O22-5. Diabetes aggravates cisplatin origin-related nephrotoxicity 坂本達彦1, 齋藤佳敬1, 武隈洋1, 小林正紀2, 岡本敬介1, 品川尚文3, 清水康4, 木下一郎4, 菅原満1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 636-636, 2023. |
|---|
|
|
3-10-O23-1. The effectiveness of the new antirheumatic drug by the network meta-analysis and safe comparison 大西真由, 劉臨風, 吉井優花, 安部賀央里, 頭金正博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 638-638, 2023. |
|---|
|
|
3-10-O23-2. The search of pharmacokinetics and the effect on central side effect factor of the mirogabalin: Observational, prospective study 濱口直美1, 岡本明大1, 平井利典1, 高橋梨恵1, 金田真吏2, 川口晃司2,3, 高尾仁二2, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 639-639, 2023. |
|---|
|
|
3-10-O23-3. The predictor analysis of the immune-mediated adverse event with the checkpoint inhibitor + platinum combination therapy for the non-small cell lung cancer of immunity: Multicenter study 藤本愛理1, 薮内由里香2, 甲斐達夫3, 小園亜希4, 松尾圭祐1, 永田祐子5, 桑原貴美子6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 640-640, 2023. |
|---|
|
|
3-10-O23-4. Hepatotoxic factor analysis in the acute phase of cerebral infarction and the transient cerebral ischemic attack 安高勇気1,2, 藤岡伸助3, 坪井義夫3, 大藪康平1,2, 芝口浩智2, 神村英利1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 641-641, 2023. |
|---|
|
|
3-10-O23-5. Analysis of the risk factor having the asymptomatic bacteriuria onset in patients receiving SGLT2 inhibitor 伊藤亮太1, 渡邊卓嗣2, 星野祐太1, 菊地未由1, 内山弘子1, 外岡久和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 642-642, 2023. |
|---|
|
|
3-10-O24-1. Investigation of factors involved in the development of CMV infection under letermovir prophylaxis 岩男聖弥, 白岩健, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 644-644, 2023. |
|---|
|
|
3-10-O24-2. Study on tazobactam/piperacillin using an adverse event spontaneous report database and the medical record and factor of the onset of liver damage with the meropenem 白石ちひろ1, 加藤秀雄1, 小椋透3, 今井寛2, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 645-645, 2023. |
|---|
|
|
3-10-O24-3. Systematic review for effective antimicrobial choices for the childhood Clostridioides difficile infection, meta analysis 三原貴之1, 田代渉1, 大川力也1, 田中葉子1, 佐村優1,2, 榎木裕紀1, 田口和明1, 松元一明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 646-646, 2023. |
|---|
|
|
3-10-O24-4. PK/PD analysis of ganciclovir in patients with congenital cytomegalovirus infection 糸原光太郎1, 藤中俊輔1, 山本和宏1, 橋本真梨1, 田村直暉1, 北廣優実1, 大村友博1, 藤岡一路2, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 647-647, 2023. |
|---|
|
|
3-10-O24-5. Population pharmacokinetics analysis of vancomycin for neonates and anticipatory comparison with the existing model 赤間田悠刀1, 小松敏彰1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 648-648, 2023. |
|---|
|
|
3-11-O25-1. Efforts of the pharmacist to Clozapine introduction 栗原梢, 瀧祐介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 650-650, 2023. |
|---|
|
|
3-11-O25-2. 1 case that treatment-resistant schizophrenia became stable by blood level adjustment of the lithium carbonate under the Clozapine combination 松原寛子, 竹田馨, 高木昭佳, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 651-651, 2023. |
|---|
|
|
3-11-O25-3. Inspection of the pharmacist intervention in the Clozapine TDM 藤江直輝, 青木涼, 原田学, 下村好子, 四方佳美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 652-652, 2023. |
|---|
|
|
3-11-O25-4. Evaluation about the blood level when we gave lamotrigine to patients with bipolar disorder at a dose according to a package insert 坪内清貴1, 金俊孝1, 磯田和也1, 嶋田努1, 内藤暢茂2, 菊知充3, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 653-653, 2023. |
|---|
|
|
3-11-O25-5. We evaluate the effectiveness for the delirium prevention after the stroke of the melatonin receptor agonist in elderly people and the orexin receptor blocker 三好由希子1, 重面雄紀1, 平大樹1, 眞木崇州2, 杉田尚子3, 川島啓嗣3, 須賀原教子4, 平井真智子1, 圓東寛基1, 川田将義1, 北田徳昭1, 中川俊作1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 654-654, 2023. |
|---|
|
|
3-11-O26-1. Sleeplessness and the effect factor (interim report) in middle elderly patients 野田久美子1, 工藤雅史1, 椋本啓介1, 馬場一秀1, 川口啓之1, 横浜吏郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 656-656, 2023. |
|---|
|
|
3-11-O26-2. The effect that the efforts of the delirium measures team led by the pharmacist gave for sleep-related prescription and fall 大森俊和, 米内洸, 臼田昌弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 657-657, 2023. |
|---|
|
|
3-11-O26-3. Change of efforts and the prescription trend to sleeping drug proper use by the multi-type of job cooperation in the Chuo, Asahi, Yokohama General Hospital 高橋照明, 小串興平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 658-658, 2023. |
|---|
|
|
3-11-O26-4. Correspondence and effect on patients investigation accompanied with the supply stop of biperiden tablets 中山洋輔1, 福石和久1, 渡辺健二1, 石井秀明1, 古賀亮次1, 岡辰也1, 藤瀬陽子2, 糸永侑華3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 659-659, 2023. |
|---|
|
|
3-11-O26-5. The relation to dementia, the delirium patients through dementia care team (DCT) and the evaluation 佐藤史織1,2, 橋本晴香1,2, 田原良一2,3, 森永克彦2,4, 陸丸幹男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 660-660, 2023. |
|---|
|
|
3-11-O27-1. The use history of the immune checkpoint inhibitor is association of the interstitial pneumonia of EGFR-TKI: Matched-pair cohort analysis using the national inpatient database 祝千佳子1, 城大祐2,3, 小西孝明1, 藤田あさひ4, 道端伸明2, 松居宏樹1, 康永秀生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 662-662, 2023. |
|---|
|
|
3-11-O27-2. Onset of hypothyroidism prediction by the Pembrolizumab using the neutrophilic/lymphocytes ratio 中澤佑介1, 元日田阿子1, 渡部可奈子1, 内海裕文2, 荒屋潤2, 川久保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 663-663, 2023. |
|---|
|
|
3-11-O27-3. Look at the rear about the oxaliplatin-induced peripheral neuropathy protective efficacy by the proton pump inhibitor combination; mark clinical studies 峯圭佑1,2, 川尻雄大1, 小林大介1, 森皓平1, 江頭伸昭3,4, 小柳悟2, 大戸茂弘2, 家入一郎3, 島添隆雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 664-664, 2023. |
|---|
|
|
3-11-O27-4. The low four extremities skeletal muscle mass index before the treatment is a risk factor of the febrile neutropenia with the DCF therapy 奈良克彦1, 山本武人1, 佐藤靖祥2, 八木浩一2, 瀬戸泰之2, 高田龍平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 665-665, 2023. |
|---|
|
|
3-11-O27-5. Examination about the expression of the infusion reaction at the antihistamine non-administration in the ramucirumab + nab-paclitaxel therapy 前田太一1, 根來寛2, 五十嵐弘幸3, 重森美奈2, 田中敏博2, 伊藤幸男3, 谷澤範彦1, 西川翔太1, 小川純也1, 上谷幸男2, 渡邉享平4, 塚本仁2, 後藤伸之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 666-666, 2023. |
|---|
|
|
3-11-O28-1. Risk assessment of the HBV reactivation in the cancer chemotherapy of the HBV history infection patients: Clinical significance of HBc antibody titers 大久保真貴1, 勝山繁佳1, 土岐浩介1, 鈴木嘉治1, 瀬尾恵美子2, 関根郁夫3, 本間真人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 668-668, 2023. |
|---|
|
|
3-11-O28-2. Improvement of the cancer cachexia with the anamorelin administration and participation in neutrophilic/lymphocytes ratio 渡部可奈子1, 中澤佑介1, 元日田阿子1, 宇和川匡2, 川久保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 669-669, 2023. |
|---|
|
|
3-11-O28-3. Examination of the side effect of difference frequency of the quantity of hydromorphone introduction 加藤涼子1,8, 高岡龍蔵2,8, 小園友明1,8, 立花京香3,8, 鳥居昌太4,8, 吉田加代3,8, 越野明花3,8, 長戸大空3,8, 齋藤旭美4,8, 後藤健志5,8, 遠山幸男2,8, 築山郁人6,8, 宮崎雅之7,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 670-670, 2023. |
|---|
|
|
3-11-O28-4. Elucidation of the phenytoin pharmacokinetics change factor at the ketogenic diet therapy for intractable epilepsy 赤下学1,2, 宮川雄一1, 橋本美紀恵3, 中谷絵理子2, 黄倉崇2, 嶋田努1, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 671-671, 2023. |
|---|
|
|
3-11-O28-5. It is predicted analgesic effect and the respiratory depression effect after the pediatric operation by pentazocine pharmacokinetics/pharmacodynamic model 大森崇行1, 青山隆彦2, 松本宜明2, 辻泰弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 672-672, 2023. |
|---|
|
|
3-11-O29-1. A large quantity of ascites in patients with gastrointestinal carcinoma reduces blood level of the ramucirumab 金子卓也1, 土岐浩介1,2, 山田武史3, 山本祥之3, 森脇俊和3, 鈴木嘉治1,2, 本間真人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 674-674, 2023. |
|---|
|
|
3-11-O29-2. Pharmacokinetic/genome pharmacologic analysis of tramadol in the hepatectomy patients 北川優香1,2,3,4,5, 神谷貴樹2, 山田日向美1, 井手径子3, 上島智1,2, 平大樹1,2,4, 飯田洋也5, 角本幹夫1, 谷眞至5, 森田真也2, 寺田智祐2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 675-675, 2023. |
|---|
|
|
3-11-O29-3. Pharmacokinetics of the Clozapine in patients with Japanese childhood schizophrenia, an N-demethyl body, the N-oxide body 中村紗緒里1, 猪川和朗1, 浅野芽依1, 岡田瑞希1, 井村友哉1, 村田香奈恵1, 坂田睦2, 堀川直希2, 森川則文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 676-676, 2023. |
|---|
|
|
3-11-O29-4. The effect that the change of the triglyceride level gives to the early period of administration and blood steady-state amiodarone levels 高橋諒多, 辻本高志, 加納宏樹, 川本由加里, 後藤仁和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 677-677, 2023. |
|---|
|
|
3-11-O29-5. Blood level change of tacrolimus after switching from itraconazole private business liquid to an itraconazole capsule 正木寛1, 宮田大資1, 川島光明2, 此枝千尋2, 佐藤雅昭2, 高田龍平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 678-678, 2023. |
|---|
|
|
3-11-O30-1. Evaluation ... of the usefulness to result in simultaneous measurement - plasma concentration analysis and the TDM of the Clozapine in patients with schizophrenia, an N-demethyl body, the N-oxide body 井村友哉1, 猪川和朗1, 浅野芽依1, 岡田瑞希1, 中村紗緒里1, 村田香奈恵1, 坂田睦2, 堀川直希2, 森川則文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 680-680, 2023. |
|---|
|
|
3-11-O30-2. Genetic polymorphism and effect of the cachectic progress to give to blood naldemedine concentrations and bowel movement effect at the cancer condition of a patient 中津川瑛美1, 内藤隆文2, 柴田海斗2, 前川真人3, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 681-681, 2023. |
|---|
|
|
3-11-O30-3. Effect of the CYP2C19 genetic polymorphism on impaired renal function with lansoprazole 福井里佳1, 野田哲史1,3, 澤山裕一2, 中川義久2, 池田義人1, 森田真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 682-682, 2023. |
|---|
|
|
3-11-O30-4. Change of gastrointestinal absorption/excretion change of glucose through the transporter with metformin 荻さやか, 白坂善之, 竹村美由記, 玉井郁巳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 683-683, 2023. |
|---|
|
|
3-11-O30-5. Development of the eyelid application troxipide nanopreparation aiming at application to dry eye therapy 小坂太陽1, 渡辺彩花1, 板橋瑞稀1, 油納美和1, 大竹裕子1, 長井紀章1, 岡本紀夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 684-684, 2023. |
|---|
|
|
4-7-O31-1. About the questionary survey about the effect of the Saku General Hospital group "outside Parliament prescription inquiry simplification protocol" 堀内賢一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 686-686, 2023. |
|---|
|
|
4-7-O31-2. Periodical prescription input support ... by efforts - pharmacist for the duties burden reduction of the physician 永島久義, 大江敬太郎, 菅野晴香, 石井重亮, 吉田裕美, 星正弘, 須藤孝浩, 黒田純子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 687-687, 2023. |
|---|
|
|
4-7-O31-3. Examination about the usefulness of the prescription support using PBPM in the foreign chemotherapy room 竹本竜平1, 中村大学1, 菱谷まどか1, 大橋一輝1, 外海友規1,2, 手崎世織1, 竹本将士1, 朝岡みなみ1,2, 堀田祐志1,2, 近藤勝弘2,3, 日比陽子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 688-688, 2023. |
|---|
|
|
4-7-O31-4. Evaluation of task shift/share in the pharmacist outpatient specialized in a cancer utilizing the representation prescription order authority 今村牧夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 689-689, 2023. |
|---|
|
|
4-7-O31-5. Intervention ... of the pharmacist using efforts - clinical path for the secondary bone fracture prevention of patients with proximal thighbone bone fracture 瀬名波暢子1,2, 塚田加奈子1, 吉良俊彦1, 宇野百合香1, 門馬佳代子1, 辻井佳代1, 堤良祐2, 小林政彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 690-690, 2023. |
|---|
|
|
4-7-O32-1. Viewpoint of a specialty, the authorized pharmacist in the attitude survey of the hospital pharmacist about normal business routine, the career plan 坂本靖宜1, 川邊一寛1, 田中利樹2, 川邉桂1, 原広司3, 小池博文1, 佐橋幸子1, 後藤隆久4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 692-692, 2023. |
|---|
|
|
4-7-O32-2. Effect on task shifting and ward drug duties of the examination of vancomycin note (VCM) prescription order representation input by the AST pharmacist 高橋希1, 古川早矢香1, 河野綾香1, 鈴木信也1, 井口恵美子1, 渋江寧2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 693-693, 2023. |
|---|
|
|
4-7-O32-3. It is ... including an effect of the task shifting from evaluation ... physician from the type of job other than the drug control summary making at hospital transfer by the pharmacist 伊藤有美, 水野由紀子, 柴田大地, 滝本典夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 694-694, 2023. |
|---|
|
|
4-7-O32-4. Inspection of the effect in the current situation of the pharmaceutical intervention and the medical security on perioperative patients 小松沙希1, 齋藤豪1, 平泉達哉2, 佐々木良1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 695-695, 2023. |
|---|
|
|
4-7-O32-5. It is improved the vaccination ratio by the vaccination protocol introduction for patients after the splenectomy 堀内望, 土手賢史, 前間優衣, 漣航平, 松尾基樹, 小林由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 696-696, 2023. |
|---|
|
|
4-7-O33-1. A case of the children whom tongue black hairy and tooth discoloration occurred in during meropenem, vancomycin intravenous injection administration 山田真由美1, 福田哲也1, 詫間梨恵1, 山尾晶子1, 伊藤栞1, 村山彩1, 庄司健介2, 宇佐美憲一3, 荻原英樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 698-698, 2023. |
|---|
|
|
4-7-O33-2. Investigation into blood pressure changes during and after discontinuation of clazosentan sodium administration 瀬戸亘, 齊藤伸, 木元健寛, 吹谷真紀子, 八代佳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 699-699, 2023. |
|---|
|
|
4-7-O33-3. Research on whether caffeine side effects are explained and the nocebo effect 小島彩香1, 加藤未来1, 泉谷優佳1, 本間遥香1, 井澤美苗1, 清宮啓介1, 石川春樹1,3, 望月眞弓1, 青森達1,3, 大谷壽一1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 700-700, 2023. |
|---|
|
|
4-7-O33-4. Systematic review about the case report which developed a serious liver damage with the Saibokuto and the Chinese medicine-induced liver damage 星茜1, 百賢二2, 船越晴喜1,2, 音山裕美3, 吉田仁3, 佐々木忠徳4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 701-701, 2023. |
|---|
|
|
4-7-O33-5. Drug-related hypoglycemic seasonal inspection using the adverse event spontaneous report database 坂崎友香, 近藤悠希, 福田真依, 石塚洋一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 702-702, 2023. |
|---|
|
|
4-7-O34-1. Survey on the use of iodine contrast media in patients prescribed Imeglimin 延藤勇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 704-704, 2023. |
|---|
|
|
4-7-O34-2. The current situation investigation of the information collected in an in-hospital side effect report 宇野英理子, 野々垣知行, 川澄紀代, 後藤裕美子, 佐久間晶基, 大西正文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 705-705, 2023. |
|---|
|
|
4-7-O34-3. Fact-finding of the hypersensitivity symptom onset with the contrast media administration 鈴木千愛1, 嶋田沙織1, 篠崎拓哉1, 落合美伽1, 宮田真理子2, 小嶋良幸2, 中島崇仁2,3, 本間真人1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 706-706, 2023. |
|---|
|
|
4-7-O34-4. Investigation about anemia of the JAK inhibitor in patients with rheumatoid arthritis 小西正晃1, 三木賢人1, 平林弘美2, 竹内洋平3, 徳田道昭3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 707-707, 2023. |
|---|
|
|
4-7-O34-5. Examination about the onset of hepatic dysfunction risk factor by the nintedanib 上田真也1, 植松若那1, 奥隅拓朗1, 成田和希1, 蜂巣寿哉2, 薄雅人3, 山本吉章4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 708-708, 2023. |
|---|
|
|
4-7-O35-1. One patient whom methemoglobinemia developed in after using rasburicase 谷本憲哉1, 杉尾由希子2, 鳥山陽子2, 大窪典子2, 山形真一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 710-710, 2023. |
|---|
|
|
4-7-O35-2. Expression situation and association between infusion related reaction and immune-mediated adverse event investigation by the Pembrolizumab 中村圭菜1,2,3,4, 秦啓子1, 前田真一郎1,2,3, 前田真貴子1,2,3,4, 藤尾慈1,2,3,4, 廣部祥子1,2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 711-711, 2023. |
|---|
|
|
4-7-O35-3. Rate of decline in estimated glomerular filtration rate and lipid metabolism parameters after initiation of tenofovir alafenamide : comparison with abacavir 日笠真一1, 田澤佑基2, 石井聡一郎3, 溝端友希4, 上原仁5, 阿部憲介6, 國本雄介7, 村田龍宣8, 島袋翔多1, 日笠聡9, 木村健1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 712-712, 2023. |
|---|
|
|
4-7-O35-4. One case of the cardiac activity disorder attributable to taking minoxidil 今井雄介1, 田中雅幸1,2, 諏訪惠信3, 尾崎春菜1, 谷口綾1, 宇都宮敦子1, 前田千尋1, 西山徳人1, 打谷和記1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 713-713, 2023. |
|---|
|
|
4-7-O35-5. One case of the lung adenocarcinoma which produced hemorrhagic cystitis during Ipilimumab/Nivolumab combination immune therapy 八瀬恵理子1, 林洋太郎1, 上柳汐果1, 中嶋尚子1, 森本健幹1, 荒木博賢3, 今北卓間2, 小田亮介1, 丸山直岳1, 森吉弘毅4, 奥野博3, 三尾直士2, 土井敏行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 714-714, 2023. |
|---|
|
|
4-7-O36-1. The effect that use of Daikenchuto and the enoxaparin gives for a liver damage 渡辺宏晃, 平井啓太, 中澤佑香, 小池彩花, 土屋広行, 内藤隆文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 716-716, 2023. |
|---|
|
|
4-7-O36-2. Examination of the risk factor about acute renal failure onset in the combination of tazobactam/piperacillin and vancomycin case 村岡理沙子1, 今井雄介1, 岩根詩織1, 田中雅幸1,2, 西山徳人1, 打谷和記1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 717-717, 2023. |
|---|
|
|
4-7-O36-3. A case that the intervention based on "the drugstore vision for patients" contributed to side effect becoming severe evasion 佐藤史也1,2, 薄井健介2, 渡邊卓嗣2, 大内竜介2, 菅原幸乃1, 岡田浩司2, 藤村務2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 718-718, 2023. |
|---|
|
|
4-7-O36-4. The effect that flurbiprofen gives to failure of the sutures after the digestive organ surgery 鈴木喬也, 杉本智哉, 奥苑朱加, 山室栄一, 遠山幸男, 久田達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 719-719, 2023. |
|---|
|
|
4-7-O36-5. Examination of the new instillation method for the purpose of the reduction of the adverse event out of the eyes 池田博昭1, 河野清尊2, 中妻章1, 芳地一1, 川添哲嗣1, 飯原なおみ1, 池田純子3, 夛田羅勝義4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 720-720, 2023. |
|---|
|
|
4-8-O37-1. Examination about the safety at frequencies and the readministration of fever, the dermatopathy by Gemcitabine 相楽勇人1, 佐々木勇人2, 進藤吉明2, 田中雄一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 722-722, 2023. |
|---|
|
|
4-8-O37-2. Fact-finding of the cardiac troponin level change in the dysfunction thyroid with the immune checkpoint inhibitor 川之辺淳, 渋谷悠真, 鈴木真也, 川崎敏克 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 723-723, 2023. |
|---|
|
|
4-8-O37-3. The effectiveness of the S-1 dose design using eGFR and safe examination: Look at the single institution rear; a mark observational study 吉澤朝枝1, 白川博文2, 櫻澤有紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 724-724, 2023. |
|---|
|
|
4-8-O37-4. Comparison between risk of developing diarrhea and disease severity by the opioid combination at Abemaciclib start 吉田弘樹, 鈴木雅人, 高原悠子, 牧原明秀, 三屋良太, 近藤舞子, 木全司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 725-725, 2023. |
|---|
|
|
4-8-O37-5. Factorial experiments of the drug-related pulmonary disorder in the breast cancer chemotherapy 大谷豊司, 南目祐希, 谷章子, 北郷真由絵, 松浦智子, 南目梨江, 河角康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 726-726, 2023. |
|---|
|
|
4-8-O38-1. Effect by the manual introduction of the opioid parenteral injection 岩永崇志1,2, 原田未紗1, 荻野裕介1, 池田敦1, 森光保武1, 川波利子2, 寺尾正子2, 岡崎正典3, 藤井秀一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 728-728, 2023. |
|---|
|
|
4-8-O38-2. Inspection about the effect of the naldemedine tosyl acid salt on patients with cancer during hydromorphone tablets internal use 北口剛吉1, 山瀬大雄3, 井幡圭佑2, 大城美希2, 有江宏樹3, 辻井佳代3, 端裕之4, 小林政彦3, 村田久枝1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 729-729, 2023. |
|---|
|
|
4-8-O38-3. Examination of anamorelin for the cancer cachexia and the weight gain-related factor 奥田泰考1, 齋藤賢宏1, 三瓶祐貴1, 品田誠1, 藤村昭太1, 菅留理1, 小林直人1, 中田雅人1, 荒井大地1, 中澤寛仁1, 山口博紀2, 今井靖1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 730-730, 2023. |
|---|
|
|
4-8-O38-4. Elucidation of the effect predictor of the anamorelin using the CONUT score in the cancer cachexia patients during cancer chemotherapy 藤井宏典1, 牧山明資2, 西村佳代子3, 飯原大稔1, 廣瀬智恵美1, 大畑紘一1, 山田友奈美1, 小林亮1,4, 鈴木昭夫1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 731-731, 2023. |
|---|
|
|
4-8-O38-5. Fact-finding of the intervention instruction to patients with cancer by the mild medical therapy authorization pharmacist and comparison with the non-authorized pharmacist 中川隼一1, 田中怜2,3, 菅幸生4, 宮崎雅之5, 佐藤由美6, 萩原諒一7, 内田まやこ8, 高瀬久光9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 732-732, 2023. |
|---|
|
|
4-8-O39-1. Investigation about the use actual situation of the combination drug with the fluorouracil system anticancer agent 竹増理恵1, 長井克仁2, 富樫由美1, 福野修平2, 小西廣己2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 734-734, 2023. |
|---|
|
|
4-8-O39-2. Is the CYP3A conduction of the dexamethasone not strong at the high dose either? Consideration ... from the case that used ... tacrolimus together and publication information 大野能之1, 折山豊仁1, 本田晃2, 黒川峰夫2,3, 高田龍平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 735-735, 2023. |
|---|
|
|
4-8-O39-3. Elucidation of the mechanism of lorlatinib-induced liver injury in combination with rifampicin - Study on immune activation using THP-1 cells - 野田拓誠1,2, 浦嶋和也3, 田中沙織1, 幸田祐佳1, 宮部貴識2, 加藤隆児1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 736-736, 2023. |
|---|
|
|
4-8-O39-4. In vitro analysis about the CYP4F2 metabolic block activity with anti-peptic ulcus agents and the dyslipidemia therapeutic drug 桜木優太, 佐藤裕, 前川正充, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 737-737, 2023. |
|---|
|
|
4-8-O39-5. Effect of osmotic pressure to give to the interaction between drug - drink and OATP and the contribution analysis 竹村美由記, 白坂善之, 玉井郁巳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 738-738, 2023. |
|---|
|
|
4-8-O40-1. A case which rifampicin after the cancellation influenced it, and suffered from control of the optimal blood level of voriconazole 山本幹典, 伊藤雄紀, 梅村拓巳, 河村隆登, 伊藤聡一郎, 山田哲也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 740-740, 2023. |
|---|
|
|
4-8-O40-2. Questionary survey about drug interactions of Warfarin and 5-fluorouracil 國場訓, 外間登, 石井岳夫, 山内祐子, 佐久川卓, 山田智史, 鈴木毅, 難波有智, 潮平英郎, 中村克徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 741-741, 2023. |
|---|
|
|
4-8-O40-3. Examination of the effect on vancomycin-sensitive enterococcus bloodstream infection index of vancomycin 小松敏彰1, 内藤綾麻2, 赤間田悠刀1, 二本柳伸3, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 742-742, 2023. |
|---|
|
|
4-8-O40-4. Examination of the interaction of warfarin and the pre-bioThich-containing thickness regulator 若林仁美1,2, 唐沢浩二3, 岡本まとか3, 嶋村弘史1,2, 千葉正博3, 田中克巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 743-743, 2023. |
|---|
|
|
4-8-O40-5. Fact-finding about the serum selenium concentration in the severeness people experiencing disability taking an antiepileptic drug 桶本幸1, 関本裕美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 744-744, 2023. |
|---|
|
|
4-8-O41-1. Precision evaluation of blood drug concentration measuring equipment "LM1010" in the own institution for psychiatry drugs 森田和弥1, 阿部裕子1, 小場佐仁美1, 宮崎賢三1, 牧坂ナツミ1, 高橋英範1, 林裕子2, 尾田一貴3, 城野博史3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 746-746, 2023. |
|---|
|
|
4-8-O41-2. We look at the rear of the new predictive model of vancomycin for patients with cancer and examine a mark 伊藤和磨1,2, 田中怜1,3, 相川祐貴1, 森本重輝1, 鴨志田武1, 石川寛1, 佐古兼一4, 篠道弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 747-747, 2023. |
|---|
|
|
4-8-O41-3. Effect ... of analysis - drug liver turnover rate and the genetic polymorphism of the factor affecting the blood posaconazole levels in the hematopoietic stem cell transplantation patients 安井友佳子1,4, 岡山裕介2, 久野雅智2, 康秀男3, 柴多渉4, 掛屋弘4, 安井裕之5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 748-748, 2023. |
|---|
|
|
4-8-O41-4. The effect that renal function and physique give to clearance of the Teicoplanin 朝岡みなみ1,2, 堀田康弘1,2, 堀田祐志1,2, 日比陽子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 749-749, 2023. |
|---|
|
|
4-8-O41-5. It is an absorption improvement effect of coenzyme Q10 by becoming it the emulsion using the milk ingredient 山内佑紀恵1, 八巻義朗1, 佐藤夕紀2, 柏木仁2, 梨本俊亮2, 武隈洋3, 菅原満2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 750-750, 2023. |
|---|
|
|
4-8-O42-1. Examination of the anticancer agent pollution status investigation and exposure measures effect using the BD(R)HD check system 石川駿1, 西垣玲奈1, 陳美樹1, 宇田川涼子1, 渡部大介1, 齋藤義正1, 赤木徹1, 伊藤暖子2, 近藤俊輔2, 橋本浩伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 752-752, 2023. |
|---|
|
|
4-8-O42-2. Examination of the infusor pump preparation method that is safer, and is effective 細谷潤, 山崎成基, 金子康子, 大手直樹, 下山遥, 大野瑞恵, 大垣友香, 阿部正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 753-753, 2023. |
|---|
|
|
4-8-O42-3. Conduct in-hospital exposure to anticancer medicine investigation (the fourth report) 平野雄一, 長山晃, 川上典子, 森下和美, 近藤昌子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 754-754, 2023. |
|---|
|
|
4-8-O42-4. Floor anticancer medicine exposure to Aichi cancer center investigation in the environment treated like an anticancer herbalist 堀恭子1, 前田章光2, 曾根裕美子1, 村田史子2, 高野裕佑2, 橋本直弥2, 加藤正孝1, 内田幸作2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 755-755, 2023. |
|---|
|
|
4-8-O42-5. Aseptic inspection of the new cleaning of the safety cabinet with the water generation device water to electrolyze to electrolyze for the medical care 野々宮悠真, 清水久範, 谷口愉香, 岩崎加奈子, 小林一男, 山口正和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 756-756, 2023. |
|---|
|
|
4-8-O42-6. The quantity of duties change of the pharmacist by the anticancer agent preparation robot introduction and psychological change 坂井紀水, 栗栖章紘, 後藤愛実, 畑武生, 濱田武, 西原雅美, 根尾昌志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 757-757, 2023. |
|---|
|
|
4-9-O43-1. Plant; is effect ... at internal use start time after the examination - direct action type oral anticoagulant drug technique of the risk factor about the formation of hematoma after the type heart electricity device shrubbery 石田有希, 中田早音, 西田祥啓, 多賀允俊, 清水善仁, 政氏藤玄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 759-759, 2023. |
|---|
|
|
4-9-O43-2. It is ... about the spreading effect to role - drug duties of the pharmacist in the postoperative pain management team of our hospital and the prospects 篠田健一, 川原由紀子, 後藤益生, 久保智子, 上坂真依子, 藤井佳奈枝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 760-760, 2023. |
|---|
|
|
4-9-O43-3. Examination about the intervention of the suggestion of the bone-salt fixed-quantity examination by the pharmacist leadership for the purpose of the prevention of steroidal osteoporosis and the prescription suggestion of the osteoporosis therapeutic drug 廣瀬達也1, 森光輝1, 木村美智男1, 山下修司2, 林秀樹2, 宇佐美英績1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 761-761, 2023. |
|---|
|
|
4-9-O43-4. Evaluation of the risk of upper gastrointestinal bleeding due to concomitant use of PPIs in aspirin/prasugrel dual antiplatelet therapy and investigation of the optimal PPI 井出悠太郎1, 森川剛1, 吉田享平1, 高野由貴1, 久保田健1, 岡澤香津子1, 安武夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 762-762, 2023. |
|---|
|
|
4-9-O43-5. The current situation investigation of the medical treatment for the chronic cardiac insufficiency to be able to put of our hospital 上田浩貴1, 山本奈美2, 山本克己2, 濱口良彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 763-763, 2023. |
|---|
|
|
4-9-O44-1. A case which was able to evade a prescription cascade by the consideration of the drug-related adverse event and pharmacodynamic interaction 伊波樹1, 渡邊亜矢子1,3, 小泉朱里1,3, 米澤夏里2,3, 越塚宏美1,3, 柏原由佳1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 765-765, 2023. |
|---|
|
|
4-9-O44-2. Examination of the effect that rem decibuilding administration gives to estimation glomerular filtration rate 松木克仁1, 平野淳1, 後藤拓也1, 薄雅人1, 林誠2, 吉田知由1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 766-766, 2023. |
|---|
|
|
4-9-O44-3. Verification of the antioxidant effect of topiroxostat in vascular endothelial cells 野田雅人1,2, 武田涼馬3, 堀英生1,3, 近藤勝広2,4, 松永民秀1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 767-767, 2023. |
|---|
|
|
4-9-O44-4. One case that we suggested Teduglutide introduction for the patients with short bowel syndrome and further connected with the medicine medicine cooperation after the discharge 北爪教貴1, 高橋怜史1, 眞壁聡2, 増尾昌則1, 仲鉢英夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 768-768, 2023. |
|---|
|
|
4-9-O44-5. Analysis of the design of the drug controlled release type contact device using Tranilast nanosuspension and the intraocular drug behavior 矢野詩歩1, 衣川美宇1, 田所朋久1, 小早川信一郎2, 松永透3, 檜野栞3, 長井紀章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 769-769, 2023. |
|---|
|
|
4-9-O45-1. For development of the oral made-to-order type preparation with the 3D printer: The measurement of the making of Rebamipide tablets and the drug behavior 辻極瑞希, 岩上歩紗, 畑見理奈, 和久田耀, 城山空翔, 出口粧央理, 大竹裕子, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 771-771, 2023. |
|---|
|
|
4-9-O45-2. Evaluation of making of the polyvinyl alcohol gel including rebamipide nanoparticles and the drug release behavior 小松美莉, 西田未来, 和久田耀, 大竹裕子, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 772-772, 2023. |
|---|
|
|
4-9-O45-3. Search of the crude drug component which can improve zinc deficiency disorders 池田義人1, 山田泰之2, 宗兼将之3, 佐野紘平4, 向高弘4, 神戸大朋5, 士反伸和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 773-773, 2023. |
|---|
|
|
4-9-O45-4. Translational cycle aiming at construction of the safe cholesterol transportation therapy for the congenital dyslipidemia Niemann-Pick disease C type 山田侑世1,2, 西澤まど香2, 西山麻美2, 石井亮良2, 白川愛奈2, 近藤悠希2, 竹尾透3, 中潟直己3, 三輪徹4, 竹田大樹5, 折田頼尚5, 東大志2, 本山敬一2, 有馬英俊6, 関貴弘7, 倉内祐樹2, 香月博志2, 檜垣克美8, 南謙太朗1, 吉川直樹1, 池田龍二1, 松尾宗明9, 入江徹美2, 石塚洋一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 774-774, 2023. |
|---|
|
|
4-9-O45-5. Suggestion of the nanopreparation prescription that assumed Arabian gum a stabilizer: Skin transmission behavior of the indometacin transdermal preparation 大明沙季, 伏木葵, 森玲奈, 大竹裕子, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 775-775, 2023. |
|---|
|
|
4-9-O46-1. One case with suspected delirium drug-related from adherence improvement of insulin by the famotidine reduction depending on renal function 浅野恭平1, 高木昭佳2, 月岡良太3, 加藤敦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 777-777, 2023. |
|---|
|
|
4-9-O46-2. Comparison of the patients background to give it to adverse event expression to lead to mirogabalin administration cancellation 森住誠, 浦田元樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 778-778, 2023. |
|---|
|
|
4-9-O46-3. Examination of the infusion reaction expression risk factor with the rituximab therapy for the intractable nephrotic syndrome 西浦広将1,2, 高橋正也1,3, 杉本崇1, 森克仁4, 繪本正憲4, 中村安孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 779-779, 2023. |
|---|
|
|
4-9-O46-4. Inspection of the effectiveness of the sodium valproate for the cisplatin-induced acute renal failure 吉岡俊彦1,2, 合田光寛1,2, 神田将哉1,2, 杉本祐悟2, 石澤有紀2, 八木健太2,3, 相澤風花1,2, 宮田晃志2, 新村貴博2,3, 櫻田巧1,2, 石澤啓介1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 780-780, 2023. |
|---|
|
|
4-9-O46-5. The inspection of the factor to be mismatched, and to influence of the estimated eGFR level by the serum creatinine level in elderly people and cystatin C level: Crossing study 足達尚美, 本田篤子, 濱名麻衣子, 小林百合絵, 片岡裕貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 781-781, 2023. |
|---|
|
|
4-9-O47-1. Inspection of the number of training, the training time for pharmacist training specialized in local pharmacy care in University of Toyama Hospital 高木昭佳, 高橋則正, 石川雄大, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 783-783, 2023. |
|---|
|
|
4-9-O47-2. Evaluation (evaluation of short-term effects of degree of knowledge and the technical acquisition and the training) of the communication education that collaborated with clinical phycologist 西田麻以1, 今村隆2, 小林宏太朗1, 赤木晋介1, 西村健二1, 長尾由佳1, 古谷祥子1, 藥師径子1, 徳田衡紀1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 784-784, 2023. |
|---|
|
|
4-9-O47-3. The present situation of the medical therapy workshop by University of Shizuoka, hospital, the community pharmacy cooperation 大澤隆志1, 伊藤邦彦2, 森本達也2, 黒川絢子2, 内田信也2, 矢部勝茂2, 河西きよみ2, 鈴木貴也2, 井原摂子2, 櫻井健史2, 井上達秀2, 山田静雄2, 賀川義之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 785-785, 2023. |
|---|
|
|
4-9-O47-4. An effect about the personnel training in the pharmacy long-term training of the staff of Pharmaceuticals and Medical Devices Agency and the future prospects 有山真由美1, 増田純一1, 朝倉佑実2, 堀内直哉2, 寺門浩之3, 西村富啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 786-786, 2023. |
|---|
|
|
4-9-O47-5. The current situation of a specialty, the authorized pharmacist system in the career path of the pharmacist and future problem 三宅健文1, 柴田啓智2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 787-787, 2023. |
|---|
|
|
4-9-O48-1. Usefulness of the infusion formulation study tool utilization in the nutrition education for the trainee 越智良明, 石井弘幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 789-789, 2023. |
|---|
|
|
4-9-O48-2. The effect that continuous article commentary training gives for improvement in critical examination skill on hospital business trainee 安島秀友1, 美馬朱美1, 杉本涼佳1, 櫻井雄太1, 横山絢香1, 高木彰紀2, 廣原正宜2, 松崎貴志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 790-790, 2023. |
|---|
|
|
4-9-O48-3. ... full the pharmacy business training by the corona evil about invention of accepting it not ... limit 田浦稔基, 山崎直樹, 前川大輔, 小野川明美, 田邉輝, 仲川剛, 松下夏子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 791-791, 2023. |
|---|
|
|
4-9-O48-4. The training result in the investigation examination business participation for the enforcement that the after graduation clinical practice is effective for 2022 and the problem 小松沙裕里1, 小松真紀子1, 赤嶺由美子2, 大越英雄3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 792-792, 2023. |
|---|
|
|
4-9-O48-5. Development of the pharmacist education service that mishaps in medical practice reduction with the medicine aimed at becoming it 木村郁哉1, 牛尾聡一郎2, 川端崇義1, 三浦太郎1, 東恩納司1, 濱野裕章1, 座間味義人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 793-793, 2023. |
|---|
|
|
4-9-O48-6. Activity for clinical studies promotion by the hospital pharmacist 高武嘉道1, 山口泰弘1, 大橋邦央1, 花田聖典2, 橋本雅司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 794-794, 2023. |
|---|
|
|
4-10-O49-1. Aim AUC to evade renal failure by initial administration plan of vancomycin 飯田萌子1,2, 堀田康弘1,2,3, 広瀬永愛4, 朝岡みなみ1,2, 木村理恵2, 大橋一輝2, 加藤秀紀2, 江崎哲夫2, 河原昌美4, 堀田祐志1,2, 中村敦3, 日比陽子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 796-796, 2023. |
|---|
|
|
4-10-O49-2. Renal failure frequencies and therapeutic range achievement quotient investigation after the clinical introduction of the AUC evaluation of vancomycin 加藤秀紀1, 堀田康弘1,2, 朝岡みなみ1,2, 和知野千春1,2, 飯田萌子1,2, 三村佳久1,2, 杉山洋介1,2, 江崎哲夫1,2, 堀田祐志1,2, 日比陽子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 797-797, 2023. |
|---|
|
|
4-10-O49-3. Attempt of the blood drug levels cross validation test for the TDM practical use of the antimicrobial linezolid 辻泰弘1, 矢作彩2, 櫻井里咲2, 栗原絵2, 奥田詩織2, 川筋仁史3, 青山隆彦1, 山本善裕3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 798-798, 2023. |
|---|
|
|
4-10-O49-4. Study on blood level monitoring at the gentamicin administration for the infective endocarditis and renal function change 篠田康孝, 大橋健吾, 松岡知子, 新井かおり, 堀田奈央, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 799-799, 2023. |
|---|
|
|
4-10-O49-5. Evaluation of the renal failure frequencies by the change to the TDM based on the vancomycin one point drawing blood AUC level 山田翔也1, 丹羽隆1, 山田悠人1, 小野友利恵2, 鷲見和之1, 大坪愛実1, 丹羽今日子1, 安江萌夏1, 山本泰士1, 小林亮1,2, 鈴木昭夫1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 800-800, 2023. |
|---|
|
|
4-10-O50-1. The voriconazole administration experience to highly obese (BMI47kg/m2) Japanese: A case which obtained an appropriate therapeutic range by ideal weight conversion 岡本朋子1, 中村彩芳2, 眞継賢一1, 伊藤博美1, 南谷晃誠2, 吉見育馬2, 大原房子3, 山下裕史3, 河野千尋3, 松末武雄2, 濱口良彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 802-802, 2023. |
|---|
|
|
4-10-O50-2. The TDM enforcement situation by the prior agreement protocol enforcement of vancomycin 大月慎之助, 鬼頭尚子, 北村幸代, 福島信一郎, 宮澤憲治, 高木亮 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 803-803, 2023. |
|---|
|
|
4-10-O50-3. Comparison of AUC and the trough value by one point of drawing blood in the vancomycin renal failure prediction for the elderly aged 75 or over 原田紗希1, 羽田野励次2, 菅田哲治2, 陸丸幹男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 804-804, 2023. |
|---|
|
|
4-10-O50-4. Clinical practice evaluation of the vancomycin administration plan nomogram according to the renal function 竹内陽亮, 小松原靖二郎, 長島裕樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 805-805, 2023. |
|---|
|
|
4-10-O50-5. A case which caused a blood level drop of oral voriconazole (VRCZ) by nutrient for intestinal administration sustained administration 須山由佳子1, 河野礼2, 杉山恭平1, 古谷翔太1, 神戸宏憲1, 櫻井和子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 806-806, 2023. |
|---|
|
|
4-10-O51-1. Can the large-scale insurance claim information classify infection opportunities of the multidrug-resistant Acinetobacter infection? 上本花南1, 村木優一1, 後藤良太1, 福岡千晴1, 水野香菜子1, 豕瀬諒1, 大毛宏喜2, 大曲貴夫3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 808-808, 2023. |
|---|
|
|
4-10-O51-2. It is a prescription suggestion effect of the infection prophylaxis antimicrobial after the operation by the operating room pharmacist in otolaryngology, the head and neck surgery patients: Look at the single institution rear; a mark observational study 北川遼1, 冨澤淳1,2, 瀬戸良教1, 小川隆弘1, 小松敏彰1, 山下拓3, 尾鳥勝也1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 809-809, 2023. |
|---|
|
|
4-10-O51-3. Problem for consumption reduction in the use situation investigation of the macrolide derivative antimicrobial before and after the COVID-19 outbreak and the drug-resistant measures action plan 高木栄希, 坂本拓也, 川村ひとみ, 中尾耕治, 荒井宏人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 810-810, 2023. |
|---|
|
|
4-10-O51-4. A descriptive epidemiology study of the inpatient background that took advantage of aspiration pneumonia: Group characteristic examination for the analytical epidemiology study enforcement on the basis of polypharmacy measures 石田亮1,2, 仁熊宏樹2, 西田麻衣2, 村越千恵2, 松本真由2, 脇本彩2, 西村健二2, 亀井健人2, 赤木晋介2, 徳田衡紀2, 高柳和伸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 811-811, 2023. |
|---|
|
|
4-10-O51-5. Clinical examination of the antimicrobial lock therapy of the catheter in catheter-associated bloodstream infections 川本莉緒1, 大林巧志1, 弓場達也2, 小森桂子1, 板倉祥嗣1, 苅田明子1, 舩越真理1, 土谷有美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 812-812, 2023. |
|---|
|
|
4-10-O52-1. Evaluation of the effect to give an examination of blood culture pollution rate and antimicrobial consumption by the check list introduction at blood culture sampling utilizing J-SIPHE 米谷領太1, 中谷茉佑香1, 福田俊2, 谷久弥3, 多湖ゆかり3, 岡本菜摘5, 神田健志4, 古俵孝明1, 月野光博5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 814-814, 2023. |
|---|
|
|
4-10-O52-2. About the antimicrobial proper use support to the blood culture-positive patients for cardiovascular surgery inpatients 町田聖治1,2, 福島将友1,2, 曽我弘道1, 入江利行1,2, 宮崎博章2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 815-815, 2023. |
|---|
|
|
4-10-O52-3. Examination about the patients background associated with the Corynebacterium genus bacteremia 小林紀香1, 和知野千春1,2,3, 早川智章1,2, 堀田康弘1,2,3, 堀田祐志1,3, 日比陽子1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 816-816, 2023. |
|---|
|
|
4-10-O52-4. Relative inspection with the appropriate practice rate of the mention situation and the process index of the use of antimicrobial report book under the AST support 田中雄大1,2,3, 山口諒1, 山本武人1, 龍野桂太2,3, 岡本耕3, 森屋恭爾2,3, 高田龍平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 817-817, 2023. |
|---|
|
|
4-10-O52-5. Investigation about the effect that bacteremia due to the ESBL-producing gram-negative bacteria gives for the treatment outcome of the cardiovascular device custody patients 中蔵伊知郎1, 坂倉広大1,2, 若林智仁1, 山口弥久1, 大畑彩也香1, 佐々木京子1, 高橋彩子2, 佐田誠2, 坂本麻衣1, 中野一也1, 上野智子1, 川端一功1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 818-818, 2023. |
|---|
|
|
4-10-O53-1. The development of the surgical-site infections predictive model in the mandibular extraction of impacted wisdom teeth surgery: Pre-rear predictive model using the technique to resample 山神彰1, 鳴海克也2,3, 齋藤佳敬1, 古堅彩子2, 今井俊吾4, 北川善政5, 大廣洋一6, 高木諒7, 武隈洋1, 菅原満1,8, 小林正紀2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 820-820, 2023. |
|---|
|
|
4-10-O53-2. About clinical path Committee which we intervened in urologic clinical path and led to the quinolone oral antimicrobial consumption decrease, AST combination review meeting 佐藤香子1,6, 平山伸朗1, 曽根理恵2,4, 安部夏紀3,4, 齋藤政子3,4, 及川京子3, 佐藤貞子3,4, 泉美幸5, 栫井成彦5, 角川陽一郎4,7, 三木誠6,7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 821-821, 2023. |
|---|
|
|
4-10-O53-3. The effect that a cataract surgery clinical path change gives to endophthalmitis after the antimicrobial proper use and the operation 西山晃1, 沢田佳祐1,2, 中谷丈之1, 吉川宗光3, 河野修治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 822-822, 2023. |
|---|
|
|
4-10-O53-4. About the effectiveness by the local highly-concentrated antimicrobial continuation perfusion therapy for the bone soft tissue infection in our hospital and safety 松浦紘生, 松下雅昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 823-823, 2023. |
|---|
|
|
4-10-O53-5. It is evaluated the endophthalmitis after the operation accompanied with the intravenous antimicrobial cancellation before operation in the cataract surgery 内田和孝1, 高濱啓太1, 草野雄貴2, 松本光希2, 宮本浩子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 824-824, 2023. |
|---|
|
|
4-10-O54-1. Examination of the effect that an antimicrobial proper use support team activity in connection with infection internal medicine gives to intravenous antimicrobial proper use 杉井麻耶1,2, 山本理紗子1,2, 相曽啓史1,2, 永田将司1, 井手聡2,3, 栗田崇史2,3, 具芳明2,3, 田頭保彰2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 826-826, 2023. |
|---|
|
|
4-10-O54-2. Outcome evaluation in patients with bacteremia by the antimicrobial proper use support team link pharmacist system introduction 吉川結美1, 橋本麻衣子1, 松本剛2, 平井啓太1, 土屋広行1, 内藤隆文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 827-827, 2023. |
|---|
|
|
4-10-O54-3. One step of the beginning of infection with hospital pharmacist measures regional alliances 遠山潤1, 高橋哲2, 佐藤みづき1, 西千春1, 井口有紀1, 平賀洋子1, 中村初美1, 櫻間啓基1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 828-828, 2023. |
|---|
|
|
4-10-O54-4. Efforts in our hospital for the cooperation of ward drug duties and the AST activity 中村佳菜, 藤脇孝哉, 岩倉弥生子, 合田明博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 829-829, 2023. |
|---|
|
|
4-10-O54-5. It is ... for efficiency of usefulness ... patients intelligence in application development and the AST activity for the use situation investigation of the antimicrobial 山田将悟, 藤林遼, 前川英輝, 高橋誠, 田中正臣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 830-830, 2023. |
|---|
|
|
4-11-O55-1. Investigation about the factor of the direct hospital admission of emergency of patients not to deceive in the Kurashiki center Hospital 樋口純一, 小林宏太朗, 友國綾香, 溝部裕介, 宮下佳大, 石原泰子, 徳田衡紀, 高柳和伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 832-832, 2023. |
|---|
|
|
4-11-O55-2. The outcome in the anticancer agent-related eye disorders using the adverse event spontaneous report database and analysis of the onset time 新田侑生1, 中馬真幸1, 新田悠一朗1, 真鍋貴行2, 神山直也2, 岩山訓典1,3, 山本譲1, 小野尚志1, 田崎嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 833-833, 2023. |
|---|
|
|
4-11-O55-3. Cancer gene panel testing status and pharmacist involvement at cancer genome medical collaboration hospitals - Current situation and issues - 佐藤一求1, 世良真愛子1, 川原邦仁1, 比良大輔1, 栗原晋太郎1, 別所千枝1, 安原昌子1, 本永正矩2, 斎藤敦子3, 橋詰淳司3, 檜井孝夫4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 834-834, 2023. |
|---|
|
|
4-11-O55-4. Inspection of the effect that a gastric-acid secretion antagonist gives to effect of treatment and the side effect of the immune checkpoint inhibitor 岡本敬介1, 齋藤佳敬2, 武隈洋1, 菅原満1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 835-835, 2023. |
|---|
|
|
4-11-O55-5. Examination of the effect that SGLT2 inhibitor combination gives to CDDP-induced acute renal failure 石神友介1, 高橋正也1,2, 中務ひとみ1, 西浦広将1,3, 古原優也1, 中村安孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 836-836, 2023. |
|---|
|
|
4-11-O56-1. Serious neutropenia in the amrubicin therapy for recurrent small cell lung cancer and association of the progression-free survival period 石田翔1, 妹尾啓司1, 宮嵜純治1, 中井將人1, 水上皓喜1, 白木政博1, 阪田安彦2, 渡邊篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 838-838, 2023. |
|---|
|
|
4-11-O56-2. Usefulness by the true clinical practice of the electronic patient-reported outcome monitoring in the immune checkpoint inhibitor-treated patients by the pharmacist 桂英之, 太田浩士, 高田直子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 839-839, 2023. |
|---|
|
|
4-11-O56-3. Examination of the early infection incidence and risk factor of the Venetoclax+Azacitidine combination therapy in our hospital 金子憲太郎1, 田中圭祐2, 川口文誉1, 川村僚一郎1, 野口果歩1, 岩瀬弘明1, 豊田茂雄3, 小林路子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 840-840, 2023. |
|---|
|
|
4-11-O56-4. Rearward observational study about relations with the relative dose intensity and effect of treatment in the pancreatic cancer gemcitabine +nab paclitaxel combination therapy 中谷祐介1, 平井利典1, 早崎碧泉2, 岸和田昌之2, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 841-841, 2023. |
|---|
|
|
4-11-O56-5. The effect that a pharmacist outpatient gives in treatment continuity of the Abemaciclib 中村大学1, 近藤勝弘2,3, 堀田祐志2,3, 朝岡みなみ1,3, 外海友規1,3, 手崎世織1, 竹本将士1, 細江昂誠4, 山本清司4, 浦野公彦4, 松浦克彦4, 日比陽子1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 842-842, 2023. |
|---|
|
|
4-11-O57-1. Fact-finding of the foreign cancer medical therapy enforcement situation under the COVID-19 outbreak 島貫裕実子1, 下村昭彦2, 小室雅人1, 西村富啓1, 清水千佳子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 844-844, 2023. |
|---|
|
|
4-11-O57-2. The effectiveness of the cetuximab combination radiotherapy for local progress epithelium squamous head and neck cancer which coexisted for renal failure of the cisplatin intolerance and safe inspection 今井千晶1, 佐伯宏美1, 山本晃平1, 市川彩乃1, 鈴木貴明1, 山崎伸吾1, 滝口裕一2, 花澤豊行3, 石井伊都子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 845-845, 2023. |
|---|
|
|
4-11-O57-3. Examination about the effect of treatment of the immune checkpoint inhibitor which paid attention to an inflammatory marker 大石大祐, 山本圭祐, 矢部勝茂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 846-846, 2023. |
|---|
|
|
4-11-O57-4. Antineoplastic drug for the multiple liver metastases nodules in the same individual using a triple negative breast cancer liver metastases model-sensitive evaluation 相良篤信1, 里史明1, 小日向晃昇1, 沢結理1, 岡田大地2, 安部智哉2, 平出誠1, 佐野元彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 847-847, 2023. |
|---|
|
|
4-11-O57-5. Effect on ischemic heart disease with the platinum administration 伊藤博美, 上田浩貴, 濱口良彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 848-848, 2023. |
|---|
|
|
4-11-O58-1. Usefulness evaluation of the pharmacist outpatient department for patients with breast cancer to take Abemaciclib 押切華映1, 前川麻央1, 赤井文香1, 岩渕理子1, 田中里奈1, 松浦正樹1, 原田成美2, 菊地正史1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 850-850, 2023. |
|---|
|
|
4-11-O58-2. Development of the cooperation documentation system in the foreign cancer chemotherapy cooperation full addition 牧原明秀, 近藤舞子, 三屋良太, 高原悠子, 鈴木雅人, 吉田弘樹, 木全司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 851-851, 2023. |
|---|
|
|
4-11-O58-3. Fact-finding of retching, the vomiting situation and the antiemetic contents in patients receiving oxaliplatin 島田浩和1, 大神正宏1, 鈴木嘉治1, 立原茂樹1, 天貝賢二2, 小島寛3, 鈴木美加1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 852-852, 2023. |
|---|
|
|
4-11-O58-4. Comparison of the effect that difference in cancer of gastric cancer, colon cancer gives the CINV onset situation at SOX therapy and CapeOX therapy enforcement and search of the risk factor 平賀七帆1, 安藤洋介2, 豊里星来2, 松岡宏3, 勝野秀稔4, 水野智博2, 河田健司5, 守瀬善一4, 池田義明1, 山田成樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 853-853, 2023. |
|---|
|
|
4-11-O58-5. Examination of the factor associated with the retching vomiting expression with the nogitecan administration to patients with lung cancer 川村僚一朗, 川口文誉, 常木隆史, 金子憲太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 854-854, 2023. |
|---|
|
|
4-11-O59-1. About the effectiveness and safety when we changed it to a generic drug from an azacitidine innovator drug 大野真史, 中村雄亮, 助畑歩, 高橋優聡, 小森均, 深井敏隆 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 856-856, 2023. |
|---|
|
|
4-11-O59-2. The effect that supply restrictions of the albumin suspension type paclitaxel gave to treatment preferences 矢田部恵1, 小川千晶2, 石嶋麗2, 工藤彰2, 大塚知信2, 山岸美奈子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 857-857, 2023. |
|---|
|
|
4-11-O59-3. Safety of the nanoliposomal irinotecan + fluorouracil/levofolinate parallel administration for the pancreatic cancer 若林茜1,2,5,6, 川上武志2, 田中怜1,3,4, 福室友里絵5, 盛啓太6, 石川寛1, 篠道弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 858-858, 2023. |
|---|
|
|
4-11-O59-4. High pharmaceutical care of the quality using a tracing report and the drug remedy history in the oral anticancer medicine remedy patients 林田大輝, 天方奉子, 沼田朋和, 牛濱直樹, 宮本竜太朗, 澤村理英, 宇都直哉, 近藤元三, 稲葉一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 859-859, 2023. |
|---|
|
|
4-11-O59-5. Examination of a factor about a vasculitis caused by vinorelbine and the vascular pain and the prophylactic method 石井俊一1,2, 市村丈典1, 市倉大輔1, 縄田修一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 860-860, 2023. |
|---|
|
|
4-11-O60-1. The efforts which aimed at the security of the quality of on-the-job training and the data of clinical studies 藤井千賀1, 合澤啓二2, 青山剛3, 中島寿久4, 吉川英里5, 松本光史6, 倉田宝保7, 今村知世8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 862-862, 2023. |
|---|
|
|
4-11-O60-2. Usefulness of outpatient pharmacists in preventing the onset of apalutamide-induced skin disorders 梅原健吾1, 高田慎也1, 山岸佳代1, 高田徳容2, 丸山覚2, 原林透2, 佐藤秀紀3, 橋下浩紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 863-863, 2023. |
|---|
|
|
4-11-O60-3. Inspection of the prognosis-related factor in immune-mediated adverse event (irAE) 小島一晃1, 小西史子1, 濱武清範1, 野間敏也1, 松田ちひろ1, 橋本仁美1, 福井美礼1, 仲忠士1, 美和孝之1, 六車英光2, 神田直樹3, 北英夫4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 864-864, 2023. |
|---|
|
|
4-11-O60-4. 1 case that showed vision blurred during adjuvant chemotherapy after the CAPOX technique in sigmoid colon cancer 沢仁美1,2, 中村暢彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 865-865, 2023. |
|---|
|
|
4-11-O60-5. The effect that sarcopenia gives for the checkpoint inhibition therapy in craniocervical part cancer of immunity 西山由紀子1, 中川祐紀子1, 志村裕介1, 山本奈歩1, 菅幸生1,2, 嶋田努1, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 866-866, 2023. |
|---|
|
|
5-7-O61-1. Doubt inquiry of the drugstore pharmacist utilizing the test value QR cord improves patients outcome 渡邊大貴1, 神山直也2, 安達理恵1, 松野明香1, 佐藤美峰1, 千葉薫1, 田崎嘉一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 868-868, 2023. |
|---|
|
|
5-7-O61-2. The development of the prescription checking support system corresponding to the decreased renal function and the evaluation 眞木秀子, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 869-869, 2023. |
|---|
|
|
5-7-O61-3. Efforts about the drug inventory control utilizing RPA (Robotic Process Automation) 田口佳奈1, 鍵谷徹1, 安田憲隆1, 宮本義浩1, 榎本真治2, 浅野正太郎3, 村山典久3, 中島純子1, 平出耕石1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 870-870, 2023. |
|---|
|
|
5-7-O61-4. Multicenter questionary survey in Hyogo for the inflection promotion of the electronic prescription notebook 柴谷直樹1,2,6, 鶴田洋平1,3, 浅井浩之4, 福田英克1,5, 平野達也6, 山崎彬史7, 清水倫子1,8, 藤田一弘1,9, 石井雅人1,10, 中村豪志11, 安達嘉織12, 小玉博一1,13, 室井延之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 871-871, 2023. |
|---|
|
|
5-7-O61-5. Can ChatGPT (GPT-4) become the support of the anticancer agent regimen registration duties? 前田章光, 下村一景, 橋本直弥, 内田幸作 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 872-872, 2023. |
|---|
|
|
5-7-O62-1. It is made the oral tablet for the custom tailoring utilizing the technique freeze dry or 3D printer technique and nano 大迫華乃, 下前憂梨咲, 板東彩香, 和久田耀, 城山空翔, 出口粧央里, 大竹裕子, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 874-874, 2023. |
|---|
|
|
5-7-O62-2. The actual situation and problem of the proper use of the nonprescription drug in the person of new coronavirus infection seventh wave home medical treatment 藤本卓磨1, 岩田紘樹1,2, 小林典子1,2, 近藤慎吾1,2, 中村友紀1,2, 山浦克典1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 875-875, 2023. |
|---|
|
|
5-7-O62-3. The exploring of the additive candidate contributing to evasion effect extension of DEET: Usefulness of cyclodextrin and the POE-POP butyl ether 松本夏奈1, 川口麻由2, 酒井琢朗1, 吉富丈治1, 笹邉達志2, 延原健二2, 松原晶2, 長井紀章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 876-876, 2023. |
|---|
|
|
5-7-O62-4. National fact-finding about sexual intercourse in this country and the use of the urgent contraceptive 百賢二1, 前田絵里加1,2, 服部はるか1,3, 磯崎遥1,4, 瀧田寛子5, 諸星北人6, 龍家圭7, 肥田典子8, 三邉武彦9,10, 白土なほ子5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 877-877, 2023. |
|---|
|
|
5-7-O62-5. For the presbyopia prevention: Suggestion of hardening of the crystalline lens with the sodium selenite administration and the rating system 久保田ちか1, 門脇玲太1, 浅井拓己1, 大竹裕子1, 中澤洋介2, 山本直樹3, 長井紀章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 878-878, 2023. |
|---|
|
|
5-7-O63-1. Fact-finding of the visit drug control instruction by the hospital pharmacist 水野智博1, 長谷川章2, 溝神文博2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 880-880, 2023. |
|---|
|
|
5-7-O63-2. Prediction of the fall risk in nursing facility entering elderly people using the machine learning 中田雄大1, 石坂優奈1, 佐藤宏樹1,2, 柳奈津代1, 澤田康文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 881-881, 2023. |
|---|
|
|
5-7-O63-3. Pharmaceutical intervention effect of the pharmacist in the urination care team 大屋和福, 細野真吾, 堀浩子, 山崎崇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 882-882, 2023. |
|---|
|
|
5-7-O63-4. The current situation investigation about the frailty in the health insurance pharmacy use patients 面谷幸子1,2, 石坂敏彦2,3, 鈴木利次3, 鹿嶋隆行3, 宮川道英1,3, 初田泰敏1, 名徳倫明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 883-883, 2023. |
|---|
|
|
5-7-O63-5. ... to alert to reporting and the electronic medical chart of the drug influencing deglutition functional decline in relation ... conference of the pharmacist to the eating deglutition support team 宮崎雄紀1, 百瀬将晃2, 古清水元子3, 網野一真1, 登内盛治1, 巨島文子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 884-884, 2023. |
|---|
|
|
5-8-O64-1. The BD Rowa(TM) system (automatic warehousing, formulations support system) introduction in the health insurance pharmacy and interpersonal duties: Descriptive vertical section study 田中佑樹, 松木史, 片岡剛司, 木村涼子, 松井優子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 886-886, 2023. |
|---|
|
|
5-8-O64-2. The foreign efforts that a pharmacist sits and foreign team approach in medical care 勇内山英暢1, 牛尾幸子1, 八反丸善文2, 小川晃一3, 比田井明憲4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 887-887, 2023. |
|---|
|
|
5-8-O64-3. Investigation (the first report) of the pharmaceutical management of the at-home self-injection instruction in the immune pharmacist outpatient 大場啓貴1,2,3, 平田一耕1,2, 小倉千亮1,2, 森健太郎1,2, 六反田諒4, 舟越亮寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 888-888, 2023. |
|---|
|
|
5-8-O64-4. Evaluation of the common use medicine confirmation system by the foreign new establishment before operation of the perioperative charge pharmacist 田村真由子, 野々内裕紀, 仲宗根千佳, 濱口良彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 889-889, 2023. |
|---|
|
|
5-8-O64-5. Examination about the usefulness of the pharmacist permanent residence in the hospitalization support section 村上菜月, 疋田絵梨, 高木茂実, 和田実佳子, 安西麻衣子, 松林明美, 城田幹生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 890-890, 2023. |
|---|
|
|
5-8-O65-1. Zero of the postponement of surgery by evaluation - discontinuation lapse of memory of the risk factor of the patients discontinuation in the admitting department for becoming it - 遠藤愛樹1, 佐久間大樹1, 中根優1, 山本弓子1, 松本香織1, 小林義文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 892-892, 2023. |
|---|
|
|
5-8-O65-2. Doubt inquiry contents in by hospitalization front and the analysis 山崎亮, 渡辺研弥, 須藤孝浩, 黒田純子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 893-893, 2023. |
|---|
|
|
5-8-O65-3. Than pharmacist intervention to the foreign chemotherapy room at the small and medium size hospital and evaluation - questionary survey ... 菅野雄太, 坂野昌志, 杉浦茂樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 894-894, 2023. |
|---|
|
|
5-8-O65-4. The burden reduction of pharmacist duties by the fosnetupitant introduction and investigation about the patients line of flow 澤村彩菜, 橋本浩伸, 齋藤義正, 赤木徹, 渡部大介, 中島寿久, 佐藤公彦, 有馬崇充, 陳美樹, 寺田公介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 895-895, 2023. |
|---|
|
|
5-8-O65-5. Risk factor of the unobservance of the explanation about the discontinuation of a pharmacist and the medicine influencing the surgery that we underwent from other types of job 赤嶺聡彦1, 長崎裕也2, 冨澤淳3, 尾鳥勝也2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 896-896, 2023. |
|---|
|
|
5-8-O66-1. The example that a pharmacist specialized in local pharmacy care became a family pharmacist, and performed outpatient follow in a telephone and a visit 沖和代, 榊原さやか Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 898-898, 2023. |
|---|
|
|
5-8-O66-2. Spread of anticancer medical use tracing reports and problem - Japan cure association arts and sciences first subcommittee ... to utilization 山本圭祐1, 清水久範2, 月岡良太3, 川口崇4, 加藤肇5, 辻大樹6, 山口拓洋7, 鈴木賢一8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 899-899, 2023. |
|---|
|
|
5-8-O66-3. Examination about the current situation and the problem in the pharmacist (cancer) training specialized in local pharmacy care 近藤元三1, 天方奉子1, 稲葉一郎1, 楠本将裕2, 田中由起子2, 山室蕗子2, 菊川佳敬3, 山崎浩3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 900-900, 2023. |
|---|
|
|
5-8-O66-4. Relations of the pharmaceutical intervention using the tracing report for a communication skill and the polypharmacy patients of the drugstore pharmacist 桜田尚季1, 佐々木麻里2, 土井真喜3, 阿南圭祐4, 紙谷司5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 901-901, 2023. |
|---|
|
|
5-8-O66-5. The correspondence actual situation to the foreign patients in the urban area drugstore: Inventory survey 鈴木渉太1,2,3, 岡田浩1,2, 西川佳孝2, 中山健夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 902-902, 2023. |
|---|
|
|
5-9-O67-1. It is the visit actual situation according to the residence place in six months after the visit pharmacist introduction to elderly people living in an area: Medical care, care connection data analysis 田口怜奈1,2, 浜田将太1,3,4, 土屋瑠見子1, 石川智基1, 西田和正1, 北村智美1, 服部真治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 904-904, 2023. |
|---|
|
|
5-9-O67-2. Watch the area by the health insurance pharmacy; an agreement and the effect 佐野稜, 佐々木剛, 植村由香, 中田祐一, 佐藤翼, 澤野剛, 高橋友樹, 伊藤隆紀, 正木雅, 谷藤隼人, 谷口亮央, 中島史雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 905-905, 2023. |
|---|
|
|
5-9-O67-3. One case of the end-stage heart failure that shifted to treatment at home with continuing continuously administering it of the dobutamine injection drug 赤松隼人1, 江藤良2, 黒部昌也2, 山口ゆかり3, 馬場妙子3,4, 桑原薫4, 矢野雄大5, 井川幸子3, 中野国枝3, 中川博雄1, 兒玉幸修1, 大山要1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 906-906, 2023. |
|---|
|
|
5-9-O67-4. The need of the multi-type of job cooperation judging from the actual situation of the drug incident for the medical care in being at home 深田悠花1, 関口亮子1, 石川武雅1, 小玉伽那1, 勝眞久美子1, 笠松弥咲2, 大西真愛2, 齊前裕一郎2, 勝久美月2, 竹下悠子2, 藤井美咲2, 森木友紀2, 糀屋絵理子2, 竹屋泰2, 生田花澄3, 肥後友彰4, 大塚泰葉4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 907-907, 2023. |
|---|
|
|
5-9-O67-5. The disposal situation every medical type of industry about the drug for the medical care and comparison of the disposal of Fukuoka-shi and the Kumamoto-shi health insurance pharmacy 原口恵子1, 太田麻美2,4, 立麻香帆4, 猪阪日向子4, 樋口義則2, 西名武士2, 磯野寿光1, 長迫信一1, 藤本拓郎1, 野島実1, 吉田健1, 柴山和弘1, 田中智枝1, 北智之1, 田城涼子1, 高木淳一1, 木原太郎1, 天方奉子3, 稲葉一郎3, 川尻雄大4, 小林大介4, 島添隆雄4, 田中泰三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 908-908, 2023. |
|---|
|
|
5-9-O68-1. Attitude survey about the acceptance of the childhood treatment at home in the health insurance pharmacy under Mie 中川裕司1,2, 小西友美3, 山本高範3, 小林竜也4, 佐藤賛治3, 加藤秀雄2, 岩本卓也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 910-910, 2023. |
|---|
|
|
5-9-O68-2. Utilization investigation of effectiveness of the training in the healthy support drugstore training completion person and the training contents 戸井真也1, 棚橋嵩一郎1, 今西孝至2, 長澤吉則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 911-911, 2023. |
|---|
|
|
5-9-O68-3. Efforts from a pharmacist to the local inclusion care system 栗原弘充 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 912-912, 2023. |
|---|
|
|
5-9-O68-4. It is examined the relative analysis of the medication adherence factor for the medication situation using logistic regression/LightGBM and the importance Masanori 飯野温1, 木崎速人2, 今井俊吾2, 堀里子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 913-913, 2023. |
|---|
|
|
5-9-O68-5. Evaluation of the medication follow-up activation of the local demographic division of medical services by the version tracing report business common throughout the prefecture 大東敏和1,2, 里章平2, 岡田博恵1,3, 白井敦史1,4, 舟原宏子1,5, 別所千枝1,6, 村上秀治1,7, 石本新1,8, 大塚茂雄1,9, 竹本貴明1,10, 山田真弘1,11, 竹井英介1,12, 西原昌幸1,13, 先森満子1,14, 松尾裕彰1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 914-914, 2023. |
|---|
|
|
5-9-O69-1. Efforts and evaluation of the pharmacist in the nursing orientation 岡田怜子, 小柳津瞳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 916-916, 2023. |
|---|
|
|
5-9-O69-2. Theoretical consideration about the safety at mother's milk shift and nursing of famciclovir 大久保正1,2, 田中真理子2, 大久保七枝3, 大久保美穂4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 917-917, 2023. |
|---|
|
|
5-9-O69-3. Establish the pregnancy and the nursing medicine consultation desk by the pharmacist 遠藤清香, 渡會明希, 大場有紗, 磯部樹里, 齊藤那奈, 高橋優歩, 田口未菜, 板垣有紀, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 918-918, 2023. |
|---|
|
|
5-9-O69-4. DHA, 1 case that an anesthesia method of the cesarean section was changed by taking EPA-containing folic acid supplement 山本翔子, 三木陽介, 中島春佳, 石井聡一郎, 真志田絵美子, 柴田ゆうか, 松尾裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 919-919, 2023. |
|---|
|
|
5-9-O69-5. Analysis of the factor to disturb the voluntary learning of the medication counseling e-learning system to a hearing person with a disability 俵口奈穂美1, 吉田力久2, 小倉秀美3, 山崎博史4, 田中泰三5, 窪田敏夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 920-920, 2023. |
|---|
|
|
5-10-O70-1. Decrease in common use medicine-related incident by conducting pharmacist duties in hospitalization and release support section 山本泰士1, 山田友奈美1, 藤井宏典1, 飯原大稔1, 加藤寛子1, 西田承平1, 星野良1, 丹羽隆1, 小林亮2, 熊田恵介3, 清水雅仁4, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 922-922, 2023. |
|---|
|
|
5-10-O70-2. About the way of the effective manual in our hospital 田村曉識, 松井俊典, 谷田彩, 池田和之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 923-923, 2023. |
|---|
|
|
5-10-O70-3. Development of groundbreaking audiovisual materials contributing to the prevention of the pharmaceutical products-related incident in a student, the new face pharmacist 松本准1,2, 塩川葉月2, 西原茂樹2, 岡野志のぶ2, 森彩美2, 吉川潤子2, 武田達明1,2, 槇枝大貴2, 小沼利光2, 市川裕規2, 濱野裕章2, 鍛治園誠2, 村川公央2, 有吉範高1, 座間味義人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 924-924, 2023. |
|---|
|
|
5-10-O70-4. Possibility in the international medical relief of the pharmacist whom we saw in the long-term support for the humanitarian crisis relief in Ukraine 仲里泰太郎1,2, 河合謙佑2, 池田戴子2, 光森健二2, 小林政彦1, 中出雅治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 925-925, 2023. |
|---|
|
|
5-10-O70-5. Examination of the method to promote behavior modification facing each other at the disaster in the drug section 岡田千賀子1, 梶原千里2, 青木勇樹1, 柏原道志1, 山尾真貴子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 926-926, 2023. |
|---|
|
|
5-10-O71-1. Survey on the actual use of factor Xa inhibitor neutralizers 濱口綾花, 西田麻以, 小林宏太朗, 赤木晋介, 西村健二, 西江美智子, 徳田衡紀, 高柳和伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 928-928, 2023. |
|---|
|
|
5-10-O71-2. Attempt of visualization and the optimization of the use of antimicrobial by the construction of the antimicrobial evaluation support system during the operation 和知野千春1,2,3, 早川智章1,2, 堀田康弘2,3, 小林紀香2, 堀田祐志2,3, 江崎哲夫2, 日比陽子2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 929-929, 2023. |
|---|
|
|
5-10-O71-3. The use of antimicrobial situation and problem of our hospital based on an old and new AMR measures action plan 高多瞭治, 多賀允俊, 西田祥啓, 政氏藤玄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 930-930, 2023. |
|---|
|
|
5-10-O71-4. Expectation to pharmacist intervention judging from results of the osteoporosis therapeutic drug taste investigation 畝知己1, 影本紀子1, 前田和彦1, 松原菜美1, 渡部里香2, 河野紘輝3, 大本卓二3, 荒木慧3, 小林孝明4, 岡井由美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 931-931, 2023. |
|---|
|
|
5-10-O72-1. The benzodiazepine drugs (BEZ) prescription in patients with old cancer during foreign chemotherapy and examination of the fall risk 岡田咲樂1,2, 満間綾子2, 宮崎雅之3, 池田義明1, 安藤雄一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 933-933, 2023. |
|---|
|
|
5-10-O72-2. Look at the rear of the intervention example in the role - cancer practice cooperation base Hospital single institution of the pharmacist in the metastases to bone practice team; mark investigation ... 兼平暖1, 橋本光弘1, 鈴木麻由香1, 後藤恵美子2, 大澤まりえ3, 小林伶子3, 内野慶太4, 鈴木正寛5, 豊田達也3, 福田明6, 山田高嗣7, 田中昌代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 934-934, 2023. |
|---|
|
|
5-10-O72-3. The case that utilized ICT in the loss of voice patients during pharyngeal cancer outpatient department chemotherapy, and supported the cooperation with multiple medical institutions and area inclusion support systems and hospitalization 鈴木智香子1, 岩高美帆1, 小徳由梨絵1, 大島聖也1, 赤城優希2, 赤城友章2, 山中國暉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 935-935, 2023. |
|---|
|
|
5-10-O72-4. Having been able to see it through a tracing report from the cooperation full addition start for three years 大崎真美1, 疋田絵梨1, 鈴木礼乃1, 村上菜月1, 黒木あかね1, 秦哲磨1, 浦山泰典1, 丸藤義翔2, 岡野咲子2, 安武夫2,3, 城田幹生1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 936-936, 2023. |
|---|
|
|
5-10-O72-5. Efforts to internal use anticancer agent proper use of the outside Parliament prescription and the effect 安江萌夏1, 廣瀬智恵美1, 大畑紘一1, 飯原大稔1,2, 藤井宏典1, 加藤寛子1, 關谷久美子1, 北洞美佳1, 菱田史織1, 山本扇里1, 渡辺大地1, 松岡芹佳1, 安田浩二1, 丹羽隆1, 小林亮1,3, 熊田恵介2, 清水雅仁2,4, 鈴木昭夫1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 937-937, 2023. |
|---|
|
|
5-11-O73-1. The effect that the reporting from a hospital to the health insurance pharmacy gives for the heart failure rehospitalization prevention 岸孝行, 間宮知子, 井出朋子, 根来早紀子, 中尾倫子, 樫葉利人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 939-939, 2023. |
|---|
|
|
5-11-O73-2. Confirmation, instruction of the cancellation medicine before surgery to work on by regional alliances 坂根美和子1, 森谷道生1, 田中みずほ1, 上島聖秀1, 能澤真希子1, 高橋慎太郎1, 山本麗央奈1, 飴谷友菜1, 小林奈瑠美2, 原直子2, 三浦唱子2, 稲村勝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 940-940, 2023. |
|---|
|
|
5-11-O73-3. Local joint ownership of the pharmaceutical products stock information using the Web system 御手洗彰信1, 谷口公章2, 葉田昌生2, 小嶋祐一郎1, 下川要二1, 菅田哲治1, 脇田佳幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 941-941, 2023. |
|---|
|
|
5-11-O73-4. About tracing report use and application by test value, the comment printing every drug to outside Parliament prescription 山本浩史, 延藤勇, 日野裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 942-942, 2023. |
|---|
|
|
5-11-O73-5. Effect - to give to the duties of questionary survey - hospital, the health insurance pharmacy pharmacist about the efforts of the illness medicine cooperation in the foreign chemotherapy 齋藤一樹, 二瓶哲, 大坂紗也佳, 後藤慎平, 於本崇志, 朝賀純一, 工藤賢三 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 943-943, 2023. |
|---|
|
|
5-11-O74-1. Attitude survey of the health insurance pharmacy pharmacist for "a reporting book about the foreign chemotherapy" 栗原昌也, 楠原佳那子, 川澄賢司, 川崎敏克, 松井礼子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 945-945, 2023. |
|---|
|
|
5-11-O74-2. Effect by the tracing report operation of the antiHIV medicine 櫛田宏幸, 祝洸太郎, 溝口捺美, 岸田啓太郎, 矢倉裕輝, 村津圭治, 山下大輔, 吉野宗宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 946-946, 2023. |
|---|
|
|
5-11-O74-3. Practice and the prospects of the medicine medicine cooperation in the HIV practice 泉澤友宏, 金子知由, 妹尾裕美子, 長谷川英雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 947-947, 2023. |
|---|
|
|
5-11-O74-4. Efforts of the medicine medicine cooperation utilizing the drug control summary 北侑未, 森京子, 竹中克之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 948-948, 2023. |
|---|
|
|
5-11-O74-5. Investigation about the information necessary for drug control summary in the psychiatry 坂本靖之1,2, 坂井原美希1, 中島綾夏1, 松田将史1, 田頭尚士1, 大塚茂雄2, 鷹橋紀幸2, 大塚幸三2, 藤田秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 949-949, 2023. |
|---|
|
|
5-11-O75-1. Effect of the efforts about the steroidal osteoporosis prophylaxis utilizing the tracing report 山下修司1, 石原ののこ2, 清木静乃1, 筒井啓登1, 加藤寛子3, 櫻井秀司3, 丹羽今日子3, 河合琢良4, 鈴木昭夫3,5, 林秀樹1,2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 951-951, 2023. |
|---|
|
|
5-11-O75-2. The effect that the difference of the report pattern of the tracing report in the Residual medicine adjustment gives to subsequent change of prescription 福田喬士, 原田貴子, 渡邉愛梨, 下野紀子, 澤田真嗣, 野口裕介, 神田英一郎, 友金幹視 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 952-952, 2023. |
|---|
|
|
5-11-O75-3. Consideration about the present situation report by the operation of a subtracter formulations and the role of the hospital pharmacist 中村雄太郎, 磯部樹里, 今田良樹, 山下勇輝, 眞木秀子, 西村雅次, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 953-953, 2023. |
|---|
|
|
5-11-O75-4. 3 cases that a pharmacist interview before hospitalization led to the drug adjustment by the health insurance pharmacy 若松雄太, 杉生雅和, 新康憲, 今西可奈子, 高子優子, 正置耕一, 吉岡睦展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 954-954, 2023. |
|---|
|
|
5-11-O75-5. Study on polypharmacy screening sheet development to use at a drugstore 神保美紗子1,2,3,4,5, 上野明日香1, 市原千花1, 須田潤1, 溝神文博2, 早川裕二3, 加藤瑛一4, 間瀬広樹5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 955-955, 2023. |
|---|
|
|
IO-01. Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-positive non-small cell lung cancer Tomoki Hori1,2, Kazuhiro Yamamoto2, Takefumi Ito3, Shigeki Ikushima1, Kotaro Itohara2, Yumi Kitahiro2, Tomohiro Omura2, Ikuko Yano2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 957-957, 2023. |
|---|
|
|
IO-02. Population pharmacokinetic analysis and dosing optimization of tacrolimus in lung transplant recipients with itraconazole Ren Takahashi1, Kotaro Itohara1,2, Shunsaku Nakagawa1, Yoshiki Katada1, Mitsuhiro Sugimoto1, Keisuke Umemura1, Katsuyuki Matsumura1, Yuki Shigetsura1, Natsuki Imayoshi1, Yurie Katsube1, Daiki Hira1, Masahiro Tsuda1, Satoshi Imai1, Atsushi Yonezawa1, Takayuki Nakagawa1, Satona Tanaka3, Akihiro Ohsumi3, Daisuke Nakajima3, Miki Nagao4, Hiroshi Date3, Tomohiro Terada1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 958-958, 2023. |
|---|
|
|
IO-03. External Validation of a Risk Prediction Model of Denosumab-Induced Hypocalcemia Developed by Analysis of Hospital-Based Administrative Database Keisuke Ikegami1, Shungo Imai1, Osamu Yasumuro2, Masami Tsuchiya3, Naomi Henmi3, Mariko Suzuki3, Katsuhisa Hayashi3, Chisato Miura3, Haruna Abe3, Hayato Kizaki1, Ryohkan Funakoshi2, Satoko Hori1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 959-959, 2023. |
|---|
|
|
IO-04. Use of machine learning for predicting delirium from the Japanese Adverse Drug Event Report database Koumi Miyasaka1, Mika Maezawa1, Sakiko Hirofuji1, Wataru Wakabayashi1, Satoshi Nakao1,2, Mari Iwata1,3, Yuka Nokura1, Moe Yamashita1, Kensuke Matsui1, Nanaka Ichihara1, Koki Mori4, Tomoaki Yoshimura5, Masatoshi Inden6, Kazuhiro Iguchi7, Mitsuhiro Nakamura1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 960-960, 2023. |
|---|
|
|
IO-05. Population Pharmacokinetics of Tacrolimus in Adult Liver Transplant Patients during the Period of 3 Months to 1 Year Post Transplantation Ningjia Tang1, Shinichirou Maeda1,2, Masahiro Okuda1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 961-961, 2023. |
|---|
|
|
IO-06. Associations between the use of proton pump inhibitors and immune checkpoint inhibitors and the risk of acute kidney injury : a nested case-control study Keiko Ikuta1, Chinami Yamawaki1, Shunsaku Nakagawa1, Natsuki Imayoshi1, Yurie Katsube1, Yuki Shigetsura1, Daiki Hira1, Masahiro Tsuda1, Shinya Yamamoto2, Takeshi Matsubara2, Mokoto Yanagita2, Tomohiro Terada1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 963-963, 2023. |
|---|
|
|
IO-07. Factors associated with failure to undergo secondary examinations after an annual checkup from population-based cohort study (Tsuruoka Metabolomics Cohort Study) Minako Matsumoto, Sei Harada, Miho Iida, Aya Hirata, Kazuyo Kuwabara, Naoko Miyagawa, Tomonori Okamura, Toru Takebayashi Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 964-964, 2023. |
|---|
|
|
IO-08. Impact of ALBI grade on lenvatinib treatment discontinuation due to adverse events in hepatocellular carcinoma patients Daichi Enomoto1,2, Kazuhiro Yamamoto2, Yuki Matsumoto2, Asami Morioka2, Tomohiro Omura2, Shohei Komatsu3, Yoshihiko Yano4, Takumi Fukumoto4, Kohji Takara1, Ikuko Yano2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 965-965, 2023. |
|---|
|
|
IO-09. Evaluating the safety and efficiency of robotic dispensing systems Tomoki Takase1, Norio Masumoto1, Naoki Shibatani1, Fumiaki Tanaka1, Masaki Hirabatake1, Itaru Nishioka2, Hiroaki Ikesue1, Tohru Hashida1,3, Naoshi Koide1,4,5, Nobuyuki Muroi1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 966-966, 2023. |
|---|
|
|
IO-10. Respiratory drugs and antibiotics use before and during COVID-19 in asthma and COPD patients : a quasi-experimental study Sherif Eltonsy1,6, Laila Aboulatta1, Emily Barr2, Christine Leong1,3, Kaarina Kowalec1,4, Joseph Delaney1,5, Jamie Falk1, Silvia Alessi-Severini1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 967-967, 2023. |
|---|
|
|
P0001-3-PM1. The case that it was hard to take the soft capsule (eldecalcitol capsule), and the patients became able to take in the tentative plan of "the simple suspension thickness method" with the tablet 朝倉寛達, 橘田章子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 972-972, 2023. |
|---|
|
|
P0002-3-PM2. Analysis of trends in pre-avoidance reports aimed at implementing appropriate ward operations 高橋千紘1, 曽根敦子1, 平綿洋子1, 丸谷善紀2, 鈴木優司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 973-973, 2023. |
|---|
|
|
P0003-3-PM1. Examination about efforts for the acquisition of the drug global assessment adjustment addition and the evaluation 枝廣茂樹1, 松波寿雄2, 大川浩子2, 河原葉子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 974-974, 2023. |
|---|
|
|
P0004-3-PM2. The establishment of the postoperative pain management team and examination of the usefulness 栗崎貴啓1, 黒田安純1, 赤星璃1, 相方靖史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 975-975, 2023. |
|---|
|
|
P0005-3-PM1. The making of the injection drug incompatibility chart and evaluation of the usefulness in the ICU 岡林由, 宮崎俊明, 筒井由佳, 丸岡由貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 976-976, 2023. |
|---|
|
|
P0006-3-PM2. Fact-finding - of the pharmaceutical intervention that we classified for each relation - anesthesia method of the pharmacist to the perioperative patients 増田博也, 佐々木健志, 川村大輔, 大荒政志, 間千晴, 鹿沼奈央, 梶貴裕, 木原稔文, 青柿和樹, 山崎佳奈, 坪田美風, 松浦克樹, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 977-977, 2023. |
|---|
|
|
P0007-3-PM1. Relation to postoperative pain management in our hospital 黒田幸佑, 浦上知香, 久喜優実, 山野菜穂, 町谷安紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 978-978, 2023. |
|---|
|
|
P0008-3-PM2. Efforts for efficiency and the task shift of ward medication counseling duties 田中こずえ, 高田桃子, 山下恵梨香, 上條美咲, 上西咲穂, 山村智代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 979-979, 2023. |
|---|
|
|
P0009-3-PM1. It is an effect by the addition of the pain-killer after the operation to perioperative clinical path at the appointed hour 真島美佳, 宮原強, 草葉一友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 980-980, 2023. |
|---|
|
|
P0010-3-PM2. Efforts from the nurse evaluation for the ward pharmacist in our hospital to a model ward project start 長田明浩1, 高橋怜史1, 中山美加2, 仲鉢英夫1, 亀谷恵美子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 981-981, 2023. |
|---|
|
|
P0011-3-PM1. Evaluation ... using efforts - template for the secondary bone fracture prevention of patients with proximal thighbone bone fracture 塚田加奈子, 吉良俊彦, 宇野百合香, 瀬名波暢子, 門馬佳代子, 辻井佳代, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 982-982, 2023. |
|---|
|
|
P0012-3-PM2. In the true clinical practice is the intervention of the pharmacist for the use situation of the Xa inhibitor and the dose adequacy directly 岩本祐子, 森光保武, 藤井秀一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 983-983, 2023. |
|---|
|
|
P0013-3-PM1. Attitude survey of efforts and the pharmacist for the perioperative drug control addition 川瀬由莉, 坂井克也, 後藤梓沙, 堀部一晃, 桑山隼, 犬飼真裕, 中島文男, 岩田智樹, 桜田宏明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 984-984, 2023. |
|---|
|
|
P0014-3-PM2. Change of the adequacy of the instruction record for the high-risk medicine by the drug control instruction record template modification and drug control instruction charges calculation 木城美保, 安達明央, 二階堂恵子, 榎本英明, 高山慎司, 後藤一美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 985-985, 2023. |
|---|
|
|
P0015-3-PM1. Survey on the use of clazosentan sodium in our hospital 櫻塲絵梨香1, 大久保莉菜1, 原弘士1, 澤村公志1, 山本郁生1, 三宅茂太2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 986-986, 2023. |
|---|
|
|
P0016-3-PM2. Questionary survey about the study session for the nurses by the ward pharmacist 齊藤晃司, 阿部美知花, 土橋千夏, 七戸菜月, 伊藤直哉, 門間貴大, 高橋健太, 佐々木弘好 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 987-987, 2023. |
|---|
|
|
P0017-3-PM1. The current state of polypharmacy in convalescent rehabilitation wards and cost changes due to medication reduction 加耒由彩1, 江藤康汰1, 今川知香1, 久保和彦2, 河波豊1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 988-988, 2023. |
|---|
|
|
P0018-3-PM2. Change of the number of the periodical internal use agents in aspiration pneumonia-treated patients 花房伸幸1, 小池彩子1, 甲元大樹2, 大道淳二1, 岡崎英子1, 平良奈々1, 竹内誠3, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 989-989, 2023. |
|---|
|
|
P0019-3-PM1. It is a 1 case with suspected bromism by the long-term continuous use of the nonprescription drug including the bromovalerylurea 濱崎浩一1, 松田翔平1, 竹田凌1, 福原伸治1, 西園寺真二1, 山崎美保1, 津田真莉子2, 木村充2, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 990-990, 2023. |
|---|
|
|
P0020-3-PM2. We look at a syndrome and the rear about the side effect at drug origin-related old age and study a mark 早川裕二1, 溝神文博2, 長谷川章3, 間瀬広樹4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 991-991, 2023. |
|---|
|
|
P0021-3-PM1. Examination of the orthopedics surgery case that presented high blood pressure after the operation in our hospital 樽屋志保, 藏本裕信, 長谷川大悟, 大西貴法, 権藤直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 992-992, 2023. |
|---|
|
|
P0022-3-PM2. Intervention pharmaceutical for the patients who complicated myopathy for pseudoaldosteronism with the Shakuyakukanzoto and one case that supported the use of adverse drug reaction relief system 棚町将之1, 田山理恵1, 下田賢一郎1, 森崎崇文1, 杉山留美子1, 星野輝彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 993-993, 2023. |
|---|
|
|
P0023-3-PM1. The sleeping drug addition situation investigation in the tuberculosis ward and duties examination of the pharmacist 喜多智生1,2,3, 岩成敬子1, 溝口莉沙1, 廣川萌1, 西本有紘1, 小橋美由紀1, 上野良夫1, 辰巳由美子2, 尾下豪人3, 池上靖彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 994-994, 2023. |
|---|
|
|
P0024-3-PM2. The case that resulted in a neuromyelitis optica spectrum disorder by nivolumab therapy for patients with progressive renal cell carcinoma 神原諒, 中條悠, 早川太朗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 995-995, 2023. |
|---|
|
|
P0025-3-PM1. A case which made a fool of a candy as herpes zoster treatment, and accompanied meningitis after the building administration 岩鼻優1, 佐々木康弘1, 小野嘉文2, 益子里美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 996-996, 2023. |
|---|
|
|
P0026-3-PM2. Efforts toward treatment and the domiciliary treatment of the patients with super short bowel syndrome 須賀原知世, 鳥山裕稀, 舛友美緒, 川西綾菜, 徳永由紀, 奥村暢子, 三宅沙央莉, 高松祐子, 長澤祥子, 木村真策 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 997-997, 2023. |
|---|
|
|
P0027-3-PM1. Usefulness evaluation about the delirium study session to the nurse by the pharmacist 北村梨菜, 足立易子, 澤井健太, 多賀野正嗣, 堀哲史, 竹田和也, 藤村保夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 998-998, 2023. |
|---|
|
|
P0028-3-PM2. The relation of the pharmacist in the perinatal medical care "conducts questionary survey in the making of the booklet propelling use of aptitude of the drug" and 鈴木真貴子1, 松本ゆいこ1, 森亜樹1, 平野公美1, 宮本康敬1, 川口千香1, 岡田喜親2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 999-999, 2023. |
|---|
|
|
P0029-3-PM1. Examination of the factor to influence the at-home return using the drug-related factor in the convalescent rehabilitation ward 田中絵里子1, 三井奈緒1,2, 中村彰子1,2, 柳原麻里1, 島本一志1,2, 藤原久登2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1000-1000, 2023. |
|---|
|
|
P0030-3-PM2. Construction of the in-hospital system working on the issue of polypharmacy 関恭子1, 長井円香1, 大西政典1, 奥鈴花1, 土佐直子1, 廣田功平2, 井上聖也2, 佐藤稔2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1001-1001, 2023. |
|---|
|
|
P0031-3-PM1. Attitude survey of the physician about the polypharmacy 長井円香, 関恭子, 大西政典, 奥鈴花, 松浦里穂, 村上知奈美, 松村恵理奈, 宮西有紗, 足立聡子, 盛重あずさ, 池田咲樹, 岸井加代子, 先崎健造, 長田知子, 土佐直子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1002-1002, 2023. |
|---|
|
|
P0032-3-PM2. Efforts to the drug control instruction for a seriously disabled child (person) and the protector 高良恵理, 坂口美智子, 西村幾美, 服部雄司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1003-1003, 2023. |
|---|
|
|
P0033-3-PM1. Classification of medicinal effect and drug costs reduction effect accompanied with the polypharmacy improvement in our hospital 上尾正和1, 近藤博紀1, 松本遼太郎1, 河崎一久1, 二階堂邦夫3, 片桐一彦4, 古俵孝明1, 角田恒2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1004-1004, 2023. |
|---|
|
|
P0034-3-PM2. Efforts of the pharmaceutical management by the pharmacist in the urination care team 眞部遥香1, 臼井麻琴1, 宮本乃ぞみ2, 登立裕美2, 首藤佳代子2, 山田杏奈2, 吉留由紀恵3, 篠崎聡1, 新田茜1, 村井宗正1, 本多秀俊1, 村田太郎4, 並木路広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1005-1005, 2023. |
|---|
|
|
P0035-3-PM1. Usefulness evaluation of the rate of application tool of the intravenous-feeding solution 朝倉幹己, 山田将悟, 藤林遼, 橋本咲季, 高橋誠, 田中正臣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1006-1006, 2023. |
|---|
|
|
P0036-3-PM2. Maintenance of the information sharing system of the pharmacist for the perioperative drug control addition calculation 河合美凪, 打田由希, 濱浦弘光, 大谷寧次郎, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1007-1007, 2023. |
|---|
|
|
P0037-3-PM1. A case which suffered from treatment of the diabetes insipidus that craniopharyngioma occurred in postoperatively 吉野禎章1, 高橋彩花1,2, 宮沢唯1, 鶴岡優里1, 菅井一真1, 小川雅史1, 桑原琴1, 秋元敬貴1, 吉若健太郎1, 篠崎浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1008-1008, 2023. |
|---|
|
|
P0038-3-PM2. Survey about the effect that the prescription support of the basic therapeutic drug results in to the prescription situation on heart failure inpatient by the pharmacist 小川侑佳, 岩内大佑, 菱田啓介, 三浦誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1009-1009, 2023. |
|---|
|
|
P0039-3-PM1. Let's increase to the reporting to issuance situation - institution interval of the drug control summary in our hospital! 久岡清子, 増田博也, 合田さやか, 佐々木健志, 澤口友紀, 大荒政志, 川村大輔, 鹿沼奈央, 坂本真衣, 吉川真央, 小滝亜梨紗, 井上萌, 梶貴裕, 青柿和樹, 山崎佳奈, 坪田美風, 黒田悠加 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1010-1010, 2023. |
|---|
|
|
P0040-3-PM2. Efforts with a ward pharmacist and the discharge adjustment nurse for the discharge 古畑俊英1,2, 林美和1, 松島千明2, 六波羅孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1011-1011, 2023. |
|---|
|
|
P0041-3-PM1. Role of the pharmacist at preparation introduction for the amikacin inhalation 地田凌, 鈴木亮平, 溝口和代, 滝久司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1012-1012, 2023. |
|---|
|
|
P0042-3-PM2. Risk management effect to be obtained as a ward pharmacist confirms medicine set Distribution of medicine 本木邦明, 大澤祐樹, 西久保龍男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1013-1013, 2023. |
|---|
|
|
P0043-3-PM1. Efforts and evaluation to the simple suspension method proper use in the Handa City solder hospital neurosurgery ward 吉川直利, 横田学, 板倉由縁, 伊藤実優 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1014-1014, 2023. |
|---|
|
|
P0044-3-PM2. Intervention to a postoperative pain team round in our hospital 渕上翔太1, 天野杏南1, 村井陽一1, 水谷早希2, 木全司1, 棚橋順治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1015-1015, 2023. |
|---|
|
|
P0045-3-PM1. Activity result of the urination care team in our hospital 林剛史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1016-1016, 2023. |
|---|
|
|
P0046-3-PM2. About the relation of efforts and the pharmacist of the secondary bone fracture prevention team 野里直子1, 佐藤浩二1,2, 香川雅一1,2, 西岡達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1017-1017, 2023. |
|---|
|
|
P0047-3-PM1. Fact-finding of the use of postoperative pain-killer situation in the Fukuoka Saiseikai Fukuoka General Hospital gynecology 二神咲子, 由井薗陽一, 槙林智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1018-1018, 2023. |
|---|
|
|
P0048-3-PM2. Effect on postoperative pain by the use of brochure at PCA explanation 黒田安純, 栗崎貴啓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1019-1019, 2023. |
|---|
|
|
P0049-3-PM1. Investigation of tablet dysphagia in the person with a physical disability institution using PILL-5 浜田茂明, 山本一輝, 森本真仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1020-1020, 2023. |
|---|
|
|
P0050-3-PM1. About fact-finding of the pharmaceutical participation of the ward pharmacist in the perioperative drug control addition calculation patients 濱浦弘光, 河合美凪, 打田由希, 大谷寧次郎, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1023-1023, 2023. |
|---|
|
|
P0051-3-PM2. Efforts to establish a system for the use of a direct-acting factor Xa inhibitor reversal agent (andexanet alfa) 桃原周杜1, 佐藤誠一1, 坂本広登2, 高野耕一郎1, 小林澄雄3, 前島光廣1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1024-1024, 2023. |
|---|
|
|
P0052-3-PM1. A case which a pharmacist participated in in the multi-type of job ethic conference for the terminal phase in the emergency ward 新井花緒, 植田有希, 中井綾乃, 大橋明歩, 平高拓, 堀友紀, 立川奈保美, 沖山美都子, 山東真寿美, 藤田敬子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1025-1025, 2023. |
|---|
|
|
P0053-3-PM2. Evaluation of Ward Pharmacists' Work in an Open Intensive Care Unit - Verification of Pre-Avoid - 荒川希美, 西田祥啓, 高橋喜統, 政氏藤玄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1026-1026, 2023. |
|---|
|
|
P0054-3-PM1. In the postoperative pain management team in the friendship medical center, the multi-type of job cooperation is a key 小杉卓大1, 金城勝大1, 宮良遥奈1, 藤田翔1, 吾津千秋1, 梶原理恵2, 宜保さと子3, 赤嶺智教3, 新里泰一3, 國分千代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1027-1027, 2023. |
|---|
|
|
P0055-3-PM2. Fact-finding about the prescription inspection of the thrombomodulin alpha in the infection-related DIC treatment 今浦将治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1028-1028, 2023. |
|---|
|
|
P0056-3-PM1. Efforts of the pharmacist at in-hospital sudden change (Code Blue) in our hospital occurrence 保志場康人, 山口茉由夏, 古賀彩花, 清水和香, 小山奈津実 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1029-1029, 2023. |
|---|
|
|
P0057-3-PM2. Treatment efficiency accompanied with the task sharing practice in the intensive care unit and effect on safety 堤克成1,2,3, 本田勝亮1, 柏原道志1, 長岡翔1, 塩田亮介1, 石野清亮1, 立石実2, 小出昌秋2, 渥美生弘3, 土手尚3, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1030-1030, 2023. |
|---|
|
|
P0058-3-PM1. Duties burden reduction effect of other types of job by the operating room permanent residence of the pharmacist 糸山佳奈子1, 行武由美子1, 小林夕莉1, 當真菜央1, 知念ほのか1, 水摩ひかり1, 有銘千賀子1, 宮川千珠1, 井上理美1, 田仲祐子1, 森智子1, 喜多洋嗣1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1031-1031, 2023. |
|---|
|
|
P0059-3-PM2. Cooperation example of the operating room pharmacist in the perioperative medical therapy 宮本佳奈, 柴田ゆうか, 板村まりの, 三好真希子, 松尾裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1032-1032, 2023. |
|---|
|
|
P0060-3-PM1. It is one patient with suspected toxicoderma (bromoderma) with disturbance of consciousness by the potassium bromide with pseudo hyperchloremia subsequently 藏本裕信1, 中村英夫2, 濱英雄3, 権藤直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1033-1033, 2023. |
|---|
|
|
P0061-3-PM2. The current situation and problem of the proton pump inhibitor long-term use patients in the intensive care unit 石木仁美, 横山夏季, 重松舞, 奥迫彩華, 玉城亜寿香, 和泉勝一, 白木萌, 坂口結斗, 府川祥子, 喜多洋嗣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1034-1034, 2023. |
|---|
|
|
P0062-3-PM1. The current situation of the patients who consulted a critical care center by medication in large quantities 榊原洋一, 野崎達也, 伊藤実優, 横田学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1035-1035, 2023. |
|---|
|
|
P0063-3-PM2. Effect on adsorption of the antiMRSA medicine in the sustained hemofiltration dialysis circuit model using AN69ST membrane hemofilter 稲野祥宗1, 土屋香代子1, 熊野諒太1, 三浦剛1, 仲佐啓詳1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1036-1036, 2023. |
|---|
|
|
P0064-3-PM1. Clinical usefulness evaluation of kit SIGNIFYTMER for the drug intoxication detection 濱田一成 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1037-1037, 2023. |
|---|
|
|
P0065-3-PM2. Examination of the usefulness of the loading dose in the decreased renal function case of the seriously ill section and the sustained hemocatharsis introduction case 小林洋平1, 釜野健太郎1, 中川貴弘1, 河津敏明1, 烏野隆博1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1038-1038, 2023. |
|---|
|
|
P0066-3-PM1. A case which they presented with acute renal failure during purulent gonitis treatment and became the cefepime encephalopathy, and suffered from treatment 鳥海未奈1, 松沼悟1, 吉元公一1, 蒲原英伸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1039-1039, 2023. |
|---|
|
|
P0067-3-PM2. Operation of the bowel movement protocol in the intensive care unit and the evaluation 畠山英司1, 今浦将治1, 宮田慎也1, 岡部賢司1, 金田明子2, 高橋宏行3, 菅野浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1040-1040, 2023. |
|---|
|
|
P0068-3-PM1. One case of patients with methanol poisoning saved by early ethanol administration 北島健士1, 松木美幸1, 田中一平1, 原俊輔2, 柴崎功1, 原田尚重2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1041-1041, 2023. |
|---|
|
|
P0069-3-PM2. Efforts for the order unionization of the injection high risk medicine in the care unit 西村健二, 亀井健人, 赤木晋介, 徳田衡紀, 高柳和伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1042-1042, 2023. |
|---|
|
|
P0070-3-PM1. Evaluation of the super acute phase ward training in the Okayama University hospital pharmacy using the upbringing 22nd report customer satisfaction analysis of the pharmacist carrying the next generation 大川恭昌1, 久保和子1, 真鍋洋平1, 川西秀明1, 上田久美子1, 村尾卓哉1, 宮本朋佳2, 佐田光1, 勝部理早1, 猪田宏美1, 濱野裕章1, 西原茂樹1, 村川公央1, 座間味義人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1043-1043, 2023. |
|---|
|
|
P0071-3-PM2. Satisfaction investigation of the emergency visit (ER) training for the new face pharmacists by the pharmacist engaging in emergency care 高橋雪乃, 宮田祐一, 岩崎睦, 藤村一軌, 中村雅敏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1044-1044, 2023. |
|---|
|
|
P0072-3-PM1. Relation of the pharmacist to postoperative pain management team duties construction 日江井和英1, 土本暁斗1, 安田翔1, 中村英嗣1, 高澤圭輔1, 松由幸司1, 宮部芳之1, 若尾留美2, 山崎潤二3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1045-1045, 2023. |
|---|
|
|
P0073-3-PM1. Inspection of the effect that calculation, the measurement formulations of the injection drug give to a task share 乾佐登子, 郡妙恵, 山田美映子, 篠崎聡, 新田茜, 村井宗正, 本多秀俊, 林由紀子, 並木路広 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1049-1049, 2023. |
|---|
|
|
P0074-3-PM2. About the prescription representation input (PBPM) introduction after doubt inquiry by the pharmacist for the oral anticancer medicine 伴修平, 橋本幸輝, 羽鳥正浩, 鈴木莉羅, 木村俊哉, 古谷良太, 鈴木亘, 蓑輪雄一, 瀧口友美, 川上和宜, 清水久範, 山口正和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1050-1050, 2023. |
|---|
|
|
P0075-3-PM1. It is ... for the efficiency of the burden reduction of efforts ... physician of the representation correction of the prescription by the pharmacist and the duties of the pharmacist 南利彩子, 増川みなみ, 吉田敏人, 佐々木美緒, 寺沢匡史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1051-1051, 2023. |
|---|
|
|
P0076-3-PM2. The safety assessment after the task shift to a non-pharmacist: Effect on incident incidence by the pharmacist in compounding of medicines duties 齊藤茉子, 安島秀友, 杉村春奈, 松崎貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1052-1052, 2023. |
|---|
|
|
P0077-3-PM1. Dose adjustment ... of PBPM introduction effect and the problem - Total Knee Arthroplasty (TKA)/total hip replacement (THA) postoperative edoxaban in the orthopedics domain 森菜々美, 藤井若奈, 多留木崇志, 村田龍宣, 小野勝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1053-1053, 2023. |
|---|
|
|
P0078-3-PM2. It is evaluated the instructions support protocol one package of the in-hospital prescribed medicine by the pharmacist 松本夢実, 宮原強, 草葉一友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1054-1054, 2023. |
|---|
|
|
P0079-3-PM1. Effect of task shift/share after the substitute suggestion introduction of the bringing medicine by the set input 中川ちひろ, 井出和男, 濃野乃文, 若杉正, 小池博文, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1055-1055, 2023. |
|---|
|
|
P0080-3-PM2. Effect of task shift/share in the Shinshu medical center pharmacy 三澤貴美1, 大塚さほり1, 香川貴亮1, 有賀敦1, 田中健二1, 堀勝幸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1056-1056, 2023. |
|---|
|
|
P0081-3-PM1. Examination about the duties efficiency by a task shifting bringing medicine order issuance from a physician to a pharmacist 菅直恵1, 西村健二1, 石田亮2, 亀井健人1, 赤木晋介1, 徳田衡紀1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1057-1057, 2023. |
|---|
|
|
P0082-3-PM2. The PBPM introduction results in the Secomedic Hospital and examination about the task share 西須永実理1, 山田浩介1, 勝田良子1, 島盛一郎1, 渡辺孔明1, 長澤宏之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1058-1058, 2023. |
|---|
|
|
P0083-3-PM1. Task shift/share promotion and effect of the pharmacist duties by the drug duties assistant 西岡達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1059-1059, 2023. |
|---|
|
|
P0084-3-PM2. Duties efficiency by efforts - task shift to attractive pharmacy construction and central operational ... 吉成宏顕1, 佐藤淳也3, 大矢智則1,2, 玉井一也1, 宮内輝人1, 久保倫美1, 風岡真実1, 入野真紀1, 梅田鈴香1, 守田侑真1, 神坐美弥子1,2, 橋本竜1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1060-1060, 2023. |
|---|
|
|
P0085-3-PM1. Task share with the floor nurse in simple suspension confirmation duties 松西葵1, 川上隆弘1, 松本和也1, 花房伸幸1, 土屋絵莉子1, 河村茉衣1, 平井淳子1, 渡部咲輝2, 三宅裕子2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1061-1061, 2023. |
|---|
|
|
P0086-3-PM2. It is a proper use investigation of the infection prophylaxis antimicrobial after the drug and the operation that cancellation needs preoperatively in the perioperative drug control addition duties of the Nippon Life Insurance Co. Hospital 池田久雄, 平田貴宏, 千原亜紀子, 森岡浩子, 宮原阿友美, 神原弘和, 足立充司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1062-1062, 2023. |
|---|
|
|
P0087-3-PM1. Establishment of the preoperative pharmaceutical intervention system in cooperation with hospitalization and release support section 遠藤栞奈1, 堀之内藍1, 小泉綾乃1, 庄司沙織2, 鈴木しのぶ2, 上野達也2,3, 田中敏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1063-1063, 2023. |
|---|
|
|
P0088-3-PM2. Usefulness evaluation to a task having shifted Distribution of medicine duties to a non-pharmacist 鈴木寛人, 松野真梨子, 板倉愛, 山崎みわ子, 岡部翔太郎, 上地めぐみ, 山城武志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1064-1064, 2023. |
|---|
|
|
P0089-3-PM1. Efforts of the hepatitis measures for patients who received chemotherapy by the pharmacist using PBPM 渡部寿康1, 武藤芳和1, 菊地洋平1, 二階堂雄平2, 佐藤隆昭2, 新國智子3, 野地静香3, 市橋淳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1065-1065, 2023. |
|---|
|
|
P0090-3-PM2. Construction of the input support system of the examination for blood drug concentration order by the critical care center working full time pharmacist 吉川直樹1, 是枝秀彦1, 松崎裕紀1, 宮田千秋1, 畠中健吾2, 平原康寿1, 岩切智美1, 落合秀信2, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1066-1066, 2023. |
|---|
|
|
P0091-3-PM1. Inflection of PBPM for the appropriate enforcement of the vancomycin TDM order in first aid, the intensive care 鎌田里紗1,2, 田村亮1, 藤田拓俊1, 瀬尾龍太郎2, 平畠正樹1, 橋田亨1, 室井延之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1067-1067, 2023. |
|---|
|
|
P0092-3-PM2. Evaluation for the practice of the TDM by PBPM 鶴村真大1, 長山優介1, 井幡圭佑1, 東加奈子1, 島田浩1, 大城美希1, 藤吉徹也1, 大井美和1, 寺本有里2, 藤尾みどり1, 村田久枝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1068-1068, 2023. |
|---|
|
|
P0093-3-PM1. PBPM in the skin care team for the onset of dermatopathy patients in the antiEGFR antibody medicine is one case of rectal cancer that it showed contribution for treatment continuation 久保村優1,2, 輪湖哲也1,2, 伊勢雄也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1069-1069, 2023. |
|---|
|
|
P0094-3-PM2. Attempt of the task shift in chemotherapy duties of our hospital 曽根章貴, 生駒辰夫, 石橋里穂, 大塚祐紀子, 高澤圭輔, 安田翔, 近藤章吾, 山口雄士, 松由幸司, 宮部芳之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1070-1070, 2023. |
|---|
|
|
P0095-3-PM1. Effect of the examination order support based on PBPM in the foreign cancer medical therapy 梁川稔規1, 片岡幸三2, 山下典子1, 柳井美奈1, 田中邦佳1, 板東純子1, 福田知子1, 宮崎美貴子1, 緒方文洪1, 平山未佑1, 久保亜里菜1, 池田正孝2, 木村健1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1071-1071, 2023. |
|---|
|
|
P0096-3-PM2. For practice of PBPM, it is questionary survey about the representation order by the pharmacist 新倉匠, 市川慶, 大谷隆之, 栗山明子, 八木仁史, 高田宏文, 河井良智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1072-1072, 2023. |
|---|
|
|
P0097-3-PM1. Survey of the vancomycin administration protocol operation situation in our hospital 田口諒, 元木孝, 渡邊清人, 高柳昌宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1073-1073, 2023. |
|---|
|
|
P0098-3-PM2. Efforts of the task shift of the specific antimicrobial report duties by the ward pharmacist 東恩納司, 森下陽介, 川西秀明, 大川恭昌, 村尾卓哉, 平山知美, 大月理恵子, 勝部理早, 濱野裕章, 村川公央, 座間味義人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1074-1074, 2023. |
|---|
|
|
P0099-3-PM1. Investigation of the usefulness of the cartridge for the suspension exercise in the blender operation instruction of the biphasic insulin preparation 鎌田敬志1, 虎石顕一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1075-1075, 2023. |
|---|
|
|
P0100-3-PM2. The current situation and the prospects of the postoperative pain management team activity in the Osaka Red Cross hospital 吉良俊彦, 木下里紗, 吉野秀紀, 辻井佳代, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1076-1076, 2023. |
|---|
|
|
P0101-3-PM1. Expansion targeted for the comprehensive prior agreement protocol in the outside Parliament prescription and the effect 吹上勇真1, 宮崎元康1,2, 久留須恭香1, 後藤美和1, 鵜木亜矢子1, 前山明香1, 中島章雄1,2, 今給黎修1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1077-1077, 2023. |
|---|
|
|
P0102-3-PM2. Operation of the doubt inquiry prior agreement protocol in the outside Parliament prescription 最勝寺雅広, 田所正年, 上村豪 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1078-1078, 2023. |
|---|
|
|
P0103-3-PM1. The invention about confirmation of common use medicine before hospitalization aiming at the number of doubt inquiries reduction duties and examination about the usefulness 緒方健二1, 祖川倫太郎1, 湯川美紗子1, 加茂真宏1, 江本晶子1, 木村早希子1, 吉田ひとみ2, 江崎幹宏2, 島ノ江千里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1079-1079, 2023. |
|---|
|
|
P0104-3-PM2. The effect that prescription support based on the protocol of the ward pharmacist gives for an internal use-related incident 杉本智哉1, 小園利加2, 杉野晃希1, 山田和奈1, 納富智基1, 遠山幸男1, 久田達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1080-1080, 2023. |
|---|
|
|
P0105-3-PM1. About the efforts of an operating room pharmacist and the ward pharmacist in surgery and the modified type electroconvulsive therapy 水谷妙子, 原かおる, 五味裕大, 杉村博基, 北原和花子, 木村奈波, 佐藤伶奈, 清水颯人, 松尾治樹, 登内盛治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1081-1081, 2023. |
|---|
|
|
P0106-3-PM2. Introduction of the member of functional pharmacy for the purpose of task shift/share from a pharmacist in the cottage-hospital out of the district 岸本真1, 徳丸章佳1, 北園幸大1, 田中恭人1, 池沢若菜1, 森永崇史1, 中村杏果1, 石渡美樹1, 徳永楓果1, 栗田泰樹1, 上野菜巳1, 上野怜良1, 屋敷大輔1, 淵脇ゆかり1, 長ヶ原琢磨1, 荻尾夕起子1, 児玉友和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1082-1082, 2023. |
|---|
|
|
P0107-3-PM1. Doubt inquiry contents and problems after the outside Parliament prescription doubt inquiry simplification protocol (inside the hospital-adaptive) introduction 山内章嗣, 西村亮, 原田卓弥, 磯部佳歩, 松岡勇作, 奥野昌宏, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1083-1083, 2023. |
|---|
|
|
P0108-3-PM2. Examination of the intervention number of patients after the postoperative pain management team start in our hospital 柏原聖人1, 滝浪素由1, 石田恵章2,3, 鳥羽好恵3, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1084-1084, 2023. |
|---|
|
|
P0109-3-PM1. Examination - in attempt - oral proton pump inhibitor to drug costs reduction by the medicine charge writing together to the drug name on the prescription system 松沼悟, 磯貝博之, 吉元公一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1087-1087, 2023. |
|---|
|
|
P0110-3-PM2. Risk of developing diabetes in the hypertriglyceridemia 藤田和暉, 上條千尋, 関口佳純, 矢島綾美, 米盛由喜, 菅野淳史, 西圭史, 辻泰弘, 大場延浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1088-1088, 2023. |
|---|
|
|
P0111-3-PM1. Effect on chronic kidney disease (CKD) by the use of angiotensin II receptor antagonist (ARB) 市川颯人, 伊与久翼, 中村光穂, 内田菜々子, 菅野淳史, 大場延浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1089-1089, 2023. |
|---|
|
|
P0112-3-PM2. About the expression situation and the folinic acid preparation combination of the methotrexate-related lymphoproliferative disorder 村上正樹, 石原慎之, 玉木宏樹, 矢野貴久, 直良浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1090-1090, 2023. |
|---|
|
|
P0113-3-PM1. Costs minimization analysis - using medical economical impact - real world data of the Chinese medicine in comparison with the Western medicine for common cold treatment 赤瀬朋秀1,5, 田中里園2, 新井信3, 湯本哲郎4, 豊島久雄5, 土屋孝範5, 濃沼政美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1091-1091, 2023. |
|---|
|
|
P0114-3-PM2. Search of the factor affecting the collect rate of the sortation equipment one package 稲垣晃熙, 谷江梨奈, 山本恭平, 植松夏子, 奥平正美, 杉浦洋二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1092-1092, 2023. |
|---|
|
|
P0115-3-PM1. It is evaluated the usefulness about the hospital management of the tablet sortation equipment one package that considered a return working hour 谷江梨奈, 稲垣晃熙, 山本恭平, 植松夏子, 奥平正美, 杉浦洋二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1093-1093, 2023. |
|---|
|
|
P0116-3-PM2. Analysis of the factor to have an influence on the adherence of the dyslipidemia therapeutic drug through "knob medicine bag motion" 立麻香帆1, 猪阪日向子1, 國武さくら1, 小林大介1, 川尻雄大1, 木原太郎2, 高木淳一2, 田中泰三2, 赤嶺裕之3, 阿部みどり3, 濱野明子4, 浅尾一夫4, 島添隆雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1094-1094, 2023. |
|---|
|
|
P0117-3-PM1. Examination of single use of vial multiple times and Residual medicine reduction by the new capacity standard introduction that paid their attention to bendamustine medication method and the exposure risk reduction effect 宇佐美英績1, 浅野裕紀1, 福岡智宏2, 兼松哲史3, 木村美智男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1095-1095, 2023. |
|---|
|
|
P0118-3-PM2. Investigation of the economical effect by the reuse of the disposal factor and the cancellation drug after the anticancer medicine preparation 柳野紗智子1, 菊池由宣2, 有田仁紀1, 渡辺和美1, 宮田祥一1, 菅井瞳1, 坂本真紀1, 島田英昭3, 松本高広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1096-1096, 2023. |
|---|
|
|
P0119-3-PM1. An association between use and inborn character malformation of the child born of the Ephedra-containing Chinese medicine in the early stage of the pregnant woman: Northeastern medical megabank plan three generations cohort study 野田あおい1,2,3, 小原拓1,2,3, 松崎芙実子1,2, 小原竜1,2, 森下啓2, 上野史彦2,3, 篠田元気1,2, 大類真嗣1,2, 村上慶子1,2, 石黒真美1,2, 栗山進一1,2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1097-1097, 2023. |
|---|
|
|
P0120-3-PM2. A change of the number of the drugs of the at-home visit patients and examination of drug costs 滝澤康志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1098-1098, 2023. |
|---|
|
|
P0121-3-PM1. Time-series analysis of search data of Google about the Web search behavior of the cannabis and Wikipedia 牛尾聡一郎1, 江角悟2, 江口幸臣1,3, 入江圭一1, 佐野和憲1, 三島健一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1099-1099, 2023. |
|---|
|
|
P0122-3-PM2. Cost effect analysis of the glaucoma therapeutic drug 坂本優佳1, 中川直人1, 柏原正美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1100-1100, 2023. |
|---|
|
|
P0123-3-PM1. Cost effectiveness analysis about the uric acid synthase inhibitor 鈴木拓磨, 中川直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1101-1101, 2023. |
|---|
|
|
P0124-3-PM2. Cost effect analysis of the antihistamine for the perennial allergic rhinitis 菅野静輝, 中川直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1102-1102, 2023. |
|---|
|
|
P0125-3-PM1. The effect that loperamide gives to CYP2J2 enzyme activity 加藤美紀, 灘井雅行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1104-1104, 2023. |
|---|
|
|
P0126-3-PM2. Comparison of midazolam metabolism in human liver microsomes under the temperature of temperature management therapy 井上知美, 石橋芙起, 加藤理乃, 中原良太, 石渡俊二, 小竹武 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1105-1105, 2023. |
|---|
|
|
P0127-3-PM1. Examination of the xanthine oxidoreductase activity in the apoplectic easy onset hypertensive spontaneous rat liver 藤井千穂, 田山剛崇, 森脇智也, 前田志津子, 杉原数美, 三宅勝志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1106-1106, 2023. |
|---|
|
|
P0128-3-PM2. Pharmacokinetic characteristic of α 2 receptor agonist dexmedetomidine in the In vivo membrane oxygenator model rat out of the body 佐藤雄己1, 元石恵理奈1, 花田実夢1, 半田 (永塚) 由佳1, 阿部拓也2, 藤井豊2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1107-1107, 2023. |
|---|
|
|
P0129-3-PM1. The best case of the non-small cell lung cancer which we suggested the blood level measurement that disturbance of consciousness developed after the sotorasib start and excluded a drug adverse effect, and to evaluate it and connected with administration resumption 仲鉢英夫1, 北爪教貴1, 丸藤義翔2, 安武夫2, 鎌田理子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1109-1109, 2023. |
|---|
|
|
P0130-3-PM2. Examination about the correlation of the UHPLC-MS/MS, LTIA in blood Everolimus densitometry and ACMIA method 宮城知佳, 白岩健, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1110-1110, 2023. |
|---|
|
|
P0131-3-PM1. Blood level prediction of the Teicoplanin based on cystatin C in patients with neurologic intractable disease 山科卓也1, 山崎貴史2, 青柳千愛1, 下村真代1, 平木洋一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1111-1111, 2023. |
|---|
|
|
P0132-3-PM2. Usefulness of STAT3 genetic polymorphism and the sorafenib blood level for the sorafenib-induced hand-and-foot syndrome in the progress hepatocellular carcinoma 高塚博一1,2, 菅原隆人2, 内田雅士1,2, 山崎伸吾1, 鈴木貴明1,2, 石井伊都子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1112-1112, 2023. |
|---|
|
|
P0133-3-PM1. Practice of the mycophenolic acid AUC calculation by LSS in heart-transplant recipients and examination of the aim area 永田理香子1, 井倉恵1, 中村任2, 島本裕子1, 上野智子1, 渡邊琢也3, 塚本泰正3, 川端一功1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1113-1113, 2023. |
|---|
|
|
P0134-3-PM2. Transitional evaluation out of correlation with the blood level based on the densitometry out of the brain of the Perampanel and the brain 植田優花1, 川田将義1, 平大樹1, 米澤淳1, 峰晴陽平2, 溝田敏幸3, 山尾幸広2, 古川恵子4, 中川俊作1, 津田真弘1, 荒川芳輝2, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1114-1114, 2023. |
|---|
|
|
P0135-3-PM1. Frequencies of Augmented Renal Clearance of patients with injury in the critical care center 中野貴文1,2, 弓彩華1, 青柳美紗希1, 仲村佳彦3, 林稔展1, 石倉宏恭3, 神村英利2, 松尾宏一1,2, 江川孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1115-1115, 2023. |
|---|
|
|
P0136-3-PM2. One case that was available for the control of the thyroid hormone level by administration of oral levothyroxine preparation for patients with short bowel syndrome 横山恵里南, 松屋翔太, 林洋平, 兼行由佳, 福澤正隆, 竹田克明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1116-1116, 2023. |
|---|
|
|
P0137-3-PM1. One case of aplastic anemia that intervention to the administration plan of the cyclosporine note was useful for the patients who were hard to be given it orally 水岡大策1,2, 山口佳津騎2, 篠原尚樹1, 元木貴大1, 田中裕章1, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1119-1119, 2023. |
|---|
|
|
P0138-3-PM2. Examination of the clinical factor affecting the early acute renal failure onset in the vancomycin administration 鎌田裕介, 菅野雄太, 斯波将史, 高村誠人, 鈴木奏絵, 吉岡熏, 本川聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1120-1120, 2023. |
|---|
|
|
P0139-3-PM1. A case which had difficulty in removal of the Teicoplanin by the haemodialysis with the polysulfone membrane 西山菜摘, 青戸和宏, 小阪直史, 四方敬介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1121-1121, 2023. |
|---|
|
|
P0140-3-PM2. Examination for the high sensitive fixed-quantity and blood voriconazole levels prediction of the melatonin using two kinds of stable isotope labeling compounds 藤吉正哉, 山本達郎, 島田美樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1122-1122, 2023. |
|---|
|
|
P0141-3-PM1. Analysis of the background factor requiring the peak blood level measurement in the AUC estimate of patients receiving vancomycin 佐藤ありす, 吉川直樹, 松崎裕紀, 是枝秀彦, 山田侑世, 保田和哉, 平原康寿, 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1123-1123, 2023. |
|---|
|
|
P0142-3-PM2. Management of the AUC using C12 obtained by administration in the tacrolimus extended-release night kidney transplantation one year later 高橋優聡1, 中村雄亮1, 大野真史1, 助畑歩1, 三浦正義2, 東山寛2, 小森均1, 深井敏隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1124-1124, 2023. |
|---|
|
|
P0143-3-PM1. Investigation of the effect that peritonitis gives to the blood level after the vancomycin peritoneal dialysis fluid coinfusion administration of peritoneal dialysis patients 高嶋祥匡, 高橋弘泰, 市江敏和, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1125-1125, 2023. |
|---|
|
|
P0144-3-PM2. 1 case that blood voriconazole levels decreased by pneumonia symptom improvement complicated with COVID-19 竹崎正明, 山本達郎, 齋木雄介, 小玉菜央, 藤吉正哉, 島田美樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1126-1126, 2023. |
|---|
|
|
P0145-3-PM1. Voriconazole out of the dialytic fluid by the high performance liquid chromatography and phenytoin pro-simultaneous measurement development 青山隆彦, 工藤佑介, 並木一朗, 松本宜明, 辻泰弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1127-1127, 2023. |
|---|
|
|
P0146-3-PM2. Monitoring blood concentrations in patients receiving additional CYP3A4 inhibitors during the venetoclax maintenance phase 久保利樹1, 祖川倫太郎1, 松尾俊佑1, 安武夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1128-1128, 2023. |
|---|
|
|
P0147-3-PM1. Development of the assay of the sunitinib in the human nail using the LC-MS/MS analysis 里美貴1, 八島秀明2, 荒木拓也2, 大林真幸1, 神山紀子1, 山本康次郎2, 向後麻里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1129-1129, 2023. |
|---|
|
|
P0148-3-PM2. Examination about Teicoplanin blood level and the high-dose loading dose 唐川聖司1, 松岡怜1, 酒井義朗1, 國武正幸1, 上瀧喬仁1, 樋口恭子1, 渡邊浩2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1130-1130, 2023. |
|---|
|
|
P0149-3-PM1. Investigation about the estrangement of a trough guide and the AUC guide in the TDM of vancomycin 伊藤悠里子1,2, 久保茜1, 友寄旬1,2, 山下友輝1, 村中一大1, 樋浦一哉3, 棚谷貢1, 船木映二1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1131-1131, 2023. |
|---|
|
|
P0150-3-PM2. Examination of the usefulness of the Teicoplanin concentrations revision in patients with hypoalbuminemia 多賀野正嗣, 浜田凌介, 澤井健太, 堀哲史, 竹田和也, 藤村保夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1132-1132, 2023. |
|---|
|
|
P0151-3-PM1. Efforts and the current situation report of the TDM which assumed Area under the Blood Concentration Time Curve (AUC) of vancomycin (VCM) in our hospital an index 村田翔, 芳山健太郎, 川崎亮輔, 相原敏彦, 仲鉢英夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1133-1133, 2023. |
|---|
|
|
P0152-3-PM2. Education effect of the AST charge pharmacist on vancomycin initial loading dose 植竹宣江, 立川文崇, 本岡真弥, 國重将大, 村上礼隆, 北本真一, 宮森伸一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1134-1134, 2023. |
|---|
|
|
P0153-3-PM1. The current situation investigation of medication method and the renal failure incidence of vancomycin 鈴川誠, 内山耕作, 平尾祐樹, 芥子川純里, 出口真人, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1135-1135, 2023. |
|---|
|
|
P0154-3-PM2. The effectiveness of the loading dose to a decreased renal function case of the Teicoplanin in the Gifu comprehensive medical care center, safe examination 尾藤里奈, 小栗良介, 関谷泰明, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1136-1136, 2023. |
|---|
|
|
P0155-3-PM1. Examination about the difference in administration recommendation quantity of two points of blood vancomycin levels drawing blood and one point of drawing blood using PAT in our hospital 只佐宣子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1137-1137, 2023. |
|---|
|
|
P0156-3-PM2. Examination about the loading dose to patients with severe impaired renal function of the Teicoplanin 川端俊介, 松屋翔太, 福澤正隆, 竹田克明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1138-1138, 2023. |
|---|
|
|
P0157-3-PM1. Usefulness evaluation of new software practical AUC-guided TDM (PAT) in the childhood vancomycin TDM 中村成志, 福元裕介, 東和博, 瀬戸口誠, 有馬純子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1139-1139, 2023. |
|---|
|
|
P0158-3-PM2. 1 case that we performed TDM of vancomycin through before and after childbirth for the infective endocarditis that occurred during pregnancy 渡邊瑛理, 富島喜朗, 古庄弘和, 早野聡史, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1140-1140, 2023. |
|---|
|
|
P0159-3-PM1. Establishment of a plasma concentration measurement system for vadadustat using HPLC-UV method 横山智士1, 中川潤一1, 島田美智子2, 上野桂代1, 石山雅大3, 中村典雄1,4, 富田泰史5, 新岡丈典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1141-1141, 2023. |
|---|
|
|
P0160-3-PM2. Blood level during the thiamylal sustained administration in children and the effectiveness, safety assessment 平田憲史郎1, 小原隆史2, 渡邊博志3, 古庄弘和4, 陣上祥子4, 丸山徹3, 平井克樹5, 石黒貴子1, 宮村重幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1142-1142, 2023. |
|---|
|
|
P0161-3-PM1. Development of the quick assay of nintedanib and tacrolimus using LC-MS/MS 鈴木南緒1, 松下紗季2, 山崎瑞季1,3, 廣瀬智恵美3, 山田悠人1,3, 飯原大稔1,3, 柳瀬恒明4, 遠渡純輝4, 山下修司1, 鈴木昭夫1,3, 林秀樹1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1143-1143, 2023. |
|---|
|
|
P0162-3-PM2. Usefulness evaluation of the vancomycin initial administration method nomogram of our hospital making 古川早矢香, 高橋希, 河野綾香, 梶野哲, 佐藤浩太郎, 鈴木信也, 井口恵美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1144-1144, 2023. |
|---|
|
|
P0163-3-PM1. It is a case receiving LVFX to the low weight patients 野口遥1, 長峰守2, 川端康太1, 村山美輝3, 田村賢士1, 前田佳真3, 立花栄三1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1145-1145, 2023. |
|---|
|
|
P0164-3-PM1. Fact-finding of the checking prescription affecting the preparation of the immune checkpoint inhibitor 古田裕幸1, 窪田悠希1, 石田晶子1, 米田詩織1, 荒谷恭子1, 前田裕行1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1147-1147, 2023. |
|---|
|
|
P0165-3-PM2. Safe examination of the Pola-R-CHP therapy for DLBCL in our hospital 百瀬貴史, 内山倫宏, 網野一真, 横山征史, 前澤優圭, 北原和花子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1148-1148, 2023. |
|---|
|
|
P0166-3-PM1. Efficiency of the anticancer agent regimen administrative work using VBA of Microsoft Excel 佐澤卓哉, 吉田裕生, 上之将明, 加世田良一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1149-1149, 2023. |
|---|
|
|
P0167-3-PM2. Efforts ... to regimen management - antiemesis supportive care standardization in our hospital cancer chemotherapy 久田真規子1, 竹中智子1, 石田志穂1, 宇佐美順子1, 秦真由美2,3, 川瀬朋乃2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1150-1150, 2023. |
|---|
|
|
P0168-3-PM1. Preparation and administration procedure for the photoimmunotherapy drug cetuximab sarotalocan and its evaluation 山岡健太1, 浅沼玲美1, 入江慶1,2, 平畠正樹1, 久米学1, 橋田トオル1,2, 室井延之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1151-1151, 2023. |
|---|
|
|
P0169-3-PM2. Efforts for the computerization of the cancer medical therapy regimen management in the Osaka Red Cross hospital 尾本和彦, 山瀬大雄, 湯井政志, 塚田加奈子, 中嶋江美, 原田慶子, 松本早織, 山田邦義, 辻井佳代, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1152-1152, 2023. |
|---|
|
|
P0170-3-PM1. Use of premedication fact-finding in the anticancer agent enforcement day 山下敦史, 田本光莉, 金澤沙衣, 石田陽美, 田中悠季, 三本松泰孝, 鈴木千波, 田村広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1153-1153, 2023. |
|---|
|
|
P0171-3-PM2. A case that Durvalumab after CCRT was not effective in EGFR-positive stage IIIB NSCLC 冨井隆弘1, 輿石徹1, 吉元公一1, 梶原直央2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1154-1154, 2023. |
|---|
|
|
P0172-3-PM1. Attempt of the regimen making for the Blinatumomab outpatient department administration in the childhood cancer base Hospital 賀川智子1, 田中美咲1, 鮎田利恵1, 増田早織1, 松井基浩2, 鈴木喬悟2, 湯坐有希2, 廣井順子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1155-1155, 2023. |
|---|
|
|
P0173-3-PM2. Usefulness investigation of the check list about the screening enforcement before cancer chemotherapy start 伊藤昌美1, 片山広美1, 伊藤弥生2, 山田裕香3, 井上正朗3, 鈴木崇太4, 杉浦誠治5, 鈴木厚志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1156-1156, 2023. |
|---|
|
|
P0174-3-PM1. Attempt of the regimen making for the Blinatumomab hospitalization administration in the childhood cancer base Hospital 鮎田利恵1, 田中美咲1, 賀川智子1, 増田早織2, 峯岸英博2, 松井基弘2, 鈴木喬吾2, 横川裕一2, 湯坐有希2, 廣井順子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1157-1157, 2023. |
|---|
|
|
P0175-3-PM2. Construction of the uniform management system for an injection, the internal use combination regimen aiming at medical security 田中玲奈1, 松谷直樹1, 隅田大己1, 富施哲也1, 岡安伸晃1, 伊藤博2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1158-1158, 2023. |
|---|
|
|
P0176-3-PM1. The effect that oral anticancer agent medication support application gives for medication management 畑中由香子1, 大里勇二1, 北宅良祐1, 江本文代1, 島田健1, 座間味義人2, 平松靖史3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1161-1161, 2023. |
|---|
|
|
P0177-3-PM2. Efforts for an attitude survey and the follow-up promotion for the immune checkpoint inhibitor 金子絵里奈1, 中島佳彦1, 加藤正久1, 五十嵐保陽2, 加留部信介1, 鷲山厚司1, 神村英利2, 田中泰三3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1162-1162, 2023. |
|---|
|
|
P0178-3-PM1. 2 cases that was engaged in adverse event management in the BEACON regimen 河村茉衣1, 小池彩子1, 松本和也1, 花房伸幸1, 諏訪耕三1, 井上雅文2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1163-1163, 2023. |
|---|
|
|
P0179-3-PM2. Activity report of "the irAE support team" in our hospital 甲谷章1, 市川美紗1, 森祥史1, 浅沼真樹1, 谷村紀代子1, 高谷伸治1, 菊井利伸1, 奥田昌也2, 澤崎美幸3, 秋吉由利子4, 澁谷昌広5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1164-1164, 2023. |
|---|
|
|
P0180-3-PM1. We work in PDCA cycle by a problem of the ACP (Advance Care Planning) 牛膓沙織1, 加藤幾1, 野村翔1, 吉川朝子2, 大場麻里2, 木村晃子3, 内山真子4, 長谷川哲也5, 小島美保6, 加藤祐一郎7, 稲垣正巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1165-1165, 2023. |
|---|
|
|
P0181-3-PM2. Can do it as significance - ward, outpatient department of the hospital pharmacist, a pharmacist of cancer support, the palliative care team 小山奈津実1,2, 古賀彩花1,2, 秋廣涼雅2, 柳川真有美2, 丸山泰世2, 今留卓2, 石野美恵2, 千葉香織2, 前田彰宏2, 井上和洋2, 小林政義2, 保志場康人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1166-1166, 2023. |
|---|
|
|
P0182-3-PM1. A change of the calculation situation of the cooperation full addition in our hospital and future problem 柿原圭佑, 上津沙織, 小笠裕斗, 西村直朗, 塚原邦浩, 小倉秀美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1167-1167, 2023. |
|---|
|
|
P0183-3-PM2. Usefulness of the early intervention by the multi-type of job cooperation in the dermatopathy due to EGFR inhibitor 佐野尚平1, 亀位耕平1, 伊藤雄大2, 栩野有輝1, 嶋本めぐみ1, 江川英毅1, 平岡芹菜1, 岸部美和子3, 杉本里美3, 上中智香子4, 山本有紀4, 上田弘樹5, 須野学2, 中川貴之1, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1168-1168, 2023. |
|---|
|
|
P0184-3-PM1. Observational, prospective study (M-CAST study) first report about the clinical response of the multi-type of job cooperation team activity in patients who received cancer chemotherapy 流石智恵子1, 飯村洋平1, 古川直樹1, 石橋正祥1, 馬場啓介2, 中澤光子3, 佐藤朋子3, 都留由香里3, 吉井栄子3, 冨樫仁美4, 本田友絵4, 松原康朗2,4, 黒田誠一郎1, 朴成和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1169-1169, 2023. |
|---|
|
|
P0185-3-PM2. The making of the pancreatic cancer pass and the operational situation 小池彩子1, 原田亮2, 畑賢俊3, 東直美4, 山本水緒1, 出宮千聖1, 西長あゆ子1, 山本祥子5, 中尾麻結6, 河野上昌美6, 藤岡香代子6, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1170-1170, 2023. |
|---|
|
|
P0186-3-PM1. Through reinforcement - seminar activity of the support system of children, the AYA generation hosted by a pharmacist - 高橋侑伽1, 佐々木実緒1, 長谷川まゆみ1, 岡村理帆1, 坪井久美1, 鈴木宏和1, 北條隆2, 板谷雪子3, 高井泰3, 近藤正巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1171-1171, 2023. |
|---|
|
|
P0187-3-PM2. Our hospital's efforts toward outpatient administration of blinatumomab and our experience with its use 桑崎綾子1, 町田梨絵子1, 谷川昇1, 原友子1, 森美都子2, 衛藤徹也3, 野中敏治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1172-1172, 2023. |
|---|
|
|
P0188-3-PM1. It is the role of ... pharmacist about the characteristic of the drug in the light immune therapy and the management 森陽祐, 出町拓也, 平田力 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1173-1173, 2023. |
|---|
|
|
P0189-3-PM2. About the acquisition and operation of the CAR-T therapy institution authorization utilizing the pharmacy sterile preparation room in the Mie University faculty of medicine hospital 川瀬亮介1, 向原里佳1, 山田真帆1, 石橋美紀1, 世古口典子1, 大石晃嗣2,3, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1174-1174, 2023. |
|---|
|
|
P0190-3-PM1. Examination of the multi-type of job intervention using the anamorelin for the cancer cachexia of elderly people 福泉智子1, 久松大祐2, 西嶋智洋3,4, 後藤隆2, 清水裕彰2, 高田正温1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1175-1175, 2023. |
|---|
|
|
P0191-3-PM2. Intervention of the pharmacist about HBV reactivation measures 清水久美子1,2,3, 頓宮弘子2, 川上恭弘2, 桑木健志3, 児島亨3, 池田房雄3, 藤岡真一3, 則武有美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1176-1176, 2023. |
|---|
|
|
P0192-3-PM1. Efforts and evaluation of the tracing report for foreign chemotherapy patients in our hospital 野田聖奈子1, 桑村恒夫1, 清原珠美2, 中川義浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1177-1177, 2023. |
|---|
|
|
P0193-3-PM2. The current situation report of the medicine medicine cooperation using the cancer medical treatment tracing report common throughout an area 山本倫数, 中田将基, 濱田達志, 青山瑛里子, 南野智志, 草薙みか, 大里恭章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1178-1178, 2023. |
|---|
|
|
P0194-3-PM1. Fact-finding of the tracing report in the foreign cancer chemotherapy 小川直希, 鶴島克将, 藤井千賀, 柳下祐貴子, 長楽寿子, 遠藤晋吾, 藤井一美, 安井友佳子, 石坂敏彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1179-1179, 2023. |
|---|
|
|
P0195-3-PM2. Usefulness of the cardiac activity evaluation that manual making and a pharmacist for the myocardial disorder prevention with the anthracycline anticancer agent conduct 高林真貴子1, 増江俊子1,2, 佐藤晃一2, 下島正也3, 岩城憲子4, 武内章彦5, 石川聡子6, 藤木俊寛7, 薄井荘一郎3, 谷内江昭宏2, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1180-1180, 2023. |
|---|
|
|
P0196-3-PM1. The drug vial optimization introduction using the anticancer medicine preparation robot and the evaluation 佐藤聖, 加藤文美, 内田千瑛, 加藤彩, 山本和輝, 青野浩直, 見野靖晃, 川上純一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1182-1182, 2023. |
|---|
|
|
P0197-3-PM2. Efforts of the cost cut accompanied with the use of CSTD range expansion in our hospital 木村錦子, 治田匡平, 小川恵美子, 池田和之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1183-1183, 2023. |
|---|
|
|
P0198-3-PM1. Investigation about instruction to patient contents for prevention of anticancer medicine exposure 廣原成, 谷川大夢, 平綿洋子, 丸谷善紀, 鈴木優司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1184-1184, 2023. |
|---|
|
|
P0199-3-PM2. Inspection of the chemical resolution effect of cyclophosphamide with the sodium hypochlorite 田崎眞生, 桑原晶子, 植村有加里, 大川恭子, 田内義彦, 辻本勉, 濱宏仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1185-1185, 2023. |
|---|
|
|
P0200-3-PM1. Inspection about exposure measures and the effect for 5FU which exposure investigation after the closed system anesthesia drug transportation system full-scale introduction showed 齋藤順, 延川正雄, 松田圭一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1186-1186, 2023. |
|---|
|
|
P0201-3-PM2. Examination of preparation duties of cyclophosphamide using the anticancer medicine preparation robot 菊地佑太, 矢田山瑞稀, 久保萌美, 福島麻里乃, 田中悠季, 三本松泰孝, 鈴木千波, 田村広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1187-1187, 2023. |
|---|
|
|
P0202-3-PM1. About exposure investigation after the closed system anesthesia drug transportation system introduction drug expansion in our hospital outpatient department chemotherapy room (the first report) 庄司美侑1,2, 田中弘人1,2, 井ノ口岳洋1,2, 敦賀剛気1,2, 久保村優1,2, 吉川聡美1, 村上美聖1, 輪湖哲也1,2, 伊勢雄也1, 笠原寿郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1188-1188, 2023. |
|---|
|
|
P0203-3-PM2. Examination about the law contracted at albumin suspension type paclitaxel parenteral injection time to redissolve it 久住祐介, 児玉暁人, 森信介, 今井兼貴, 岩田智津子, 西岡啓子, 角明香里, 和田諭可子, 勝浦正人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1189-1189, 2023. |
|---|
|
|
P0204-3-PM1. Examination of the simple removal method using the ozone water of the anticancer agent which attached to a vial 五月女拓也1, 外山智章1, 大塚瑠里1, 日向野理輝1, 太田栄亮1, 押坂勇志2, 白川賢宗3, 井上尚3, 別納弘法3, 仁保誠治3, 篠崎桂子1, 臼井悟1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1190-1190, 2023. |
|---|
|
|
P0205-3-PM2. Examination (the second report) of the effect that an altitude difference gives for vial internal pressure in the anticancer medicine preparation 高野秀仁1, 渡邉航平1, 安室修2, 渡邉浩志1, 舟越亮寛2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1191-1191, 2023. |
|---|
|
|
P0206-3-PM1. Efforts to anticancer agent exposure measures in hepatic artery chemoembolisation (TACE) 長谷悠紀, 町田聖治, 松本彩咲, 平野真健, 千々和未歩, 富田敏章, 入江利行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1192-1192, 2023. |
|---|
|
|
P0207-3-PM2. Comparison of the anticancer agent decontamination effect in a bed bath method using the ozone water and the existing bed bath method 陳美樹1, 西垣玲奈1, 宇田川涼子1, 渡部大介1, 齋藤義正1, 赤木徹1, 山本酉子2, 藤井健太郎2, 橋本浩伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1193-1193, 2023. |
|---|
|
|
P0208-3-PM1. The current situation and problem in the closed system anesthesia appliance expansion 田代聡美1, 川野昭1, 福重昇吾1, 杉慎介1, 百崎やよい2, 藤永理恵子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1194-1194, 2023. |
|---|
|
|
P0209-3-PM2. Understanding degree investigation about exposure to anticancer medicine measures using the video education material in the dustman 森祐佳1, 小林一男1, 川上和宜1, 清水久範1, 森田幾代2, 横井麻珠美2, 長崎礼子2, 黒田直子2, 清水多嘉子2, 山口正和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1195-1195, 2023. |
|---|
|
|
P0210-3-PM1. Introduction of the fosnetupitant to breast cancer EC therapy and the evaluation 篠崎千尋, 桑村恒夫, 三上忠司, 中川義浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1197-1197, 2023. |
|---|
|
|
P0211-3-PM2. Study on effectiveness, safety of the prophylactic antiemesis therapy for the docetaxel + cyclophosphamide therapy in patients with breast cancer 富田温子1, 飯原大稔1,2, 藤井宏典1, 北洞美佳1, 渡邊大地1, 山本扇里1, 市橋菜月1, 徳丸剛久3, 丹羽好美3, 森龍太郎3, 二村学3, 鈴木昭夫1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1198-1198, 2023. |
|---|
|
|
P0212-3-PM1. Comparison of the antiemesis effect of aprepitant and the fosnetupitant in the EC therapy 村上絢香, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1199-1199, 2023. |
|---|
|
|
P0213-3-PM2. The use situation investigation of the fosnetupitant in the Saku medical center 柳澤沙織, 杉山昌秀, 篠原佳祐, 宮田智陽, 吉池麻衣, 征矢あや乃, 堀内賢一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1200-1200, 2023. |
|---|
|
|
P0214-3-PM1. Fosnetupitant introduction and the use results in Tokyo Metropolitan Tama Medical Center 殿村直也, 佐藤香織, 佐野弥里, 山下理菜, 羽田真理子, 宮澤真帆, 寺山義泰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1201-1201, 2023. |
|---|
|
|
P0215-3-PM2. A case of hepatocellular carcinoma treated with miriplatin transarterial chemoembolization using antiemetic therapy with a high emetogenic risk 石田優理香, 佐藤裕, 森下啓, 佐藤祐司, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1202-1202, 2023. |
|---|
|
|
P0216-3-PM1. The clinical effectiveness, safety assessment after the fosnetupitant chloride hydrochloride parenteral injection introduction 米山栄司1, 吉塚奈美2, 佐々木良子2, 椎名由紀乃2, 長能優子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1203-1203, 2023. |
|---|
|
|
P0217-3-PM2. Investigation of the antiemesis effect by changes from aprepitant to fosnetupitant 鶴田和樹, 中川夕芽, 呉山友教, 廣瀬孝一, 金田典子, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1204-1204, 2023. |
|---|
|
|
P0218-3-PM1. Examination about the usefulness of the fosnetupitant in the Carboplatin (AUC >= 4)-containing regimen 千住陽子1,2, 古野龍也1, 桑原淳1, 荒金尚子2, 島ノ江千里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1205-1205, 2023. |
|---|
|
|
P0219-3-PM2. The use situation investigation of fosnetupitant repeated doses in our hospital: Investigation of injection site reaction and vomiting in the anthracycline anticancer agent periphery administration case 石崎文子, 相原敏彦, 寺島里枝, 芳山健太郎, 北爪教貴, 辻中里穂, 仲鉢英夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1206-1206, 2023. |
|---|
|
|
P0220-3-PM1. Examination about the usefulness of 2.5 mg of olanzapine for AC/EC therapy-induced retching, vomiting 松下尚弘, 古賀清弘, 原友子, 羽田野明子, 田中早穂子, 黒木吟美, 野中敏治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1207-1207, 2023. |
|---|
|
|
P0221-3-PM2. Investigation of the expression situation of retching, vomiting in patients with colon cancer after the fosnetupitant introduction 佐藤優希子, 山村真貴子, 長谷川将, 木本秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1208-1208, 2023. |
|---|
|
|
P0222-3-PM1. Evaluation of retching, vomiting of the steroid spare ring for the CAPOX regimen adaptation patients 今田良樹, 佐藤奈実, 吉田崇志, 西村雅次, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1209-1209, 2023. |
|---|
|
|
P0223-3-PM1. One case of the cancer of the esophagus which developed the hypothyroidism with the CK rise during nivolumab administration 井口仁美, 志野訓之, 野村泰生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1216-1216, 2023. |
|---|
|
|
P0224-3-PM2. Examination about the association between onset of proteinuria and concomitant drug of the bevacizumab using JADER 小竹優希, 向井淳治, 坂本竜平, 竹原涼子, 西村真央, 山田佳菜子, 辻田早紀, 森本亜美, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1217-1217, 2023. |
|---|
|
|
P0225-3-PM1. Questionary survey to patients about Gee raster subcutaneous injection 3.6 mg body pod (R) 加藤幾, 稲垣正巳, 牛膓沙織, 野村翔, 木村桂子, 柴田雅央 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1218-1218, 2023. |
|---|
|
|
P0226-3-PM2. A case of hyperglycemia monitored using an intermittent scanning continuous glucose monitor (isCGM) during administration of enfortumab vedotin in an obese patient 松野知寛, 久原紀子, 井上和洋, 北村憲雅, 中野祐樹, 大竹野久雄, 蓮輪博嗣, 横尾賢乗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1219-1219, 2023. |
|---|
|
|
P0227-3-PM1. 1 case of stage IV renal cell carcinoma which became the pathological complete response by the ipilimumab + nivolumab therapy of 2 courses while accepting multiple serious irAE 高田遼1,2, 藤原未稀1, 牧賢利1, 野村直幸1, 藤田曙2, 行廣和真2, 増本弘史2, 高橋洋子1, 長谷川泰久2, 田村浩二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1220-1220, 2023. |
|---|
|
|
P0228-3-PM2. Examination of the factor involved in Infusion reaction expression by the trastuzumab for patients with breast cancer 黒部健太郎1, 音成結泉1, 白羽根健吾2, 草葉カズトモ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1221-1221, 2023. |
|---|
|
|
P0229-3-PM1. Examination of the risk factor to develop a neutropenia by amrubicin hydrochloride monotherapy for the small cell lung cancer 武良卓哉1, 松本拓真2, 瀬戸美穂1, 荒神一博1, 小川喜通1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1222-1222, 2023. |
|---|
|
|
P0230-3-PM2. 1 case that differentiated a response and hypersensitivity accompanied with the infusion with the fulvestrant administration, and was involved in treatment continuation 藤本亜弓1,2, 石坂崚2, 山崎直樹1, 中尾將彦1, 森宏幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1223-1223, 2023. |
|---|
|
|
P0231-3-PM1. Examination about the immune-mediated adverse event expression accompanied with the combination of immune checkpoint inhibitor and Chinese medicine with the Japanese adverse event spontaneous report database 輿石徹, 吉元公一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1224-1224, 2023. |
|---|
|
|
P0232-3-PM2. The effect on anticancer medicine-induced peripheral neuropathy investigation that the incretin analogous drug gives 宮川真由子1, 稲野寛1, 山本悠樹1,2, 瀬戸良教1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1225-1225, 2023. |
|---|
|
|
P0233-3-PM1. Importance of side effect frequency and the pharmacist intervention by the Osimertinib 國安和仁, 中居肇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1226-1226, 2023. |
|---|
|
|
P0234-3-PM2. Examination of the onset of vascular pain situation of the bendamustine ten minutes administration in our hospital 平池美香子, 松藤敬佑, 馬場結子, 齋藤巨樹, 小園亜希, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1227-1227, 2023. |
|---|
|
|
P0235-3-PM1. Examination about the effectiveness of the sustained granulocyte colony-stimulating factor preparation administration for hippopotamus diTaki cell weight loss treated patients 村上礼隆, 北本真一, 阪田安彦, 古谷智裕, 佐藤実由, 金田公平, 武井秀樹, 宮森伸一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1228-1228, 2023. |
|---|
|
|
P0236-3-PM2. Effect of in front of dexamethasone administration to give it to infusion reaction occurring at the trastuzumab therapy in patients with breast cancer and the pertuzumab combination 田渕祐輔1, 辻本雅之2, 山本皓介1, 清水瞭3, 小阪直史1, 阪口晃一4, 土淵尚也3, 西口工司2, 四方敬介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1229-1229, 2023. |
|---|
|
|
P0237-3-PM1. A case of difficulty in controlling pain after completing dinutuximab treatment 日高朋1, 新田美奈1, 西川拓朗2, 岡本康裕2, 武田泰生1,3,4, 寺薗英之1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1230-1230, 2023. |
|---|
|
|
P0238-3-PM2. Participation of the pharmacist for the patients anxiety in resumption of cancer medical therapy stopped by a side effect 亀岡貴哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1231-1231, 2023. |
|---|
|
|
P0239-3-PM1. The fact-finding of the cardiac function diagnostic procedures in patients receiving VEGF inhibitor and future problem 小林裕平, 丸山真一, 菅野浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1232-1232, 2023. |
|---|
|
|
P0240-3-PM2. Protective efficacy of the hypothermia to correspond to chemotherapy-induced peripheral neuropathy by the paclitaxel 西長あゆ子1, 杉本綾香1, 河村茉衣1, 小池彩子1, 森川希実2, 原享子2, 吉富誠二2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1233-1233, 2023. |
|---|
|
|
P0241-3-PM1. The effect that antidiarrheal drug commuter pass prescription gives to treatment continuation on diarrhea to occur early in Abemaciclib administration 大野安里1, 伊藤将2, 前田守2, 市ノ渡真史2, 長谷川佳孝2, 月岡良太2, 大石美也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1234-1234, 2023. |
|---|
|
|
P0242-3-PM2. Analysis of the adverse event by the Abemaciclib using adverse event spontaneous report database (JADER) 實久茂樹1, 伊藤将2, 前田守2, 市ノ渡真史2, 長谷川佳孝2, 月岡良太2, 大石美也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1235-1235, 2023. |
|---|
|
|
P0243-3-PM1. A case which type I diabetes mellitus developed during Atezolizumab administration in the patients with dementia, and suffered from blood sugar control 西岡菜々子1, 今井健太郎2, 吉元公一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1236-1236, 2023. |
|---|
|
|
P0244-3-PM2. The effect that a choice of the saline cathartic in consideration of the interaction with the gastric-acid secretion antagonist gives for constipation with palonosetron 土屋直彦1, 中島弘樹2, 浜善久2, 佐野史穂2, 池上悦子1, 小山茂1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1237-1237, 2023. |
|---|
|
|
P0245-3-PM1. A case of skin damage caused by extravasation of enfortumab vedotin 三村一平1, 座光寺秀典2, 添田真司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1238-1238, 2023. |
|---|
|
|
P0246-3-PM2. Factor search to influence the effectiveness of the zinc acetate hydrate preparation for the dysgeusia with the hypozincaemia in patients with cancer during the use of anticancer agent 高岡龍蔵, 桂川健司, 高取裕司, 遠山幸男, 久田達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1239-1239, 2023. |
|---|
|
|
P0247-3-PM1. Investigation of the HBV reactivation that was due to the anticancer agent which there was not of alerting it in a package insert 浅野寿規, 川瀬洋次, 杉野善彦, 伊藤弘美, 竹田優作, 馬場未沙子, 桜田宏明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1240-1240, 2023. |
|---|
|
|
P0248-3-PM2. Examination about the onset of vascular pain of lyophilized products and liquid preparations of the gemcitabine 北野安紀, 望月かおり, 平田大氣, 丸山寛之, 平野智理, 須藤祥代, 東加奈子, 竹内裕紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1241-1241, 2023. |
|---|
|
|
P0249-3-PM1. Factor analysis to have an influence on the expression of the lymphocytopenia at the Bendamustine administration 小川晃宏, 今西航, 野口祥紀, 三宅知宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1242-1242, 2023. |
|---|
|
|
P0250-3-PM2. The effect that the steroid to preload in the lung cancer compound immune therapy application case gives in a cortisol level 樋口智恵1, 吉野真樹1, 牛膓明広1, 大平直樹1, 佐々木奈穂1, 田川千明1, 田中佳美1, 勝山里佳1, 木村宏之1, 三浦理2, 田中洋史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1243-1243, 2023. |
|---|
|
|
P0251-3-PM1. For KRAS G12C-positive stage IV non-small cell lung cancer after CheckMate 9LA about the effectiveness, the safety of 2 cases receiving sotorasib 成田綾香1, 中積広貴2, 曽根崇2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1244-1244, 2023. |
|---|
|
|
P0252-3-PM2. Investigation of the enforcement situation of the drug lymphocyte stimulation test of the anticancer medicine in the northeastern Medical and Pharmaceutical University Hospital 平川寛之1, 野上佳奈子1, 鈴木直人1, 山内雅仁1, 高橋将典1, 岡田浩司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1245-1245, 2023. |
|---|
|
|
P0253-3-PM1. We look at the rear about the effect that dexamethasone supplementation at CDDP + VNR therapy enforcement gives blood poison characteristics and effect of treatment and examine a mark 山下登, 濟川聡美, 飛鷹範明, 田中守 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1246-1246, 2023. |
|---|
|
|
P0254-3-PM2. Related examination of side effect expression and GNRI of the gastric cancer chemotherapy 山口亜由美1, 渡辺一章1, 島田真弥1, 三ツ木健二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1247-1247, 2023. |
|---|
|
|
P0255-3-PM1. Examination about the effect that dexamethasone coadministration gives to oxaliplatin-induced hypersensitivity reaction 名和田幸介, 古川誠之, 山崎智加, 玉重良樹, 大庭瑠菜, 河濟悠生, 川中明宏, 渡邊太朗, 手嶋ひさ子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1248-1248, 2023. |
|---|
|
|
P0256-3-PM2. Lassitude evaluation of patients with chronic myelogenous leukemia due to BFI (Brief Fatigue Inventory) and the CFS (Cancer Fatigue Scale) 鷲巣晋作1, 葉山達也1, 内池明博1, 坪井伸也1, 長木弓子1, 宮城愛1, 矢萩温子1, 入山規良2, 三浦勝浩2, 大塚進1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1249-1249, 2023. |
|---|
|
|
P0257-3-PM1. The effectiveness of the Goreisan for the diarrhea in the head and neck cancer TPF therapy 出町拓也1, 平田力1, 渡邉昭仁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1250-1250, 2023. |
|---|
|
|
P0258-3-PM2. Consideration for the effect of pegG-CSF in the dose-dense therapy 服部豊1, 齊藤麻衣子1, 仲嶋祐希1, 鈴木真彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1251-1251, 2023. |
|---|
|
|
P0259-3-PM1. Oral supplementary water liquid OS-1 at the anticancer agent, radiotherapy, questionary survey about the OS-1 jelly receptiveness 中村久美, 鬼窪利英, 古川正光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1252-1252, 2023. |
|---|
|
|
P0260-3-PM2. We look at the safe rear about the Olaparib and examine a mark 片岡憲昭1, 畑武生1, 細見光一2, 平田敦士3, 藤原聡枝4, 後藤愛実1, 西原雅美1, 大道正英4, 根尾昌志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1253-1253, 2023. |
|---|
|
|
P0261-3-PM1. Efforts of PBPM of antiHER2 antibody medicine-related heart disorder measures 佐藤彩伽1, 徳留章1,2, 樋浦一哉3, 山下美妃3, 木明貴幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1254-1254, 2023. |
|---|
|
|
P0262-3-PM2. Investigation about the effect of the DPP-4 inhibitor on oxaliplatin-induced peripheral neuropathy 藤田隼輔1, 藤田強記2, 清水裕彰2, 山脇一浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1255-1255, 2023. |
|---|
|
|
P0263-3-PM1. The frequencies of steroid withdrawal symptoms after the dexamethasone cancellation in the breast cancer perioperative medical therapy and the percent improvement with the gradual decrease administration 藪田直希1, 須藤正朝1, 野田哲史1,2, 若杉吉宣1, 日置三紀1, 中村春香1, 道家雄太郎1, 小出博義1, 森井博朗1, 冨田香3, 森田真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1256-1256, 2023. |
|---|
|
|
P0264-3-PM2. A case of vascular pain in a patient receiving carfilzomib - A report including a retrospective survey of patients receiving carfilzomib - 阿部史誉, 小山加奈世, 早川太朗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1257-1257, 2023. |
|---|
|
|
P0265-3-PM1. Investigation about the pharmacist intervention for the use situation of the immune checkpoint inhibitor in the International University of Health and Welfare Narita Hospital and the immune-mediated adverse event 長瀬友樹, 嶋臣人, 大石智香, 石岡美樹, 篠崎浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1258-1258, 2023. |
|---|
|
|
P0266-3-PM2. About effect of the proton pump inhibitor giving it to onset of hand-and-foot syndrome by the capecitabine 荒神一博1, 松本拓真2, 武良卓哉1, 小倉千奈1, 濱岡照隆1, 小川喜通1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1259-1259, 2023. |
|---|
|
|
P0267-3-PM1. One case that produced a neutropenia by the Avelumab therapy enforcement for patients with urothelial carcinoma 中村朋瑛1, 田中弘人1,2, 井ノ口岳洋1,2, 敦賀剛気1,2, 久保村優1,2, 輪湖哲也1,2, 伊勢雄也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1260-1260, 2023. |
|---|
|
|
P0268-3-PM2. Investigation of the secondary hypogammaglobulinemia in daratumumab treated patients 兼松哲史1, 山下智穂1, 中根茂喜1, 前田芳樹1, 伊藤貴彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1261-1261, 2023. |
|---|
|
|
P0269-3-PM1. 2 cases that we gave entrectinib to patients with ROS1 fused gene-positive old non-small cell lung cancer in every other week and were able to continuously administer for a long term 中西大介1, 藤原研太郎2, 畑地治2, 牛田浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1262-1262, 2023. |
|---|
|
|
P0270-3-PM2. Risk factor analysis of anemia in patients with Olaparib administration ovarian cancer 松本彩子1, 山岡健太1,2, 久米学1, 吉野新太郎1, 平畠正樹1, 清水忠2, 林信孝3, 青木卓哉3, 室井延之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1263-1263, 2023. |
|---|
|
|
P0271-3-PM1. CIPN expression investigation of the Pola-R-CHP therapy 山下紗瑛奈, 宮澤憲治, 山田桃子, 杉田郁人, 田代匠, 森下拓哉, 高木亮 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1264-1264, 2023. |
|---|
|
|
P0272-3-PM2. The effect that ifosfamide, fluid replacement of the doxorubicin therapy and dexamethasone weight loss give a side effect on malignant bone soft part tumor 中川祐紀子1, 中村良恵1, 志村裕介1, 吉田幸司1, 板井進悟1, 嶋田努1, 菅幸生2, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1265-1265, 2023. |
|---|
|
|
P0273-3-PM1. Search of the serious hepatic dysfunction risk factor by the Abemaciclib in patients with hormone acceptor-positive HER2 negative transference-related breast cancer 辰見明俊1, 角川幸男2, 富田遼1, 森藤那理1, 長谷川聡司2, 竹田健志2, 高木麻里2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1266-1266, 2023. |
|---|
|
|
P0274-3-PM2. About the incidence of skin disorders caused by enfortumab vedotin and patient background at our hospital 松藤敬佑, 平池美香子, 馬場結子, 齋藤巨樹, 小園亜希, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1267-1267, 2023. |
|---|
|
|
P0275-3-PM1. The onset of peripheral neuropathy situation investigation before and after the cancellation of the prophylaxis of the Goshajinkigan for acute peripheral neuropathy of oxaliplatin 和賀信継1, 谷地真亜子2, 鈴木誠規1, 鵜浦利江1, 星田徹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1268-1268, 2023. |
|---|
|
|
P0276-3-PM2. 2 cases that was able to discover a decreased renal function during lung cancer chemotherapy early by Long term eGFR plot 小山加奈世1, 山中理1, 阿部史誉1, 早川太朗1, 中澤純2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1269-1269, 2023. |
|---|
|
|
P0277-3-PM1. One consideration about the case that developed myositis, myasthenia gravis during Pembrolizumab administration 比嘉真理1, 丸山真一1, 岩田基秀2, 木塚祐太3, 永瀬怜司1, 菅野浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1270-1270, 2023. |
|---|
|
|
P0278-3-PM2. Retrospective investigation of the effects of adding or switching from osmotic laxatives to epithelial function-altering drugs in cancer patients 小澁朝子1, 五十嵐隆志1, 中村真穂1, 熊澤名穂子1, 三浦智史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1271-1271, 2023. |
|---|
|
|
P0279-3-PM1. A case that the combination of the antidiarrheal drug was effective for diarrhea by the Abemaciclib 山田春香, 加藤良隆, 大坪達弥, 野口裕介, 神田英一郎, 友金幹視 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1272-1272, 2023. |
|---|
|
|
P0280-3-PM2. Effect of the Yokukansan on NTRK fused gene-positive solid carcinoma target new anticancer medicine entrectinib-induced cognitive dysfunction 岩田直大1, 牛尾聡一郎2, 白水翔也1, 田中雄太1, 濱野裕章1, 鍛治園誠1, 座間味義人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1273-1273, 2023. |
|---|
|
|
P0281-3-PM1. Search of the background factor which causes the serious neutropenia onset when we provided RAM + DTX therapy after having used PEG G-CSF together for non-small cell lung cancer 志水優衣1, 安藤洋介2, 林高弘1,2, 小幡由紀1, 水野智博2, 廣瀬正裕3, 今泉和良4, 山田成樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1274-1274, 2023. |
|---|
|
|
P0282-3-PM2. The use situation investigation of butylscopolamine bromide for the Colin symptom during irinotecan administration and factorial experiments of the dysarthria 合澤啓二, 西上依里, 小山勢納, 岩田一史, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1275-1275, 2023. |
|---|
|
|
P0283-3-PM1. We feel the intervention point of the pharmacist to the hypoadrenalism by the immune-mediated adverse event 吉澤季里子1, 秦英司1, 足立美菜子1, 齋尾真希1, 岩井ちさと1, 山本崇弘1, 矢内正晶2, 小谷昌広2, 藤吉正哉1, 島田美樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1276-1276, 2023. |
|---|
|
|
P0284-3-PM2. Side effect investigation of the Pembrolizumab combination FP therapy for head and neck cancer and pharmaceutical intervention 佐東あやめ1, 出町拓也1, 平田力1, 渡邉昭仁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1277-1277, 2023. |
|---|
|
|
P0285-3-PM1. Search of the factor involved in aggravation of the anticancer medicine extravasation 米谷麻絵1, 新谷拓也1, 渡邊梓1, 吉本綾香2, 田墨恵子3, 竹田充伸4, 山本智也1, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1278-1278, 2023. |
|---|
|
|
P0286-3-PM2. Safety assessment of the old Ixazomib treatment in a recurrence, patients with intractable multiple myeloma 神田友江, 廣瀬達也, 杉山智紀, 竹中翔也, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1279-1279, 2023. |
|---|
|
|
P0287-3-PM1. Examination of the administration method using a syringe pump in DARZQURO Combination Subcutaneous Injection 松本拓真1, 武良卓哉2, 濱岡照隆2, 升味紀子3, 小川喜通2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1280-1280, 2023. |
|---|
|
|
P0288-3-PM2. Investigation of the hypertensive expression of patients with hepatocellular carcinoma situation in the Lenvatinib administration 袰岩靖子, 熊谷史由, 高松謙, 大友眞菜, 内山弘子, 外岡久和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1281-1281, 2023. |
|---|
|
|
P0289-3-PM1. Examination about the administration of the primary prophylaxis of PEG-GCSF for the non-elderly people in the regimen docetaxel-containing for the breast cancer perioperative period 鶴島克将, 小川直希, 藤井千賀, 柳下祐貴子, 長楽寿子, 藤井一美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1282-1282, 2023. |
|---|
|
|
P0290-3-PM2. Investigation of the renal function change in the use of immune checkpoint inhibitor patients 水野康平, 高橋利佳子, 秋山留里, 安里衣真, 松下貴英, 宇根良祐, 阿部多嘉浩, 人見百合子, 駒井勇太, 長濱藍, 喜多洋嗣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1283-1283, 2023. |
|---|
|
|
P0291-3-PM1. Association investigation of the neutrophils, lymphocytes ratio in patients receiving immune checkpoint inhibitor and the platelet, lymphocytes ratio and the immune-mediated adverse event expression 佃美穂1, 松本拓真2, 武良卓哉1, 小倉千奈1, 濱岡照隆1, 小川喜通1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1284-1284, 2023. |
|---|
|
|
P0292-3-PM2. A case which suffered from control of the dysarthria with the FOLFIRINOX therapy, and came to have difficulty in treatment continuously 脇田恵里1, 伊藤果奈1, 丹村貴之1, 近藤勝弘1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1285-1285, 2023. |
|---|
|
|
P0293-3-PM1. A case of progress colon cancer that developed drug-related thrombotic microangiopathy by Ramucirumab 坂林加奈子, 吉川英里, 城口将太, 麻生美佐子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1286-1286, 2023. |
|---|
|
|
P0294-3-PM2. Side effect investigation of our hospital of the Atezolizumab + bevacizumab combination therapy 小倉功, 竹下和輝, 山村央, 吉武由華, 熊澤志歩, 堀内ともえ, 松山哲史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1287-1287, 2023. |
|---|
|
|
P0295-3-PM1. Introduction and operation of Gee raster subcutaneous injection 3.6 mg body pod (R) in our hospital 植田真理1, 佐藤浩二1, 井上咲紀1, 小久保祐希1, 島田敏江2, 浅井真由美2, 香川雅一1,4, 西岡達也1, 藤田淳也2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1288-1288, 2023. |
|---|
|
|
P0296-3-PM2. A case that a nutrient for intestinal administration was effective for serious hypomagnesemia by the panitumumab 臼井理央, 平野美優, 野村洋道, 福嶋浩一, 石本学司, 中浴伸二, 田中詳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1289-1289, 2023. |
|---|
|
|
P0297-3-PM1. Investigation for the onset of vascular pain by the agent type of the gemcitabine hydrochloride 網代真史, 敦見真由美, 窪田奈津子, 緒方優, 谷口由理, 西山裕也, 松井瑞季, 松井一樹, 宮脇舞, 亀本浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1290-1290, 2023. |
|---|
|
|
P0298-3-PM2. The expression situation of the constipation in patients with cancer during cancer chemotherapy and future problem 小島晴美, 丸山真一, 菅野浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1291-1291, 2023. |
|---|
|
|
P0299-3-PM1. Search of the risk factor associated with serious anemia in Olaparib treated patients 福井美奈子, 中岡真悠子, 池村健治, 山本智也, 奥田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1292-1292, 2023. |
|---|
|
|
P0300-3-PM2. Examination about the onset of neutropenia risk factor at the bendamustine initial administration 岩本大紀, 西村巧, 寳福誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1293-1293, 2023. |
|---|
|
|
P0301-3-PM1. Exploratory study of onset of febrile neutropenia by the amrubicin and the effectiveness of the primary prophylaxis 水田秀貴, 黒部健太郎, 塩川裕美, 末松耕輔, 宮原強, 草葉一友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1294-1294, 2023. |
|---|
|
|
P0302-3-PM2. A case which caused more serious infusion reaction by the second administration in the Rituximab + Bendamustine therapy for follicular lymphoma treatment 大友眞菜, 袰岩靖子, 熊谷史由, 外岡久和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1295-1295, 2023. |
|---|
|
|
P0303-3-PM1. Biliary cancer GC, the expression situation of the cisplatin hypersensitivity reaction in the GCS therapy and experience of the desensitization 川島悠吾, 平松英司, 宗本尚子, 村嶋彩加, 岩泉奈央, 松本圭司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1296-1296, 2023. |
|---|
|
|
P0304-3-PM2. Two cases that pharmaceutical intervention was useful for a side effect of breast cancer medical therapy 安部一弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1297-1297, 2023. |
|---|
|
|
P0305-3-PM1. Pharmaceutical intervention to the case that caused hyperammonemia by mFOLFOX6 therapy 合田明博1, 永井海舟1, 山下亜由子1, 益田宏代1, 新原亨2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1298-1298, 2023. |
|---|
|
|
P0306-3-PM2. Magnesium measurement at the cisplatin administration in the Kasugai Municipal Hospital and acute nephropathic fact-finding 竹内健悟, 中村敏史, 田中伸明, 鈴木大吾, 鈴木敦詞, 石黒有希, 坂田洋, 服部芳明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1299-1299, 2023. |
|---|
|
|
P0307-3-PM1. The effect that pertuzumab, trastuzumab, a change of the supportive care medicine in the taxane system anticancer medicine combination therapy give to the onset of side effect 高木海那1,2,3,4, 前田真一郎1,2,3, 前田真貴子1,2,3,4, 藤尾慈1,2,3,4, 廣部祥子1,2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1300-1300, 2023. |
|---|
|
|
P0308-3-PM2. The HMG-CoA reductase inhibitor -GST signal inhibits neuropathy by oxaliplatin and the paclitaxel 相澤風花1, 岡林亜美2, 森山大嗣2, 八木健太1,3, 合田光寛1,2, 新村貴博1,3, 石澤有紀1,4, 石澤啓介1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1301-1301, 2023. |
|---|
|
|
P0309-3-PM1. Two cases of the COVID-19 infection related to rem decibuilding with suspected drug-related liver damage 衛藤大輝, 山村亮太, 森永裕子, 岩男元志, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1303-1303, 2023. |
|---|
|
|
P0310-3-PM2. Survey on the use of remdesivir and molnupiravir in COVID-19 patients after the Omicron strain epidemic and factors influencing release from isolation 金子真弓1, 先名健太1, 石塚仁保1, 宮村有貴1, 松本由香莉1, 北川裕也1, 坂本和央1, 中村裕一1, 須藤美穂子1, 樋浦一哉2, 棚谷貢1, 船木映二1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1304-1304, 2023. |
|---|
|
|
P0311-3-PM1. The use of new coronavirus infection therapeutic drug situation in our hospital 石橋真実1, 大道淳二1, 花房伸幸1, 平井淳子1, 別所昭宏2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1305-1305, 2023. |
|---|
|
|
P0312-3-PM2. Safety of the rem decibuilding administration for patients with impaired renal function 大隅智之1, 中村友里乃1, 川田智子2, 清水博之3, 喜古康博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1306-1306, 2023. |
|---|
|
|
P0313-3-PM1. About the relation of the pharmacist to the oral therapeutic drug in the SARS-CoV-2 infection 百瀬公博, 関口展貴, 有澤佳純, 伏見幸浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1307-1307, 2023. |
|---|
|
|
P0314-3-PM2. The effect single institution retrospective study that new coronavirus patients hospitalization gave for antimicrobial consumption and the resistant bacteria detection 津曲恭一1,2,3,4, 上原智博1, 荒木志乃1, 東盛裕里1, 長谷部歩1, 千田祥子1, 黒原健1, 木下晶惠1, 石新あおい1, 花木祐介2, 長山あゆみ3, 大湾勤子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1308-1308, 2023. |
|---|
|
|
P0315-3-PM1. The effect that the intervention by the pharmacist gives for oral antiviral drug treatment preferences for the new coronavirus infection (COVID-19) patients 安河内寿成, 中野祐樹, 大竹野久雄, 蓮輪博嗣, 横尾賢乗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1309-1309, 2023. |
|---|
|
|
P0316-3-PM2. Two cases that FGM (Flash Glucose Monitoring) was useful in the medical treatment management for the sudden blood sugar change accompanied with the aggravation of COVID-19 梶原洋文1, 山田雅也1, 生山祥一郎2, 濱口和之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1310-1310, 2023. |
|---|
|
|
P0317-3-PM1. The actual situation of the rem decibuilding administration for the decreased renal function patients in the COVID-19 practice 彦坂麻美1, 小林将貴2, 清田奈那1, 門井実1, 黒川敬史3, 長谷川森一4, 吉富裕久5, 鈴木善貴1, 定盛理純1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1311-1311, 2023. |
|---|
|
|
P0318-3-PM2. Examination about the effectiveness of the rem decibuilding for elderly people new model coronavirus infections 75 years or older 植田徹1,3, 櫻本稔2,3, 北澤文章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1312-1312, 2023. |
|---|
|
|
P0319-3-PM1. We look at the rear about the effectiveness of the rem decibuilding in the decreased renal function patients and the safety and examine a mark 小平美優, 池村健治, 山本智也, 奥田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1313-1313, 2023. |
|---|
|
|
P0320-3-PM2. Second response analysis after the new corona 2 values vaccination of the staff 佐藤智功 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1314-1314, 2023. |
|---|
|
|
P0321-3-PM1. Rem decibuilding administration experience to the decreased renal function patients in our hospital 矢部雅子, 邉見光利 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1315-1315, 2023. |
|---|
|
|
P0322-3-PM1. Evaluation of the pharmacist intervention effect on drug-related problem in the COVID-19 patients 福澤翔太, 宮川泰宏, 川原田祐貴, 松永安未, 當麻丹香, 西村映里, 溝口博之, 山田清文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1317-1317, 2023. |
|---|
|
|
P0323-3-PM2. Consciousness change before and after the intramuscular injection training participation for pharmacists 高橋恵美利, 高橋雄太, 長嶺歩, 前田恵里, 中村卓郎, 大林恭子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1318-1318, 2023. |
|---|
|
|
P0324-3-PM1. A study on adherence and safety of patients taking Monulpirable Capsules 200mg 福田由紀子1, 細見光一2, 岡野昌平1, 山口貴大1, 新藤祐久1, 奥田大地1, 村田卓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1319-1319, 2023. |
|---|
|
|
P0325-3-PM2. About effect of COVID-19 in patients not to deceive 中川幸紀1, 岡田雅弥1, 大本奈緒子1, 細直子1, 三宅美有紀1, 中谷亮介2, 阪口臨3, 下川福子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1320-1320, 2023. |
|---|
|
|
P0326-3-PM1. One case of the malignant lymphoma that a new coronavirus infection did not become negative 三宅美有紀1, 阪口臨2, 下川福子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1321-1321, 2023. |
|---|
|
|
P0327-3-PM2. It is ... with the making of system of use situation - early therapeutic drug administration of therapeutic drug for the new coronavirus infection of haemodialysis patients 浦崎清美1, 玉城哲子2, 渡慶次真由美2, 木奈崎昭男2, 安座間照子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1322-1322, 2023. |
|---|
|
|
P0328-3-PM1. Examination of the need of drugstore's original distribution function in the new coronavirus infection medical treatment 安井好次郎, 窪井裕美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1323-1323, 2023. |
|---|
|
|
P0329-3-PM2. Attempt to proper use at new coronavirus infection related to workflow therapeutic drug prescription 重田純一1, 安田佑紀1, 和田良浩1, 西原悠二2, 今北菜津子2, 笠原敬2, 池田和之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1324-1324, 2023. |
|---|
|
|
P0330-3-PM1. At new coronavirus infection expansion and correspondence in the following palliative care unit 塚本貴庸子1, 中島理絵1, 錦織昌裕1, 五十嵐貴代子2, 村松美樹子3, 伴敏信3, 河嶋亨3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1325-1325, 2023. |
|---|
|
|
P0331-3-PM2. Investigation about the change of the hygiene idea of the hospital pharmacist before and after the new coronavirus infection pandemic 岡田雅弥1, 中谷亮介2, 小山貴久3, 加藤渓4, 野田明宏4, 篝忠宏5, 下川福子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1326-1326, 2023. |
|---|
|
|
P0332-3-PM1. Duties burden investigation of the hospital pharmacist in the corona evil 遠藤可奈子, 田村広志, 鈴木千波, 三本松泰孝, 田中悠季, 渕上俊介, 村上冴美, 越野早紀, 島津智行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1327-1327, 2023. |
|---|
|
|
P0333-3-PM2. Effect of the corona evil analyzed than questionary survey about the drugstore business training 宇野リオ1, 原口珠実1,2, 吉田都1,2, 桑原晶子1, 田内義彦1, 波多江崇2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1328-1328, 2023. |
|---|
|
|
P0334-3-PM1. Effect of the corona evil analyzed than questionary survey about the hospital business training 吉田都1,2, 宇野莉央1, 原口珠実1,2, 桑原晶子1, 田内義彦1, 波多江崇2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1329-1329, 2023. |
|---|
|
|
P0335-3-PM1. Use situation evaluation of the antimicrobial medicine in our hospital using infection measures cooperation common platform (J-SIPHE) 白川敦規1, 坂口晋哉2, 田代紘士2, 桑原貴美子2, 鈴田浩孝2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1334-1334, 2023. |
|---|
|
|
P0336-3-PM2. One case that chose oral antimicrobial administration for infective endocarditis by E.coli, and realized ambulant treatment 甲元大樹1, 花房伸幸1, 石橋友樹1, 砂場亜希1, 森本雅生1, 坂東優希2, 福家聡一郎2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1335-1335, 2023. |
|---|
|
|
P0337-3-PM1. Survey on Lascufloxacin Hydrochloride administration cases and their progress 鹿島弥生, 木原星衣, 奧村梨央, 青木旦未, 小林奈緒, 松本勝城, 海野明子, 長澤彩華, 深沢貴志, 加藤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1336-1336, 2023. |
|---|
|
|
P0338-3-PM2. Use of in-hospital antimicrobial turn of eventss accompanied with the meropenem supply stop 吉田悦朗1, 臼井和明1, 安藤暢彦1, 大石丸美1, 近藤真由1, 和泉寿紀1, 谷彩花1, 大倉尚子2, 長島章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1337-1337, 2023. |
|---|
|
|
P0339-3-PM1. About the change of the appearance ratio of resistant bacteria for other antimicrobial consumption accompanied with the meropenem supply stop and Pseudomonas aeruginosa 河野友里, 西裕美, 上田和明, 藤田隼輔, 小坂隆介, 藤野奈緒, 山脇一浩, 肥山和俊 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1338-1338, 2023. |
|---|
|
|
P0340-3-PM2. Change investigation of AUD and the infection mortality of our hospital under distribution restrictions of the wide area antimicrobial 後藤拓也, 木内丈滉, 梅橋梨永, 田淵克則, 薄雅人, 吉田知由 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1339-1339, 2023. |
|---|
|
|
P0341-3-PM1. Examination of side effect frequency and the risk factor of sulfamethoxazole/trimethoprim combination drug 左高侑奈, 小栗良介, 関谷泰明, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1340-1340, 2023. |
|---|
|
|
P0342-3-PM2. An effect after the vancomycin initial administration plan chart presentation and the compliance 岡平将志, 饗庭孝一, 永川秀徳, 播磨里美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1341-1341, 2023. |
|---|
|
|
P0343-3-PM1. Examination of the vancomycin treatment parameter to use for Enterococcus faecium bacteremia treatment 野田晃洋1, 平山和登2, 中川未菜1, 副島啓司1, 福山雄卯介1, 三角紳博1, 近藤晃3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1342-1342, 2023. |
|---|
|
|
P0344-3-PM2. De-escalation of antibiotics for management of febrile neutropenia in patients with solid tumors : a retrospective study 松本千明1,3, 岩渕聡1,3, 栃倉尚広1,3, 今井徹1, 福島栄1, 大塚進1, 西山宏幸2,3, 梅村啓史3,4, 中山智祥3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1343-1343, 2023. |
|---|
|
|
P0345-3-PM1. One case of the MRSA bacteremia that we were able to continuously administer by weight loss for patients with impaired renal function that produced linezolid-induced thrombocytopenia 渡辺祐子1, 門村将太1, 稲井邦宏1, 松川雅子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1344-1344, 2023. |
|---|
|
|
P0346-3-PM2. Examination of the Candida blood symptom isolate in the Fukuoka University Hospital for 10 years 萩原大樹1, 鹿志毛信広2, 兼重晋3, 神村英利3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1345-1345, 2023. |
|---|
|
|
P0347-3-PM1. Efforts for the oral third generation cephalosporin antimicrobial consumption reduction by the intervention of the antimicrobial proper use support team 古川大樹1, 伊藤嘉英1, 大橋武司1, 伊藤優子1, 林房枝2, 梶田麻美2, 菱田志乃3, 小林都仁夫4, 中尾彰宏5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1346-1346, 2023. |
|---|
|
|
P0348-3-PM2. Effective evaluation based on AUC/MIC of vancomycin for the Enterococcus faecium bacteremia 清水星香1, 森脇典弘1,2, 中野貴文1,2, 江口幸臣1, 池内忠宏1, 戸川温2,3, 兼重晋1, 神村英利1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1347-1347, 2023. |
|---|
|
|
P0349-3-PM1. Collaboration example with antimicrobial proper use support team (AST) for 1 case of the purulent spondylitis by methicillin-resistant Staphylococcus lugdunensis 石川智子1, 宮田志生1, 野澤寿吉1, 加藤由香里2, 舟瀬和美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1348-1348, 2023. |
|---|
|
|
P0351-3-PM1. Effect to give to efforts and the number for the in-hospital consumption reduction of the third generation oral cephalosporin antimicrobial of foreign antimicrobial prescription 井上敬之1, 松本真衣1, 小井里香2, 日照田敦子3, 福田央子3, 山田寛之4, 長田学2,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1350-1350, 2023. |
|---|
|
|
P0352-3-PM2. Stratagem and effect of the antimicrobial proper use support activity on levofloxacin-resistant rate of Escherichia coli 中村聡志1,2, 有馬隆司2,3, 田代良一2,4, 安水里美2,5, 愛甲隼人1, 中島隆司1, 黒木優歩1, 藤崎崇史1, 東勇希1, 桑波田聡6, 竹中俊宏6, 本屋敏郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1351-1351, 2023. |
|---|
|
|
P0353-3-PM1. Effect of the intervention by the conditional registration system and AST exclusive duty pharmacist in the middle scale hospital 中野祐樹1,2, 安河内寿成1,2, 大竹野久雄1, 辻村啓史1, 浦和也2,3, 末安禎子2,4, 蓮輪博嗣1, 横尾賢乗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1352-1352, 2023. |
|---|
|
|
P0354-3-PM2. Examination of the role demanded from the antimicrobial proper use support team which we saw from a use clinical department and the intervention rate of the carbapenem-based medicine according to the infection 小野祐志, 高久保佑一, 宇佐美順子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1353-1353, 2023. |
|---|
|
|
P0355-3-PM1. About various effect accompanied with the meropenem supply stop 平田亮介, 高武嘉道, 橋本雅司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1354-1354, 2023. |
|---|
|
|
P0356-3-PM2. About efforts to the oral antimicrobial proper use in the chronic phase hospital 富野圭介1, 澤野蒼汰1, 篠原真一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1355-1355, 2023. |
|---|
|
|
P0357-3-PM1. The use of antifungal agent situation after the posaconazole marketing and cause bacterial species of the candidemia 重村明香1, 坂本靖宜1,3, 井出和男1,2, 長谷川拓也1, 渡邉直優1, 畠山成寛1, 西垣哲太1,2, 川邊一寛1, 鈴木智代1,2, 榎木裕紀3, 田口和明3, 小池博文1, 加藤英明2, 松元一明3, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1356-1356, 2023. |
|---|
|
|
P0358-3-PM2. The effect analysis of the internal use therapeutic drug for the Clostridioides difficile infection and future problem 足岡秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1357-1357, 2023. |
|---|
|
|
P0359-3-PM1. Fact-finding of the oral antimicrobial switch therapy in the use of ceftriaxone case 成島俊輔1, 鈴木智貴1, 鯉沼縁1, 青山美恵子2, 武藤博美3, 原信田努1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1358-1358, 2023. |
|---|
|
|
P0360-3-PM2. Management for the fungemia 伊藤嘉英, 古川大樹, 大橋武司, 伊藤優子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1359-1359, 2023. |
|---|
|
|
P0361-3-PM1. Relative examination of renal failure and the infusion in patients receiving vancomycin 薗部万由香1, 上山雅美1, 奈良悠汰1, 加藤梢2, 晴山知拓1, 安土菜美1, 車塚千穂1, 佐藤弘康1, 今井隆人2, 和泉秀明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1360-1360, 2023. |
|---|
|
|
P0362-3-PM2. Evaluation of the wide area antimicrobial inspection that took advantage of improvement in infection measures addition 1 institution cooperation 中野克哉1, 村澤寛美1, 佐々木康弘2, 常松健一郎3, 上蓑義典4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1361-1361, 2023. |
|---|
|
|
P0363-3-PM1. Investigation into the occurrence of bone marrow suppression during long-term administration of tedizolid 馬島務, 山本諭, 小田剛史, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1362-1362, 2023. |
|---|
|
|
P0364-3-PM2. Activity report of AST for the meropenem supply difficulty 佐伯星依奈, 関戸美咲, 菅加奈子, 菅近晴美, 又吉嘉寿人, 船臺三央, 肥後美月, 野下綾子, 喜友名侑舞, 井上千尋, 久田潤平, 村雲智久, 仲村亮太, 喜多洋嗣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1363-1363, 2023. |
|---|
|
|
P0365-3-PM1. A case which was able to heal for Candida endophthalmitis to the macula part early by quick Antifungal stewardship 菊地未由, 星野祐太, 伊藤亮太, 内山弘子, 外岡久和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1364-1364, 2023. |
|---|
|
|
P0366-3-PM2. The use situation of the preparation for the amikacin sulfate inhalation in our hospital 山内円1, 嶋本藍1, 宇都早希1, 石本学司1, 中浴伸二1, 瀧口純司2, 田中詳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1365-1365, 2023. |
|---|
|
|
P0367-3-PM1. Automatic mention ... of the long time administration instructions to usefulness - injection prescription of the long time administration of beta-lactam derivative injection antimicrobial 中谷亮介1, 岡田雅弥2, 下川福子2, 森井聖二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1366-1366, 2023. |
|---|
|
|
P0368-3-PM2. Evaluation of the antimicrobial proper use support for the tazobactam piperacillin 向後寧信, 相原由里, 近藤忠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1367-1367, 2023. |
|---|
|
|
P0369-3-PM1. About carbapenem-based resistance of use and Pseudomonas aeruginosa of the carbapenem-based antimicrobial in neonates 舘林絵茉里, 岡本剛, 伊藤大典, 小林恵美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1368-1368, 2023. |
|---|
|
|
P0370-3-PM2. Efforts to oral third generation cephalosporin medicine consumption reduction 石山晶子, 本田貴朗, 山下勇輝, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1369-1369, 2023. |
|---|
|
|
P0371-3-PM1. Result evaluation of the efforts of the wide area antimicrobial surveillance by the antimicrobial proper use support team (AST) activity 堀本厚子, 組橋由記, 保岡尭, 大久保真由美, 森井聖二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1370-1370, 2023. |
|---|
|
|
P0372-3-PM2. About the effect that a choice gives in the early period of antimicrobial on bacteremia due to substrate specific expansion type beta lactamase production bacteria in our hospital 宮田拓周, 山田政典, 吉原涼子, 松下馨介, 稲田夏実, 坂口美也子, 齋藤巨樹, 小園亜希, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1371-1371, 2023. |
|---|
|
|
P0373-3-PM1. Efforts of our hospital AST for carbapenem-based antimicrobial supply restrictions 近藤貴子1, 盛麻美1, 川村萌人1, 片平雄之3, 門脇雅子2, 大久保博史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1372-1372, 2023. |
|---|
|
|
P0374-3-PM2. The effect that introduction of the blood culture quickness identification technique gives to the use of antimicrobial situation 古庄弘和1, 日高敏哉2, 井村美月1, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1373-1373, 2023. |
|---|
|
|
P0375-3-PM1. Effect by the oral third generation cephalosporin antimicrobial deletion in the cataract surgery 貞重卓哉1, 七尾大観2, 山下敦志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1374-1374, 2023. |
|---|
|
|
P0376-3-PM2. Use turn of eventss by the use report start of TAZ/PIPC and the oral new quinolone antibacterial 井村美月, 古庄弘和, 徳丸尚人, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1375-1375, 2023. |
|---|
|
|
P0377-3-PM1. A choice of the antimicrobial for the ESBL-producing bacillaemia style infection and effective evaluation 徳山ことみ1, 藤里駿1, 馬生良則2, 崎田彩弥加2, 二階堂弘美3, 中務陽子4, 矢野朋文5, 沖田健太郎1, 船越幸代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1376-1376, 2023. |
|---|
|
|
P0378-3-PM2. Evaluation of the contribution to effect of treatment, safety by the observance of the AS pocket guide 中村友里乃1, 大隅智之1, 川田智子2, 清水博之3, 喜古康博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1377-1377, 2023. |
|---|
|
|
P0379-3-PM1. AntiMRSA medicine consumption pulse-taking at the missing part for the vancomycin hydrochloride infusion 高橋有, 小林和博, 上田覚, 尾上雅英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1378-1378, 2023. |
|---|
|
|
P0380-3-PM2. The treatment of the MRSA continuation bacteremia is difficult in now when multiple new drugs are marketed (case report) 江藤康汰, 石橋美希, 横山裕士, 八板謙一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1379-1379, 2023. |
|---|
|
|
P0381-3-PM1. Fact-finding of the use of antimicrobial situation of terminally ill patients 大矢智則1,2, 守田侑真1, 岩下沙織1, 永岡大輝1,3, 大曽根寛晃1, 神坐美弥子1,2, 橋本竜1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1380-1380, 2023. |
|---|
|
|
P0382-3-PM2. Examination of a renal failure incidence and the aim AUC level at the vancomycin administration 松木祥彦1, 小島雄太郎1, 武田紋奈2, 石毛宏治1, 石田雅也1, 金井絵美1, 長谷川雄介1, 米井万紀子1, 柳恵1, 森木麻未1, 山崎茜1, 石倉裕美1, 大竹千夏1, 藤岡功3, 佐古兼一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1381-1381, 2023. |
|---|
|
|
P0383-3-PM1. About substitution medicine suggestion at the SBT/CPZ understock by the pharmacist 更谷和真, 徳濱潤一, 原田晴司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1382-1382, 2023. |
|---|
|
|
P0384-3-PM2. Relation to the antimicrobial proper use in the situation of a ward charge pharmacist and each infection control team exclusive duty pharmacist 清川明慶1,2, 矢田康司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1383-1383, 2023. |
|---|
|
|
P0385-3-PM1. See 3 all; about the use situation of ceftazidime of patients with CAPD peritonitis of the ward inpatient 森雅俊, 皆木優門, 鈴木正樹, 橋本光生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1384-1384, 2023. |
|---|
|
|
P0386-3-PM2. One patient who showed improvement of the overall status by the prescription suggestion through the AS activity 井須恭平, 平野龍一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1385-1385, 2023. |
|---|
|
|
P0387-3-PM1. Examination about the antimicrobial therapy using the piperacillin for pertussis 大石博史1, 中嶋敏紀2, 片山陽介1, 古海和博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1386-1386, 2023. |
|---|
|
|
P0388-3-PM1. The pharmacist of the perinatal special hospital worked ... children to get over lack of the antimicrobial 運天奈緒美, 浅原章裕, 飯野香菜子, 岩西雄大, 大津由美子, 望月千枝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1390-1390, 2023. |
|---|
|
|
P0389-3-PM2. Effect by monitoring and the feedback enforcement from an early stage of the wide area antimicrobial by the person in charge of ward for the full-time equivalent improvement of the pharmacist 守田侑真, 大矢智則, 岩下沙織, 永岡大輝, 大曽根寛晃, 神坐美弥子, 橋本竜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1391-1391, 2023. |
|---|
|
|
P0390-3-PM1. Enforcement and activity evaluation of the feedback by the antimicrobial proper use support team utilizing the electronic medical chart approval function 中西剛志1,2,3,4,5, 末吉愛美2, 森松孝文3, 原田美羽3, 磯崎嘉人4, 松尾彩子5, 黒川綾子1, 中牟田翔吾1, 古川和弘1, 川俣洋生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1392-1392, 2023. |
|---|
|
|
P0391-3-PM2. Evaluation of the antimicrobial proper use support (AS) activity that a pharmacist played a key role 保良結1, 森葉子1, 藤田翔1, 姫野智子1, 小杉卓大1, 川門礼子2, 眞境名豊文4, 西平守邦5, 國分千代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1393-1393, 2023. |
|---|
|
|
P0392-3-PM1. About the bundle observance situation for the candidemia in our hospital 高橋真一, 伊東充, 新井由希, 四方公亮, 鮎川英明, 佐藤香織, 加藤潤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1394-1394, 2023. |
|---|
|
|
P0393-3-PM2. Investigation about the effect that biological drug administration gives for bacteremia treatment 山下友輝1, 伊藤悠里子1,2, 阿部珠妃3, 柴波明男1, 樋浦一哉3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1395-1395, 2023. |
|---|
|
|
P0394-3-PM1. Examination of risk factors for thrombocytopenia due to tedizolid administration 吉川慧1,2, 小森亮子3, 鈴木ゆきえ3, 花房喜子3, 草野元3, 佐藤陽1,2, 吉川真一1, 松本司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1396-1396, 2023. |
|---|
|
|
P0395-3-PM2. The study implementation situation investigation to prevent hepatitis B reactivation with the chemotherapy 早川裕里, 指宿貴博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1397-1397, 2023. |
|---|
|
|
P0396-3-PM1. One case of the diabetic foot lesion which caused pancytopenia during vancomycin (VCM) administration 香川真徳1, 土肥有二2, 安藤健明3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1398-1398, 2023. |
|---|
|
|
P0397-3-PM2. Risk factors for the development of azole-reduced Candida bacteremia 洲山佳寛1, 菅原隆文1, 植竹宣江2, 西綾香1, 中野葵1, 竹本嘉恵1, 國重将大2, 竹之内誠3, 立川文崇2, 田中和行1, 宮森伸一2, 松本俊治4, 渡辺篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1399-1399, 2023. |
|---|
|
|
P0398-3-PM1. Efforts for the promotion of the antimicrobial doses adequacy and the evaluation 島谷幸希1, 竹内祐介1, 石田茂伸1, 多胡友絵1, 星育子1, 小泉祐一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1400-1400, 2023. |
|---|
|
|
P0399-3-PM2. Levofloxacin of Escherichia coli in our hospital-sensitive trend 中野聡1, 織田雄一郎1, 副島將司1, 山本大策1, 大場久美1, 海瀬有沙1, 上野遥香1, 本堂千秋1, 長澤真利絵1, 泉谷千穂2, 秦有希未2, 小松隼也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1401-1401, 2023. |
|---|
|
|
P0400-3-PM1. AST activity depending on a consumption trend of the carbapenem-based antimicrobial in the Iizuka Hospital 長崎皓光1, 梅田勇一1, 内田守次1, 長谷川雄一2, 沖中友秀2, 的野多加志2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1402-1402, 2023. |
|---|
|
|
P0401-3-PM2. Findings about the approach of "infection control, the antimicrobial proper use" of the medical institution in Okayama 市川大介1,2,3, 石井澄雄2,3,4, 川端崇義2,3,5, 明田徹2,3,6, 森一徳2,3,7, 山崎恵2,3,8, 森谷康志2,3,9, 西本美淑2,3,10, 森英樹3,11 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1403-1403, 2023. |
|---|
|
|
P0402-3-PM1. An investigation of the foreign oral antimicrobial consumption using J-SIPHE data and inspection of the usefulness 田沼道也1, 櫻井隆之2, 田中昌代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1404-1404, 2023. |
|---|
|
|
P0403-3-PM2. 1 case that experienced bacteremia by Chryseobacterium indologenes 明石岩雄1, 篠崎陽一1, 李広烈2, 大川華代1, 相馬將一1, 長澤仁志1, 川久保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1405-1405, 2023. |
|---|
|
|
P0404-3-PM1. The antimicrobial consumption that AST round gave to a secondary medical institution, change of the clinical microbiologic outcome 吉田健人1, 上条泰弘1, 雨宮哲郎2, 伊藤隆哉1, 鬼窪利英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1406-1406, 2023. |
|---|
|
|
P0405-3-PM2. Effect of the quickness-resistant screening using the cefpodoxime disk in Escherichia coli and the Klebsiella pneumoniae bacteremia 酒井幹康1,2, 酒井隆全3, 永田悠起4, 駒井博子5, 三宅芳男1, 渡口賢隆6, 川端厚5, 大津史子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1407-1407, 2023. |
|---|
|
|
P0406-3-PM1. Initiatives to optimize treatment of Candida endophthalmitis in our hospital's AST 宮田祐里1, 足立麻美1, 宮川朋子2, 藤原万記子2, 岡田彩3, 藤原典子3, 柏木貴雄4, 佐伯啓介5, 松本憲幸1, 岸本光正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1408-1408, 2023. |
|---|
|
|
P0407-3-PM2. Goal setting in our hospital for the accomplishment of the new drug-resistant measures action plan 坂東翔, 竹原朗, 橋本浩, 亀山礼子, 長枝智子, 林晴美, 齊藤良子, 高柳椋, 猪谷優希, 山口美奈, 川根隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1409-1409, 2023. |
|---|
|
|
P0408-3-PM1. Support of antimicrobial proper use support team (AST) for the meropenem supply stop and the evaluation 由井薗陽一1,2, 大田典正1,2, 入江徳俊1,2, 二神咲子1, 槇林智子1, 下村武志2,4, 吉岡知美4, 末永健二2,5, 石原沙代子2,3, 岩崎教子2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1410-1410, 2023. |
|---|
|
|
P0409-3-PM2. Efforts and stocktaking to the antimicrobial proper use of the AST pharmacist in our hospital 平尾祐樹1, 佐々英也2, 内山耕作1, 鈴川誠1, 芥子川純里1, 冨田敦和1, 今西忠宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1411-1411, 2023. |
|---|
|
|
P0410-3-PM1. The in-hospital antimicrobial use turn of eventss that resulted from the supply restrictions of carbapenem drugs 坂口晋哉1, 白川敦規2, 田代紘士1, 桑原貴美子1, 鈴田浩孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1412-1412, 2023. |
|---|
|
|
P0411-3-PM2. Effect on use of antimicrobial situation that meropenem understock gave and inpatient outcome 柳原有希1, 堀内寿志2, 槇恭佑2, 原田由紀子3, 倉田賢生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1413-1413, 2023. |
|---|
|
|
P0412-3-PM1. Attitude survey in the in-hospital training about the antimicrobial proper use of the acute respiratory tract infection 綺田尚久1, 橋本拓郎1, 西野広将2, 北野裕司3, 中村忠之3, 原田吉将4, 吉田紀子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1414-1414, 2023. |
|---|
|
|
P0413-3-PM2. Effect of clinical record mention for the purpose of the proper use of Tazbactam/Piperacilin 譲原千広, 荒木遼太, 小川紗知, 波多晶子, 中澤美樹子, 橋爪和恵, 窪田真弓, 鶴居勝也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1415-1415, 2023. |
|---|
|
|
P0414-3-PM1. Questionary survey about the current situation and the consciousness of the infection measures of the member of Yamanashi hospital pharmacist society institution 神田稔1, 遠藤愛樹2, 莊司智和3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1416-1416, 2023. |
|---|
|
|
P0415-3-PM2. About a use of own institution antimicrobial situation evaluation using J-SIPHE data 葛間慎介1, 佐藤正幸2, 上野哲史1, 岩井中里香1, 卸川紘光1, 松浦しほみ1, 平林鑑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1417-1417, 2023. |
|---|
|
|
P0416-3-PM1. The making of the enlightenment video for protectors about the antimicrobial proper use of the pediatrics domain and examination of scenario contents 川村ひとみ1,2, 櫻井秀彦3, 坂本拓也1, 荒井宏人1, 直井和之4,5, 津久井理絵4, 巌本三壽6, 相澤まどか7, 岸本桂子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1418-1418, 2023. |
|---|
|
|
P0417-3-PM2. Antibacterial seat (Abyei seat (R)) development and the proof experiment to have both sterilization effect and biofilm formation inhibitory effect 山田陽一1, 林秀樹2, 吉井圭佑1, 加藤久登1, 関谷洋志3, 上田剛慈4, 細田俊1, 工藤季之1, 玉井栄治3, 柴川敏之5, 島田憲一1, 塩田澄子1, 鈴木宗6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1419-1419, 2023. |
|---|
|
|
P0418-3-PM1. Effect on surgical-site infections development by the chemical intestinal tract measures enforcement before operation by the large intestine surgery in the Saiseikai Fukuoka General Hospital 大田典正1, 入江徳俊1, 由井薗陽一1, 二神咲子1, 槇林智子1, 末永健二2, 岩崎教子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1420-1420, 2023. |
|---|
|
|
P0419-3-PM2. Comparative study of Candida bacteremia bundle compliance by AST practices 末延道太, 藤野優, 原尻学志, 陸丸幹男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1421-1421, 2023. |
|---|
|
|
P0420-3-PM1. AST use of antimicrobial turn of eventss by the change of the activity having a meeting 岩崎修1, 加藤利康1, 山田匡子2, 日谷明裕3, 松田基4, 田中大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1422-1422, 2023. |
|---|
|
|
P0421-3-PM1. Phase II study (T-CRACC study) first report about the protective efficacy of the hydrocortisone drug for external use for the capecitabine-induced hand-and-foot syndrome 古川直樹1, 飯村洋平1, 石橋正祥1, 流石智恵子1, 馬場啓介2, 阿彦友佳3,4, 小野山温那3,4, 柵山尚紀3,4, 愛甲丞3,4, 志田大3,4, 野島正寛5, 黒田誠一郎1, 朴成和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1424-1424, 2023. |
|---|
|
|
P0422-3-PM2. Efforts of the duties burden reduction utilizing the information and communication technology in the clinical experimental medicine administrative work 吉中千佳, 雨山智, 前嶋隆弘, 寺岡知寿, 佐藤祐司, 前川正充, 佐藤真由美, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1425-1425, 2023. |
|---|
|
|
P0423-3-PM1. It is efforts to magnetizing it the train of the trial-related document using the cloud type document management system 田中瑠美1,2, 田島壮一郎1,2, 三木翔伍1,2, 武田真樹2, 廣田豪2, 家入一郎1,2, 戸高浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1426-1426, 2023. |
|---|
|
|
P0424-4-PM1. Effect of the additive in the crush formulations of the film coated tablet 山添絵理子, 伊藤貴章, 田原耕平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1429-1429, 2023. |
|---|
|
|
P0425-4-PM2. Share of the change of the incident report to stop by if caused by calculation formulations management system (F-WAVE) introduction in our hospital 古谷一平, 田中佳子, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1430-1430, 2023. |
|---|
|
|
P0426-4-PM1. About duties reduction by the PBPM practice in doubt inquiry of the outside Parliament prescription 栗山紘生1, 元茂拓法1, 小原貴子2, 三上祥博1, 川口啓之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1431-1431, 2023. |
|---|
|
|
P0427-4-PM2. Usefulness evaluation of the half lock divider corresponding to oval tablet azosemide tablets and carvedilol tablets 座間亜紀子1, 北口剛吉2, 大竹裕子3, 長井紀章3, 村田久枝1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1432-1432, 2023. |
|---|
|
|
P0428-4-PM1. Accurate evaluation of the private business, medicine for external application compounding of medicines duties that the person except a pharmacist by the automatic drug picking device introduction and the pharmacist is associated with 水谷栄梨, 岡本明大, 加藤秀雄, 田坂健, 向原里佳, 岩本卓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1433-1433, 2023. |
|---|
|
|
P0429-4-PM2. Effect by the operation of representation correction/doubt inquiry PBPM in the in-house prescription 木下三緒, 植田裕美, 庄野裕志, 山西香織, 佐光留美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1434-1434, 2023. |
|---|
|
|
P0430-4-PM1. Effect on prevention of the formulations incident by the introduction of the PDA (personal digital assistant) tool 森健太郎1, 前川友宏2, 田中義人3, 舟越亮寛2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1435-1435, 2023. |
|---|
|
|
P0431-4-PM2. Attitude survey of the compounder about the picking support system introduction 高橋菜生, 渡邊裕之, 立石裕樹, 重松由加, 池田都, 松本貴行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1436-1436, 2023. |
|---|
|
|
P0432-4-PM1. The compounding of medicines duties efficiency that intended ward duties expansion 巖西真, 國津侑貴, 若杉吉宣, 神谷貴樹, 増田恭子, 池田義人, 森田真也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1437-1437, 2023. |
|---|
|
|
P0433-4-PM2. The examination of the cleaning method of the disk type powdered medicine divided powder plane in packeted formulations of mercaptopurine powders and pollution status investigations such as the powder wrapping paper, and the like 原祐1, 松原花乃1, 片倉佐都子1, 若松遼介1, 水谷彰史1, 樋浦一哉2, 棚谷貢1, 船木映二1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1438-1438, 2023. |
|---|
|
|
P0434-4-PM1. About the change by the prescription publication of the drug requiring attention at a decreased renal function 岡本賢一, 吉良俊彦, 安田成男, 谷大輔, 吉野秀紀, 辻井佳代, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1439-1439, 2023. |
|---|
|
|
P0435-4-PM2. Examination of the transluminal administration of Novell gin (R) preparation method by the difference in formulations method in the pediatric domain 工藤香澄, 堀望美, 我妻恭行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1440-1440, 2023. |
|---|
|
|
P0436-4-PM1. Contents analysis of a prescription, doubt inquiry not to inject by the pharmacist of Fukuoka Memorial Hospital 魚住秀親, 西村京子, 江藤義和, 下山真智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1441-1441, 2023. |
|---|
|
|
P0437-4-PM2. Effect of the dispensing error prevention PDA system introduction in the middle scale local government Hospital 高橋直浩, 新康憲, 森田聡子, 西山祐美, 正置耕一, 吉岡睦展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1442-1442, 2023. |
|---|
|
|
P0438-4-PM1. Evaluation after the dispensing error prevention system introduction 畠山瑞季1, 小島俊彦1, 横澤大輔2, 倉本美紀子1, 松田隆史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1443-1443, 2023. |
|---|
|
|
P0439-4-PM2. Advantage by the combination of problems and image, weight inspection device of the internal use anticancer agent formulations using the PDA terminal 中元隆浩, 古田ゆり, 石原慎之, 泙誠一, 玉木宏樹, 矢野貴久, 直良浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1444-1444, 2023. |
|---|
|
|
P0440-4-PM1. Usefulness evaluation of clinical test value for the drug proper use of the in-hospital prescription and the indication to alert 角真太郎, 嘉村知子, 飛田修康, 橘川奈生, 小部亜紗美, 橋本宇矩, 江本晶子, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1445-1445, 2023. |
|---|
|
|
P0441-4-PM2. Examination of the introduction effect of the TPN preparation duties training supporting program 水野翼, 舟橋智美, 塩田有史, 川澄紀代, 大西正文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1446-1446, 2023. |
|---|
|
|
P0442-4-PM1. Without increasing duties efficiency - formulations errors by the review of the duties flow in the out patient dispensing; inspection duties reduction - 青井博志1, 大西健太1, 田村曉識1, 横山江美1, 谷川恵子1, 谷田彩1, 小川恵美子1, 吉川一吾2, 池田和之1, 高野頌3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1447-1447, 2023. |
|---|
|
|
P0443-4-PM2. Change of the number by the handwritten prescription introduction at order ring system failure in the Osaka acute phase, comprehensive medical care center of doubt inquiries and contents 飯島聖子1, 管詩歩1, 川田希帆1, 森井絵莉香1, 橋本佑香1, 宮部祐子1, 立川奈保美1, 寺岡知香2, 中野寛之1, 下辻恒久1, 山東真寿美1, 藤田敬子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1448-1448, 2023. |
|---|
|
|
P0444-4-PM1. Change of the duties time by a change and the new introduction for formulations apparatus, system 火口裕弥, 佐々木緑, 有松利恵, 辻卓矢 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1449-1449, 2023. |
|---|
|
|
P0445-4-PM2. Effect of the picking support system introduction for the formulations misreduction 川前隆一, 立石裕樹, 松本貴行, 秋吉正貴, 田原裕希乃, 矢野洋平, 永田理佳, 高木悠資, 佐々木文野, 井上幸子, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1450-1450, 2023. |
|---|
|
|
P0446-4-PM1. A case which a local pharmacist received the drug review of the patients on dialysis who consulted multiple medical institutions, and contributed to prescription adequacy in cooperation with a medical institution 小嶋彩貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1451-1451, 2023. |
|---|
|
|
P0447-4-PM2. Investigation of doubt inquiry for the injection drug prescription in our hospital 竹内裕理佳, 岡本涼子, 中川喬統, 小田幸奈, 松本恵美, 小田剛史, 深海広平, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1452-1452, 2023. |
|---|
|
|
P0448-4-PM1. Medical cost cut effect by the small standard preparation introduction of the propofol kit preparation 見尾谷昇, 細野真吾, 磯野礼果, 山崎崇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1454-1454, 2023. |
|---|
|
|
P0449-4-PM2. Comparative study of utilization methods of "Cubixx(R)" and "NOVUMN(R)" cold storage drug management systems using RFID tags after one year of use 六波羅孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1455-1455, 2023. |
|---|
|
|
P0450-4-PM1. Examination of the traceability system (Cubixx(R), NOVUMN(R)) introduction effect on pharmaceutical products expiration disposal 宮本翔平, 松島葵, 石井聡一郎, 佐伯康之, 松尾裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1456-1456, 2023. |
|---|
|
|
P0451-4-PM2. Effect of the cubic introduction 吉田崇志, 遠藤汐梨, 佐藤清貴, 田口未菜, 菅野澄佳, 清水美保, 眞木秀子, 石山晶子, 西村雅次, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1457-1457, 2023. |
|---|
|
|
P0452-4-PM1. About an evaluation of the pharmaceutical products inventory control by the article management system N2 尾崎誠一, 山中洋, 槇恒雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1458-1458, 2023. |
|---|
|
|
P0453-4-PM2. Efforts to duties efficiency by the in-hospital adoption medicine ABC management 川崎美咲, 後藤一馬, 作山悠里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1459-1459, 2023. |
|---|
|
|
P0454-4-PM1. A case of spinal muscular atrophy treated with onasemnogene abeparvovec (Zolgensma(R)), a gene therapy vector product 細野萌子1, 猪股羽矢人1, 田中里奈1, 鈴木寿樹1, 及川善嗣2, 青木亜紀2, 菊地正史1, 松浦正樹1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1460-1460, 2023. |
|---|
|
|
P0455-4-PM2. Duties actual situation change before and after the tablet automatic assortment return device (Genie) introduction 東昌代, 中出奈津子, 石田美由紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1461-1461, 2023. |
|---|
|
|
P0456-4-PM1. From the adoption discussion of high-cost emergency drugs to the establishment of their operation - ONDEXXYA experience - 油屋恵, 松岡勇作, 吉留利香, 赤瀬博文, 奥野昌宏, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1462-1462, 2023. |
|---|
|
|
P0457-4-PM2. Effect and investigation of problems that the situation that the supply of pharmaceutical products was unstable in gave in Aichi Medical University Hospital 杉木壮吉, 野々垣知行, 宇野英理子, 大西正文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1463-1463, 2023. |
|---|
|
|
P0458-4-PM1. Comparison about preparation time for Mohs paste shortening 須藤春香1, 鈴木善貴1, 彦坂麻美1, 長谷川森一2, 定盛理純1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1465-1465, 2023. |
|---|
|
|
P0459-4-PM2. Granulating of the dexamethasone tablet crush thing for the purpose of the remedy-related improvement to children by the taste bitter reduction 山内理恵, 大野修司, 土志田珠希, 井上信宏, 久保元, 浅井和範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1466-1466, 2023. |
|---|
|
|
P0460-4-PM1. The manufacture of the gelatinous chewable tablet, lyophilization tablet using the pharmaceutical products additive for the 3D printer and mechanical strength evaluation 田上辰秋, 海野桃加, 小川昂輝, 尾関哲也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1467-1467, 2023. |
|---|
|
|
P0461-4-PM2. The case that tried the Mohs strange law which combined zinc oxide ointment with the local control of the head haemangiosarcoma 小林宇太郎1, 佐藤未千世1, 川俣洋生2, 清原龍士3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1468-1468, 2023. |
|---|
|
|
P0462-4-PM1. Preparation and taking hospital preparation Aripiprazole-containing silverberry preparation-related evaluation 河本小百合1, 田中紫茉子1,2, 三浦基靖1, 柏倉康治1, 神谷千明3, 袴田晃央3, 小田切圭一3, 乾直輝3, 渡邉裕司3, 並木徳之1,4, 内田信也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1469-1469, 2023. |
|---|
|
|
P0463-4-PM2. Usefulness of the dialytic fluid potassium level revision using hospital preparation "26% potassium chloride liquid" 清水咲, 徳力麻希, 池田久雄, 平田貴宏, 神原弘和, 足立充司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1470-1470, 2023. |
|---|
|
|
P0464-4-PM1. Preparation of the hospital preparation iodine-containing foam preparation for the purpose of pressure sore treatment 柏倉康治, 山根早紀子, 篠原佑奈, 河本小百合, 三浦基泰, 内田信也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1471-1471, 2023. |
|---|
|
|
P0465-4-PM2. Basic examination - using effect - salivation model rat that an application part of the hospital preparation scopolamine ointment gives to efficacy 桂あやの1, 大嶋祥高1, 石田奈津子1, 嶋田努2,3, 水野智詞3, 荒川大1, 崔吉道2,3, 菅幸生1, 石崎純子1, 松下良1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1472-1472, 2023. |
|---|
|
|
P0466-4-PM1. Examination of alternatives to Methylrosanilinium Chloride for pre- and intraoperative marking 森内貴子1, 高橋優実1, 藤井朋子1, 馬屋原慈理1, 中村護1, 山崎美保1, 小濱邦彦2, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1473-1473, 2023. |
|---|
|
|
P0467-4-PM1. The effect that preservation environment gives to the functional indication food of the tablet shape 栗林和美, 池田彩華, 宇多万紘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1475-1475, 2023. |
|---|
|
|
P0468-4-PM2. Advisability of the simple suspension method application in the administration through the nasal feeding catheter of capsule of the dutasteride and tablet 石田志朗1, 切詰大貴2, 吉松健太3, 安藤哲信4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1476-1476, 2023. |
|---|
|
|
P0469-4-PM1. Examination about the stability of the bromhexine hydrochloride injection 寺岡麗子1, 竹内敦子2, 都出千里2, 松川美佐子1, 中山優子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1477-1477, 2023. |
|---|
|
|
P0470-4-PM1. Promotion of digital transformation (DX) in the drug information (DI) administrative work using the tablet terminal in our hospital pharmacy 稲田顕慶, 杉野太亮, 森本健幹, 小原直紘, 小田亮介, 丸山直岳, 土井敏行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1479-1479, 2023. |
|---|
|
|
P0471-4-PM2. Fact-finding about Accessibility to the in-hospital practice information system of the hospital pharmacy gate 鈴木大吾1, 坂田洋1, 水草博希1, 石黒友希1, 竹内健悟1, 鈴木敦詞1, 田中伸明1, 中村敏史1, 服部芳明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1480-1480, 2023. |
|---|
|
|
P0472-4-PM1. List of pharmaceutical products adoption making by the RPA utilization 佐藤息吹1, 原田紗希2, 菅田哲治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1481-1481, 2023. |
|---|
|
|
P0473-4-PM2. Medication reporting study to the medical information network using the smartphone 堀川尚嗣1, 横山邦彦2, 杉本修治3, 今井康人4, 伊藤勝彦5, 榊原幹夫6, 金子周一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1482-1482, 2023. |
|---|
|
|
P0474-4-PM1. One consideration for effectively utilizing it of the electronic edition prescription notebook application 奥平誉央1, 松浦誠2, 高橋寛2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1483-1483, 2023. |
|---|
|
|
P0475-4-PM1. Examination about the stability of octreotide in the Elneopa NF1 number infusion which coinfused a Rinderon note 熊谷岳文1, 井上裕文2, 山下純2, 楢原奈穂子2, 佐藤英治2, 木平孝高2, 藤村よしの2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1486-1486, 2023. |
|---|
|
|
P0476-4-PM2. Questionary survey about the recognition of the list of distribution management items in Ehime and the satisfaction 坂本裕哉1,2, 高田裕介1,2, 浅川隆重2, 福岡竜逸2, 村上通康2, 竹内信人2, 大塚尚2, 古川清3, 舟橋達也4, 飛鷹範明1,2, 田中守1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1487-1487, 2023. |
|---|
|
|
P0477-4-PM1. Construction of "the drug database for overDors prevention" which adopted clinical on-site needs 永島一輝1,2, 比留間康二郎3, 中原未結2, 大森あすか2, 中村英里2, 渡邊真知子2, 関根祐子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1488-1488, 2023. |
|---|
|
|
P0478-4-PM2. Development of DPC data extraction, the processing application and examination of new Quality Indicator 天野哲史1, 水草博希2, 鈴木大吾2, 加藤滋宏3, 河村隆登4, 桑原悠里5, 富田いゆき3, 平野貴志6, 水野雄登7, 坂田洋2, 鈴木厚志1, 服部芳明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1489-1489, 2023. |
|---|
|
|
P0479-4-PM1. The current situation investigation of information mention about the propriety of the simple suspension method to pharmaceutical products interview form 芳野雅巳1, 青木学一2,3, 渋谷清2,3, 新井克明1, 秋山滋男4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1490-1490, 2023. |
|---|
|
|
P0480-4-PM2. About the drug information reading situation by the introduction of the drug reporting service 小川充恵1, 小枝伸行2, 香川雅一1, 西岡達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1491-1491, 2023. |
|---|
|
|
P0481-4-PM1. Investigation about the source of information of the incompatibility in the questions and answers of the drug information room 若林智仁, 坂倉広大, 安延恵, 向井優太朗, 中蔵伊知郎, 上野智子, 中野一也, 川端一巧 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1492-1492, 2023. |
|---|
|
|
P0482-4-PM2. Usefulness and problem of the straight molding AI in the drug information 松浦誠, 長澤茉依, 関本葵, 高橋寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1493-1493, 2023. |
|---|
|
|
P0483-4-PM1. Questionary survey to our hospital charge medical representative about the drug information offer activity means under the COVID-19 outbreak 勝弘毅, 平野淳, 田淵克則, 薄雅人, 吉田知由 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1494-1494, 2023. |
|---|
|
|
P0484-4-PM2. Examination, inspection for the database making to guess about the taste information of the ethical drug 尾島稔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1495-1495, 2023. |
|---|
|
|
P0485-4-PM1. DI duties, national survey subanalysis ... of relationship - medical institution of the duties actual situation and the number of the bed scale, the staff of the detailman 大幸淳1, 内倉健2, 榊原統子3, 大庭理寛4, 鈴木すみれ5, 酒井隆全6, 若林進7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1496-1496, 2023. |
|---|
|
|
P0486-4-PM2. Fact-finding about drug information duties in the metropolis and districts pharmacist society 酒井隆全1, 内倉健2, 大幸淳3, 大庭理寛4, 榊原統子5, 鈴木すみれ6, 若林進7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1497-1497, 2023. |
|---|
|
|
P0487-4-PM1. Investigation about the quantity of prescription of the oral anticoagulant drug according to the renal function based on administrative data 柏倉正太1, 菊池大輔1, 佐々木康太1, 岩井智美1, 飯沼尚己1, 岡田浩司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1498-1498, 2023. |
|---|
|
|
P0488-4-PM2. Consideration for solving problems in formulary introduction in functional hospital groups 安藤正純1, 金井紀仁1, 佐藤光2, 宮本拓也3, 澤田雄太4, 陣内智美5, 永瀬真理子6, 吾妻隼斗5, 奈良部修弘7, 下舘桃子8, 宮崎美子3, 鈴木智9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1499-1499, 2023. |
|---|
|
|
P0489-4-PM1. Crossing study - using prescription fact-finding - medical care big data in elderly people with the condition of a patient needing drinking water restrictions 越塚宏美1,2, 百賢二1,2, 渡邊亜矢子1,2, 松崎あい理1,2, 柏原由佳1,2, 田中克巳1,2, 佐々木忠徳3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1500-1500, 2023. |
|---|
|
|
P0490-4-PM2. Onset of liver damage signal search by drug interactions with the nintedanib using JADER 土川拓也, 小寺聖, 関谷泰明, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1501-1501, 2023. |
|---|
|
|
P0491-4-PM1. Examination of a change and the effect after the hospital formula reintroduction of the acid-secreting antagonist 川邊一寛, 畠山成寛, 中村明日香, 川邉桂, 若杉正, 小池博文, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1502-1502, 2023. |
|---|
|
|
P0492-4-PM2. Evaluation of the important potential risk associated with the rhabdomyolysis using the adverse event spontaneous report database 竹下和輝1,2, 田坂祐一1, 名和秀起1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1503-1503, 2023. |
|---|
|
|
P0493-4-PM1. Analysis about the hypothyroidism of hypoxia-inducible factor - proline hydroxylase (HIF-PH) inhibitor using adverse drug reaction database (JADER) 鈴木慎一郎, 今井徹, 大塚進 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1504-1504, 2023. |
|---|
|
|
P0494-4-PM2. Drug-induced hiccups and relations of the dopamine D2 receptor 細谷龍一郎1,2, 寺島朝子1, 野澤 (石井) 玲子3, 植沢芳広2, 加賀谷肇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1505-1505, 2023. |
|---|
|
|
P0495-4-PM1. Analysis of the gender gap in the adverse event expression of DPP-4 inhibitor using Japanese adverse event spontaneous report database (JADER) 宍戸正昂1, 野口義紘1, 舘知也2, 井口和也3,4, 吉村知哲1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1506-1506, 2023. |
|---|
|
|
P0496-4-PM2. Construction of the pharmacokinetic information database supporting medical treatment management and medication counseling 長尾理乃1, 村田佑香1, 市丸咲紀1, 中村拓己1, 山本祐有1, 雨宮理1, 大野逸子1, 柴崎光太郎1,2, 杉平直子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1507-1507, 2023. |
|---|
|
|
P0497-4-PM1. Prediction of the nuclear receptor, stress reply course to be involved in onset of anticancer medicine-induced diarrhea using the large-scale side effect database 奥中真白1, 植沢芳広2, 加納大輔1, 川崎敏克1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1508-1508, 2023. |
|---|
|
|
P0498-4-PM2. Risk analysis about acute renal failure of the antiSARS-CoV-2 medicine 加茂真宏, 祖川倫太郎, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1509-1509, 2023. |
|---|
|
|
P0499-4-PM1. Effect of the diabetes therapeutic drug on delirium 石橋幸子, 祖川倫太郎, 緒方健二, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1510-1510, 2023. |
|---|
|
|
P0500-4-PM2. Does an effect of the pimobendan include the difference by the left ventricular ejection fraction of patients with heart failure? 岩出佳樹1, 林太祐1, 久保田芳明2, 西野拓也3, 渡邉将央2, 橘貴大2, 松田淳也2, 加藤活人4, 太良修平2, 宮地秀樹2, 時田祐吉2, 伊勢雄也1, 岩崎雄樹2, 浅井邦也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1511-1511, 2023. |
|---|
|
|
P0501-4-PM1. Examination of the usefulness of the allergic evasion using the auxiliary pharmaceutical adjuvant database 粟野美沙1, 川東祥子1, 奥覚子1, 柴崎光太郎1,2, 栗原輝子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1512-1512, 2023. |
|---|
|
|
P0502-4-PM2. Study on international comparison of the risk management plan of pharmaceutical products approved by a pioneer pharmaceutical products-designated system 中村百合, 前田英紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1513-1513, 2023. |
|---|
|
|
P0503-4-PM1. Efficiency of the delivery such as the material, and the like for the instruction to patient by the "MONITARO-Lite" introduction 渡辺智康, 難波良平, 山崎恵, 高取孝一, 安藤哲信 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1514-1514, 2023. |
|---|
|
|
P0504-4-PM2. Does the drug information administrative work have the introduction effect of the artificial intelligence chat bot? 岩西雄大, 大津由美子, 望月千枝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1515-1515, 2023. |
|---|
|
|
P0505-4-PM1. Comparison of miconazole adhesion tablets and the amphotericin B syrup in oral candidiasis 吉田りほ子, 萩原大樹, 東恵理, 伊藤弥紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1519-1519, 2023. |
|---|
|
|
P0506-4-PM2. Proper use fact-finding of the low-dose edoxaban in our hospital 伊藤弥紀, 東恵理, 萩原大樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1520-1520, 2023. |
|---|
|
|
P0507-4-PM1. Report - about research - institution attribute and the pharmacist duties rate of use about the usefulness of the pharmacist intervention in the convalescent ward 藤原久登1,2, 岸本真1,3, 小瀬英司1,4, 篠永浩1,5, 田中絵里子1,6, 中道真理子1,7, 溝神文博1,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1521-1521, 2023. |
|---|
|
|
P0508-4-PM2. Usefulness of the use of commercial thickness adjustment food at the mesalazine granular transluminal administration 石田洋史1, 野村洋道2, 中浴伸二2, 田中詳二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1522-1522, 2023. |
|---|
|
|
P0509-4-PM1. The current situation of the hyperkalemia in the use of mineralocorticoid receptor blocker patients 石原和恭, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1523-1523, 2023. |
|---|
|
|
P0510-4-PM2. The use situation of ondansetron in the pediatric intensive care unit 小林恵子, 鈴木英二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1524-1524, 2023. |
|---|
|
|
P0511-4-PM1. The enforcement situation, attitude survey of the patients follow-up during duration of drug use of the canola flower East Japan 伊澤裟実子1, 赤川実久莉2, 奥村郁実3, 竹谷真由子6, 豊田陽子5, 豊東淳美4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1525-1525, 2023. |
|---|
|
|
P0512-4-PM2. About the utilization situation, and the like and a problem of pharmaceutical products risk management plan (RMP) in the healthcare setting 福田小夜子, 八田真美子, 岡本麻依, 漆谷隼, 養老真紀, 清水慧子, 沼田恵理, 田島康則, 大澤智子, 倉持憲路 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1526-1526, 2023. |
|---|
|
|
P0513-4-PM1. Investigation of questions and answers about the interaction of the anticoagulant in the drug information room 安延恵, 坂倉広大, 向井優太朗, 中藏伊知郎, 若林智仁, 中野一也, 上野智子, 川端一功 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1527-1527, 2023. |
|---|
|
|
P0514-4-PM2. The laxative abuse in patients with eating disorders and fact-finding about the quantity of in-hospital laxative prescription 山本ゆりえ1,2, 河合啓介2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1528-1528, 2023. |
|---|
|
|
P0515-4-PM1. Survey of clazosentan use for cerebral vasospasm after subarachnoid hemorrhage surgery in acute care hospitals 高橋謙吾1, 別所千枝1, 安原昌子1, 阿美古将2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1529-1529, 2023. |
|---|
|
|
P0516-4-PM2. Recognition degree investigation about the chic day response of the patients with rheumatoid arthritis 鶴橋智子1, 本岡千佳1, 祖川倫太郎1, 丸山暁人2, 長嶺里美3, 島ノ江千里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1530-1530, 2023. |
|---|
|
|
P0517-4-PM1. About the use situation and hypothyroidism of the Pembrolizumab in our hospital 木本秀樹, 長谷川将, 山村真貴子, 佐藤優希子, 長島章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1531-1531, 2023. |
|---|
|
|
P0518-4-PM2. Fact-finding of the cyclosporine adverse event in atopic dermatitis 松下一樹, 和田宜久, 友井理恵子, 的場美香, 木村貴, 木澤成美, 金銅葉子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1532-1532, 2023. |
|---|
|
|
P0519-4-PM1. About the use situation of the anamorelin hydrochloride in our hospital 古賀茜, 藤田謙, 夏目紗恵, 清水俊勝, 大竹満博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1533-1533, 2023. |
|---|
|
|
P0520-4-PM2. Use fact-finding of the anamorelin hydrochloride in our hospital 藤谷千紘, 米谷頼人, 松田亜希子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1534-1534, 2023. |
|---|
|
|
P0521-4-PM1. The current situation investigation of the standard precaution for ward charge pharmacists and the precaution according to the infection route and the evaluation 芥子川純里, 内山耕作, 鈴川誠, 平尾祐樹, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1535-1535, 2023. |
|---|
|
|
P0522-4-PM2. The gastrostomosis is the opportunity of the polypharmacy review by being associated with the simple suspension method introduction 熊井梢恵1, 武者薫1, 八子有沙1, 吉沢奈々1, 永野伸郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1536-1536, 2023. |
|---|
|
|
P0523-4-PM1. A survey of the use of sacubitril valsartan tablets at the Public Showa Hospital 阿部剛1, 米沢牧子1, 岡田建助3, 峯岸夕紀2, 田中茂博3, 本田一春1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1537-1537, 2023. |
|---|
|
|
P0524-4-PM2. Evaluation after the efforts for the prescription situation and the proper use of the suvorexant in the Anjo rebirth hospital 渡辺裕之1,2, 藤井友和1, 植松夏子1, 野本歩未1, 小島礼菜1, 平野貴大1, 野々山陽子1, 万塩裕之1, 澤田和久1, 木村友美1, 奥平正美1, 中村和行3, 沖哲4, 足立康則4, 鍋島俊隆2, 杉浦洋二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1538-1538, 2023. |
|---|
|
|
P0525-4-PM1. Use fact-finding of the morphine in amyotrophic lateral sclerosis (ALS) patients 杉山尭紀, 中村卓巨, 三井陽二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1539-1539, 2023. |
|---|
|
|
P0526-4-PM2. Study on prophylaxis for the steroidal osteoporosis in children 長郷あかね1,2, 神村英利1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1540-1540, 2023. |
|---|
|
|
P0527-4-PM1. Investigation into fall rates following a change from suvorexant to lemborexant 吉澤典成, 山本浩二郎, 竹村姫穂, 竹腰雄真, 岩知道美幸, 山田直輝, 濱田達志, 山本倫数, 草薙みか, 大里恭章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1541-1541, 2023. |
|---|
|
|
P0528-4-PM2. The prescription situation investigation of the osteoporosis therapeutic drug for patients with proximal thighbone bone fracture in our hospital 簑島弓未子, 井上晃汰, 荻野健吾, 竹田享平, 増渕幸二, 橋本光生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1542-1542, 2023. |
|---|
|
|
P0529-4-PM1. In the Hashima Municipal Hospital is the investigation about the dose of the type oral anticoagulant drug directly 古澤明朋, 伊藤真也, 浅井和浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1543-1543, 2023. |
|---|
|
|
P0530-4-PM2. The current situation investigation about the PONV precautionary measures for the laparoscopic cholecystectomy patients 金子泰也1, 北川原康子2, 米澤亮1, 山崎信江3, 丸山晴生1, 川上勝弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1544-1544, 2023. |
|---|
|
|
P0531-4-PM1. Alteration of consciousness of enforcement and the participant of the enlightenment classroom about the osteoporosis for inhabitants of the TambaSasayama area 橋本佳奈1,2, 木下淳1, 高良恒史1, 高本光次郎2, 志方敏幸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1545-1545, 2023. |
|---|
|
|
P0532-4-PM2. It is ... for the spread of attitude survey - CKD seals for CKD in the member of Akashi-shi pharmacist society drugstore 岩崎克也1, 山元優輝1, 寺沢匡史1, 米倉由利子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1546-1546, 2023. |
|---|
|
|
P0533-4-PM1. Examination of the laboratory study item to display in outside Parliament prescription 有馬直伸1, 村山由香里1, 松元真哉1, 下野奨平1, 武田泰生1,2, 寺薗英之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1547-1547, 2023. |
|---|
|
|
P0534-4-PM2. The impact of formulary introduction on drug use - the case of sleeping pills - 西野貴仁1, 荒川昌史1, 大平実佳1, 西島秀和1, 小林亮1, 藤村昭太1, 片野昌宏1, 今井靖1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1548-1548, 2023. |
|---|
|
|
P0535-4-PM1. Effect - that inside the hospital notified of efforts - "request for the proper use promotion of the sleeping drug for review of the use of sleeping drug" 大平実佳1, 荒川昌史1, 須田史郎2, 西野貴仁1, 新保昌久3, 片野昌宏1,3, 村林美優1, 大野翼1, 金田颯1, 金井栄里香1, 田村依珠美1, 今井靖1,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1549-1549, 2023. |
|---|
|
|
P0536-4-PM2. Patient's share of medical expenses reduction by the refill prescription introduction in our hospital and investigation about the safety 芝田雄登, 牧野洸太朗, 小阪直史, 四方敬介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1550-1550, 2023. |
|---|
|
|
P0537-4-PM1. Investigation about the needs of the pharmacist in the animal hospital 大塚登志喜, 浅井亮太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1551-1551, 2023. |
|---|
|
|
P0538-4-PM2. Pilot study about the non-proper use of the proton pump inhibitor 大久保佳孝1, 尾形勉1, 小田中啓太2, 中川直人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1552-1552, 2023. |
|---|
|
|
P0539-4-PM1. The use situation investigation of the morphine hydrochloride for patients with terminal heart failure in Tokyo Metropolitan Tama Medical Center 佐野弥里, 宮澤真帆, 寺山義泰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1553-1553, 2023. |
|---|
|
|
P0540-4-PM2. Correspondence fact-finding to a foreign inpatient in the hospital pharmacist 細野美幸1, 下村文恵1, 石田誠1, 根角泰生1, 工藤香代子1, 栗原理1, 西野紀子1,2, 津田隆1,2, 俵木登美子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1554-1554, 2023. |
|---|
|
|
P0541-4-PM1. Change after extraction and the measures of problems at opioid introduction in patients with non-cancerous chronic pain 廣田佳美, 大野凜太郎, 斎藤和悦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1555-1555, 2023. |
|---|
|
|
P0542-4-PM1. Quality evaluations such as the anti-peptic ulcus agents, and the like in the generic drug quality information review meeting 森田時生1, 吉田寛幸1, 富田奈緒美1, 稲垣葵1, 伊豆津健一1,2, 佐藤陽治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1557-1557, 2023. |
|---|
|
|
P0543-4-PM2. Clinical comparison by changes from the starting pharmaceutical products of the tolvaptan granule in patients with heart failure to generic medicine 阪元孝志1, 二宮暁代2, 横田千明1, 金澤絵莉1, 糸永昇平1, 神代広平1, 樋口ゆり1, 安藤和雅子1, 園田恵理1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1558-1558, 2023. |
|---|
|
|
P0544-4-PM1. Evaluation about the properties of matter of brimonidine tartrate eye drops and use characteristics 秋山滋男1, 米田正明2, 宮本悦子3, 毎田千恵子4, 石田志朗5, 堀祐輔1, 土井信幸6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1559-1559, 2023. |
|---|
|
|
P0545-4-PM2. Comparative study of patient instruction sheets for oral anticancer drug capecitabine-containing preparations 大滝康一1, 古庄功汰1, 高田珠有1, 岩山訓典1, 谷口亮央2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1560-1560, 2023. |
|---|
|
|
P0546-4-PM1. Efforts to Biosimilar introduction and medical service fees (the introduction addition) 江川友子1, 野口智宏2, 大久保嘉則1, 北御門由衣1, 園田美幸3, 白川敦規4, 桑原貴美子1, 鈴田浩孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1562-1562, 2023. |
|---|
|
|
P0547-4-PM2. Efforts of the early period of biofollowing article introduction addition calculation in the foreign cancer chemotherapy 杉山昌秀, 篠原佳祐, 宮田智陽, 吉池麻衣, 征矢あや乃, 柳澤沙織, 堀内賢一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1563-1563, 2023. |
|---|
|
|
P0548-4-PM1. About effect on Infusion Reaction when we changed it from a trastuzumab bio precedence product to Biosimilar and continued treatment and cardiac activity 安部智哉1, 相良篤信2, 岡田大地1, 松坂和正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1564-1564, 2023. |
|---|
|
|
P0549-4-PM2. Effect to give use investigation and the pharmaceutical products costs of the antiVEGF antibody in colon cancer 小泉宏史, 宇山佳奈, 坂本靖宜, 川邊一寛, 畠山成寛, 長谷川拓也, 中村明日香, 清水絢子, 井出和男, 小池博文, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1565-1565, 2023. |
|---|
|
|
P0550-4-PM1. Investigation of the infusion reaction frequencies in changes from a bevacizumab precedence product to Biosimilar 草野泰輝, 吉野走, 山口卓朗, 森善洋, 樋口則英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1566-1566, 2023. |
|---|
|
|
P0551-4-PM1. The example that intervened pharmaceutical for hypoglycemia with levofloxacin 間瀬尚子, 原弘士, 山口遥, 澤村公志, 山本郁生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1571-1571, 2023. |
|---|
|
|
P0552-4-PM2. One case of the low Mg blood symptom with lansoprazole that diachronic observation of urinary Mg excretion compartmentation was useful in differentiation 安東大智1, 中村駿2, 宗広樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1572-1572, 2023. |
|---|
|
|
P0553-4-PM1. One case that developed anuria by the anticholinergic inhalant for patients with chronic obstructive pulmonary disease 船越晴喜1,2, 百賢二2, 和田紀子1,2, 宮田祐人3, 佐々木忠徳4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1573-1573, 2023. |
|---|
|
|
P0554-4-PM2. 1 case of the necrotising fasciitis with suspected iodine poisoning with the iodoform gauze 竹内耕治1, 池田宏器2, 飛田修康1, 鶴橋智子1, 本岡千佳1, 井上卓也2, 杉田和成2, 島ノ江千里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1574-1574, 2023. |
|---|
|
|
P0555-4-PM1. About what we experienced the Serious ADR example with lamotrigine tablets and worked on 中島瑞貴1, 白川敦規2, 鈴田浩孝1, 桑原貴美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1575-1575, 2023. |
|---|
|
|
P0556-4-PM2. 3 cases that presented a symptom of the pseudogout by preoperative nourishment management 伊東健一1, 前田歩乃佳1, 井上由似1, 秋吉史久1, 白尾貞樹2, 福久はるひ2, 秦洋一2, 白尾一定2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1576-1576, 2023. |
|---|
|
|
P0557-4-PM1. One case of the small-cell lung cancer that developed adrenal insufficiency by the Durvalumab and joint pain, interstitial pneumonia 中島理絵1, 西田朋洋1, 大田美沙貴1, 田頭尚士1, 坂本靖之1, 藤田秀樹1, 徳永忠浩2, 久保田益亘3, 福原和秀4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1577-1577, 2023. |
|---|
|
|
P0558-4-PM2. A case of anaphylactic shock and relapse after administration of Joyclu(R) - Pharmacokinetic consideration of the cause 勝田雄太1, 大久保綾香1, 中薗健一1, 若竹春明2, 松崎貴志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1578-1578, 2023. |
|---|
|
|
P0559-4-PM1. A case of severe pleural effusion after administration of clazosentan 堺香輔1, 巖西真1, 藤本優貴2, 池田義人1, 辻篤司2, 吉田和道2, 森田真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1579-1579, 2023. |
|---|
|
|
P0560-4-PM2. About the effect that the acetaminophen intravenous administration time in the intensive care unit gives to blood pressure 浦山泰典1, 小坂慧1, 井手頌美1, 安武夫1,2,3, 城田幹生1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1580-1580, 2023. |
|---|
|
|
P0561-4-PM1. Case series of paradoxical reaction with TNF α inhibitor discovered in immune pharmacist outpatients 平田一耕1,2, 六反田諒3, 舟越亮寛1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1581-1581, 2023. |
|---|
|
|
P0562-4-PM2. Examination of an allergy, the information on adverse drug reactions registration method to the electronic medical chart that is useful for a prescription check 冨岡謙二1, 太田原顕2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1582-1582, 2023. |
|---|
|
|
P0563-4-PM1. Seamless approach ... by the construction - 3 Hospital combination of the adverse event report education base by the pharmacist in clinical duties 坪谷綾子1,7, 米澤龍2,3,7, 四十物由香4,7, 向後麻里5,7, 須永登美子3,6,7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1583-1583, 2023. |
|---|
|
|
P0564-4-PM2. Fact-finding ... of the consciousness of the pharmacist in the construction - 3 Hospital of the adverse event report education base by the pharmacist in clinical duties and the case report education system 四十物由香1, 米澤龍2,3,7, 坪谷綾子4,7, 向後麻里5,7, 須永登美子5,6,7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1584-1584, 2023. |
|---|
|
|
P0565-4-PM1. National survey ... of consciousness and the case report education system of the pharmacist for construction - adverse event report of the adverse event report education base by the pharmacist in clinical duties 米澤龍1,2,3, 坪谷綾子3,4, 四十物由香3,5, 向後麻里3,6, 須永登美子3,7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1585-1585, 2023. |
|---|
|
|
P0566-4-PM2. Time for onset of fatal arrhythmia analysis associated with the azole-based antifungal agent using JADER 大山勝宏, 秋山翔太, 飯田恵, 石井萌, 堀祐輔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1586-1586, 2023. |
|---|
|
|
P0567-4-PM1. Comparison between Palbociclib and side effect profile of the Abemaciclib using real world data 武田達明1, 松本准1, 杉本詩歩2, 岩田直大3, 中本秋彦3, 濱野裕章3, 有吉範高1, 座間味義人3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1587-1587, 2023. |
|---|
|
|
P0568-4-PM2. A case with suspected agranulocytosis with the ursodeoxycholanic acid 山村翔, 荒木良介, 山田英紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1588-1588, 2023. |
|---|
|
|
P0569-4-PM1. Survey of side effects of sacubitril valsartan in patients with chronic heart failure at our hospital 犬飼阿弥佳, 薄田百合子, 高嶋祥匡, 高橋弘泰, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1589-1589, 2023. |
|---|
|
|
P0570-4-PM2. Fact-finding of the hearing loss with the amikacin by nontuberculous acid-fast bacterium disease treatment 光武瑞穂1, 木戸上知弘2, 瀧口純司3, 山内円1, 野村洋道1, 石本学司1, 中浴伸二1, 田中詳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1590-1590, 2023. |
|---|
|
|
P0571-4-PM1. About the expression of infusion reaction situation in the daratumumab subcutaneous injection preparation 野口唯香, 阿部桂祐, 木村雄太, 高田慎也, 山岸佳代, 橋下浩紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1591-1591, 2023. |
|---|
|
|
P0572-4-PM2. The type of the drug in the fall fall accompanied with the sleeping drug remedy and investigation about the event occurrence time 細野寛貴1, 石川雄也1, 八島秀明1,2, 大島幸菜1, 荒木拓也1,2, 山本康次郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1592-1592, 2023. |
|---|
|
|
P0573-4-PM1. One patient who bradycardia by the Lacosamide was suspected by bringing medicine differentiation, and was able to evade the pacemaker custody 門口直仁, 伊東愛理, 段松雅弘, 公文登代, 田中聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1593-1593, 2023. |
|---|
|
|
P0574-4-PM2. It is one patient with suspected onset of the calcineurin inhibitor-induced pain syndrome by drug interactions after the course for a heart transplant long term 島田泉, 小林将文, 中川裕介, 外山聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1594-1594, 2023. |
|---|
|
|
P0575-4-PM1. A clinical study on risk factors for hypotension caused by sacubitril valsartan hydrate in patients with chronic heart failure 高橋岳大, 阿部晃太, 石田陽菜, 寺西真凜, 中田絵梨, 川口翔平, 門脇督, 槙田芳, 東修司, 田畑裕和, 今井隆人, 小林龍 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1595-1595, 2023. |
|---|
|
|
P0576-4-PM2. A case which developed erythema multiforme severe by sequential administration of the sorafenib after the Atezolizumab + bevacizumab 岩山竜大1, 四十物由香1, 小川竜徳1, 八木澤昂大1, 齋藤祥子1, 菊池早輝子2, 鴨志田敏郎3, 田村明広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1596-1596, 2023. |
|---|
|
|
P0577-4-PM1. The construction of the machine learning model predicting a low Na blood symptom during the chemotherapy in patients with malignant tumor and examination of the risk factor 青木優佳1, 安部賀央里1, 頭金正博1, 村島美穂2, 濱野高行2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1597-1597, 2023. |
|---|
|
|
P0578-4-PM2. One patient whom hyperammonemia and irAE developed in after mFOLFOX6 and Nivolumab combination therapy at the same time 鈴木拓也, 迎佳奈, 畠山智明, 遠藤美央, 玉木慎也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1598-1598, 2023. |
|---|
|
|
P0579-4-PM1. Examination of the protective efficacy of magnesium oxide for the cisplatin-induced renal failure and sumatriptan 石井友理1, 藤松成美1, 庄司美貴1, 高田美紀1, 小杉隆祥2, 佐藤光利1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1599-1599, 2023. |
|---|
|
|
P0580-4-PM2. 1 case that a hand-and-foot syndrome developed in the docetaxel triweekly therapy first cycle after the Dose-dense doxorubicin + cyclophosphamide therapy and aggravated 杉本亜弥1, 熊澤里美1, 水野智博1, 松田日出三1, 河田健司2, 喜島裕子3, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1600-1600, 2023. |
|---|
|
|
P0581-4-PM1. Examination of one allergic interstitial pneumonia by the paclitaxel 大瀧翔太1, 翁長寛人1, 宗岡克樹2, 古川智康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1601-1601, 2023. |
|---|
|
|
P0582-4-PM2. Frequency of the hypomagnesemia in the gemcitabine cisplatin Necitumumab combination therapy for the squamous cell carcinoma of lung and investigation of the expression time 藤田強記, 衛藤智章, 後藤隆, 高野豪, 清水裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1602-1602, 2023. |
|---|
|
|
P0583-4-PM1. A case of BRAF mutation-positive colorectal cancer with macular edema and subretinal fluid caused by cetuximab + encorafenib + binimetinib therapy 古川卓也1, 関野康2, 丸山晴生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1603-1603, 2023. |
|---|
|
|
P0584-4-PM2. Examination of the effect that PARP inhibitor gives to the serum creatinine level 有木沙織1, 大西康博2, 山崎明子1, 田中雄太1, 森本志帆2, 和田淳2, 座間味義人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1604-1604, 2023. |
|---|
|
|
P0585-4-PM1. Is giving Entrectinib for progress pancreatic cancer; one case who had gait disturbance and pubic bones, the sacrum fractured 景山康二郎1, 田頭尚士1, 西田朋洋1, 坂本靖之1, 田妻昌2, 藤田秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1605-1605, 2023. |
|---|
|
|
P0586-4-PM2. Is taking a multi-kinase inhibitor in the patients with progress renal cell carcinoma; a case with suspected purple spot type drug eruption 道家雄太郎1, 野田哲史1,2, 草場拓人3, 吉田哲也3, 池田義人1, 森田真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1606-1606, 2023. |
|---|
|
|
P0587-4-PM1. Investigation of the irAE expression situation in the Fukuyama Municipal Hospital 岩村高弘, 森光保武, 藤井秀一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1607-1607, 2023. |
|---|
|
|
P0588-4-PM2. Impaired renal function by the high-dose ST medical mixture that prompt improvement was obtained by administration cancellation, a case of the electrolyte abnormality 橋本拓郎1,2, 綺田尚久1,2, 若森裕生1, 久世彰1, 福永夏実1, 宮田侑季1, 吉田紀子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1608-1608, 2023. |
|---|
|
|
P0589-4-PM1. Meta analysis about the linezolid-induced thrombocytopenia onset factor in the Japanese patients 藤居賢, 石郷友之, 福土将秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1609-1609, 2023. |
|---|
|
|
P0590-4-PM2. Tazobactam piperacillin and impact statement to renal function at cefepime alone 小原菜美1, 小松敏彰1, 白津和慶1, 赤間田悠刀1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1610-1610, 2023. |
|---|
|
|
P0591-4-PM1. The onset of cardiovascular system side effect of guanfacine hydrochloride extended-release situation in patients with childhood attention lack, hyperkinesis symptom 越野優希1,2, 田中裕章3, 田井達也3, 山口佳津騎3, 元木貴大3, 立道貴清1, 小坂信二2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1611-1611, 2023. |
|---|
|
|
P0592-4-PM2. One case that methylergometrine maleate developed cerebral infarction by the cerebrovascular spasm thought to be precipitants 上田彩加1, 渡部真志2, 玉井宏一1, 稲見有1, 烏谷政和1, 倉田知久1, 白岡朗2, 京樂格2, 岡本憲省2, 藤原聡3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1612-1612, 2023. |
|---|
|
|
P0593-4-PM1. Examination of the dementia onset risk by the use of sleeping drug using large-scale receipt data 末吉珠莉亜, 堀井剛史, 三原潔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1613-1613, 2023. |
|---|
|
|
P0594-4-PM2. Analysis about the mesalazine intolerance in the inflammatory bowel disease case 中野敬太1, 石郷友之1, 風間友江2, 藤居賢1, 仲瀬裕志3, 福土将秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1614-1614, 2023. |
|---|
|
|
P0595-4-PM1. A case of a patient with a history of hypothyroidism whose thyroid hormone levels fell below normal levels after administration of roxadustat 神村真由, 窪田由夏, 足立充司, 池田久雄, 平田貴宏, 神原弘和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1615-1615, 2023. |
|---|
|
|
P0596-4-PM2. The side effect occurrence situation of the heart failure therapeutic drug "fantastic four" 近藤和宏, 尾形美絵, 長澤欣弘, 瀧内瑛輔, 中村慎一郎, 羽生智宏, 新関みどり, 田村和彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1616-1616, 2023. |
|---|
|
|
P0597-4-PM1. A case which accepted rapidly progressive anemia attributable to the linezolid 青柿和樹, 大荒政志, 山崎佳奈, 松浦克樹, 増田博也, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1617-1617, 2023. |
|---|
|
|
P0598-4-PM2. Investigation about the effect of the JAK inhibitor on lipid abnormality 中山紗里, 祖川倫太郎, 緒方健二, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1618-1618, 2023. |
|---|
|
|
P0599-4-PM1. One case after the living body lung transplantation with suspected drug fever with tacrolimus 松本恵実, 佐藤裕, 森下啓, 佐藤祐司, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1619-1619, 2023. |
|---|
|
|
P0600-4-PM2. One case of the drug fever that was able to identify two kinds of cover suspicion medicine by the cooperation of a physician and the pharmacist 新城唯1, 岡崎英子1, 樋口俊惠2, 矢野遥子1, 藤原隆行2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1620-1620, 2023. |
|---|
|
|
P0601-4-PM1. Examination about the adverse event that we showed during ST medical mixture administration for the purpose of the pneumocystis pneumonia prevention 平岩美穂1, 橋本みさき1, 田中雅幸3, 西山徳人1,2, 打谷和記1, 宮下修行2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1621-1621, 2023. |
|---|
|
|
P0602-4-PM2. The case that caused cognitive impairment, tardive dyskinesia and the prescription cascade which led to sialolithiasis by haloperidol prescribed in on admission delirium 藤原將平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1622-1622, 2023. |
|---|
|
|
P0603-4-PM1. Specialist in citizen of Osaka consecutive side effect Committee 2021 summary 井上千紘1,2,3,4,5,6, 坂田勝美2, 清水順子3, 平方まりこ4, 山本京5, 松本ミユキ6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1623-1623, 2023. |
|---|
|
|
P0604-4-PM2. An investigation and report about a review and the fall occurrence of the sleeplessness indicator 和田翼, 生田智基, 松本拓真, 長谷部匡史, 堀田修次, 森近俊之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1624-1624, 2023. |
|---|
|
|
P0605-4-PM1. Examination ... using search - neural progenitor cells strain PC12 of the neurologic cell line for the in vitro evaluation of the oxaliplatin-induced feeling cold erethism 手塚千裕1,2, 松本萌1, 中田千鶴1, 鈴木春花1, 田中駿也1, 二宮悠佳1, 平尾卓也1, 加藤芳徳1,2, 山田治美1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1625-1625, 2023. |
|---|
|
|
P0606-4-PM1. Effect on bowel control by the combination of magnesium oxide and gastric-acid secretion antagonist 平野徹1,2, 近藤隆瑛2, 松原千明2, 細田雄一郎2, 浅貝健介2, 西口宏一2, 大久保春輝2, 辻涼平2, 中原尚美2, 中江貴彦2, 伊藤達章2, 平原慎太郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1628-1628, 2023. |
|---|
|
|
P0607-4-PM2. Prospective cohort study about the effect on clinical response by the combination of rosuvastatin and antacid 戸倉歌緒子1, 三崎桃子1, 宮津大輔2, 中島章雄1,3, 小林邦久4, 浦田秀則5, 渡邊裕之2, 下村英紀6, 宮崎元康1,3, 今給黎修1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1629-1629, 2023. |
|---|
|
|
P0608-4-PM1. Comparison - by effect - tendency score matching of the vonoprazan in the sedation by the midazolam 児玉暁人1, 長生幸司2, 駒居真紀子1, 勝浦正人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1630-1630, 2023. |
|---|
|
|
P0609-4-PM2. A case of an elderly chronic kidney disease patient in whom the combination of vadadustat enhanced the hypoglycemic effect of mitiglinide and sitagliptin, leading to hypoglycemia 高倉歩美1, 平井利典1, 濱口直美1, 向原里佳1, 松本和隆2, 矢野裕2, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1631-1631, 2023. |
|---|
|
|
P0610-4-PM1. The effect that danazol administration gives to the metabolism enzyme activity of the CYP3A substrate drug and the internal change 福野修平1, 黒飛明美1, 佐堀友紀1, 中川涼1, 野村麗菜1, 笠原恵太2, 長井克仁1, 小西廣己1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1632-1632, 2023. |
|---|
|
|
P0611-4-PM2. Interaction analysis based on the physiologic pharmacokinetics model that incorporated time-dependent inhibition of the proguanil metabolism by the vonoprazan 大久保健二郎1, 工藤敏之1,2, 合田ひとみ1, 山岸喜彰1,2, 伊藤清美1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1633-1633, 2023. |
|---|
|
|
P0612-4-PM1. One case of mitochondrial encephalomyopathy that caused a blood level drop of the phenytoin by ciprofloxacin combination 小笠原明美, 武井桃香, 加藤典子, 高木昭佳, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1634-1634, 2023. |
|---|
|
|
P0613-4-PM2. A case which was able to be given chemotherapy avoiding interaction with the warfarin safely by having switched from aprepitant to fosnetupitant 長縄華子1, 梅村圭祐1, 片田佳希1, 中島大輔2, 伊達洋至2, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1635-1635, 2023. |
|---|
|
|
P0614-4-PM1. The effect of menthol on irinotecan killing effect with human liver cancer HepG2 cells: Possibility of the participation of breast cancer-resistant protein BCRP 長井克仁1, 大谷奎介2, 吉田尚史2, 渡邊利栄2, 福野修平1, 小西廣己1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1636-1636, 2023. |
|---|
|
|
P0615-4-PM2. Protection effect of theanine on doxorubicin-induced rat renal failure 仲村愛可, 長井克仁, 長峰由樹, 福野修平, 小西廣己 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1637-1637, 2023. |
|---|
|
|
P0616-4-PM1. Investigation about the drug interaction of CYP3A of the oral anticancer agent 吉友葵, 坂本靖宜, 川邊一寛, 畠山成寛, 井出和男, 小池博文, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1638-1638, 2023. |
|---|
|
|
P0617-4-PM2. Investigation about the effect on PT-INR level in the TAZ/PIPC administration 竹口真央, 梶原敬悟, 河田武志, 小川喜通 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1639-1639, 2023. |
|---|
|
|
P0618-4-PM1. The example that it was suggested that an effect of the linagliptin was not obtained in an adsorption of the oral spherical carbonaceous adsorbent which we took at the same time 藤田美佐子1, 小田川周平1, 浅野陽子1, 日高良昌1, 小城千枝1, 猪川和朗2, 井上愛梨2, 井村友哉2, 森川則文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1640-1640, 2023. |
|---|
|
|
P0619-4-PM2. The CKD case that a pharmacist intervened for the TSH rise with the absorption drop drug of the levothyroxine, and was improved 伊藤正輝1, 飯塚雄次1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1641-1641, 2023. |
|---|
|
|
P0620-4-PM1. Effect on probiotic preparation by the at the same time simple suspension with metronidazole 森川祥彦1, 加藤秀雄1, 萩原真生2, 三鴨廣繁3, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1642-1642, 2023. |
|---|
|
|
P0621-4-PM1. A case of using hydromorphone hydrochloride sustained-release tablets with oxycodone powder as rescue medication, taking into consideration the patient's level of understanding 小林奈緒1, 佐々木美理1, 山口莉穂1, 高山直也1, 木村尚子2, 土井千春2, 加藤一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1646-1646, 2023. |
|---|
|
|
P0622-4-PM2. A case which intervened in a shift of the medication management including the drug for the medical care for being at home 大久保晃樹, 桐原大輝, 中村薫, 鶴田翔大, 岡村俊則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1647-1647, 2023. |
|---|
|
|
P0623-4-PM1. The system construction of the drug self-care for the medical care in the inpatient subsequently 畑下真希1,2, 朝日仁美1,2, 丹藤千絵2,3, 手渡和子2,3, 市田泰彦1,2, 筒井秀知1, 豊田康義2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1648-1648, 2023. |
|---|
|
|
P0624-4-PM2. Look at the rear about the search of the risk factor contributing to somnolence expression by the mirogabalin; mark investigation 高橋梨恵1, 平井利典1, 岡本明大1, 濱口直美1, 堀内保顕1, 高尾仁二2, 川口晃司2, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1649-1649, 2023. |
|---|
|
|
P0625-4-PM1. Effect on frequency investigation of the diarrhea by introducing naldemedine with a strong opioid analgesic start 西本凜1, 松本拓真2, 武良卓哉1, 小倉千奈1, 濱岡照隆1, 小川喜通1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1650-1650, 2023. |
|---|
|
|
P0626-4-PM2. Efforts of the opioid rounds operational change 中原萌子, 高武嘉道, 大橋邦央, 花田聖典, 橋本雅司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1651-1651, 2023. |
|---|
|
|
P0627-4-PM1. A case that mexiletine was effective in the rectal tenesmus due to prostatic small cell cancer 加藤良隆1, 井上渉1,2, 江島智彦1,2, 大坪彩子1,2, 丸浜暢子1, 神田英一郎1,2, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1652-1652, 2023. |
|---|
|
|
P0628-4-PM2. The case that switched it, and was given pain control opioid from fentanyl patch high-dose during the terminal phase to low-dose oxycodone intravenous feeding 伊東充, 高澤千重理, 高橋真一, 日高あづみ, 向井晴香, 江川朱季, 佐藤香織, 加藤潤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1653-1653, 2023. |
|---|
|
|
P0629-4-PM1. Use fact-finding of the medical drug in the municipal Kashiwabara Hospital 中市里実, 佐野拓見, 山下幸大, 台野佳代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1654-1654, 2023. |
|---|
|
|
P0630-4-PM2. Construction of the foreign telephone follow-up system for patients with use of opioid analgesic cancer 森田奈々, 八木貴彦, 宮本康敬, 平野公美, 大和千穗, 外山未来, 野木村藍, 中村拓哉, 川口千香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1655-1655, 2023. |
|---|
|
|
P0631-4-PM1. It is examination ... from stocktaking and the Dr. problem - encounter questionnaire results of the opioid introduction support team for patients with cancer during foreign going to hospital 近藤綾子1,4, 山本泰大1,4, 笠原愛菜1,4, 平野茂樹1,4, 村路留美子2,4, 奥村佳美2,4, 大北淳也3,4, 加藤栄助3,4, 出口裕子1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1656-1656, 2023. |
|---|
|
|
P0632-4-PM2. Factor investigation to elderly people polypharmacy early intervention with the palliative care unit 宮部貴識, 山口志郎, 野田拓誠, 多田純平, 及川悠衣, 抱勇希, 澤田奈々, 原伸好 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1657-1657, 2023. |
|---|
|
|
P0633-4-PM1. Effect to give to stool characteristics of the naldemedine in patients with opioid-induced constipation 世古口拓也, 三宅知宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1658-1658, 2023. |
|---|
|
|
P0634-4-PM2. The use situation of the opioid in the allogeneic hematopoietic stem cell transplantation 林崎修也1, 中村和代1, 丸山紗緒里1, 大澤美紗1, 齋藤優2, 岸本寛史3, 野吾和宏2, 櫻井和子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1659-1659, 2023. |
|---|
|
|
P0635-4-PM1. The OIC expression situation investigation under the naldemedine prophylaxis at oxycodone extended-release introduction 萩原諒一1, 井上新太1, 中山弘道2, 花香淳一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1660-1660, 2023. |
|---|
|
|
P0636-4-PM2. The enforcement situation after the rescue medicine self-care manual introduction of the drug for the medical care 中西順子, 藤田早季, 篠永浩, 原田典和, 加地努 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1661-1661, 2023. |
|---|
|
|
P0637-4-PM1. About pain-killer prescription order in cancerous pain treatment and rescue medicine, aperient, the prescription situation of the antiemetic a comparison (the second report) before and after the - guidelines revision 丸山昌広, 定盛理純 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1662-1662, 2023. |
|---|
|
|
P0638-4-PM2. One patient who responded to hydromorphone oral administration for dyspnea of patients with pulmonary squamous cancer 毛利早希, 中山昂太, 清水寛将, 白崎由貴, 西出洋志, 加藤秀明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1663-1663, 2023. |
|---|
|
|
P0639-4-PM1. A case which was available for a diet intake while continuously administering the midazolam note for end-of-life retching, vomiting 今中智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1664-1664, 2023. |
|---|
|
|
P0640-4-PM2. The current situation of the palliative care screening of our hospital which is area cancer practice cooperation base Hospital and future problem 玉井宏一1,5, 末廣拓1, 中野友寛1, 原田嵩大1, 松岡葉子1, 西畑友尋1, 烏谷政和1, 倉田知久1, 渡部早苗2, 外山修子3, 山下広恵3, 岡本千愛3,5, 西谷恵3,5, 武田千津3,5, 椿雅光4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1665-1665, 2023. |
|---|
|
|
P0641-4-PM1. We look at the rear about patient factors influencing the effectiveness of the anamorelin hydrochloride for the cancer cachexia and study a mark 牧賢利1, 藤原未稀1, 高田遼1, 高橋洋子1, 大塚眞哉2, 田村浩二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1666-1666, 2023. |
|---|
|
|
P0642-4-PM2. 2 cases that an acetaminophen continuous intravenous infusion was effective for the heat generation of patients with end-stage cancer 石川敬祐, 伊藤慎二, 磯貝潤一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1667-1667, 2023. |
|---|
|
|
P0643-4-PM1. 1 case that good elimination of pain was obtained by the combination of the tramadol hydrochloride note for metastases to bone ache 伊藤慎二, 磯貝潤一, 石川敬祐, 清水千晴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1668-1668, 2023. |
|---|
|
|
P0644-4-PM2. Effect on pain control that we were able to see from questionary survey about the filling of the drug parenteral injection for the medical care and the need of the duties standardization 相田和希1,2, 吉川直樹1,2, 飯島直美1, 森田光枝1, 岡ゆかり2, 宮崎好美2, 井上卓2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1669-1669, 2023. |
|---|
|
|
P0645-4-PM1. Extraction of the factor associated with the antimicrobial administration continuation in the cancer terminally ill patients which discontinued treatment with anticancer agent 油原直乃1, 城山亮輔1,2, 鵜澤友里合1,2, 山口諒1, 山本武人1, 高田龍平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1670-1670, 2023. |
|---|
|
|
P0646-4-PM2. 1 case corresponding to shifts from cancer pain to chronic pain 加藤あゆみ1,2,3, 岡村由美子1,3,4, 伊勢雄也1,2, 鈴木規仁1,3,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1671-1671, 2023. |
|---|
|
|
P0647-4-PM1. Three cases that nausea developed by anamorelin internal use, and led to internal use cancellation 工藤範子, 島田泉, 新木貴大, 外山聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1672-1672, 2023. |
|---|
|
|
P0648-4-PM2. An effect of the anamorelin hydrochloride in patients with cancer and investigation about the side effect 鳥井小莉1, 宮本朋佳2, 三羽尚子1, 地丸裕美1, 山田正実1, 高橋一栄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1673-1673, 2023. |
|---|
|
|
P0649-4-PM1. Examination about the conversion ratio when we switch it opioid from hydromorphone parenteral injection 三羽尚子1, 地丸裕美1, 鳥井小莉1, 宮本朋佳2, 山田正実1, 高橋一栄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1674-1674, 2023. |
|---|
|
|
P0650-4-PM2. Efforts for the weight loss in the investigation of the opioid dose before and after the radiotherapy and palliative care rounds 土屋惠菜1, 岩田一史1, 釆田志麻2, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1675-1675, 2023. |
|---|
|
|
P0651-4-PM1. Efforts for the drug self-care for the medical care 梅田鈴香1, 佐藤淳也2, 塚越真由美3, 神坐美弥子1, 橋本竜1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1676-1676, 2023. |
|---|
|
|
P0652-4-PM2. About the effect that the administration of immune checkpoint inhibitor gives for analgesic effect with the opioid preparation 中尾優子, 炭本隆宏, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1677-1677, 2023. |
|---|
|
|
P0653-4-PM1. About the use of antimicrobial situation in our hospital palliative care unit 後藤義之, 森戸敏志, 角紀一郎, 岡田久美, 古本真由美, 松岡美紗, 茶野下貴恵, 島崎沙織, 青木理恵, 梅下翔, 橋本夏枝, 谷本百恵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1678-1678, 2023. |
|---|
|
|
P0654-4-PM2. A case of the foreign patients on dialysis who were able to use hydromorphone immediate-release effectively 中野智尋1, 加畑千春2, 埴生由紀恵3, 新谷圭子1, 鳥羽英理子1, 竹田和喜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1679-1679, 2023. |
|---|
|
|
P0655-4-PM1. One patient whom symptom improvement was found in by the dosage of the hydromorphone hydrochloride continuation subcutaneous injection for dyspnea due to the left lower lobe lung cancer 大内友季江1, 佐伯里紗1, 正垣耕1, 松木司1, 佐藤千穂1, 安達寛成1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1680-1680, 2023. |
|---|
|
|
P0656-4-PM2. The example that reached the pain relief after the at-home shift by a pain evaluation based on information obtained in conference before discharge and prescription suggestion 浅野陽子1, 日高良昌1, 小城千枝1, 猪川和朗2, 中村紗緒里2, 村田香奈恵2, 森川則文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1681-1681, 2023. |
|---|
|
|
P0657-4-PM1. About the use situation of the transdermal absorbing form continuous pain therapeutic agent in our hospital 芦田理沙, 古橋真理, 足立圭司, 川見里奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1682-1682, 2023. |
|---|
|
|
P0658-4-PM2. 1 case ... which used ... PCA pump for the home care of patients with cancer 小寺菜月, 勝岡美菜, 若林厚史, 坂本依利, 高橋彩, 田畑寛明, 猿谷淳, 向一美, 地野幹子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1683-1683, 2023. |
|---|
|
|
P0659-4-PM1. 1 case that showed withdrawal symptoms-like symptom improvement by setting update time two without changing a fentanyl tape daily dose 新名主泰文1,2, 屋地慶子2, 満尾明恵2, 菅原英輝2, 寺薗英之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1684-1684, 2023. |
|---|
|
|
P0660-4-PM2. Comparison of the pharmaceutical management of the health insurance pharmacy pharmacist for the medical drug of the cancer base Hospital varying in the issuance of foreign prescription style 平井俊明1, 江草徳幸1, 栗原晋太郎2, 礒貝明彦1, 中島恵子1, 安原昌子2, 渡邊英晶3, 山下大介4, 安保圭介5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1685-1685, 2023. |
|---|
|
|
P0661-4-PM1. Investigation ... of the drug needing polypharmacy - careful administration in patients with old end-stage cancer 野村祐司1,2, 櫛原秀之1, 岩永周子1, 平野美枝子2, 中野祐往3, 河合奈津子4, 湯浅典博4, 成瀬徳彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1686-1686, 2023. |
|---|
|
|
P0662-4-PM1. Investigation about use characteristics of the side effect check application in patients receiving immune checkpoint inhibitor 山下みづ穂1, 松下知世2, 北口剛吉3, 島田浩1, 森田有美子1, 猪野彩2, 國正淳一2, 村田久枝1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1693-1693, 2023. |
|---|
|
|
P0663-4-PM2. Search of the effect factor to give to treatment continuance of the Palbociclib + fulvestrant combination therapy 田中通, 黒松誠, 梶田貴司, 西川豊, 奥野智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1694-1694, 2023. |
|---|
|
|
P0664-4-PM1. The medical expenses reduction simulation which assumed the low-dose standard of the hippopotamus diTaki cell 西村充礼, 浅野裕紀, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1695-1695, 2023. |
|---|
|
|
P0665-4-PM2. About the effect that bevacizumab bio follower product adoption gives for hospital management 加藤秀明, 中山昂太, 毛利早希, 白崎由貴, 清水寛将, 西出洋志, 新田直美, 辻正宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1696-1696, 2023. |
|---|
|
|
P0666-4-PM1. Efforts and problem for the early period of biofollowing article introduction addition acquisition of the anticancer agent 細川朋弘1,2, 西尾香子1, 塩谷美由紀2, 村井明史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1697-1697, 2023. |
|---|
|
|
P0667-4-PM2. A case of the urothelial carcinoma which interstitial pneumonia by the Pembrolizumab aggravated by readministration 武田真央1, 坪谷綾子1, 伊藤由香1, 吉岡まき2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1698-1698, 2023. |
|---|
|
|
P0668-4-PM1. Safe examination of the docetaxel/ramucirumab therapy for the lung cancer for elderly people 小山田聡1, 久松直樹1, 林士元2, 野村明広2, 原信田努1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1699-1699, 2023. |
|---|
|
|
P0669-4-PM2. A case of multiple myeloma with pulmonary edema caused by daratumumab + carfilzomib + dexamethasone therapy 坂本竜平, 向井淳治, 小竹優希, 竹原涼子, 叶真央, 山田佳菜子, 辻田早紀, 森本亜美, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1700-1700, 2023. |
|---|
|
|
P0670-4-PM1. One patient whom myocarditis, thyrotoxicosis developed in by ipilimumab and nivolumab combination therapy 白崎由貴, 中山昂太, 毛利早希, 清水寛将, 西出洋志, 加藤秀明, 新田直美, 辻正宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1701-1701, 2023. |
|---|
|
|
P0671-4-PM2. Search of the sunitinib optimal relative dose intensity in patients with Japanese renal cell carcinoma 松村謙吾1, 廣部祥子1,2,3, 前田真貴子1,3, 藤尾慈1,4, 前田真一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1702-1702, 2023. |
|---|
|
|
P0672-4-PM1. The side effect expression situation of the nivolumab + chemotherapy for the gastric cancer in our center 森本奈緒美, 星田唯史, 武田祐子, 山口彩樹, 藤原大一朗, 木村佳世, 眞下惠次, 和田祥明, 野田明宏, 多喜和夫, 田辺和史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1703-1703, 2023. |
|---|
|
|
P0673-4-PM2. A comparative study of adverse events associated with trastuzumab deruxtecan in patients with HER2-positive gastric cancer in our hospital with or without ascites 橋口麻依子, 久松大祐, 後藤隆, 清水裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1704-1704, 2023. |
|---|
|
|
P0674-4-PM1. The effect that the hyperbilirubinemia at administration start in the pancreatic cancer GnP therapy results in for myelosuppression 平井成和1, 任田早紀2, 有山智博2, 真坂亙2, 増田雅行2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1705-1705, 2023. |
|---|
|
|
P0675-4-PM2. Renal function when we used the UPC ratio as an evaluation standard of proteinuria in the bevacizumab administration for colon cancer and long-term effect on following treatment 柴崎七海1, 金素安1, 大貫奏1, 立沢正臣1, 須郷広之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1706-1706, 2023. |
|---|
|
|
P0676-4-PM1. Usefulness of the inflammatory biomarker for the side effect expression in the nivolumab administration case of patients with gastric cancer and the long-term survival 長谷川将, 木本秀樹, 山村真貴子, 佐藤優希子, 長島章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1707-1707, 2023. |
|---|
|
|
P0677-4-PM2. A case of relapsed B-cell acute lymphoblastic leukemia in a child weighing 45 kg who experienced side effects due to blinatumomab administration 小園友明1, 野々垣知行1, 下村保人2, 堀壽成3, 大西正文1, 奥村彰久3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1708-1708, 2023. |
|---|
|
|
P0678-4-PM1. Analysis of the tyrosine kinase inhibitor using LC-MS/MS with all automatic pre-treatment equipment 吉川航平, 塚本多矩, 箕畑俊和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1709-1709, 2023. |
|---|
|
|
P0679-4-PM2. A case which continued the dosage of the sorafenib while measuring blood level for patients with 90-year-old hepatocytes cancer which received haemodialysis 金剛圭佑1, 刈谷美里1, 脇下大樹1, 入江慶2, 福島昭二3, 石田淳4, 橋本泰明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1710-1710, 2023. |
|---|
|
|
P0680-4-PM1. About the effect that oxaliplatin administration gives in Colin symptom frequency of irinotecan 山下慎司1, 光家勉1, 西川光1, 篠村恵理子1, 塘賢二郎2, 上田豊実1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1711-1711, 2023. |
|---|
|
|
P0681-4-PM2. Use of venetoclax + azacitidine therapy in our hospital and pharmacists' involvement in its appropriate use 馬場結子, 平池美香子, 松藤敬佑, 齋藤巨樹, 小園亜希, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1712-1712, 2023. |
|---|
|
|
P0682-4-PM1. It is the-related examination of the liver damage during ALBI Grade and treatment success period before treatment in the EGFR-TKI treatment of the non-small cell lung cancer 有原大貴1,2, 永松秀紹3, 早川裕二4, 間瀬広樹5, 新屋智之6, 北俊之6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1713-1713, 2023. |
|---|
|
|
P0683-4-PM2. Participation of the situation and the pharmacist of the examination for oncogene panel in the Kyushu cancer center 衛藤智章, 仲田浩成, 藤田強記, 清水裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1714-1714, 2023. |
|---|
|
|
P0684-4-PM1. Usefulness (lung cancer case report) of blood microRNA-29a-3p and nuclear receptor transcription factor 4a1 mRNA in the evaluation of the impoverishment by the Pembrolizumab of immunity 町田麻依子1, 竹市雄1, 今田愛也1, 山形優華2, 井藤達也2, 相坂治彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1715-1715, 2023. |
|---|
|
|
P0685-4-PM2. 1 case that developed an ANCA-related vasculitis after the Lenvatinib remedy for thymic carcinoma: Lenvatinib and consideration from blood level of IL-6 朝倉充俊1, 岩間創1, 見野靖晃2, 中津川瑛美2, 小泉知展3, 内藤隆文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1716-1716, 2023. |
|---|
|
|
P0686-4-PM1. Efforts for proper use promotion of the immune checkpoint inhibitor in our hospital 森岡沙織, 吉藤和也, 後藤志典, 山崎博子, 西美帆, 赤崎淳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1717-1717, 2023. |
|---|
|
|
P0687-4-PM2. 1 case of the Trousseau syndrome where the suggestion of the heparin Ca self note by the pharmacist made possible going to hospital treatment continuation 藤林遼, 山田将悟, 朝倉幹己, 橋本咲季, 山内萌生, 菊地亮朗, 庄崎沙耶, 田中耕太, 山本翔太, 前川英輝, 菊地義明, 高橋誠, 田中正臣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1718-1718, 2023. |
|---|
|
|
P0688-4-PM1. Efforts of HBV (HBV) reactivation measures 磯貝潤一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1719-1719, 2023. |
|---|
|
|
P0689-4-PM2. Comparison ... in only simulation ... day and the deadline of the medical expenses reduction effect by the use of single vial multiple times with the anticancer medicine preparation robot for one week 守屋昭宏, 浅野裕紀, 竹中翔也, 伊藤大輔, 岩井美奈, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1720-1720, 2023. |
|---|
|
|
P0690-4-PM1. Examination of the usefulness of the liver residual function evaluation using ALBI score in patients with nonhepatic cell cancer 細見周平, 川原田祐貴, 南島拓矢, 溝口博之, 山田清文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1721-1721, 2023. |
|---|
|
|
P0691-4-PM2. 1 case that the crizotinib administration changed to entrectinib while regulating a dose for ROS1 fused gene-positive patients 比嘉大輔, 金城雄一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1722-1722, 2023. |
|---|
|
|
P0692-4-PM1. One case that ptosis produced by initial administration of oxaliplatin for patients with sigmoid colon cancer 山口卓朗1, 吉野走1, 林田颯志1, 山根理恵子1, 草野泰輝1, 岩村直矢1, 森善洋1, 佐道紳一1, 谷口堅2, 樋口則英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1723-1723, 2023. |
|---|
|
|
P0693-4-PM2. Usefulness inspection by prescribing anamorelin hydrochloride than a pharmacist, and suggesting it 青木洸英1,2, 佐々木茂樹1, 金井詩織1, 降旗誠2, 杉田和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1724-1724, 2023. |
|---|
|
|
P0694-4-PM1. Effect of the pharmacist interview introduction before physician medical examination in the foreign cancer chemotherapy at the middle scale hospital 古浜健一1, 清水あかり2, 荻野綺2, 岩本淳平1, 相良篤信2, 稲葉健二郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1725-1725, 2023. |
|---|
|
|
P0695-4-PM2. Quality of life evaluation of patients with foreign cancer 宮澤憲治1, 安藤栞奈2, 山田桃子1, 山下紗瑛奈1, 杉田郁人1, 有原大貴3, 田代匠1, 森下拓哉1, 網岡克維2, 高木亮1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1726-1726, 2023. |
|---|
|
|
P0696-4-PM1. The effect that the display of the family function gives to the medication continuation of the aromatase inhibitor medication patients 田中翔斗1, 永野悠馬2, 前田守2, 市ノ渡真史2, 長谷川佳孝2, 月岡良太2, 大石美也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1727-1727, 2023. |
|---|
|
|
P0697-4-PM2. Effect to medicine medicine cooperation of the pharmacist outpatient department in the foreign cancer chemotherapy 稲葉健二郎1, 荻野綺2, 清水あかり2, 岩本淳平1, 相良篤信2, 古浜健一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1728-1728, 2023. |
|---|
|
|
P0698-4-PM1. Examination of the factor affecting the effect of treatment of the use of immune checkpoint inhibitor patients in our hospital urology department domain 豊田悠希1, 矢野琢也1, 星加寿子1, 松本大輝1, 加藤あゆみ1, 福岡竜逸1, 篠森健介2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1729-1729, 2023. |
|---|
|
|
P0699-4-PM2. Efforts using PBPM for the hepatitis B reactivation in the cancer chemotherapy 西原夢乃1,2, 阿部桂祐2, 木村雄太1, 高田慎也1, 山岸佳代1, 橋下浩紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1730-1730, 2023. |
|---|
|
|
P0700-4-PM1. The effect that the onset of serious neutropenia in the adjuvant chemotherapy gives to prognosis after the S-1 technique on pancreatic cancer 野口裕介1, 大坪達弥1, 小林大祐1, 加藤良隆1, 豕瀬諒2, 村木優一2, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1731-1731, 2023. |
|---|
|
|
P0701-4-PM2. A case of venetoclax + low-dose cytarabine combination therapy for elderly AML patients who was able to continue treatment while reducing the dose and discontinuing the drug 清水寛将, 中山昂太, 毛利早希, 白崎由貴, 西出洋志, 加藤秀明, 新田直美, 辻正宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1732-1732, 2023. |
|---|
|
|
P0702-4-PM1. Investigation about the safety of the six weeks space Pembrolizumab administration 新村航1,2, 元木貴大1, 吉村知華1, 國方梨乃1, 安宅希美子1, 三崎彩香1, 篠原尚樹1, 水岡大策1, 磯部芳江1, 山口佳津騎2, 田中裕章1, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1733-1733, 2023. |
|---|
|
|
P0703-4-PM2. One case of the TMB-high breast cancer that ICI was curing, and became invalid 大久保節子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1734-1734, 2023. |
|---|
|
|
P0704-4-PM1. A multicenter investigation for the intervention of the pharmacist in the foreign cancer chemotherapy and the evaluation 桑村恒夫1, 柿原圭佑2, 川原和也3, 大森義朗4, 塚原邦浩5, 秋吉史久6, 上淵未来7, 葉田昌生8, 三島直9, 嘉村基樹10, 三上忠司1, 中川義浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1735-1735, 2023. |
|---|
|
|
P0705-4-PM2. Investigation about the risk factor of the onset of dermatopathy with bendamustine in the untreated non-Hodgkin's lymphoma 清水悠太1, 南貴之1, 若月淳一郎1, 飯野昌樹2, 小林義文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1736-1736, 2023. |
|---|
|
|
P0706-4-PM1. Investigation about the incidence of proteinuria, high blood pressure in the Atezolizumab + bevacizumab therapy of patients with hepatocytes cancer 石田友規1, 宮崎雅之1, 伊藤隆徳2, 村山三佳1, 溝口博之1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1737-1737, 2023. |
|---|
|
|
P0707-4-PM2. Association between treatment continuance rate and nutrition index of the Lenvatinib treated patients for the hepatocellular carcinoma 若松遼介1, 中山瑞貴2, 若松綾華1, 山下友輝1, 須藤大雄1, 桂川みき1, 柴波明男1, 樋浦一哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1738-1738, 2023. |
|---|
|
|
P0708-4-PM1. Examination between the delay convalescence in the methotrexate excretion delay of the a large quantity of methotrexate therapy 斉藤瑞歩, 中尾將彦, 古波津美紗, 影山寛人, 森宏幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1739-1739, 2023. |
|---|
|
|
P0709-4-PM2. The use situation investigation of the peg filgrastim preparation in our hospital 青木望, 淺利亜規代, 望月英明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1740-1740, 2023. |
|---|
|
|
P0710-4-PM1. Effect on prognosis that relative intensity of treatment in the cancer of endometrium postoperative chemotherapy gives 桂川健司, 高取裕司, 高岡龍蔵, 遠山幸男, 久田達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1741-1741, 2023. |
|---|
|
|
P0711-4-PM2. Adverse event comparison of elderly people receiving CapOX therapy after the operation 和久井卓, 水上康弘, 本田和則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1742-1742, 2023. |
|---|
|
|
P0712-4-PM1. 1 case that presented severe proteinuria and high blood pressure after the ramucirumab + FOLFIRI therapy introduction early 森井悠介, 松井駿亮, 大河万顕, 瀬名波宏昌, 下村一徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1743-1743, 2023. |
|---|
|
|
P0713-4-PM2. Investigation into the use of asciminib, a novel STAMP inhibitor, for chronic myeloid leukemia 中村雄亮1, 高橋優聡1, 助畑歩1, 大野真史1, 北川瑚姫1, 大聖遥香1, 伊藤史織1, 小森均1, 太田秀一2, 深井敏隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1744-1744, 2023. |
|---|
|
|
P0714-4-PM1. One case of rectal cancer which came by treatment continuation after the nephrotic syndrome onset by Ramucirumab in Bevacizumab 高取裕司, 桂川健司, 高岡龍蔵, 遠山幸男, 久田達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1745-1745, 2023. |
|---|
|
|
P0715-4-PM2. Examination about the effectiveness of the Elobixibat in patients with cancer 生田智基, 和田翼, 松本拓真, 武智宣佳, 堀田修次, 森近俊之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1746-1746, 2023. |
|---|
|
|
P0716-4-PM1. 1 case that measured AUC for effective and safe confirmation using MMF for steroid refractoriness irAE 綾野武司1, 水岡大策1, 高本彩音1, 篠原尚樹1, 山口佳津騎2, 元木大貴1, 田中裕章1, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1747-1747, 2023. |
|---|
|
|
P0717-4-PM2. A case which developed type I diabetes mellitus as an immune-mediated adverse event by nivolumab + ipilimumab combination therapy 柿本秀樹1, 福江悠香1, 吹上勇真1, 小川新1, 高木聡子1, 鵜木亜矢子1, 眞崎晃3, 内山将伸3, 宮崎元康1,2, 今給黎修1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1748-1748, 2023. |
|---|
|
|
P0718-4-PM1. The adrenal function test enforcement situation of the use of immune checkpoint inhibitor patients in our hospital 榊原崇芳, 近藤有, 間瀬悟, 三宅芳男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1749-1749, 2023. |
|---|
|
|
P0719-4-PM2. Consideration of the expression situation of the immune-mediated adverse event in the use of immune checkpoint inhibitor patients and the factor 鈴木直人1, 渡邊卓嗣1,2, 飯沼尚己1, 高橋優花1, 塩澤誠1, 山内雅仁1, 有馬遥太朗1, 佐々木高信3, 岡田浩司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1750-1750, 2023. |
|---|
|
|
P0720-4-PM1. Changes from gemcitabine lyophilized products to a solution, examination about the vascular pain accompanied with the change of the dissolution liquid 足立紗知, 畑祐基, 宮城和代, 長谷川英利, 中橋麻友, 楢本佳代, 青野由依, 吉村芙美, 村津圭治, 山下大輔, 吉野宗宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1751-1751, 2023. |
|---|
|
|
P0721-4-PM2. One case that led to drug-induced thrombocytopenia with oxaliplatin 遠藤美央, 鈴木拓也, 畠山智明, 玉木慎也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1752-1752, 2023. |
|---|
|
|
P0722-4-PM1. Examination of the onset of muscles and bones referred pain factor by a docetaxel combination regimen and the peg filgrastim 水上康弘, 和久井卓, 本田和則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1753-1753, 2023. |
|---|
|
|
P0723-4-PM2. Relation of the pharmacist to the HBV reactivation prevention in the treatment with anticancer medicine 西村雅次, 佐藤奈実, 今田良樹, 吉田崇志, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1754-1754, 2023. |
|---|
|
|
P0724-4-PM1. The effect that the effectiveness, safety and body-surface area of Osimertinib give 西馬怜1, 田中佐季1, 田宮基裕2, 高橋幸三1, 高木麻里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1755-1755, 2023. |
|---|
|
|
P0725-4-PM2. Efforts of the health insurance pharmacy for the "drug for the medical care" outside Parliament prescription acceptance 加藤貴美, 森田京子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1756-1756, 2023. |
|---|
|
|
P0726-4-PM1. It is the correspondence of the carrying out of the prescribed medicine to the foreign tour of patients with cancer 野田佳子1, 浜田美輝1, 房垣圭祐2, 若杉吉宣3, 須藤正朝3, 蓑輪圭一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1757-1757, 2023. |
|---|
|
|
P0727-4-PM2. Use experience of Panitumumab for patients with rectal cancer with the tumor fever 田口玲実1, 伊藤紳人1, 日比聡1, 壁谷めぐみ1, 湯浅周1, 城川優子2, 古田竜一3, 伊奈研次4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1758-1758, 2023. |
|---|
|
|
P0728-4-PM1. One case that suffered from differentiation of the fever, and had difficulty in treatment continuation of colon cancer 山本佳苗1, 松沼悟1, 吉元公一1, 山本圭2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1759-1759, 2023. |
|---|
|
|
P0729-4-PM2. 1 case that performed pertuzumab + trastuzumab combination therapy for HER2-positive colon cancer of progress, the recurrence that was impossible of curative resection 宮内康夫1, 櫻井淳二1, 八島一史1, 岡田優1, 佐々木美織1, 加藤さゆり2, 佐藤伸輔1, 寺澤孝幸4, 松尾幾3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1760-1760, 2023. |
|---|
|
|
P0730-4-PM1. Evaluation of the usefulness of Prognostic Nutritional Index as the checkpoint inhibitor effect predictor in patients with non-small cell lung cancer of immunity 三好孝法1,2, 宮下裕央2, 深澤真実1, 和佐野英子1, 花田聖典1, 大橋邦央1, 橋本雅司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1761-1761, 2023. |
|---|
|
|
P0731-4-PM2. The results HACA-positive a case that suspected rituximab-induced serum sickness during the BR therapy enforcement, and suggested an examination to a physician 石田貴啓, 内田将吾, 大谷寧次郎, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1762-1762, 2023. |
|---|
|
|
P0732-4-PM1. Nutritional status in the breast cancer preoperative chemotherapy and association of the side effect expression 菊池健1, 城堀陽生2, 武田元樹1, 渡邉大毅1, 相馬貴史1, 佐藤秀紀2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1763-1763, 2023. |
|---|
|
|
P0733-4-PM2. Case investigation about the remedy situation and the effect of treatment of the anamorelin hydrochloride 濱みゆき, 木村雄太, 田初夏苗, 柳瀬真希, 山岸佳代, 橋下浩紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1764-1764, 2023. |
|---|
|
|
P0734-4-PM1. Effect investigation of the effect that anamorelin hydrochloride and Rikkunshito give to cancer cachexia 嶋田真帆1,2, 稲野寛1, 山本悠樹1,2, 瀬戸良教1, 太田智博1, 椎崇1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1765-1765, 2023. |
|---|
|
|
P0735-4-PM2. Association with continuity of elderly people usability test and the chemotherapy in patients with cancer and the adverse event 風岡真実1, 佐藤淳也3, 橋本竜1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1766-1766, 2023. |
|---|
|
|
P0736-4-PM1. The effect that the difference in Axitinib in patients with nephrocyte cancer and adverse event profile of the sunitinib gives for effect of treatment 松井頌明1, 尾崎正和2, 岡田直人2, 北原隆志2, 藤井秀一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1767-1767, 2023. |
|---|
|
|
P0737-4-PM2. Examination about the effect of treatment predictor in the Atezolizumab + Bevacizumab combination therapy for the unresectable hepatocellular carcinoma 須藤大雄1, 若松遼介1, 若松綾華1, 山下友輝1, 樋浦一哉2, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1768-1768, 2023. |
|---|
|
|
P0738-4-PM1. One patient whom fulminant type I diabetes mellitus developed in by Nivo + SOX administration 永田未希1,2, 市倉大輔1,2, 縄田修一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1769-1769, 2023. |
|---|
|
|
P0739-4-PM2. Development of the new medical therapy to patients with poor-prognosis oral cancer based on disappearance, the malignant transformation mechanism of the CYLD expression 米丸興1, 末永尚輝1,4, 吉田晋太郎2,5, 森祥輝1, 勝目泰槙2, 松山果穂2, 新垣ひとみ1, 安東実咲2, 大田雅子2, 齋藤秀之1,3, 城野博史1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1770-1770, 2023. |
|---|
|
|
P0740-4-PM1. Methods for overcoming difficulties in taking venetoclax tablets and their effectiveness - A pharmacist's approach for pediatric patients with acute myeloid leukemia - 小林灯, 岩西雄大, 大津由美子, 望月千枝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1771-1771, 2023. |
|---|
|
|
P0741-4-PM2. Examination about relative dose intensity and effect of treatment of the Olaparib for ovarian cancer and the side effect 片岡加奈恵1, 寺澤美智代1, 本西哲1, 木崎秀和1, 村田紘未2, 打谷和記1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1772-1772, 2023. |
|---|
|
|
P0742-4-PM1. Examination about the appropriateness doses in the elderly people of the CapeOX therapy provided as adjuvant chemotherapy after the colon cancer technique 小笠裕斗, 上津沙織, 柿原圭佑, 塚原邦浩, 小倉秀美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1773-1773, 2023. |
|---|
|
|
P0743-4-PM2. Association of the checkpoint inhibitor and overall survival in patients with distant metastasis-related non-small cell lung cancer with the autoimmune disease of immunity 井原康貴1, 澤兼士2, 今井匠1, 石原朝陽3, 下村由希1, 野々宮悠太1, 新谷歩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1774-1774, 2023. |
|---|
|
|
P0744-4-PM1. A case of hepatic veno-occlusive disease/sinusoidal obstruction syndrome treated with defibrotide sodium after PTCY-Haplo transplantation 佐野雅彦, 水田秀貴, 末松耕輔, 黒部健太郎, 宮原強, 草葉一友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1775-1775, 2023. |
|---|
|
|
P0745-4-PM2. Retrospective study on renal function estimation level and toxicity to use at the Carboplatin doses calculation by the Calvert type 小林美奈子1, 渡邊裕之2, 柴田直樹3, 富士芳美4, 前田剛司5, 橋詰淳哉6, 亀位耕平7, 岡田浩司8, 妹尾啓司9, 三好孝法10, 平野公美11, 政賢悟12, 奥田泰考13, 宮崎実千芸14, 吉田幹宜15, 城口将太16, 藤田行代志17, 齊藤達也18, 山室蕗子19, 天間雅美20 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1776-1776, 2023. |
|---|
|
|
P0746-4-PM1. Study of the behavior factor giving it to the participation in "workshop for improvement in quality of the foreign cancer chemotherapy" 遠藤篤1,5, 佐藤大祐2,5, 石井直人1,5, 塩原慶徳2,5, 内山一成3,5, 露木聡史4,5, 喜古康博2,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1777-1777, 2023. |
|---|
|
|
P0747-4-PM2. Efforts of the HBV reactivation prophylaxis at cancer chemotherapy regimen check by PBPM 中嶋紘文, 吉田壘, 神佳祐, 村永諒, 山本いずみ, 櫻田穣, 坂田幸雄, 長浜谷耕司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1778-1778, 2023. |
|---|
|
|
P0748-4-PM1. Examination of the effective peer support which can meet the needs of the AYA generation cancer experienced person 三浦聡至, 高山俊輔, 牧野好倫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1779-1779, 2023. |
|---|
|
|
P0749-4-PM2. Construction in an overhanging style of the simple and easy isograft model mouse aiming at an efficacy evaluation of cancer driver gene-positive leukemia 平尾卓也1, 榎本竜也1, 寺川眞由1, 青木重樹2, 手塚千裕1,3, 加藤芳徳1,3, 山田治美1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1780-1780, 2023. |
|---|
|
|
P0750-4-PM1. UGT1A1*6/*28 genetic polymorphism and a case which came by administration continuation by weight loss with CPT-11 for patients with colon cancer of the hyperbilirubinemia 一沢麻衣1, 小沼大祐2, 市田泰彦1, 宮村達雄3, 筒井秀知1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1781-1781, 2023. |
|---|
|
|
P0751-4-PM2. Examination of the side effect of treatment with liposomal irinotecan risk factor in patients with pancreatic cancer 伊藤雄大1, 江川英毅2, 平岡芹菜2, 亀位耕平2, 佐野尚平2, 松原和夫1,2, 北野雅之3, 川井学4, 須野学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1782-1782, 2023. |
|---|
|
|
P0752-4-PM1. Examination of start doses of the colon cancer adjuvant postoperative treatment in elderly people 75 years or older 安藤純子1, 中西博紀3, 衛藤英一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1783-1783, 2023. |
|---|
|
|
P0753-4-PM1. Evaluation of the intervention by the pharmacist for osteoporosis therapeutic drug proper use 守田香織1, 市川大介1, 古谷佳美1, 本田尚也1, 三原夏実1, 高田逸朗2, 平川宏之2, 松尾真二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1787-1787, 2023. |
|---|
|
|
P0754-4-PM2. We test an effect of the edoxaban 15 mg prophylaxis after the total knee prosthesis, hip joint replacement technique in our hospital 小林華奈, 木下真理子, 薄田百合子, 高嶋祥匡, 市江敏和, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1788-1788, 2023. |
|---|
|
|
P0755-4-PM1. 1 case that used cyclosporine together with adrenal cortical steroid for patients with childhood autoimmune hepatitis 枝澤瑞記, 藤田大智, 山中崇史, 天間雅美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1789-1789, 2023. |
|---|
|
|
P0756-4-PM2. The introduction situation of the heart failure standard therapeutic drug in the public hospital of the Showa era 米沢牧子1, 阿部剛1, 山崎千愛1, 峯岸夕紀2, 岡田健助3, 田中茂博3, 本田一春1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1790-1790, 2023. |
|---|
|
|
P0757-4-PM1. Use fact-finding of the edoxaban in patients who underwent lower limbs orthopedics surgery and examination of the venous thromboembolism onset risk 岩武幹乃, 吉田悦朗, 臼井和明, 長島章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1791-1791, 2023. |
|---|
|
|
P0758-4-PM2. One case of the hypokalemia that was resistant to potassium replacement therapy 上杉章紀, 鴇田雅義, 正木拓陽, 高日大介, 田邉文明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1792-1792, 2023. |
|---|
|
|
P0759-4-PM1. Comparison of an infliximab response case of the Kawasaki's disease and the refractory case 長澤祥子, 木村真策 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1793-1793, 2023. |
|---|
|
|
P0760-4-PM2. Examination of the inspiratory flow rate increase by the Nose Clip method 坂野昌志1,2, 菅野雄太1, 吉村昌紘1, 竹内章2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1794-1794, 2023. |
|---|
|
|
P0761-4-PM1. Intervention effect of the pharmacist on heart failure basics medicine introduction 片桐光1, 小林竜司1, 長谷川哲也1, 鶴田瑞葵1, 武藤浩司1, 田中裕子1, 土田圭一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1795-1795, 2023. |
|---|
|
|
P0762-4-PM2. Comparison ... which paid attention to the basic pharmaceutical characteristic of attempt - antihistamine of the hay fever therapeutic drug academic D tailing material making 岡田由美子1, 深澤佑樹1, 三好文子1, 池澤直樹1, 岩田みなみ1, 出雲貴文1, 小茂田昌代1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1796-1796, 2023. |
|---|
|
|
P0763-4-PM1. Effectiveness of corresponding ... trazodone to the delirium in patients with chronic cardiac insufficiency and safety assessment ... 杢保貴幸1, 濱田真由子1, 熊本悠哉2, 徳竹裕貴1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1797-1797, 2023. |
|---|
|
|
P0764-4-PM2. Examination of the effect on nausea post-operative vomiting of the 5-HT3 receptor blocker in the general anesthesia lower obstetrics and gynecology department surgery 蟹江千雛, 酒井幹康, 戸田州俊, 大岩由香里, 三宅芳男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1798-1798, 2023. |
|---|
|
|
P0765-4-PM1. Efforts for the postoperative pain management team start in our hospital 西浦真理, 殿村直也, 中田千晴, 佐野弥里, 宮澤真帆, 寺山義泰, 稲吉梨絵, 山本博俊 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1799-1799, 2023. |
|---|
|
|
P0766-4-PM2. Effect of the prescription intervention based on the 2021 JCS/JHFS guidelines to the heart failure that the left ventricular ejection fraction by the pharmacist decreased on heart failure medical treatment instruction person 秀島久美子1, 中野祐樹1, 岡亜矢子1, 鬼塚健2, 門上俊明2, 横尾賢乗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1800-1800, 2023. |
|---|
|
|
P0767-4-PM1. Effect to give disease severity of the cardiogenic embolism with the anticoagulant remedy 原弘士1, 佐々木有彩1, 村井遥1, 大久保莉菜1, 櫻塲絵梨香1, 澤村公志1, 山本郁生1, 山本正博2, 城倉健1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1801-1801, 2023. |
|---|
|
|
P0768-4-PM2. About medical therapy of the osteoporosis in the seriously ill people experiencing disability 齊田翌美, 林佳奈子, 今田美里, 江崎由佳, 山本晃大, 山崎貴史, 鶴崎泰史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1802-1802, 2023. |
|---|
|
|
P0769-4-PM1. Fact-finding of the statin administration for patients with super old ischemia-related cerebral infarction and examination of the validity 林杏介, 森川剛, 久保田健, 岡澤香津子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1803-1803, 2023. |
|---|
|
|
P0770-4-PM2. Effect of the Ergo thionein in the ulceration of the skin ischemia reperfusion injury mouse 西田健太朗1, 高橋萌香1, 津山陽佳1, 岩崎綾乃1, 久家貴寿2, 田中雅幸3, 北谷和之4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1804-1804, 2023. |
|---|
|
|
P0771-4-PM1. Sounding out plan of the optimal administration time of tPA for the rat septicemic DIC model 竹中リナ1, 富山桃佳1, 山田真也2, 森下英理子2, 菅幸生1, 朝倉英策2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1805-1805, 2023. |
|---|
|
|
P0772-4-PM2. Chic day correspondence in patients with heart failure during SGLT2 inhibitor administration 高橋知里, 麻生美佐子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1806-1806, 2023. |
|---|
|
|
P0773-4-PM1. Ondansetron introduction to the surgery center about PONV measures of the obstetrics and gynecology department surgery and the effect that gave an incidence 打田由希, 濱浦弘光, 大谷寧次郎, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1807-1807, 2023. |
|---|
|
|
P0774-4-PM2. About possibility of the antitumor effect of the hyperuricaemia therapeutic drug in the castration-resistant prostate cancer 鈴木康裕1,2, 岡本楓1, 鹿俣千裕1, 坂本七虹1, 山平りさ1, 太田昌一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1808-1808, 2023. |
|---|
|
|
P0775-4-PM1. Investigation of DVT under the edoxaban prophylaxis low-dose after TKA and the bleeding event rate 木村修徳, 近藤讓, 田中誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1809-1809, 2023. |
|---|
|
|
P0776-4-PM2. It is an investigation about the delirium after the Remy masochist lymphangioleiomyomatosis doses and the operation 藤原純平, 吉田三矢, 苗村彰浩, 佐光留美, 庄野裕志, 山西香織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1810-1810, 2023. |
|---|
|
|
P0777-4-PM1. One patient who underwent anticoagulation in warfarin for superior mesenteric artery embolism postoperative short bowel syndrome 奥苑朱加1, 杉村聡1, 杉田三郎2, 遠山幸男1, 久田達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1811-1811, 2023. |
|---|
|
|
P0778-4-PM2. A case that quetiapine was effective for sleeplessness with a feeling of irritation and the excitement of children 野々山陽子1, 渡辺裕之1,2, 藤井友和1, 蜂須賀水絵3, 神谷彩4, 木下薫5, 足立康則6, 宮島雄二5, 杉浦洋二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1812-1812, 2023. |
|---|
|
|
P0779-4-PM1. One patient who was able to contribute to sugar load reduction in pyruvate dehydrogenase complex (PDHC) deficiency as a pharmacist 直井一久, 植竹龍一, 窪田佳代子, 丸山千春, 高木昭佳, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1813-1813, 2023. |
|---|
|
|
P0780-4-PM2. Investigation about the factor to lead to administration of guanfacine cancellation for the ADHD 土井絹華, 祖川倫太郎, 江口祐子, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1814-1814, 2023. |
|---|
|
|
P0781-4-PM1. Effect to result in for the ADL evaluation of patients with stroke that use of the statin-based medicine is admitted to the convalescent rehabilitation ward 花岡峻輔1,2, 平井利幸2, 関利一2, 林宏行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1815-1815, 2023. |
|---|
|
|
P0782-4-PM2. Effect of the antacid to chalasia of magnesium oxide on chronic constipation of the elderly people multiple drug remedy patients 岩井琢1, 高橋寛1, 波多江崇2, 岡崎光洋3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1816-1816, 2023. |
|---|
|
|
P0783-4-PM1. One case of the nerve sarcoidosis patients avoiding becoming severe with ganciclovir-resistant cytomegalovirus infection 岩崎清子1, 安高勇気1,2, 松崎翔平1, 竹下翔3, 藤岡伸助3, 坪井義夫3, 神村英利1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1817-1817, 2023. |
|---|
|
|
P0784-4-PM2. Of the polypharmacy activity in the Saiseikai Hiroshima Hospital, actually 岡村和彦1, 山田真帆1, 浜本友絵1, 玉理千晴1, 高橋栄子1, 笹栗友佳里1, 正田朋佳1, 松本公治2, 佐々木雄啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1818-1818, 2023. |
|---|
|
|
P0785-4-PM1. One case that was able to receive good control using the oxycodone extended-release for chronic pain associated with multiple necrosis of four extremities due to the diffuse scleroderma 大内竜介1,2, 鈴木清寿3, 長尾宗紀3, 千葉美枝4, 鈴木直人2, 野上佳奈子2, 薄井健介1,2, 渡邊卓嗣1,2, 児山香3, 岡田浩司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1819-1819, 2023. |
|---|
|
|
P0786-4-PM2. Examination of the usefulness of flurbiprofen which we used as an alternative agent of the aspirin for Kawasaki's disease acute phase 柳恵, 石毛宏冶, 石田雅也, 金井絵美, 長谷川雄介, 米井万紀子, 山崎茜, 森木麻未, 本田ゆめ, 石坂優太, 大竹千夏, 松木祥彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1820-1820, 2023. |
|---|
|
|
P0788-4-PM2. Examination about the dose of the dapagliflozin for patients with heart failure who had diabetes 眞山遼太, 佐々木稜太, 村岡愛, 高取士剛, 加藤梢, 岩堀真弓, 嘉屋則子, 後藤悠, 久保淳一, 田畑裕和, 今井隆人, 小林龍 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1822-1822, 2023. |
|---|
|
|
P0789-4-PM1. The comparison of the hyperkalemic therapeutic drug of the emergency domain: Rearward investigation of zirconium cyclo sodium silicate and the calcium polystyrene sulfonate 櫻井雄太, 安島秀友, 松崎貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1823-1823, 2023. |
|---|
|
|
P0790-4-PM2. Current status of pharmaceutical operations at our hospital and pre-avoidance reports 大荒政志, 増田博也, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1824-1824, 2023. |
|---|
|
|
P0791-4-PM1. 1 case that we took medicine for predicted children patient, and a medication difficulty supported about a prednisolone tablet to use for Kawasaki's disease treatment 中村杏果, 池沢若菜, 徳丸章佳, 北園幸大, 田中恭人, 森永崇史, 石渡美樹, 徳永楓果, 米田仁保, 栗田泰樹, 上野菜巳, 上野怜良, 屋敷大輔, 淵脇ゆかり, 長ヶ原琢磨, 荻尾夕起子, 岸本真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1825-1825, 2023. |
|---|
|
|
P0792-4-PM2. Efforts for the postoperative pain team management addition calculation in the Sasebo-shi comprehensive medical care center 山口健太郎1, 前川拓治2, 岡本智子3, 濱松大吾3, 古賀聖子1, 荻野清子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1826-1826, 2023. |
|---|
|
|
P0793-4-PM1. Comparison with the article existing a medication supplement at powders remedy in children 1 year old or older under 15 years old a taking-related improvement effect of "sleeping (R) which grinds it, and sleeps at one gulp to put" 笠原沙耶香1, 齊藤順平1, 山口みほ1, 山田真由美1, 山谷明正2, 赤羽三貴1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1827-1827, 2023. |
|---|
|
|
P0794-4-PM1. Pulse-taking of internal use, the ad usum externum formulations incident by the drug inspection support system introduction 坂倉広大, 中蔵伊知郎, 向井優太朗, 安延恵, 宮部泰輔, 中野一也, 上野智子, 川端一功 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1830-1830, 2023. |
|---|
|
|
P0795-4-PM2. Analysis of the incident that a pharmacist was associated with 後藤一馬, 作山悠里, 川崎美咲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1831-1831, 2023. |
|---|
|
|
P0796-4-PM1. The effect that the number of the drugs per Press Through Package 1 sheet gives to a calculation mistake 山口泰弘, 田村彩織, 溝田愛子, 高武嘉道, 藤瀬陽子, 大橋邦央, 橋本雅司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1832-1832, 2023. |
|---|
|
|
P0797-4-PM2. The standardization promotion of the sleeping drug and the effect 廣田佳孝, 二見慎吾, 堀内麻美, 増田有紀子, 渡辺晴美, 川島美智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1833-1833, 2023. |
|---|
|
|
P0798-4-PM1. It is efforts for prevention of resumption oblivion of the stopping medicine during surgery, preoperation in our hospital 熊澤里美, 加藤さや香, 友松恵子, 角里恵子, 荒川悠樹, 牧原俊康, 鈴木孝幸, 山田成樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1834-1834, 2023. |
|---|
|
|
P0799-4-PM2. Effect of the benzodiazepine receptor agonist decrease medicine in front of the art for the cardiovascular surgery patients 森田祐基1, 原幸子1, 高梨夕稀2, 内田佳菜子1, 友塚真栄3, 竹原眞人3, 津丸真一3, 島本健3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1835-1835, 2023. |
|---|
|
|
P0800-4-PM1. About making, the operation of the prescription input protocol by the ward pharmacist 喜多えり奈, 西村知恭, 亀位耕平, 島田佳代子, 山口佳那, 佐野尚平, 田淵沙織, 秋月麻友子, 山口真衣子, 嶋本めぐみ, 神谷祐果, 西川浩子, 吉田薫, 中川貴之, 松原和夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1836-1836, 2023. |
|---|
|
|
P0801-4-PM2. Efforts of the medical security for the powders prescription order 間瀬広樹1,2, 稲垣雄一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1837-1837, 2023. |
|---|
|
|
P0802-4-PM1. The current situation of hepatitis B reactivation measures in the Showa University Hospital and problem 田川菜緒1,2,3, 坂木理3, 若林仁美1,2, 古田康之1,2, 吉田仁3, 嶋村弘史1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1838-1838, 2023. |
|---|
|
|
P0803-4-PM2. The angiopathic development situation by the nicardipine judging from an incident report and the effectiveness of the medical care security activity by the pharmacist 向井優太朗1, 中蔵伊知郎1,2, 坂倉広大1, 安延恵1, 中野一也1, 上野智子1, 福峯美智代2, 津田悦子2, 大郷剛2, 川端一功1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1839-1839, 2023. |
|---|
|
|
P0804-4-PM1. It is reported the examination situation of the off-label use of the pharmaceutical products in the hospital for 28 for acute phase, convalescence, a chronic phase 新井亘1, 土屋裕伴1, 海老根卓也2, 矢吹直寛3, 岡平将志4, 増田裕一5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1840-1840, 2023. |
|---|
|
|
P0805-4-PM2. Report about the intervention of the pharmacy in the hospitalization and release support center 山内理世, 大西真奈美, 宮本康史, 上野英文, 小嶋希望 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1841-1841, 2023. |
|---|
|
|
P0806-4-PM1. About correlation with internal use and the fall accident occurrence of the sleeping drug 田口未菜, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1842-1842, 2023. |
|---|
|
|
P0807-4-PM2. The report of the HBV reactivation case with the cancer chemotherapy in our hospital and analysis 深見優衣1, 諸角一成1, 恒川有里2, 岡田優子1, 杉浦美結1, 佐藤由美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1843-1843, 2023. |
|---|
|
|
P0808-4-PM1. About the efforts of the fall, fall measures that removed a sleeping drug of BZ origin from drug for household delivery 武藤芳和1, 渡部寿康1, 佐藤隆昭2, 市橋淳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1844-1844, 2023. |
|---|
|
|
P0809-4-PM2. The efforts which decreases a fall, a fall by night of elderly people 伊藤真也, 古澤明朋, 浅井和浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1845-1845, 2023. |
|---|
|
|
P0810-4-PM1. Construction of the medicine confirmation system targeted for discontinuation before operation of the patients participation type 鈴木洋平1, 清水佐良子1, 田辺美恵1, 曽根敦子1, 丸谷善紀2, 鈴木優司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1846-1846, 2023. |
|---|
|
|
P0811-4-PM2. The effect that the change of the test value reporting style gives to tracing report contents on outside Parliament prescription 元木貴大1, 住吉健太1, 水岡大策1, 新村航1, 松原亜季1, 川北智子1, 越野優希2,3, 山口佳津騎4, 田中裕章1, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1847-1847, 2023. |
|---|
|
|
P0812-4-PM1. Investigation, examination about the GS1 cord indication point for effectively utilizing it of the medicine collation system 後藤総太郎1,2, 濱村有那1, 瀬尾桃子1, 勝野美沙1, 池田香菜子1, 小山内美音1, 諸井良江1, 平野明穂1, 関田彩1, 浅羽遼1, 肥沼理映子1, 山村康比古1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1848-1848, 2023. |
|---|
|
|
P0813-4-PM2. The evaluation of the joint ownership method of the incident that occurred by lack of knowledge: The effect that a notice making up for basic knowledge gives for incident occurrence 小山なつの, 安島秀友, 松崎貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1849-1849, 2023. |
|---|
|
|
P0814-4-PM1. Investigation of the patients identification precision by the difference in identifier to put together in patients full name 大久保淳史1, 立沢正臣1, 今村克美2, 下泰司3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1850-1850, 2023. |
|---|
|
|
P0815-4-PM2. The work environment improvement by the 5S activity in the injection department, improvement in effectiveness and review of the stock article 鈴木莉羅, 岩崎加奈子, 杉崎崇人, 中村匡志, 名和亜利沙, 平松亜依, 三木真梨杏, 渡部秀一, 青山剛, 蓑輪雄一, 清水久範, 山口正和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1851-1851, 2023. |
|---|
|
|
P0816-4-PM1. About the study implementation situation about HBV reactivation measures in our hospital 吉藤和也, 森岡沙織, 後藤志典, 山崎博子, 赤崎淳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1852-1852, 2023. |
|---|
|
|
P0817-4-PM2. Development of the medication jelly kit for the purpose of relief, security, the simple and easy medication 盛本修司, 川崎浩延, 林茂雄, 澤田拓磨, Adam Jakob Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1853-1853, 2023. |
|---|
|
|
P0818-4-PM1. Extraction of the preventive measures by the incident report analysis 千葉慧1,2, 熊谷学1, 伊藤充子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1854-1854, 2023. |
|---|
|
|
P0819-4-PM2. Efforts for the increase of the incident report submission number in the drug department of our hospital 伊藤実優1, 横田学1, 吉川直利1, 東野斉恵2, 土川由美子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1855-1855, 2023. |
|---|
|
|
P0820-4-PM1. Introduction of the formula reeducational program in the business training of the Kitasato University Hospital 岩澤真紀子1, 春日井公美1, 菅原充広1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1858-1858, 2023. |
|---|
|
|
P0821-4-PM2. Examination of the education effect to a pharmacy student for the active prescription suggestion in the Tokushima University Hospital 高橋志門1,2, 相澤風花1,2, 八木健太2,3, 濱野裕章4, 神田将哉1,2, 近藤正輝1,2, 座間味義人4, 新村貴博2,3, 櫻田巧1,2, 桐野靖1,2, 合田光寛1,2, 石澤啓介1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1859-1859, 2023. |
|---|
|
|
P0822-4-PM1. Examination of the usefulness of e-Learning by the dentist for the improvement of knowledge and the consciousness about oral mucositis of the pharmacist in the cancer chemotherapy 星野直人1, 吉田謙介1, 矢吹剛2, 多川洋史1, 古賀雅良1, 鈴木直人1, 貝瀬眞由美3, 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1860-1860, 2023. |
|---|
|
|
P0823-4-PM2. Contents construction and evaluation of the disaster pharmacy training 横田敬之, 鈴木善樹, 栗原弘紀, 新井優, 貝嶋亮, 石川章, 小泉盛, 眞壁秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1861-1861, 2023. |
|---|
|
|
P0824-4-PM1. Evaluation of the consciousness change of the pharmacy school business trainee before and after our hospital business training program enforcement 梅内実穂1,2,3, 小林美奈子1, 阿部憲介2, 木皿重樹3, 内藤義博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1862-1862, 2023. |
|---|
|
|
P0825-4-PM2. Efforts of the securing of continuous human resources of the hospital pharmacist for the improvement of the pharmacist unevenly distributed 田村亮1, 鎌田里紗1, 平野達也2, 藤井尚子1, 木下恵1, 山岡健太1, 奥吉博之2, 新免紗也1, 杉山峰是1, 東山将己3, 橋田亨1, 室井延之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1863-1863, 2023. |
|---|
|
|
P0826-4-PM1. Production of the scenario program to support to goal setting ending in failure return marks about physical assessment from the communication with patients 徳永仁1, 緒方恵梨奈1, 岡部愛実1, 尾中宏彰1, 園田純一郎1, 橋本亜衣子1, 緒方賢次2, 興梠靖幸2, 岸本真1,3, 高村徳人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1864-1864, 2023. |
|---|
|
|
P0827-4-PM2. Effect of the simulation training in the pharmacist 大塚さほり1,2, 有賀敦1, 三澤貴美1, 田中健二1, 瀧沢康裕2, 竹内千景2, 渡辺剛2, 藤森茂晴2, 堀勝幸3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1865-1865, 2023. |
|---|
|
|
P0828-4-PM1. Construction of the student independent participation type hospital business training and investigation of the training satisfaction 橋本竜1,2, 佐藤淳也3, 近江一太1, 玉井一也1, 宮内輝人1, 吉成宏顕1, 久保倫美1, 入野真紀1, 梅田鈴香1, 守田侑真1, 風岡真実1, 大矢智則1,2, 神坐美弥子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1866-1866, 2023. |
|---|
|
|
P0829-4-PM2. Attitude survey for the carrier vision of the hospital pharmacist 河添仁1, 土屋雅美2, 藤堂真紀3, 原梓4, 大西友美子5, 堀里子6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1867-1867, 2023. |
|---|
|
|
P0830-4-PM1. Examination of the factor to improve the evaluation of achievement of the trainee at the end of the business training 石川春樹1,2, 河添仁1, 岩田紘樹1, 中村友紀1, 地引綾1, 横山雄太1, 小林典子1, 鈴木小夜1, 山浦克典1, 中村智徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1868-1868, 2023. |
|---|
|
|
P0831-4-PM2. Evaluation of online, the practical hybrid training in our hospital judging from the questionnaire results of the pharmacy student 石橋正祥, 飯村洋平, 黒田誠一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1869-1869, 2023. |
|---|
|
|
P0832-4-PM1. Evaluation of the physical assessment practical examination using the simulator for pharmacology fifth graders 緒方賢次1, 高村徳人1, 興梠靖幸1, 園田純一郎2, 徳永仁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1870-1870, 2023. |
|---|
|
|
P0833-4-PM2. Qualitative study of the I method learning method in development and the National Examination for Pharmacist of the pass probability calculation technique using the I method learning method CHAEHYEOK LEE, 川島裕也, 久保田洋子, 今井信行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1871-1871, 2023. |
|---|
|
|
P0834-4-PM1. It is ... mainly on the formulations section duties using construction and evaluation - PDCA cycle of the new face pharmacist training system by the education training team 小林義政, 三輪奈津貴, 鵜飼一歩, 山里久子, 高木裕介, 牧原明秀, 高原悠子, 鈴木雅人, 榊原恵子, 今井視保子, 葛谷真理, 高木祥子, 吉田弘樹, 今高多佳子, 木全司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1872-1872, 2023. |
|---|
|
|
P0835-4-PM2. Qualitative investigation of the psychology for the research activities of the drugstore pharmacist 田中みのり, 竹平理恵子, 盛岡正博, 有田悦子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1873-1873, 2023. |
|---|
|
|
P0836-4-PM1. Attitude survey about the thought to the study that the pharmacy school life captures 川見麗菜, 竹平理恵子, 盛岡正博, 有田悦子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1874-1874, 2023. |
|---|
|
|
P0837-4-PM2. Evaluation of the hospital business training program using text mining 西村美馨子1, 鎌田理紗子1, 斎藤祥子1, 立花京香1, 榎本晶帆2, 櫻井まりこ1, 白木小百合1, 河野太治1, 金森香澄1, 山本真椰1, 横山裕紀2, 水谷清香1, 長戸大空2, 吉田加代1, 越野明花1, 松本美緒1, 竹尾恵理子1, 酒井欣嗣2, 千崎康司1, 伊藤功治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1875-1875, 2023. |
|---|
|
|
P0838-4-PM1. Investigation about the effect of the new coronavirus infection on "relation" and "medication counseling" number of 8 representative diseases in a hospital, the drugstore business training 西川陽介1,2, 佐藤祥子2, 及川淳子2, 工藤香澄2, 我妻恭行2, 小嶋文良1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1876-1876, 2023. |
|---|
|
|
P0839-4-PM2. Efforts (online visit, online seminar) to securing of staff of the hospital pharmacist in the district and the effect 丸山真理子, 井上知哉, 原田周平, 隈部法子, 宮上桐豪, 大久保翔, 藤田靖之, 池田能利子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1877-1877, 2023. |
|---|
|
|
P0840-4-PM1. Efforts of the participation type workshop enforcement that incorporated the Small group discussion by the multicenter young person pharmacist workshop 外石昇1, 林太佑8,10, 安武夫4,10, 鶴岡翔太5,10, 津田泰正6,10, 原田大2,10, 齋藤雅俊7,10, 堀井剛史9,10, 黒田誠一郎3,10, 川久保孝2,10 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1879-1879, 2023. |
|---|
|
|
P0841-4-PM2. Investigation of the factor associated with the evaluation of the member of society basic skills in the clinical pharmacist 土屋裕伴, 塚田昌樹, 中里健志, 新井亘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1880-1880, 2023. |
|---|
|
|
P0842-4-PM1. Making of the pattern language about the research activities in clinical settings for the purpose of the improvement in ability for study of the pharmacist 渡邉慶剛1, 酒井隆全2, 大津史子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1881-1881, 2023. |
|---|
|
|
P0843-4-PM2. Investigation of the course determinant after the pharmacist resident completion 齋藤千夏1, 枦秀樹2, 井上正久3, 榎本貴一4, 鈴木慶介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1882-1882, 2023. |
|---|
|
|
P0844-4-PM1. New face pharmacist education utilizing the extra edition number of the medicine-based monthly 垣内祥宏, 緑川拓也, 渥美弘美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1883-1883, 2023. |
|---|
|
|
P0845-4-PM2. Problem - after the construction (the fourth report) - clinical ladder operational start of the hospital pharmacist staff education system 小山郁美1, 稲野寛1, 婦川貴博2, 山本悠樹2, 坂倉智子1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1884-1884, 2023. |
|---|
|
|
P0846-4-PM1. Scoping review about the case conference by the healthcare worker 板井進悟1,9, 荒木隆一2,9, 上塚朋子3,9, 長谷川裕矢4,9, 間瀬広樹5,9, 宮脇未来6,9, 矢吹拓7,9, 矢野良一8,9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1885-1885, 2023. |
|---|
|
|
P0847-4-PM1. Examination about the bar code indication to ethical drug aluminum pillow packing 吉田真也, 宇佐美英績, 木村美智男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1888-1888, 2023. |
|---|
|
|
P0848-4-PM2. Intervention of the pharmacist in the living renal transplantation start 江橋優香1, 小室治孝1, 望月拓2, 喜古康博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1889-1889, 2023. |
|---|
|
|
P0849-4-PM1. Duties efficiency of the hospital pharmacist by the hospital DX promotion using SNS for duties in the HITO MEDICAL CENTER 田中成枝1, 村山公一2, 近藤祥代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1890-1890, 2023. |
|---|
|
|
P0850-4-PM2. Efforts of our hospital about the perioperative pharmacy management 小島香織, 佃優里, 宮里裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1891-1891, 2023. |
|---|
|
|
P0851-4-PM1. Contribution of the pharmacist in the postoperative pain management team 鈴木寿樹1, 田中里奈1, 森下啓1, 本間舞子2, 杉野繁一2, 滝沢香菜3, 高野淳2, 矢吹志津葉2, 鈴木潤2, 松浦正樹1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1892-1892, 2023. |
|---|
|
|
P0852-4-PM2. Polypharmacy measures in the care health center for the elderly 白髪恵美1, 西岡陽子3, 石川真理2, 近藤祥代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1893-1893, 2023. |
|---|
|
|
P0853-4-PM1. Fact-finding before and after the protocol operational start of the inquiry simplification in the outside Parliament prescription 長田知子, 村上知奈美, 大西政典, 松浦里穂, 松村恵理奈, 盛重あずさ, 池田咲樹, 先崎健造, 岸井加代子, 関恭子, 土佐直子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1894-1894, 2023. |
|---|
|
|
P0854-4-PM2. Qualitative study - based on a problem in the medical care that the LGBTQ person concerned faces and the interview to real - person concerned of the consideration 駒井優実1, 松下綾1, 宮野康央1, 安原智久2, 永田実沙3, 上田昌宏4, 串畑太郎4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1895-1895, 2023. |
|---|
|
|
P0855-4-PM1. Japan and France comparison about the steady supply measure of pharmaceutical products 山田治美1, 加藤芳徳1,2, 平尾卓也1, 手塚千裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1896-1896, 2023. |
|---|
|
|
P0856-4-PM2. Examination of the pharmaceutical intervention investigation of the pharmacist in our hospital and the medical economical evaluation 小園亜希, 馬場結子, 松藤敬佑, 宮田拓周, 平池美香子, 齋藤巨樹, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1897-1897, 2023. |
|---|
|
|
P0857-4-PM1. Inspection of medical expenses reduction effect of the treatment at home on hospitalization medical care and the improvement in patients quality of life effect 富田悠紀1, 伊東佳美2, 坂東勉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1898-1898, 2023. |
|---|
|
|
P0858-4-PM2. Factor associated with the atrophy degree of the stomach of the helicobacter pylori sanitization patients with the drinking custom 尾関佳代子, 羽田和弘, 脇屋義文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1899-1899, 2023. |
|---|
|
|
P0859-4-PM1. Efforts of the osteoporotic liaison team in patients with proximal thighbone bone fracture 田村安希1, 岡崎英子1, 畑賢俊2, 森田桂子2, 恩藤友希3, 小西池泰三4, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1900-1900, 2023. |
|---|
|
|
P0860-4-PM2. Efforts and result to securing of pharmacist in the Handa City solder hospital 横田学, 板倉由縁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1901-1901, 2023. |
|---|
|
|
P0861-4-PM1. The furtherance system to support a project for the purpose of the promotion of the acquisition of the medical pharmacy knowledge and the medical cooperation 高木利之, 宝達寛子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1902-1902, 2023. |
|---|
|
|
P0862-4-PM2. Examination - based on factor - questionary survey to promote the research activities situation and the research activities of the pharmacist 瀧川正紀1, 近藤悠希2, 小林豊3, 飯干茜3,4, 木下雅子1, 石塚洋一2, 増田雅行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1903-1903, 2023. |
|---|
|
|
P0863-4-PM1. Questionnaire findings report about the career path of the pharmacist for people of Japanese cure association withdrawal 安原眞人1, 安藤崇仁1, 宮崎長一郎2, 山本康次郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1904-1904, 2023. |
|---|
|
|
P0864-4-PM2. Remedy - of the workplace thinking about how you improve the hospital pharmacist's experience value from - Employee Journey Mapping 榎本貴一1, 岩崎未久1, 小林可奈1, 加藤彩絵1, 八尋彩夏1, 萩原卓也1, 舘林和樹1, 山下徳一郎1, 宮内英里1, 木村泰2, 小坂鎮太郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1905-1905, 2023. |
|---|
|
|
P0865-4-PM1. The effect on collect rate that silicone oil at simple suspension method enforcement and temperature give and relations of the physicochemical nature 長崎裕也1, 友田吉則1,2, 宮坂優人1, 小松敏彰1, 春日井公美1,3, 尾鳥勝也1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1906-1906, 2023. |
|---|
|
|
P0866-4-PM2. Comparison of a color and the quantity of fixed-quantity indicator ingredient decoction of the roasting liquid by the difference in extraction in the Daiokanzoto 瓜生津智穂, 天池菜都実, 佐藤純令, 津江南瑠海, 成橋和正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1907-1907, 2023. |
|---|
|
|
P0867-4-PM1. Comparison between color and quantity of fixed-quantity indicator ingredient decoction of the roasting liquid by the difference in extraction method in the Maoto 野本衣那, 園部深央里, 瓜生津智穂, 向美麗, 成橋和正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1908-1908, 2023. |
|---|
|
|
P0868-4-PM2. Comparison of a color and the quantity of fixed-quantity indicator ingredient decoction of the roasting liquid by the difference in extraction in the Orengedokuto 園部深央里, 野本衣那, 瓜生津智穂, 向美麗, 成橋和正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1909-1909, 2023. |
|---|
|
|
P0869-4-PM1. Comparison between color and fixed-quantity indicator ingredient of the roasting liquid by the difference in extraction method in the Shakuyakukanzoto 向美麗, 白石かれん, 瓜生津智穂, 野本衣那, 園部深央里, 成橋和正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1910-1910, 2023. |
|---|
|
|
P0870-4-PM2. Survey about the approach to securing of human resources using a homepage 大成政揮1, 園部祐太1, 豊永風音1, 松原栄治1, 松本善江1, 松下香織1, 小野雅文1, 伊丹元治1, 長嶋一泰2, 松本哲哉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1911-1911, 2023. |
|---|
|
|
P0871-4-PM1. Activity report of the delirium measures in the dementia care team 瓦侑馬1, 中野美佐2, 福田祥世3, 齋籐健治4, 勝浦正人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1912-1912, 2023. |
|---|
|
|
P0872-5-PM. Inspection of the tracing report utilization example to the patients with the bleeding risk factor during edoxaban remedy 大野伴和, 市川学, 輪島圭二, 松本健春 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1915-1915, 2023. |
|---|
|
|
P0873-5-PM. The effect that the introduction of the prophylaxis protocol in the PONV technique and the intervention by the pharmacist give to PONV incidence 佐藤浩太郎, 高橋希, 近藤真理, 梶野哲, 鈴木信也, 井口恵美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1916-1916, 2023. |
|---|
|
|
P0874-5-PM. Fact-finding of the common use medicine grasp means of the pharmacist in the emergency visit 岩崎睦, 宮田祐一, 鬼村紀子, 宮下栞, 大村史, 中村雅敏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1917-1917, 2023. |
|---|
|
|
P0875-5-PM. Efforts of the pharmacist in the perioperative discontinuation management 田杭直哉, 吉田真人, 小西健太郎, 徳丸翔大, 源平麻衣, 近藤匡慶, 菅谷量俊, 高瀬久光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1918-1918, 2023. |
|---|
|
|
P0876-5-PM. Efforts of the medical office pharmacist outpatient department and future problem 坂啓子, 島崎亮司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1919-1919, 2023. |
|---|
|
|
P0877-5-PM. Examination of the usefulness of the pharmacist outpatient department for the task shift in the ambulatory practice of patients with rheumatic disease 野本敦文1, 笹川永里子1, 徳留雄太1, 武井優輝1, 新井理沙1, 川島瑞生1, 三宅優子1, 浅木知子1, 土屋雅勇1, 光永義治1, 渡部多真紀1,2, 安野伸浩1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1920-1920, 2023. |
|---|
|
|
P0878-5-PM. The need of the reevaluation in the inhalation therapy 川村大輔, 久岡清子, 増田博也, 佐々木健志, 大荒政志, 間千晴, 鹿沼奈央, 木原稔文, 坪田美風, 山崎佳奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1921-1921, 2023. |
|---|
|
|
P0879-5-PM. Is going to perform operations in our hospital; efforts for a relation and the efficiency of the prehospital pharmacist for the patients 中村孝佑, 船隠恵子, 野村直幸, 森泰子, 高橋洋子, 田村浩二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1922-1922, 2023. |
|---|
|
|
P0880-5-PM. About the current situation of a setup and the operation of the pharmacist outpatient department 村上仁志, 原田哲彦, 坂野博紀, 白井景 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1923-1923, 2023. |
|---|
|
|
P0881-5-PM. Evaluation of the continuous follow-up system for the oral anticancer agent remedy patients through the pharmacist outpatient department 北出紘規, 宮永和美, 西野正義 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1924-1924, 2023. |
|---|
|
|
P0882-5-PM. Intervention effect of the pharmacist outpatient department on regorafenib remedy patients 山崎将英, 深田英嗣, 藤居賢, 福土将秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1925-1925, 2023. |
|---|
|
|
P0883-5-PM. Medication real-time monitoring system construction of the oral anticancer medicine 川上和宜1,2,3, 小林一男1, 清水久範1, 横川貴志1, 鈴木一洋2, 森祐佳1, 鈴木亘1, 柴田直樹1, 中井恵子3, 竹内資和3, 安藤井達3, 山口正和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1926-1926, 2023. |
|---|
|
|
P0884-5-PM. Patients safety management by the outside Parliament prescription inspection containing the oral anticancer medicine 木村祐子1, 徳永愛美1, 市村丈典1, 縄田修一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1927-1927, 2023. |
|---|
|
|
P0885-5-PM. Analysis of pharmacist duties in the kidney transplantation outpatient department 富島喜朗, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1928-1928, 2023. |
|---|
|
|
P0886-5-PM. The effect that childcare experience gives to the medication counseling of children in the drugstore pharmacist 寺山香織, 内藤友博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1929-1929, 2023. |
|---|
|
|
P0887-5-PM. An iron deficiency evaluation for the purpose of the thromboembolism prophylaxis of the HIF-PH inhibitor in the circulatory organ special hospital and intervention to iron replacement therapy 戸口拓弥1, 加藤瑞季1, 谷田拓也1, 高橋義弥1, 飯坂美香1, 丸山俊夫1, 野々山由香理1, 櫻井正之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1930-1930, 2023. |
|---|
|
|
P0888-5-PM. Efforts of the family pharmacist concerned with medical care children 石原直子, 田端康幸, 丹羽直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1931-1931, 2023. |
|---|
|
|
P0889-5-PM. Efforts to foreign introduction of the preparation for the amikacin sulfate inhalation 井上潤子, 原太一, 形部文寛, 佐々木文子, 井筒理子, 幸原美奈子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1932-1932, 2023. |
|---|
|
|
P0890-5-PM. Investigation about cooperation with the health insurance pharmacy in the support before hospitalization 山田あかね1, 廣江訓子1, 猪田宏美1, 牛尾聡一郎2, 鍛治園誠1, 座間味義人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1933-1933, 2023. |
|---|
|
|
P0891-5-PM. The measures to the surgery postponement example with the drug started after the confirmation of common use medicine before hospitalization and the usefulness 合原嘉伸1,2, 緒方健二1, 祖川倫太郎1, 湯川美紗子1, 加茂真宏1, 江本晶子1, 木村早希子1, 吉田ひとみ2, 江崎幹宏2, 島ノ江千里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1934-1934, 2023. |
|---|
|
|
P0892-5-PM. Fact-finding after the doubt inquiry protocol operation 増田成美1, 池田愛1, 橋詰宏美1, 瀬戸口由1, 吉川三保子1, 池上良一1, 古川順章2, 田路章博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1935-1935, 2023. |
|---|
|
|
P0893-5-PM. Construction of the cooperation system between a hospital, the drugstores using the oral anticancer agent initial information exchange book in foreign oral cancer treatment 神原康佑, 岡田淳芳, 中村豪志, 石井一也, 大塚識稔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1936-1936, 2023. |
|---|
|
|
P0894-5-PM. The case that the cooperation of ward - outpatient department pharmacist was important at a care shift 坪田美風, 大荒政志, 青柿和樹, 山崎佳奈, 松浦克樹, 増田博也, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1937-1937, 2023. |
|---|
|
|
P0895-5-PM. Effect of the on admission interview introduction in our hospital 山本彩加, 細野真吾, 見尾谷昇, 磯野礼果, 堀浩子, 山崎崇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1939-1939, 2023. |
|---|
|
|
P0896-5-PM. It is the review of effectively utilizing it and ward drug duties the bringing medicine under the pharmaceutical products distribution restrictions 内田朱美, 秀徳優美, 北窓正孝, 續政哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1940-1940, 2023. |
|---|
|
|
P0897-5-PM. Efforts for the efficiency of bringing medicine differentiation duties using a database 吉田裕生, 佐澤卓哉, 上之将明, 加世田良一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1941-1941, 2023. |
|---|
|
|
P0898-5-PM. Experience the case that made adequate from adequacy - tacrolimus normal preparation of the medical therapy by the pharmaceutical evaluation at the bringing medicine's confirmation to a slow-release preparation; and ... 佐藤洸1, 高濱和弘1, 武田泰生1,2, 寺薗英之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1942-1942, 2023. |
|---|
|
|
P0899-5-PM. The "Yojokun" of the nonprescription drug package insert mention situation investigation 中村仁, 金野太亮, 鈴木裕之, 村井ユリ子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1944-1944, 2023. |
|---|
|
|
P0900-5-PM. Qualitative investigation about the will to the pharmacist consultation in the drugstore 野口奈桜, 竹平理恵子, 盛岡正博, 有田悦子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1945-1945, 2023. |
|---|
|
|
P0901-5-PM. Efforts of the active intervention in a nonprescription drug and the health food consultation for the purpose of the healthy support function enhancement 河田英之, 石尾みほ, 今城慶子, 三牧由依, 高橋絵梨香, 佐々木美佳, 中西友里, 福田久子, 安倉央, 高橋正志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1946-1946, 2023. |
|---|
|
|
P0902-5-PM. Analysis of the drugstore potentially serious medical errors example for proper use promotion in nonprescription drugs, and the like 長谷川浩三1,2,3, 稲葉一郎2, 門脇大介3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1947-1947, 2023. |
|---|
|
|
P0903-5-PM. The situation investigation of efforts and the tracing report to the cooperation full addition acquisition in foreign cancer chemotherapy patients 水口敦子, 宮川貴行, 永井良, 井筒理子, 安達俊江, 形部文寛, 原太一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1951-1951, 2023. |
|---|
|
|
P0904-5-PM. Change of the drug instruction time in the pharmacist accompanied with the diversification of the cancer chemotherapy regimen 本間崇正, 鳥居昌太, 武部幸江, 江崎秀樹, 榊原隆志, 滝本典夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1952-1952, 2023. |
|---|
|
|
P0905-5-PM. HADS to patients with patients evaluation - breast cancer for the interview opportunity addition of the medication support in the initial cancer chemotherapy and inventory survey ... 治田匡平, 木村錦子, 村田政軌, 池田和之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1953-1953, 2023. |
|---|
|
|
P0906-5-PM. Efforts about the reporting (tracing report) to the medical institution for hormonal therapies patients 林広成1, 山岸潔子1, 田中亜弥1, 奥田好香1, 米本眞里1, 増田直樹2, 高村康2, 阿部康治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1954-1954, 2023. |
|---|
|
|
P0907-5-PM. It is the inspection of the intervention effect by follow and the tool utilization after the medication for patients with cancer treated with various regimens 石田潤一郎1, 野嶋芳紀1, 齋藤聡夫1, 松尾宗一郎1, 邑瀬誠1, 深津英人2, 松井洸2, 阿部真也2, 山口浩2, 野村和彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1955-1955, 2023. |
|---|
|
|
P0908-5-PM. Efforts of the pharmacist associated with foreign tumor chemotherapy practice charges in our hospital 糸満盛尚, 川上博瀬, 村田利恵子, 前泊美保, 知念里佳, 松島亜紀, 島袋優花, 本村恵, 大城将吾, 大城優衣, 浜元善仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1956-1956, 2023. |
|---|
|
|
P0909-5-PM. Standardization of the information on adverse drug reactions offer to the hospital in the telephone follow-up for the specific drug management instruction addition 2 calculation patients 汐待加織1, 佐藤絵美1, 小野寺香里1, 高崎隼颯1, 江藤陸1, 西山実菜1, 渡辺涼2, 吉田恭子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1957-1957, 2023. |
|---|
|
|
P0910-5-PM. Why can anamorelin not continue; actual situation ... of the anamorelin administration in ... our hospital 齊藤直美, 赤城佳奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1958-1958, 2023. |
|---|
|
|
P0911-5-PM. A case which developed a serious mental disorder by Lorlatinib 田中佐季1, 西馬怜1, 竹田健志1, 國政啓2, 高木麻里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1959-1959, 2023. |
|---|
|
|
P0912-5-PM. A case which was able to contribute to appropriate treatment by the cooperation with the hospital for patients with renal cell carcinoma of the Lenvatinib + Pembrolizumab combination therapy enforcement 西川育子1, 平田崇代1, 宮崎恵1, 鈴木泰帆1, 森田渚映子1, 早川太朗2, 高井佳江1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1960-1960, 2023. |
|---|
|
|
P0913-5-PM. The limit of the side effect of telephone follow-up evaluation: One case that presented cutaneous symptom during Cabozantinib administration 田村知子1,2, 吉岡睦展2, 高子優子2, 近藤万友美2, 澁谷奈穂2, 細見真世2, 若松雄太2, 狩野佑実1, 小溝優子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1961-1961, 2023. |
|---|
|
|
P0914-5-PM. How to share information and collaborate with newly registered RevMate clinics and affiliated hospitals 鈴木善貴1,2,3,4, 橋本雅子2, 坂野博紀2, 中西慶子2, 倉橋信悟3, 杉浦勇4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1962-1962, 2023. |
|---|
|
|
P0915-5-PM. What Pharmacists Can Do: A Case of HER2-Positive Breast Cancer 菅原茂樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1963-1963, 2023. |
|---|
|
|
P0916-5-PM. The medication follow-up in the chemotherapy enforcement patients, the examination of the factor that is easy to lead to the sending of the tracing report and analysis of sending contents 田中秀幸1, 羽賀真里子1, 西田浩平1, 野村由貴1,3, 玉木啓文2, 井口和弘2,3, 加藤寛子4, 鈴木昭夫4, 佐口弥3,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1964-1964, 2023. |
|---|
|
|
P0917-5-PM. The one instance case that a drugstore pharmacist was able to intervene in the breast cancer supportive care of adherence delinquent patients appropriately 正木研1, 本田雅志2, 下川友香理2, 中村泰朗3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1965-1965, 2023. |
|---|
|
|
P0918-5-PM. Intervention effect to the polypharmacy by the pharmacist on patients with foreign cancer 八木貴彦, 平野公美, 森田奈々, 大和千穂, 外山未来, 中村拓哉, 野木村藍, 宮本康敬, 川口千香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1966-1966, 2023. |
|---|
|
|
P0919-5-PM. A case which was able to intervene in prescription adequacy for patients during hormonal therapies after the postmenopausal breast cancer technique as a specialized medical institution cooperation drugstore pharmacist 荒井元志1, 原田剛光1, 本田雅志2, 下川友香理2, 石原孝2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1967-1967, 2023. |
|---|
|
|
P0920-5-PM. About the efforts to an immune-mediated adverse event in the use of immune checkpoint inhibitor 石黒友希1, 鈴木敦詞1, 竹内健悟1, 鈴木大吾1, 中村敏史1, 田中伸明1, 坂田洋1, 服部芳明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1968-1968, 2023. |
|---|
|
|
P0921-5-PM. 2 cases that the telephone follow-up to patients with breast cancer by the health insurance pharmacy pharmacist was useful as a support of the heart 中村俊貴1,2, 爲我井一統1, 坂本岳志1, 境美智順1, 木村雅彦1, 平山武司2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1969-1969, 2023. |
|---|
|
|
P0922-5-PM. Contents investigation ... of role - tracing report of the specialized medical institution cooperation drugstore for foreign cancer chemotherapy patients 和田憲周, 山本侑記, 田中亜優実, 和田恵理, 林智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1970-1970, 2023. |
|---|
|
|
P0923-5-PM. The cooperation full addition in the foreign cancer chemotherapy of our hospital and the current situation and problem of the medicine medicine cooperation 高橋久樹, 柴田勝弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1971-1971, 2023. |
|---|
|
|
P0924-5-PM. A case of the therapy with cisplatin and radiation exposure for the locally invasive bladder cancer of the low renal function patients 竹原涼子, 向井淳治, 坂本竜平, 小竹優希, 叶真央, 山田佳菜子, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1972-1972, 2023. |
|---|
|
|
P0925-5-PM. One case that intervened in the anticancer agent internal use patients by a tracing report 小林竜也1, 大野真之1, 阿部康治2, 高村康2, 増田直樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1973-1973, 2023. |
|---|
|
|
P0926-5-PM. Relation with specific drug management instruction addition 2 patients with cancer to think about from the current situation of calculating it 玉田麻利子1, 中村文哉2, 松井洸3, 阿部真也3, 山口浩3, 野村和彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1974-1974, 2023. |
|---|
|
|
P0927-5-PM. The relation with a drugstore pharmacist and patients with cancer: One case of patients receiving Abemaciclib tablets 森下敦彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1975-1975, 2023. |
|---|
|
|
P0928-5-PM. Fact-finding of the telephone follow-up in the hospitalization chemotherapy 廣岡賢輔, 山下奈津子, 櫻井有紀, 清水浩幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1976-1976, 2023. |
|---|
|
|
P0929-5-PM. Development of pharmacists who can play an active role in interpersonal work and possibilities in the oncology field based on pre-avoidance reports 大森義朗, 川幹子, 松田泰子, 石光一幾, 菅香理, 佐藤真也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1977-1977, 2023. |
|---|
|
|
P0930-5-PM. To contribute as follow-up - specialty medical institution cooperation drugstore to make up for the difference of the staff of drugstore for the chemotherapy; ... 安斎沙織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1978-1978, 2023. |
|---|
|
|
P0931-5-PM. Examination about the effect that the cooperation full addition gives in instruction duties and the tracing report of the health insurance pharmacy 大野謙太朗, 佐々木良, 遠藤征裕, 齋藤雅隆 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1979-1979, 2023. |
|---|
|
|
P0932-5-PM. The holding of the cooperation enhancement addition web workshop for outside Parliament drugstore pharmacists and future problem 中野友寛1, 末廣拓1, 十亀將輝1, 宇都本孝夫1, 和田伊代1, 新居田能章1, 村井望1, 越智啓介1, 松岡葉子1, 西畑友尋1, 玉井宏一1, 烏谷政和1, 倉田知久1, 渡部早苗2, 山下広恵3, 武田千津3, 井上考司4, 森高智典4, 中西徳彦4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1980-1980, 2023. |
|---|
|
|
P0933-5-PM. Efforts to cooperation full addition calculation in our hospital and future problem 十亀將輝1, 末廣拓1, 中野友寛1, 宇都本孝夫1, 和田伊代1, 新居田能章1, 村井望1, 越智啓介1, 松岡葉子1, 西畑友尋1, 玉井宏一1, 烏谷政和1, 倉田知久1, 渡部早苗2, 山下広恵3, 武田千津3, 井上考司4, 森高智典4, 中西徳彦4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1981-1981, 2023. |
|---|
|
|
P0934-5-PM. Examination about the need of the pharmacist intervention for the oral anticancer agent medication patients in the outpatient department 和田依子, 樋口美奈子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1982-1982, 2023. |
|---|
|
|
P0935-5-PM. Evaluation after the cancer tracing report operational start using the Google form 佐藤奈実, 今田良樹, 吉田崇志, 眞木秀子, 西村雅次, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1983-1983, 2023. |
|---|
|
|
P0936-5-PM. The current situation and problem of the cooperation full addition in our hospital 高濱啓太1, 中村郁勝1, 山田充宏1, 大佐古智文2, 中野正啓2, 藤末真実子2, 宮本浩子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1984-1984, 2023. |
|---|
|
|
P0937-5-PM. Survey on the occurrence of neuropsychiatric adverse events associated with the initiation of cabotegravir + rilpivirine and analysis using POMS 合原嘉寿1, 大橋邦央1,2, 橋本雅司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1986-1986, 2023. |
|---|
|
|
P0938-5-PM. Consideration, the operation of the tracing report specialized in the HIV domain aiming at illness medicine cooperation reinforcement and the evaluation 住吉健太1, 水岡大策1, 新村航1, 松原亜季1, 川北智子1, 山口佳津騎2, 元木貴大1, 田中裕章1, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1987-1987, 2023. |
|---|
|
|
P0939-5-PM. 1 case of dialysis patients with HIV infection that we introduced 大道淳二1, 出宮千聖1, 宮下雄博2, 蒲生直幸3, 細川忍4, 佐久川亮4, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1988-1988, 2023. |
|---|
|
|
P0940-5-PM. Examination of the division supply method for the at-home management of the domestic nonrecognition ω 3 system lipid microsphere 瀬戸口誠1, 武藤充2, 福岡龍一3, 有馬純子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1990-1990, 2023. |
|---|
|
|
P0941-5-PM. Efforts to drug proper use using nourishment metrics 石井照樹1,2,3,4, 森黒唯1, 大嶋成奈優1, 沖廣絵里子1, 高橋公子1, 石原瑛太郎1, 篠永浩1, 加地努1, 石山晃子2, 中津守人3, 矢野禎浩4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1991-1991, 2023. |
|---|
|
|
P0942-5-PM. The case that an undernourished patient with the poor intestinal absorption was given infliximab, and was improved 田中恭人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1992-1992, 2023. |
|---|
|
|
P0943-5-PM. A case in which preventive intervention for refeeding syndrome in a severely underweight patient with a BMI of 10.8 led to early improvement in cardiac function 眞野裕1, 迫田弘基2, 石田茂伸1, 多胡友絵1, 徳元一樹3, 星育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1993-1993, 2023. |
|---|
|
|
P0944-5-PM. Examination of the use situation investigation of the anamorelin hydrochloride in our hospital and the effect 中川こはる, 中嶋丈晴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1994-1994, 2023. |
|---|
|
|
P0945-5-PM. Survey on the actual use of Kidmin after the package insert was revised 上田真隆, 濱崎淳哉, 裏山悠哉, 村高紫野, 奥田広志, 向井淳治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1995-1995, 2023. |
|---|
|
|
P0946-5-PM. A study on the ENORAS in serum potassium levels after taking Inolas combined enteral liquid 筒井千晴1, 横山千紘1, 川邊一寛1, 松本真琴1, 岡村央2, 小森智也1, 小池博文1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1996-1996, 2023. |
|---|
|
|
P0947-5-PM. Examination of the factor affecting the rise in serum zinc levels of patients on dialysis 細野真吾, 見尾谷昇, 堀浩子, 磯野礼果, 細野亜由美, 早野いずみ, 倉橋実希, 山崎崇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1997-1997, 2023. |
|---|
|
|
P0948-5-PM. Investigation of the effect that a gastric-acid secretion antagonist gives to a diarrhea improvement effect of the pectin-containing digestion state nutrient preparation 小野達昌, 渡邊瑛理, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1998-1998, 2023. |
|---|
|
|
P0949-5-PM. Examination of the effect that COVID-19 gives to the frailty of elderly people 近藤宏樹1,2, 篠永浩1,2, 加地努1,2, 矢野禎浩2, 和泉和子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1999-1999, 2023. |
|---|
|
|
P0950-5-PM. Research for a pharmacist to receive smooth team approach in medical care by NST, pressure sore team 陣内智美1, 宮崎美子2, 吾妻隼斗1, 村田秋緒1, 安齋七生1, 志田貴彦3, 鈴木智4, 濃沼政美4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2000-2000, 2023. |
|---|
|
|
P0951-5-PM. A case that Teduglutide accepted improvement of the nutritional status by administration for patients with advanced age short bowel syndrome three times a week 大平サラ1, 木村純子1, 白石童子1, 黒川友博2, 酒井敏直1, 鈴木悠里1, 早乙女彩子3, 竹下光弘3, 早乙女浩之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2001-2001, 2023. |
|---|
|
|
P0952-5-PM. Attempt of the benzodiazepine receptor agonist decrease medicine using the support sheet in the psychiatry outpatient department 進健司, 森高啓太, 梅田勇一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2004-2004, 2023. |
|---|
|
|
P0953-5-PM. Effect of the pharmaceutical support by the pharmacist interview before medical examination in the psychiatry outpatient department 森高啓太, 進健司, 梅田勇一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2005-2005, 2023. |
|---|
|
|
P0954-5-PM. Efforts - of the sleeplessness instructions adequacy about activity report - delirium measures of the patients support team in our hospital 濱田昌志1, 字廻祐輔1, 金田好弘2, 志方敏幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2006-2006, 2023. |
|---|
|
|
P0955-5-PM. Intention investigation for the blonanserin patch in patients with ambulatory schizophrenia 土田さおり, 松本早苗, 山本和幸, 五味和彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2007-2007, 2023. |
|---|
|
|
P0956-5-PM. Survey and consideration of lurasidone use for schizophrenia in our hospital 松村俊希, 石川章, 水村亮介, 須貝昌平, 真壁秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2008-2008, 2023. |
|---|
|
|
P0957-5-PM. A report of the use of the sleeplessness use drug of the inpatient and participation of the delirium care team 小倉弥生1, 望月温子2, 上原香織3, 石山真3, 大木孝夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2009-2009, 2023. |
|---|
|
|
P0958-5-PM. The investigation of the sleeping drug in the bringing medicine of the Suwa Red Cross hospital and future problem 五味裕大1,4, 松原ちはる1,4, 登内盛治1, 濱優理2,4, 小松智子2,4, 丸山史3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2010-2010, 2023. |
|---|
|
|
P0959-5-PM. Clinical features and measures of patients with acute drug intoxication with the nonprescription drug 石川章1, 上村永2, 須貝昌平1, 松村俊希1, 水村亮介1, 鈴木善樹1, 眞壁秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2011-2011, 2023. |
|---|
|
|
P0960-5-PM. Examination of frequencies and the risk factor of the nightmare by the use of orexin receptor blocker 山下佑麻, 中村安孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2012-2012, 2023. |
|---|
|
|
P0961-5-PM. Search of the associated factor of the side effect that is hard to be manifested in patients with bipolar disorder 清水侑真1, 森康徳2, 竹内一平2,3, 半谷眞七子1,2, 藤田潔3, 亀井浩行1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2013-2013, 2023. |
|---|
|
|
P0962-5-PM. Effect on drug overdosage of COVID-19 pandemic resulted in, hurting itself 冨永麻里子, 菅野浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2014-2014, 2023. |
|---|
|
|
P0963-5-PM. Use experience of the Clozapine for treatment-resistant schizophrenia in our hospital 大治万喜子1, 西村寛1, 神薗淳司2, 山田茂人2, 大治太郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2015-2015, 2023. |
|---|
|
|
P0964-5-PM. After the operation of the ramified microglia in the elective operation patients of the digestive organ surgery about an effect of the delirium prevention 片岡美咲1, 水野良祐2, 古野和歌子3, 巽弥生1, 野村洋道1, 石本学司1, 中浴伸二1, 田中詳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2016-2016, 2023. |
|---|
|
|
P0965-5-PM. Retrospective study about the predictor of a concomitant drug and the fall fall event of the orexin receptor blocker 吹谷真紀子, 齊藤伸, 木元健寛, 瀬戸亘, 鈴木ひとみ, 仙葉悠紀, 齋藤香織, 篠田和人, 山崎恵葉, 金美紀, 一関美江子, 八代佳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2017-2017, 2023. |
|---|
|
|
P0966-5-PM. About medicine medicine cooperation to affect outside Parliament prescription issuance of the agent Clozapine for treatment-resistant schizophrenia 川崎美雪, 亀井美緒, 廣田竜亮, 大坂祐依, 岡井美可, 木村千尋, 新田直美, 辻正宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2018-2018, 2023. |
|---|
|
|
P0967-5-PM. Investigation about the effect of the sleeping drug on fall fall in the elderly people in our hospital psychiatry ward 佐藤舞由子, 小嶋希望, 渡邊康太, 平井彩也香, 日下陽介, 上野英文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2019-2019, 2023. |
|---|
|
|
P0968-5-PM. Examination of the fall risk with the sleeping drug in the inpatient 中原友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2020-2020, 2023. |
|---|
|
|
P0969-5-PM. One patient who conducted mother's milk inhibition with the cabergoline 川端加恵1, 柴田雪乃1, 小鳥遊明2, 稲村達生2, 大野真由2, 岸上靖幸2, 小口秀紀2, 遠山幸男1, 久田達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2023-2023, 2023. |
|---|
|
|
P0970-5-PM. Effect of the pharmaceutical management using the risk assessment list on venous thromboembolism prophylaxis after the cesarean section 杉浦あゆみ1, 水谷友香1, 近藤寿美子1, 山中規明1, 佐々治紀2, 桜田宏明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2024-2024, 2023. |
|---|
|
|
P0971-5-PM. The consultation duties system architectural evaluation by the pharmacist about the lactational medical therapy 太田千絢1, 田村美穂1, 石村光1, 浦田唯1, 有近仁美1, 荒木ちなみ1, 坂井康仁1, 税所篤行1, 村田晋2, 岡田直人1, 北原隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2025-2025, 2023. |
|---|
|
|
P0972-5-PM. Intervention after the outpatient department to the antimicrobial choice for the pregnant woman with a history of allergy to beta-lactam derivative antimicrobial 風間静香, 加賀美由有, 遠藤愛樹, 山本弓子, 松本香織, 小林義文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2026-2026, 2023. |
|---|
|
|
P0973-5-PM. Efforts of the pharmacist for the high-risk pregnancy and childbirth lying in woman in our hospital 美馬郁代1, 六車浩史1, 松田麻由2, 増田秋穂2, 梶原志保2, 森陽子3, 後藤真樹3, 岡野愛子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2027-2027, 2023. |
|---|
|
|
P0974-5-PM. Investigation of the drug information offer about a pregnant woman, the nursing mother for the healthcare worker in our hospital pharmacy 伏見久美子, 向山郁美, 三輪茜, 小森桂子, 大林巧志, 舩越真理, 土谷有美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2028-2028, 2023. |
|---|
|
|
P0975-5-PM. The annual use trend of the early or threatened labour therapeutic drug and epidemiologic survey of the side effect 石村淳1, 猪爪信夫1, 大田祥子2, 松田佳和1, 都築稔1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2029-2029, 2023. |
|---|
|
|
P0976-5-PM. The actual situation of the triptan drugs prescription for the pregnant woman: Investigation based on the receipt database 赤坂和俊1, 小原拓1,2,3, 有山智博4, 大柳元1, 森下啓1,2, 小原竜2, 石川智史5, 眞野成康1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2030-2030, 2023. |
|---|
|
|
P0977-5-PM. Safety assessment about the use of antihistamine during pregnancy 大柳元1, 齋藤颯一郎2, 石川智史3, 小原拓1,4, 岡田裕子5, 高橋信行2,3, 眞野成康1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2031-2031, 2023. |
|---|
|
|
P0978-5-PM. 1 case that rhabdomyolysis developed after the ritodrine hydrochloride administration, and the myotonica dystrophia of the mother's body was diagnosed by 岩澤春奈1, 綾野武司1, 一瀬ひろみ1, 篠原尚樹1, 山口佳津騎2, 元木貴大1, 田中裕章1, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2032-2032, 2023. |
|---|
|
|
P0979-5-PM. Investigation about the safety of the mother's milk childcare during zolpidem remedy 岩渕理子1, 佐藤祐司1, 菊地紗耶2, 小林奈津子2, 松本恵実1, 岡部奈穂1, 前川麻央1, 佐藤信一3, 岩間憲之4, 埴田卓志3, 齋藤昌利4, 富田博秋2, 小原拓1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2033-2033, 2023. |
|---|
|
|
P0980-5-PM. One patient who evaluated the placenta transitivity of the levetiracetam in the Japanese pregnant woman who had epilepsy 松澤菜津子1, 小澤秀介1, 布施谷千穂2, 菊地範彦2, 内藤隆文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2034-2034, 2023. |
|---|
|
|
P0981-5-PM. Elucidation of the mother's milk shift mechanism of mirtazapine based on the drug transportation experiment 畠山史朗, 小倉次郎, 山口亜耶子, 志田敏宏, 山口浩明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2035-2035, 2023. |
|---|
|
|
P0982-5-PM. About the association between remedy medicine for mental disorder merger mother's body and neonates 木村亜実1, 川田希帆1, 寺岡知香3, 野本貴子1, 北川直1, 立川奈保美1, 下辻恒久1, 山東真寿美1, 藤田敬子1, 白石淳4, 小垣滋豊2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2036-2036, 2023. |
|---|
|
|
P0983-5-PM. Result of a measurement one report of fexofenadine concentrations in human mother's milk 中川朋代1, 堤美帆1, 千葉貴子2, 大坪広美2, 西光優衣3, 森本未緒3, 井上知美3, 石渡俊二3, 小竹武3, 早田憲司4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2037-2037, 2023. |
|---|
|
|
P0984-5-PM. A case of the late child-bearing who had the primary aldosteronism 塚本由佳1, 高島絵里2, 長尾知3, 田村賢士1, 金子智一1, 立花栄三1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2038-2038, 2023. |
|---|
|
|
P0985-5-PM. Making of the drug control summary that established an emphasis for a maneuver, the management for exclusive use of the insulin injection 伊藤隆哉, 中曽根美香, 東健太郎, 小林愛美, 鬼窪利英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2041-2041, 2023. |
|---|
|
|
P0986-5-PM. Efforts of usefulness and the drug department of the use of insulin pump (770G) mounted with a smart guard (TM) in the SAP therapy automatic mode 佐藤瞳, 安井景子, 永澤亜貴子, 平尾志帆, 毛利有美子, 米元治朗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2042-2042, 2023. |
|---|
|
|
P0987-5-PM. Examination of the bone fracture risk of metformin in patients with type 2 diabetes using Meta-analysis 坂田仁紀, 益戸智香子, 小川ゆかり, 田島純一, 西牟田章戸, 堀井剛史, 湯浅勝敏, 小清水治太, 高尾良洋, 三原潔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2043-2043, 2023. |
|---|
|
|
P0988-5-PM. Rearward investigation about the effectiveness of the SGLT2 inhibitor administration for patients with type I diabetes mellitus in the true clinical practice 西村博之1, 吉田陽1, 塩山由紀1, 守田彩文1, 高田雅文1, 栗並昇2, 鈴木知子2, 稗島州雄2, 杉山正悟2, 陣内克紀2, 陣内冨男2, 陣内秀昭2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2044-2044, 2023. |
|---|
|
|
P0989-5-PM. The effectiveness of the oral GLP-1 receptor agonist semaglutide (reBartha's) in patients with type 2 diabetes and safe examination 古市依里菜1, 早川伸樹1,2, 津川透1,4, 桑原宏貴4, 戸邊隆夫3, 伊藤佳織1,3, 平塚いづみ2, 中島優華2, 鈴木敦詞2, 山田成樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2045-2045, 2023. |
|---|
|
|
P0990-5-PM. Use fact-finding of the perioperative SGLT2 inhibitor in the Fukuoka Saiseikai Fukuoka General Hospital 力丸奈央, 二神咲子, 由井薗陽一, 槇林智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2046-2046, 2023. |
|---|
|
|
P0991-5-PM. One-year efficacy and safety of semaglutide (Ozempic), a novel GLP-1 receptor agonist injection, in patients with type 2 diabetes 森青葉1, 早川伸樹1,2, 津川透1,4, 桑原宏貴4, 戸邊隆夫3, 伊藤佳織1,3, 吉野寧維2, 松尾悠志2, 鈴木敦詞2, 山田成樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2047-2047, 2023. |
|---|
|
|
P0992-5-PM. One case of the normoglycemia diabetic ketoacidosis that a stomach duodenal ulcer was regarded as an opportunity during use of SGLT2 inhibitor 五十川達哉1, 瀬口優里1, 河野祥三1, 泊秀史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2048-2048, 2023. |
|---|
|
|
P0993-5-PM. Adverse event investigation during an oral semaglutide tablets remedy period 山崎雄平1,2, 多胡友絵1, 星育子1, 小泉祐一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2049-2049, 2023. |
|---|
|
|
P0994-5-PM. Association of the diabetic kidney disease for the polypharmacy extension in patients with diabetes 永野浩之1,2, 小林正太郎2,4, 宮森彩香2,5, 疋田絵梨6,7, 小岩まの1, 高橋雅弘2, 眞壁秀樹1, 菊池貴子3, 櫛山暁史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2050-2050, 2023. |
|---|
|
|
P0995-5-PM. Liver, renal function protection of the fruit clinical SGLT2 inhibitor to be able to put, We look at the multicenter rear using Multiple Propensity Score and study a mark 樋浦一哉1, 鈴木千波2, 久保淳一3, 後藤悠3, 高取士剛3, 田中悠季2, 石田陽美2, 山下友輝4, 水谷彰史4, 車塚千穂5, 高木明彦6, 小林龍3, 柴波明男2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2051-2051, 2023. |
|---|
|
|
P0996-5-PM. Comparison judging from blood sugar control and the side effect expression situation by semaglutide and the Dulaglutide in our hospital 人見志保里, 春名康裕, 東碧, 武田智子, 長谷川晃司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2052-2052, 2023. |
|---|
|
|
P0997-5-PM. Two cases of obesity diabetes that led before we aimed at the remission by medical treatment mainly on the semaglutide 吉川貴教1, 山田雅也1, 梶原洋文1, 生山祥一郎2, 濱口和之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2053-2053, 2023. |
|---|
|
|
P0998-5-PM. Examination about making and the operation of the current situation of telephone medication support (R) and telephone check sheet 染谷光洋1, 石尾有司1, 谷口亮央1, 田中伶奈2, 樋浦一哉2, 山下美妃2, 中島史雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2054-2054, 2023. |
|---|
|
|
P0999-5-PM. Look back on efforts of the diabetes medical treatment instruction team participation in planning in the drug department 佐々木弘好 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2055-2055, 2023. |
|---|
|
|
P1000-5-PM. The screening situation investigation at introduction for the HIF-PH inhibitor proper use 八木亮夕子, 関田和樹, 早船真弘, 宮澤真帆, 寺山義泰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2057-2057, 2023. |
|---|
|
|
P1001-5-PM. eGFR test value change change investigation before and after the CKD seal pasting in our hospital 元木孝, 渡邊清人, 高柳昌宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2058-2058, 2023. |
|---|
|
|
P1002-5-PM. What has become clear from the results of use of upacicalcet sodium hydrate at our hospital 中村和彦, 中村嘉孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2059-2059, 2023. |
|---|
|
|
P1003-5-PM. Case series study on usefulness of the immunosuppressive drug 4 drug regimen in renal-transplant recipients 二村哲未1, 星茜1,2, 内倉健1, 百賢二1, 杉山恵理花3, 田島正教3, 加藤容二郎4, 吉武理4, 佐々木忠徳5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2060-2060, 2023. |
|---|
|
|
P1004-5-PM. Research about the effect to give the phosphate binder medication adherence of haemodialysis patients 山内牧子1, 田中みずき1,2, 西隆博3, 山川浩子3, 柳直樹1, 山本陽平1, 大部令絵4, 坂口眞弓1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2061-2061, 2023. |
|---|
|
|
P1005-5-PM. A case in which LDL-C was significantly reduced by administration of roxadustat 村上七海1, 佐藤伸輔2, 櫻井淳二2, 高橋健人1, 河野資1, 宮内康夫2, 高橋知子1, 佐藤譲3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2062-2062, 2023. |
|---|
|
|
P1006-5-PM. 1 case of the haemodialysis patients that caused the infection of cytomegalovirus and the small intestine bleeding during rituximab administration 瀬古高裕, 伊田厚輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2063-2063, 2023. |
|---|
|
|
P1007-5-PM. Study on effect on lipid metabolism with the HIF-PH inhibitor 桐井亜佑美1, 岡田優2, 櫻井淳二2, 佐藤伸輔2, 高橋健人1, 河野資1, 宮内康夫2, 高橋知子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2064-2064, 2023. |
|---|
|
|
P1008-5-PM. Change of the basement membrane ingredient gene expression in the renal function recovery in vitro model 片桐文彦, 佐藤佳苗, 臼井愛友未, 木村耕二, 高柳理早, 山田安彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2065-2065, 2023. |
|---|
|
|
P1009-5-PM. Search of urinary biomarker about extension of subclinical rejection in the kidney transplantation 田島壮一郎1, 小野未央里2, 重松智博1, 荻野敬史1, 廣田豪1, 岡部安博3, 家入一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2066-2066, 2023. |
|---|
|
|
P1010-5-PM. The calculation situation of the drug global assessment adjustment addition and the drug adjustment addition and the change of prescription analysis 山下弘毅, 青柳和代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2069-2069, 2023. |
|---|
|
|
P1011-5-PM. Effect of prescription suggestion, the representation prescription by the pharmacist in the care health center for the elderly 大熊範和1, 新木美枝1, 宮本卓馬2, 横澤真吾3, 鈴木達宙4, 蟻川勝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2070-2070, 2023. |
|---|
|
|
P1012-5-PM. Investigation about the suggestion contents of the polypharmacy measures team 成田佳奈1, 鶴野結花理1, 齋藤君美佳1, 堀内美樹博1, 米山尚慶2, 小山茂3, 塩地園代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2071-2071, 2023. |
|---|
|
|
P1013-5-PM. About the efforts of the dementia care support team facing each other at sleeplessness, the unrest of the inpatient in our hospital 加藤蒼生1,2, 小林俊博1,2, 小宮詠子1, 坪谷綾子1, 松本浩1, 吉田香2,3, 佐々木友理加2,4, 三宅誕実2,4, 大熊壮尚2,5, 伊藤由香1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2072-2072, 2023. |
|---|
|
|
P1014-5-PM. Construction of the simple and easy delirium risk screening and inspection of the effectiveness 永江隆二1, 屋敷久恵2, 中川友樹1, 塩崎真由3, 金井弘美2, 内山幸子1, 松田守弘4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2073-2073, 2023. |
|---|
|
|
P1015-5-PM. A consumption change and activity report of a sleeping drug by the dementia care support team intervention and antipsychotics 深尾那実1, 薄雅人1,2, 岡田智子1,2, 田淵克則1,2, 後藤拓也1, 山田泰聖2, 宮本直樹2, 小林麗2, 吉田知由1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2074-2074, 2023. |
|---|
|
|
P1016-5-PM. Pulse-taking of the restless time, sleeplessness indicator after the dementia care team start 上野沙恵子1, 玉木範子2, 奥薗文代2, 水田弘人3, 枌裕二3, 山川健太郎4, 尾崎彰彦4, 辻井佳代1, 小林政彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2075-2075, 2023. |
|---|
|
|
P1017-5-PM. Examination of the pharmaceutical intervention in the care health center for the elderly 笠原なつみ1, 松本和也2, 浅野志津1, 森英樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2076-2076, 2023. |
|---|
|
|
P1018-5-PM. A problem and measures to think about from the results of the secondary bone fracture prevention follow-up charges calculation patients 森崎崇文, 杉山留美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2077-2077, 2023. |
|---|
|
|
P1019-5-PM. Efforts of the pharmacist in the House of care medical care 高井杏弥子, 川崎美紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2078-2078, 2023. |
|---|
|
|
P1020-5-PM. Spreading effect by the cooperation of a care health center for the elderly additional post pharmacist and the prescription adequacy team 陶山泰治郎1, 十川友那1, 近藤宏樹1, 高原紗知子1, 篠永浩1, 原田典和1, 加地努1, 松野美歩2, 福田京子3, 中津守人4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2079-2079, 2023. |
|---|
|
|
P1021-5-PM. Effect of the thickness adjustment food giving it to the collapse of amlodipine OD tablets and drug release 下山哲哉, 竹村あすか, 上田菜々子, 伊藤邦彦, 小林道也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2080-2080, 2023. |
|---|
|
|
P1022-5-PM. The current situation investigation of the hypokalemia onset in Yokukansan internal use patients 65 years or older 辰巳真穂, 田中優希, 植原誠, 金子久美子, 龍田寛子, 橋本美香子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2081-2081, 2023. |
|---|
|
|
P1023-5-PM. Efforts for the drug proper use in the care health center for the elderly 浅野志津1, 笠原なつみ1, 松本和也2, 森英樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2082-2082, 2023. |
|---|
|
|
P1024-5-PM. We correspond to the reporting of the pharmacist in mouth care, the eating deglutition team, and it is evaluated by the type of job 岡部賢司1, 今浦将治1, 比嘉真理1, 武田康平1, 木幡雄至1, 宮田慎也1, 畠山英司1, 大和田里菜2, 小峰淳3, 小林理沙4, 星野泰慶5, 渡部真弥5, 雨宮剛志6, 下村忠賛7, 長田麻衣子8, 菅野浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2083-2083, 2023. |
|---|
|
|
P1025-5-PM. Examination of the factor that zinc acetate affects the improvement of the serum zinc level in the elderly people 宗村盛1, 初山佳苗2, 田嶋美幸1, 植木理恵3, 辻泰弘4, 鈴木豊史5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2084-2084, 2023. |
|---|
|
|
P1026-5-PM. Inspection of the validity of the pharmaceutical evaluation by the pharmacist in pressure sore measures 渡邊喜暁, 若林桜子, 香取優介, 沢田裕介, 中島瞳, 久保幸代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2086-2086, 2023. |
|---|
|
|
P1027-5-PM. About the efforts of the pharmacist in pressure sore treatment by the multi-type of job cooperation 石井麻紗子1, 角井義昌2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2087-2087, 2023. |
|---|
|
|
P1028-5-PM. Investigation of the descriptive epidemiology of the drug associated with the drug-induced pressure sore 日野洋明1, 菊池大輔1, 野上佳奈子1, 星恭子2, 遠藤悠江2, 岡田浩司1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2088-2088, 2023. |
|---|
|
|
P1029-5-PM. Relation of the pharmacist to the pressure sore measures accompanied with the medical service fees revision 藤井実穂, 中村亮博, 櫻井明子, 村田和歌子, 安達嘉織, 合田泰志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2089-2089, 2023. |
|---|
|
|
P1030-5-PM. Evaluation of the pharmaceutical management in the pressure sore practice by the cooperation with a ward exclusive duty pharmacist and the pressure sore measures team 篠崎聡1, 杉山華菜1, 秡川恵子2, 本多秀俊1, 林由紀子1, 三井浩3, 並木路広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2090-2090, 2023. |
|---|
|
|
P1031-5-PM. Contents examination ... of 1 attempt - two ways type drug control summary of bracken, the Toda district drug information sharing network construction 稲秀士1, 宮崎美子1, 加藤綾乃2, 濱浦睦雄2, 福田稔1, 濃沼政美3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2093-2093, 2023. |
|---|
|
|
P1032-5-PM. Specific example ... of the interactive type drug summary utilization in 2 attempt - bracken municipal hospital of bracken, the Toda district drug information sharing network construction 加藤綾乃1,2,3, 稲秀士2, 宮崎美子2, 福田稔2, 濱浦睦雄1, 濃沼政美3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2094-2094, 2023. |
|---|
|
|
P1033-5-PM. The unevenly distributed of the treatment at home offer drugstore using geographical information system statistics and access-related examination 外山和弥1, 玉木啓文1, 長内理大1, 伊野陽子2, 中村光浩3, 井口和弘1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2095-2095, 2023. |
|---|
|
|
P1034-5-PM. -affiliated examination of "the pharmacist unevenly distributed index" that was shown to by inhabitants cover rate and Ministry of Health, Labour and Welfare which expressed the regional unevenly distributed of the drugstore pharmacist 玉木啓文1, 外山和弥1, 長内理大1, 伊野陽子2, 中村光浩3, 井口和弘1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2096-2096, 2023. |
|---|
|
|
P1035-5-PM. Effect - interim report ... that continuous medication follow using the application gives to patients 嶋田努1, 山下千佳子2, 赤坂聡之3, 安田圭子3, 山下恵4, 長基健人2, 岡島正2, 橋本昌子3, 沖崎歩4, 工藤知也4, 中尾豊4, 崔吉道1, 玉井郁巳5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2097-2097, 2023. |
|---|
|
|
P1036-5-PM. Questionary survey ... to the medical institution of operational ... area of the drug information contact book between institutions 深津昌弘1, 松本茂1, 湯浅浩之2, 水野大介3, 山田哲也1, 近藤康博4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2098-2098, 2023. |
|---|
|
|
P1037-5-PM. Fact-finding ... of operational ... efforts situation of the drug information contact book between institutions 松本茂1, 深津昌弘1, 湯浅浩之2, 水野大介3, 山田哲也1, 近藤康博4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2099-2099, 2023. |
|---|
|
|
P1038-5-PM. Subjective evaluation of the dispatch physician for the pharmacist engaging in remote island medical care in remote area 宮田祐一1, 宮坂善之2, 中村雅敏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2100-2100, 2023. |
|---|
|
|
P1039-5-PM. Fact-finding of the continuous educational intervention effect in the community pharmacy 根本崇史, 菅原淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2101-2101, 2023. |
|---|
|
|
P1040-5-PM. Intervention to the adverse event of the pharmacist in the treatment at home 高山翔太1, 三谷貴子1, 秋元義幸2, 玉井典子3, 武藏汐里3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2102-2102, 2023. |
|---|
|
|
P1041-5-PM. It is a study on fact-finding of the information sharing with the type of job other than the drugstore pharmacist in visit drug control instruction duties 高橋寛1, 岡崎光洋2, 溝神文博3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2103-2103, 2023. |
|---|
|
|
P1042-5-PM. Research about the activation of the information sharing by the category analysis of the at-home report between a pharmacist and the multi-types of job 横井杏菜1, 堀英生1,8, 水野正子2,8, 水野紀子2, 浅井治行3, 山田葉子3, 三宅宏季4, 石川友康5, 供田将志6, 菊池千草7, 鈴木匡1,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2104-2104, 2023. |
|---|
|
|
P1043-5-PM. An evaluation and examination of the duty system in our hospital 樋本繭子, 木村有子, 新免徹, 高瀬尚武 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2105-2105, 2023. |
|---|
|
|
P1044-5-PM. Of inquired analysis ... hospital and dispensing pharmacy of the incompatibility in the TPN put to the infusion DI center is different, and pay the attention; and ... 掛水瑞芳, 五十嵐遼, 竹林佑花, 松田直子, 吉岡小都子, 星泉, 佐々木美由紀, 福田まゆみ, 岩原良晴, 河野裕則, 沢田憲彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2106-2106, 2023. |
|---|
|
|
P1045-5-PM. Efforts and problem to an at-home palliative care shift by the use of PCA pump in the depopulated aging area 鶴居勝也, 荒木遼太, 小川紗知, 讓原千広, 波多晶子, 中澤美樹子, 橋爪和恵, 窪田真弓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2107-2107, 2023. |
|---|
|
|
P1046-5-PM. A problem and the prospects to see from the support two case in the drug for the treatment at home to other drugstores concerned with as regional alliances drugstore 江口真理子1, 高武華子2, 築地奈々星2, 纉雅仁3, 梶栗直子3, 井上友貴3, 山北哲也3, 佐伯友香3, 児島拓也1, 濱地進吾4, 鄭唯学4, 中堀亮一5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2108-2108, 2023. |
|---|
|
|
P1047-5-PM. It is ... after the information confirmation between hospitalization and release support ... hospital by the pharmacist before the hospitalization 清水利匡, 高根貴子, 坂東めぐみ, 岡添進 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2109-2109, 2023. |
|---|
|
|
P1048-5-PM. The prescription observance situation after the discharge in patients with stroke 福田裕子1,5, 伊東里紗1, 柿花美沙紀1, 金本哲二2, 高橋務3, 佐原敏之1, 辻川正彦4, 恩田光子5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2110-2110, 2023. |
|---|
|
|
P1049-5-PM. For safe medication self-care - self-care flow sheet making and effect - 宮永幸実, 仲田涼, 前かほり, 高梨明恵, 濱田初美, 小杉満孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2111-2111, 2023. |
|---|
|
|
P1050-5-PM. Investigation about the sterile preparation processing in the treatment at home enforcement drugstore 志賀美月1, 伊野陽子1,2, 玉木啓文1, 長内理大1, 井口和弘1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2112-2112, 2023. |
|---|
|
|
P1051-5-PM. Scoping review about the prevention, the enlightenment activity of the osteoporosis in the community pharmacy 庄司雅紀, 寺前成美, 恩田光子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2113-2113, 2023. |
|---|
|
|
P1052-5-PM. Analysis of the factor to have an influence on the use of the home care patient online medication counseling 近藤優歩1, 野々村和哉2,3, 玉木啓文2, 長内理大2, 伊野陽子4, 高島英滋5, 甲斐絢子1, 林秀樹1,6, 井口和弘1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2114-2114, 2023. |
|---|
|
|
P1053-5-PM. Attitude survey about the pharmacist utilization in the timing not to bring a prescription 横倉南, 竹平理恵子, 盛岡正博, 有田悦子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2115-2115, 2023. |
|---|
|
|
P1054-5-PM. About the current situation investigation of the tracing report in our hospital 岡本涼子, 竹内裕理佳, 中川喬統, 小田幸奈, 小田剛史, 松本恵美, 深海広平, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2120-2120, 2023. |
|---|
|
|
P1055-5-PM. It is ... from the position of current situation and problem - health insurance pharmacy pharmacist whom we saw from the questionary survey in the tracing report 荻野由華1, 森井悠介2, 松井駿亮2, 大河万顕2, 瀬名波弘昌2, 松野純男3, 宮崎充宏1, 森正彦1, 下村一徳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2121-2121, 2023. |
|---|
|
|
P1056-5-PM. Duties burden reduction effect of the doubt inquiry simplification protocol in the outside Parliament prescription 鈴木一志, 浦崎圭太, 白崎真由子, 山下由貴, 河井和子, 小川裕美, 久田純生, 伊藤和幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2122-2122, 2023. |
|---|
|
|
P1057-5-PM. Intervention to patients with heart failure utilizing a heart failure notebook, the tracing report 福島奈津美1, 桝本光子1, 白石大理1, 竹家広志2, 小坂香菜子3, 森田悦代4, 中村美樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2123-2123, 2023. |
|---|
|
|
P1058-5-PM. It is ... through questionary survey about usefulness of the illness disease cooperation between pharmacists using the changing hospital follow-up request handwriting and the usefulness of the cooperation between example - pharmacists 柿原聡美1,2, 菅原隆文1, 阿部圭輔1, 石田翔1, 田中和行1, 寺岡豊2, 渡邊篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2124-2124, 2023. |
|---|
|
|
P1059-5-PM. Contents investigation of the drug control summary about the discharge drug information cooperation addition and questionary survey to the health insurance pharmacy 伊佐治麻里子, 松本琢博, 笠原真理, 前田直大, 鶴谷勝実 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2125-2125, 2023. |
|---|
|
|
P1060-5-PM. Evaluation of the usefulness of the reporting document at discharge using the writing a postscript from the health insurance pharmacy 上野ひとみ, 相澤聡子, 椎葉有樹, 大江彰彦, 小野祐志, 宇佐美順子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2126-2126, 2023. |
|---|
|
|
P1061-5-PM. The introduction of the pharmacist interview before hospitalization for the purpose of the request for on admission drug reporting for the health insurance pharmacy and the effect 新康憲, 若松雄太, 杉生雅和, 高子優子, 正置耕一, 吉岡睦展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2127-2127, 2023. |
|---|
|
|
P1062-5-PM. Efforts to instruction and the medicine medicine cooperation system construction to foreign cancer medical therapy patients 鎌田恵子, 相原善弥, 瀬川満, 佐藤英二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2128-2128, 2023. |
|---|
|
|
P1063-5-PM. Evaluation of the patients maneuver every device using the inhalant instruction reporting book 鈴木葵1, 原田優1, 横山敦1, 小泉晴美2, 中島研1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2129-2129, 2023. |
|---|
|
|
P1064-5-PM. PBPM satisfaction investigation after the outside Parliament prescription doubt inquiry simplification protocol introduction 十川友那1, 渡邊舞1, 高橋公子1, 加福夏織1, 篠永浩1, 原田典和1, 加地努1, 矢野禎浩2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2130-2130, 2023. |
|---|
|
|
P1065-5-PM. Comparison of the number of Residual medicine adjustment at the health insurance pharmacy that introduced a doubt inquiry simplification protocol and the health insurance pharmacy that we do not transduce 伊藤一馬1, 関川千尋2, 角田洋輔3, 飯山貴子4, 石井弘幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2131-2131, 2023. |
|---|
|
|
P1066-5-PM. Efficiency of the duties operation by construction and the introduction of electronic tracing report service (AAdE-Report) 吉田優子1, 上森美和子1, 池見泰明1, 中川俊作1, 米澤淳1, 黒田知宏2, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2132-2132, 2023. |
|---|
|
|
P1067-5-PM. The current situation investigation of the tracing report in our hospital 山脇一浩1, 齋藤由紀1, 井上清勝2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2133-2133, 2023. |
|---|
|
|
P1068-5-PM. Questionary survey about the medicine for cardiovascular disease medicine cooperation in Ishikawa 多田郁1, 西田祥啓1, 坂野由宇希2, 丸一泰雅3, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2134-2134, 2023. |
|---|
|
|
P1069-5-PM. The current situation and the future task which we saw from the study operation of the tracing report 永井孝正, 鈴川誠, 今井邦行, 内山耕作, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2135-2135, 2023. |
|---|
|
|
P1070-5-PM. About efforts for the inflection of the medication reporting book in our hospital and medical economic effect 山田早1, 土屋裕伴1, 本間さとみ1, 大登剛1, 諸橋賢人1, 小林このみ1, 中里健志1, 加藤聡2, 村橋憲2, 水井亮3, 新井亘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2136-2136, 2023. |
|---|
|
|
P1071-5-PM. Effect in the medicine medicine cooperation using the information contact book between institutions before hospitalization about the discontinuation before bloody measures 新町圭央, 大塚識稔, 石井一也, 神原康佑, 中村豪志, 岡田淳芳, 上村拓生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2137-2137, 2023. |
|---|
|
|
P1072-5-PM. Medicine medicine cooperation (case report) using the medication reporting book for the CDK4/6 inhibitor which door front Hospital releases 福島岳1, 安斎沙織1, 宮田広樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2138-2138, 2023. |
|---|
|
|
P1073-5-PM. The cooperation full addition in the Hiroshima-shi Asa area and the current situation of specific drug management instruction addition 2 北本真一, 阪田安彦, 古谷智裕, 村上礼隆, 佐藤実由, 金田公平, 宮森伸一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2139-2139, 2023. |
|---|
|
|
P1074-5-PM. Questionary survey about medicine, the medicine cooperation enforcement situation in the foreign chemotherapy for a health insurance pharmacy, patients 阿部まり絵, 済川聡美, 眞鍋綾, 伊賀久美, 矢野安樹子, 飛鷹範明, 田中守 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2140-2140, 2023. |
|---|
|
|
P1075-5-PM. Inspection of the efforts for improvement in collect rate of the tracing report in the foreign cancer chemotherapy 高橋則正, 谷道あかり, 江守勇紀, 石川雄大, 高木昭佳, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2141-2141, 2023. |
|---|
|
|
P1076-5-PM. It is efforts ... in ... Kure district about the introduction of the medicine medicine cooperation tool in irAE measures 田頭尚士1, 西田朋洋1, 景山康二郎1, 坂本靖之1, 大塚茂雄2, 鷹橋紀幸2, 大塚幸三2, 藤田秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2142-2142, 2023. |
|---|
|
|
P1077-5-PM. Attitude survey of the pharmacist for cancer locomotive syndrome 直井美萌1, 角坂惟生1, 坂口涼2, 安部智哉1, 松坂和正1, 武井大輔1, 中山季昭1, 大塚公庸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2143-2143, 2023. |
|---|
|
|
P1078-5-PM. It is ... about a role of content analysis - hospital pharmacist of the foreign cancer medical therapy tracing report and a future problem 岡田法子, 長井聡子, 下菊早紀, 植田真理, 北野こずえ, 小川充恵, 香川雅一, 西岡達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2144-2144, 2023. |
|---|
|
|
P1079-5-PM. Workshop to the health insurance pharmacy that we went with multiple medical institutions 鬼窪利英1, 中村久美1, 渡辺宏晃2, 岩本大紀3, 石曽根好雅3, 内藤隆文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2145-2145, 2023. |
|---|
|
|
P1080-5-PM. Examination about the acceptance situation and the problems of the outside Parliament prescription containing the antiHIV medicine 平野淳1, 矢倉裕輝2, 増田純一3, 國本雄介4, 田澤佑基5, 井上正朝6, 佐藤萌7, 安井淳子8, 三枝祐美9, 田川尚行10, 成田綾香11, 田中和行12, 西勇治13, 大東敏和14, 合原嘉寿15, 吉田知由1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2146-2146, 2023. |
|---|
|
|
P1081-5-PM. Effect on effect of treatment that the prescription situation and the characteristic of the patient of patients with diabetes utilizing Residual medicine adjustment PBPM give 平井利幸1, 花岡峻輔2, 寺門祐介1, 関利一1, 渡邉文之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2147-2147, 2023. |
|---|
|
|
P1082-5-PM. Questionary survey ... about DKD, the CKD medical therapy - current situation and the problem of a drugstore, the hospital pharmacist in the Naka area 中西俊介, 阪野和重, 武内恭範, 中川愛理, 野尻真帆 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2148-2148, 2023. |
|---|
|
|
P1083-5-PM. About polypharmacy measures to be carried out by regional alliances (the first report) 上島聖秀1, 山本麗央奈1, 高橋慎太郎1, 坂根美和子1, 飴谷友菜1, 能澤真希子1, 田中みずほ1, 森谷道生1, 石浦嘉之2, 川崎聡3, 畠山規明4, 西尾公秀5, 稲村勝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2149-2149, 2023. |
|---|
|
|
P1084-5-PM. About polypharmacy measures to be carried out by regional alliances (the second report) 山本麗央奈1, 上島聖秀1, 高橋慎太郎1, 坂根美和子1, 飴谷友菜1, 能澤真希子1, 田中みずほ1, 森谷道生1, 石浦嘉之2, 川崎聡3, 畠山規明4, 西尾公秀5, 稲村勝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2150-2150, 2023. |
|---|
|
|
P1085-5-PM. Efforts (the third report) of the medicine medicine cooperation in the Komaki Municipal Hospital 水谷貴樹, 山本泰大, 山本将司, 出口裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2151-2151, 2023. |
|---|
|
|
P1086-5-PM. Because do not make invention - medical treatment to fix drug summary in a drugstore break off; ... 廣野友祈子1, 山日祐平1, 長井晴教1, 永井洋子2, 狭間研至1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2152-2152, 2023. |
|---|
|
|
P1087-5-PM. The efforts of the illness medicine cooperation workshop aiming at improvement in quality of the community medical care and the evaluation 松尾宗一郎1, 野嶋芳紀1, 佐藤聖2, 田中達也2, 邑瀬誠1, 深津英人3, 松井洸3, 阿部真也3, 山口浩3, 野村和彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2153-2153, 2023. |
|---|
|
|
P1088-5-PM. The effect that a tracing report style revision gives to report contents depending on the medical information cooperation network registration of patient situation and evaluation of the style 高村優太1, 平井利幸1, 小橋川祥2, 秋山裕史1, 関利一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2154-2154, 2023. |
|---|
|
|
P1089-5-PM. The investigations of the format used for the sending of the offer book (tracing report) such as medication information, and the like and examination of required specifications 水野桃花1, 玉木啓文1, 長内理大1, 井口和弘1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2155-2155, 2023. |
|---|
|
|
P1090-5-PM. Current situation and problem ... of the tracing report in cooperation reinforcement - our hospital of a health insurance pharmacy and the hospital 野村祥子, 河合美凪, 飯田昭宏, 市江敏和, 大谷寧次郎, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2156-2156, 2023. |
|---|
|
|
P1091-5-PM. The current situation investigation of recognition and the utilization situation of the tracing report 田村美咲, 稲川智子, 花香淳一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2157-2157, 2023. |
|---|
|
|
P1092-5-PM. A report of the efforts which cooperated with a health insurance pharmacy at large-scale system failure, and contributed to the treatment continuation of the outpatient and investigation of doubt inquiry contents 脇條靖治1, 綛谷哲也1, 大橋明歩1, 寺田椋2, 森井絵莉香1, 橋本佑香1, 宮部祐子1, 寺岡知香3, 山東真寿美1, 下辻恒久1, 藤田敬子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2158-2158, 2023. |
|---|
|
|
P1093-5-PM. Research about the mention situation of the patients information of the prescription notebook 野呂菜緒美1, 秦光平1, 脇由香里1, 相松伸哉1, 小島さおり1,2, 松田浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2159-2159, 2023. |
|---|
|
|
P1094-5-PM. New efforts to the medicine medicine cooperation in the Kobe low infestation cancer medical center 松田ゆかり1, 平井みどり1, 橋本泰明1, 安部仁人2, 鈴木仁3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2160-2160, 2023. |
|---|
|
|
P1095-5-PM. Efforts of the medicine medicine cooperation using "the heart failure treatment discharge reporting book" for patients with heart failure of our hospital 中村眞梨1, 甲斐真由美1, 芝崎由美子1, 冨田晴樹2, 中村智弘3, 百村伸一3, 野村淳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2161-2161, 2023. |
|---|
|
|
P1096-5-PM. The cooperation actual situation between hospital - drugstores between hospital - hospital in the pharmacist in Saitama 大木稔也1,2, 金井紀仁1,3, 新井真澄1,4, 林野守将1,5, 小川桂1,6, 土屋宏二朗1,7, 若林純平1,8, 眞壁秀樹1,9, 濱浦睦雄1,10, 町田充11,12 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2162-2162, 2023. |
|---|
|
|
P1097-5-PM. Efforts of the medication management through the medicine medicine cooperation to the idiopathic pulmonary fibrosis therapeutic drug remedy patients 川島佳恵1, 野村洋道1, 石本学司1, 中浴伸二1, 冨岡洋海2, 田中詳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2163-2163, 2023. |
|---|
|
|
P1098-5-PM. It is the present of pharmacist society and the medicine medicine cooperation that we built at a local community medical care support hospital 鶴崎泰史1, 安永麗子2, 江崎由佳1, 齊田翌美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2164-2164, 2023. |
|---|
|
|
P1099-5-PM. Based on operation of the inside the hospital-adaptive doubt inquiry protocol in the outside Parliament prescription of our hospital and the effect by the acquisition difficulty of problems - antiepileptic drug - 福島悠太郎, 矢嶋隆宏, 山本吉章, 古屋裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2165-2165, 2023. |
|---|
|
|
P1100-5-PM. Efforts for the construction of the cooperation system at disaster with the door front drugstore 渡邊卓巳1, 坂本拓也1, 中尾耕治1, 白石貴寿2, 荒井宏人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2167-2167, 2023. |
|---|
|
|
P1101-5-PM. Attitude survey to a trainee about the disaster medical care 角田健, 小室治孝, 喜古康博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2168-2168, 2023. |
|---|
|
|
P1102-5-PM. Inspection of development and the attendance effect of the business continuity plan (BCP) development support program that established an axis for the local correspondence at disaster as the pharmacist society 飯沼公英1, 永田実沙2, 上田昌宏3, 木下淳4, 安原智久5, 吉野宗宏6, 福田利明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2169-2169, 2023. |
|---|
|
|
P1103-5-PM. Operational training using the disaster action card in the pharmacy 星野まりや1, 八木仁史1, 満田正樹3, 高田宏文1, 矢尾淳2, 河井良智1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2170-2170, 2023. |
|---|
|
|
IP-01. A Study of Exposure to Drug Dust to Pharmacists While Grinding Tablets Takenori Tamaki1, Yuji Yoshiyama2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2172-2172, 2023. |
|---|
|
|
IP-02. Digitization of ethical drug package inserts and utilization of international code GTIN Takao Orii1, Koichi Uemura2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2173-2173, 2023. |
|---|
|
|
IP-03. Electronic package inserts, benefits and problems from aspect of barcodes use Koichi Uemura1, Takao Orii2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2174-2174, 2023. |
|---|
|
|
IP-04. Effect of Implementing a Monitoring Program on the Safe Use of Zolpidem Dong Young Park, Yu Jeong Lee, Eun Kyeong Choi, Sung Jin Bae Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2175-2175, 2023. |
|---|
|
|
IP-05. Sex- and age-specific all-cause mortality in insomnia with hypnotics : Findings from Japan multi-institutional Collaborative Cohort Study Rintaro Sogawa1, Chisato Shimanoe1, Megumi Hara2, Yuichiro Nishida2, Takuma Furukawa2, Keitaro Tanaka2, J-MICC study group Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2176-2176, 2023. |
|---|
|
|
IP-08. P-gp-mediated drug-drug interaction promotes gastrointestinal absorption of pimozide and the risk of QT prolongation due to hERG channel inhibition - Fundamental studies and validation in clinical practice Liyanage Manosika Buddhini Perera1, Hiroki Morishita2,3, Hiroki Sunakawa2, Takuo Ogihara1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2180-2180, 2023. |
|---|
|
|
IP-09. Inhibition kinetics of Citrus jabara juice on CYP3A4 activity and identification of its inhibitory components Kana Koinuma1, Kenji Noto2, Tokio Morita1,3, Yoshinori Uekusa1,2, F.Peter Guengerich4, Katsunori Nakamura5, Koujirou Yamamoto6, Ayuko Imaoka1,2, Takeshi Akiyoshi1,2,7, Hisakazu Ohtani1,2,7,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2181-2181, 2023. |
|---|
|
|
IP-10. Doxorubicin decreases sweet taste sensitivity in mice Keisuke Mogi, Misaki Azuma, Shiori Iwaki, Chisaki Yoshioka, Katsuya Morito, Kentaro Takayama, Kazuki Nagasawa Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2182-2182, 2023. |
|---|
|
|
IP-11. Monitoring saliva and plasma concentrations of tedizolid and linezolid in rats Yuki Inoue1, Yuki Sato2, Hitoshi Kashiwagi2, Shunsuke Nashimoto2, Mitsuru Sugawara2,3, Yoh Takekuma3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2183-2183, 2023. |
|---|
|
|
IP-12. Population pharmacokinetic analysis of remimazolam in Japanese patients under general anesthesia Satoshi Ueshima1, Serina Nagahara1, Kenta Nakaya1, Mayu Kawamura1, Daiki Hira1,2, Yu Matsuura3, Kaneyuki Kawamae3,4, Mikio Kakumoto1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2184-2184, 2023. |
|---|
|
|
IP-13. Verification of a cocktail approach for quantitative drug-drug interaction assessment by a comparative analysis between the results of a single drug and cocktail drug Motoyasu Miura1, Shimako Tanaka1,2, Chiaki Kamiya3, Naoki Katayama3, Akio Hakamata3, Keiichi Odagiri3, Naoki Inui3, Junichi Kawakami4, Hiroshi Watanabe3, Noriyuki Namiki1,5, Shinya Uchida1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2185-2185, 2023. |
|---|
|
|
IP-14. SPK1 / S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib Yan Chen1,2, Rui Zhang2, Dandan Mi1, Qiuju Wang3, Tingwenli Huang2, Xinwei Dong4, Hongwei Zhang5, Hongtao Xiao2, Sanjun Shi1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2186-2186, 2023. |
|---|
|
|
IP-15. The case of quality control of COVID vaccine by pharmacists in process of vaccination in Yomitan, Okinawa Kikuko Urashima1, Hiroto Urashima1, Akinari Nakama2, Takeshi Gibo2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2188-2188, 2023. |
|---|
|
|
IP-16. Two cases of COVID-19 patients using Paxlovid(R) PACK with concomitant drugs Michiya Akabane1, Hiroyoshi Koide1, Rika Fukui1, Masashi Matsuda1, Satoshi Noda1,2, Masaki Sumi1, Yoshito Ikeda1, Shin-ya Morita1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2189-2189, 2023. |
|---|
|
|
IP-17. Survey on trends in the use of the OTC drug in the recovery accommodation facilities for Covid-19 patients Kikuno Matsukuma1, Soyoka Yamamura1, Ai Nakamura1, Mao Tsuji1, Nao Yoshida1, Ai Kanzaki1, Megumi Katsuta1,2, Takafumi Nakano1, Toshinobu Hayashi1, Takashi Egawa1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2190-2190, 2023. |
|---|
|
|
IP-18. Stillbirth rates before and during the COVID-19 pandemic in Manitoba (Canada) and Japan Laila Aboulatta1, Kenji Momo2, Tadanori Sasaki3, Qier Tan4, Sherif Eltonsy1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2191-2191, 2023. |
|---|
|
|
IP-19. Pediatric and Adolescent Medication Use Before and During COVID-19 : A Population-Based Cohort Study in Manitoba, Canada Christine Vaccaro1, Simran Diocee1, Laila Aboulatta1, Christine Leong1,2, Kaarina Kowalec1,3, Silvia Alessi-Severini1, Joseph Delaney1,4, Katherine Kearns5, Christina Raimondi5, Jamison Falk1, Dan Chateau6, Qier Tan7, Sherif Eltonsy1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2192-2192, 2023. |
|---|
|
|
IP-20. Analysis of the nutritional status of renal failure patients who received CRRT and the intervention effect of the NST Jisu Chung, Minkyun Kang, Sukyung Park, Bomi Kim, Inah Choi, Sungjin Bae Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2194-2194, 2023. |
|---|
|
|
IP-21. Effects of improvement of inhaler medication consultation on medication adherence and understanding of inhaler use Hyo Jung Kang, Ji Young Park, Kyung Duk Kim, Yeon Ji Lee, Jeong Yi Yoon, Jin Suk Kang Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2195-2195, 2023. |
|---|
|
|
IP-22. Report on the Activities and Achievements of Pharmacists in a Respiratory Care Support Team Akihiro Yasutomi, Ai Hirata, Kayoko Momma, Kayo Tsujii, Masahiko Kobayashi Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2196-2196, 2023. |
|---|
|
|
IP-23. Strategies for disaster relief responses by pharmacy students in a disaster situation Nao Yoshida1, Mao Tsuji1, Kikuno Matsukuma1, Soyoka Yamamura1, Ai Nakamura1, Ai Kanzaki1, Megumi Katsuta1,2, Takafumi Nakano1, Toshinobu Hayashi1, Takashi Egawa1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2197-2197, 2023. |
|---|
|
|
IP-24. A Diachronic Comparison of Faculty Publication Trends in a Japanese National University's Pharmaceutical and Medical Faculties Theron Muller, Miho Takano Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2198-2198, 2023. |
|---|
